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ABSTRACT 
Treated HIV+ individuals rarely suffer from AIDS-related morbidity and mortality due to 
advancements in combination antiretroviral therapy (cART). However, despite viral 
suppression with cART, virologically suppressed (VS) HIV+ individuals have elevated rates 
and risk of non-AIDS-related conditions such as cardiovascular disease (e.g. atherosclerosis) 
and neurocognitive decline, which are traditionally associated with ageing. These diseases 
are thought to be driven by a chronic inflammatory state known as ‘inflamm-ageing’ which 
occurs in the elderly, and is characterised by high levels of proinflammatory cytokines (e.g. 
IL-6 and TNF). Chronic inflammation also persists in VS HIV infection and is thought to 
contribute to age-related disease pathogenesis in a similar manner. Whilst the drivers of 
chronic inflammation in HIV infection and inflamm-ageing remain ill-defined, chronically 
elevated levels of bacterial components such as lipopolysaccharide (LPS) are observed in 
both HIV+ individuals and the aged and may contribute to immune activation.  
 
Our laboratory has previously shown that monocytes, key innate immune cells which 
respond to LPS by producing cytokines (e.g. IL-6, TNF), are functionally and phenotypically 
similar in younger HIV+ individuals and older HIV- individuals. The similarities between 
these groups suggests that HIV infection accentuates and/or accelerates age-related 
changes that may drive disease pathogenesis in young HIV+ individuals; although, the 
mechanisms driving this are currently unknown.  
 
Therefore, we hypothesised that 1) monocyte activation in HIV+ individuals is altered in a 
similar manner to healthy ageing and is not restored by cART, 2) chronically elevated LPS 
levels alters monocyte response and function which may drive inflammation in these 
groups, and 3) monocyte activation associated with chronic inflammation may have 
functional implications which affect the pathogenesis of diseases where monocytes are 
important, such as atherosclerosis.  
  
We have previously shown that biomarkers of monocyte activation from HIV+ individuals 
are heightened in comparison to HIV- controls and that these changes were similar to those 
of older HIV- individuals. However, how these biomarkers of monocyte activation were 
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altered with age is unknown. Age-related changes to the proportion of monocyte subsets 
(classical, intermediate and non-classical) and levels of soluble markers (CXCL-10, neopterin, 
sCD14, sCD163) and drivers (LPS) of monocyte activation in healthy ageing, and viremic and 
VS HIV infection, were evaluated by linear regression modelling combining data from six 
independent studies conducted in our laboratory (n=309). Markers of monocyte activation 
from viremic HIV+ individuals increased with age at a similar rate to changes in HIV- 
individuals; however, the levels were higher in HIV infection. Therefore age-related changes 
to biomarkers of monocytes were accentuated (i.e. occurred at a higher level) in viremic 
HIV+ individuals. Monocyte biomarkers were slightly lower in VS HIV+ individuals in 
comparison to viremic HIV+ individuals, although they remained higher than young controls, 
indicating these changes persist despite cART. Of the markers tested, CXCL-10 levels 
positively correlated with the majority of biomarkers, indicating it is a surrogate biomarker 
of monocyte activation. To estimate the number of ‘years’ earlier HIV+ individuals 
experience a given level of a biomarker, linear regression models with age as the outcome 
were created. Viremic and VS HIV+ individuals had CXCL-10, neopterin and sCD163 levels 
similar to those in HIV- individuals aged approximately 9-12 and 2-4 years older, 
respectively. Therefore, monocyte activation in HIV+ individuals increases with age at a 
similar rate to changes in HIV- individuals; however, age-related changes are accentuated in 
HIV infection and persist despite cART. 
 
To determine whether monocyte activation in HIV infection and ageing contributes to 
chronic inflammation, the response of monocytes from young viremic and VS HIV+ 
individuals and young and older HIV- individuals (n=10 per group) to LPS was evaluated 
using whole blood flow cytometry. Monocytes from HIV+ individuals and the elderly had 
higher basal and LPS-induced levels of proinflammatory cytokines (i.e. IL-6, TNF) than 
younger HIV- men (p<0.05 for all), indicating that monocytes from these individuals are 
hyper-activated and hyper-responsive to LPS challenge. Surface expression of the LPS 
receptor TLR-4 on monocytes from HIV+ individuals and the elderly were higher than in 
young HIV- controls; however, surface TLR-4 expression and plasma LPS levels correlated 
with IL-6 and TNF gene expression in HIV-, but not in HIV+ individuals, indicating that the 
mechanisms driving primed responses differ in ageing and HIV infection.  
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Lastly, a parallel study in our laboratory identified that monocytes from HIV+ individuals 
have a higher propensity to form foam cells (lipid-laden macrophages important in the 
pathogenesis of atherogenesis) than those of HIV- individuals. Due to similar changes to 
monocytes in HIV+ individuals, the ability of monocytes from young and elderly HIV- men to 
form foam cells was compared using a human model of atherogenesis that combines foam 
cell formation and trans-endothelial migration. Monocytes from elderly men formed foam 
cells more readily than those from younger men and the ability of cells to reverse migrate 
out of collagen gels were impaired (p<0.05 for both). Monocytes from elderly donors also 
had impaired cholesterol efflux possibly due to lower expression of the cholesterol efflux 
transporter ABCA1 (p<0.05) that may contribute to heightened foam cell formation 
(p<0.05). Furthermore, intermediate monocytes (expanded in the elderly) formed foam 
cells more readily than classical or non-classical subsets (p<0.05 for both), suggesting that a 
higher percentage of these cells may contribute to enhanced foam cell formation in the 
elderly. Interestingly, sera from elderly men was also found to enhance foam cell formation 
(p<0.05 for all), indicating that both intrinsic and extrinsic mechanisms promote foam cell 
formation by monocytes from elderly individuals. 
 
Taken together, this study has identified that biomarkers of monocyte activation from HIV+ 
individuals are increased in a similar manner to ageing; however this relationship is 
accentuated by HIV infection and not abrogated by cART. Monocytes from both HIV+ 
individuals and the elderly are also hyper-activated and hyper-responsive to LPS, but the 
mechanisms driving these primed responses differ. These changes and heightened 
monocyte responsiveness translates to altered function as monocytes from the elderly are 
more prone to forming foam cells. Therefore, changes to monocyte function may have 
implications for pathogenesis of atherosclerosis and potentially other inflammatory 
diseases in both HIV+ individuals and the elderly. 
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1 CHAPTER 1 
Ageing is associated with increased risk of inflammatory diseases such as cardiovascular 
disease (CVD), which is the leading cause of death in the developed and developing world. 
Due to the widespread use of combination antiretroviral therapy (cART), the disease 
burden in human immunodeficiency virus infected (HIV+) individuals has shifted from 
acquired immune deficiency syndrome (AIDS)-related mortality, to age-related co-
morbidities such as CVD. Furthermore, HIV+ individuals show increased risk of age-related 
co-morbidities than HIV- individual of a similar age; however, the mechanisms driving 
heightened age-related disease pathogenesis in these individuals are unknown.  
 
Increasing evidence suggests that enhanced risk of age-related diseases in cART treated 
HIV+ individuals may be driven by heightened immune activation and inflammation that 
persists despite viral suppression due to cART. Furthermore, HIV infection may induce 
immunological changes typically associated with advanced age, suggesting that HIV+ 
individuals may experience ‘premature’ immune ageing that could contribute to age-
related disease pathogenesis. In this introduction a case will be made that chronic 
inflammation drives immune activation and age-related disease pathogenesis in HIV+ 
individuals and the elderly. Furthermore, similarities in the phenotype and function of 
monocytes (central regulators of inflammation) in HIV infection and ageing will be 
implicated as key contributors to chronic inflammation and age-related disease 
pathogenesis in these individuals. 
 
Finally, the potential implications of age-related changes to monocyte function in the 
inflammatory condition of atherosclerosis will be discussed; exploring how chronic 
inflammation may contribute to altered monocyte function and how pathogen-associated 
inflammation may drive this in HIV+ individuals and the elderly. 
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1.1 Age-related disease burden in HIV infection and ageing 
1.1.1 Disease burden in the elderly 
As a consequence of improved therapeutics and enhanced clinical management prolonging 
life expectancy globally, the effects of age-related diseases are increasingly becoming a 
major public health issue. It is estimated that by 2050 approximately 32% of the population 
of Western countries will be over the age of 60 years (Division 2013). Ageing is associated 
with increased risk and incidence of morbidities such as atherosclerosis and other CVDs 
((Grundy et al. 1999; Otto et al. 1999), reviewed in (North and Sinclair 2012)), frailty ((Fried 
et al. 2001), reviewed in (Fulop et al. 2010)), cancers (Siegel et al. 2014), neurocognitive 
disease (e.g. dementia, (Plassman et al. 2007)), and renal (Stevens et al. 2010) and bone 
diseases that contribute to disability and death (reviewed in (Niccoli and Partridge 2012)). 
In a study evaluating the causes of death of Australian men and women in 2007, more than 
17% of all deaths of individuals aged over 65 were due to ischaemic heart disease (including 
atherosclerosis-related coronary artery disease (CAD), (AIHW 2010)), and a further 30% of 
deaths were caused by chronic inflammatory diseases including other CVDs (men: 10.0%, 
women: 15.1%), cancer (14.5%, 8.9%) and chronic obstructive pulmonary disease (5.1%, 
3.4%). Treatment for these diseases represents a significant proportion of health care 
expenditure as individuals over the age of 55 accounted for approximately 70% of 
Australian government expenditure on pharmaceuticals in 2005-06, with medication for 
ischaemic heart diseases and arthritis the major causes (AIHW 2007). Therefore, age-
related diseases pose a significant medical and financial burden. 
1.1.2 HIV infection and non-AIDS age-related diseases 
1.1.2.1 HIV infection in the cART era 
The introduction of cART in the early 1990s had a significant impact on HIV+ individuals by 
reducing morbidity and mortality from AIDS-defining illnesses, such that infected persons 
are living longer, healthier lives without progressing to AIDS. Of volunteers who enrolled in 
the Australian HIV Observation Database, only 16% (n=655, October 2014) of participants 
presented with AIDS prior to enrolment in the cohort (Kirby 2014). Furthermore, 45-75% of 
HIV+ individuals in Australia are estimated to be treated with cART (Kirby 2014), indicating 
that majority of HIV+ individuals seek therapy which prevents the development of AIDS-
defining illness that lead to death. In Australia, as in most Western countries, HIV infection 
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is mainly present in the homosexual community with approximately 86.9% of newly 
diagnosed infections present in men who have sex with men (MSM, (Kirby 2014)).  
1.1.2.2 Managing HIV infection with cART 
cART, a combination of three or more antiretroviral drugs targeting different stages of HIV 
viral replication, is the gold standard of HIV-1 therapy resulting in almost complete viral 
suppression in HIV+ individuals (<20 copies HIV RNA/mL of plasma). Early monotherapy 
with antiretroviral drugs such as azidothymidine (AZT) was ineffective as long-term therapy 
for HIV infection due to rapid development of drug resistance and high drug toxicity (Larder 
and Kemp 1989; De Clercq 2007, 2009). However, these effects were countered by the use 
of a combination of antiretroviral drugs in 1995 defined as highly active antiretroviral 
therapy (HAART), now redefined cART, which has overcome these adverse effects (Collier et 
al. 1996). Multiple stages of the viral life cycle are simultaneously targeted by cART 
including reverse transcription by nucleoside reverse transcriptase inhibitors (NRTIs, e.g. 
tenofovir disoproxil fumarate, lamivudine, abacavir) and non-NRTIs (NNRTIs, e.g. efavirenz, 
rilpivirine (de Bethune 2010)), integration of viral cDNA into the host cell chromosome by 
integrase inhibitors (e.g. raltegravir (Espeseth et al. 2000; Hazuda et al. 2000)), fusion of the 
HIV envelope with host cell plasma membrane by fusion inhibitors (e.g. maravaroc (Lalezari 
et al. 2003)) as well as proteolytic cleavage of Gag and Gag-Pol polyproteins by protease 
inhibitors (e.g. lopinavir, ritonavir (Turk 2006)). Initial cART treatment guidelines suggested 
that therapy should be initiated when patients had a CD4+ T cell count of lower than 350 
cells/µL (Thompson et al. 2010), a common indicator of HIV disease progression, in order to 
minimise the possibility of drug resistance and toxicity. Current Australian guidelines now 
suggest that cART should be initiated regardless of the CD4+ T cell count of the patient at 
presentation and recommendations intensify with decreasing CD4+ T cell count (DHHS 
2014). The full impact of delayed initiation of cART in HIV+ individuals who had higher CD4+ 
T cell counts has not been conclusively established. Conversely, the full effect of long term 
cART use is also ill-defined, highlighting the requirement of further studies to answer these 
questions.  
 
Individuals receiving effective cART have undetectable plasma viral load and reduced risk of 
developing AIDS-related conditions (Palella et al. 1998), however cART does not eliminate 
HIV from cellular and anatomical reservoirs in the body (discussed further in section 1.5.2). 
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The large multi-centre Strategies for Management of Antiretroviral Therapy (SMART) study 
evaluating the effect of therapy interruption on viral replication showed that controlled 
therapy interruption of just two weeks can result in HIV replication rebounding to near 
untreated levels and a significantly increased risk of both AIDS and non-AIDS associated 
diseases such as CVD (El-Sadr et al. 2006). Therefore, poor compliance to the prescribed 
therapy regimen or the development of resistance to cART may result in both AIDS and 
non-AIDS-related morbidity and mortality due to incomplete suppression of the virus.  
1.1.2.3 Age-related disease in cART-treated HIV+ individuals 
Despite an almost complete suppression of viral replication due to cART, the incidence of 
age-related conditions such as atherosclerosis (Triant et al. 2007; Hasse et al. 2011; 
Schouten et al. 2014), frailty (Desquilbet et al. 2009), non-AIDS cancers (Shiels et al. 2009; 
Deeken et al. 2012), renal and bone diseases (Tebas et al. 2000), osteoporosis-related 
fracture (Triant et al. 2008) and neurological decline (Heaton et al. 2010) is significantly 
higher for HIV+ than HIV- individuals. Interestingly, many of these diseases are typically 
observed in significantly older HIV- individuals (discussed in section 1.1.1). The increased 
risk of age-related conditions and non-AIDS cancers suggests that, whilst cART reduces the 
risk of AIDS-related morbidity and mortality, it does not completely eliminate the risk of 
non-AIDS related co-morbidities (Goulet et al. 2007; Deeks and Phillips 2009; Gill et al. 
2010). Furthermore, the risk of developing these conditions increases with length of HIV 
infection (Hasse et al. 2011). Therefore, HIV+ individuals may have higher risk of developing 
age-related diseases at a younger age despite effective treatment with cART (Appay and 
Sauce 2008; High et al. 2008). However, whether HIV infection accelerates the onset of 
disease, or acts as an additional risk factor to accentuate the development of diseases 
uniformly with age remains an important question to be answered. This is pertinent due to 
an ageing HIV+ population; predicted that over 50% of HIV+ individuals in the United States 
will be >50 years of age by 2015 (Kirk and Goetz 2009)). Therefore, the additional effect of 
HIV infection on age-related disease pathogenesis may constitute a significant burden on 
HIV+ individuals. 
 
Interestingly, many of these conditions, which are traditionally associated with ageing, 
show an inflammatory pathogenesis, suggesting that increased inflammation and immune 
activation may be a key factor in the pathogenesis of these HIV associated comorbidities in 
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a manner similar to ageing in HIV-individuals (reviewed in (Desai and Landay 2010; Hearps 
et al. 2014), discussed further in section 1.3).  
1.2 HIV infection mimics immune changes associated with advanced 
age 
Ageing is associated with a compromised immune state characterised by impaired adaptive 
immune responses (reviewed in (Weng 2006)), cellular senescence, thymic involution, 
impaired immune clearance, decreased CD4+:CD8+ T cell ratio and shrinkage of 
“immunological space” for naïve CD4+ T cells (Table 1.1). Despite decreased cellular 
function, ageing is also characterised by a chronic low level inflammatory state known as 
inflamm-ageing driven at least in part by accumulation of senescent cells that release 
proinflammatory cytokines (Franceschi et al. 2000). Chronically elevated serum/plasma 
levels of inflammatory mediators such as interleukin-6 (IL-6, (Ershler et al. 1993)), tumor 
necrosis factor (TNF, (de Gonzalo-Calvo et al. 2010)) and high-sensitivity C reactive protein 
(hs-CRP) are thought to arise from years of continual immune stimulation by exposure to 
pathogens (De Martinis et al. 2006; Franceschi 2007; Franceschi et al. 2007) and are 
independently associated with age-related disease (discussed further in section 1.2.2). 
Many of the immunological changes observed the elderly are also present in significantly 
younger HIV+ individuals suggesting that these individuals may undergo an accelerated 
ageing process (Appay and Rowland-Jones 2002; Appay and Sauce 2008). The similarities in 
immunological changes between HIV infection and ageing are described more fully below. 
1.2.1 Cellular changes in HIV infection and ageing 
1.2.1.1 Adaptive immune changes 
Ageing is associated with a state of immunosenescence, a gradual degradation of the 
adaptive immune system, which is characterised by expansion of non-functional immune 
effectors. Telomeres, repeats of short nucleotide sequences which protect the ends of 
chromosomes during cell division, are gradually shortened with age due to repetitive 
cellular division (Herbig et al. 2004) or damage induced by host and environmental stress or 
reactive oxygen species (ROS). Cells reach a state of replicative senescence, whereby cells 
undergo irreversible growth arrest and cannot divide (Hayflick 1974). Senescent cells are 
also functionally impaired due to loss of the T cell costimulatory receptor CD28 and show  
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Table 1.1 Comparison of immune changes in VS HIV infection and ageing 
Cell Type Age-associated alterations HIV-associated alterations 
T cells 
Impaired CD4+:CD8+ T cell ratio 
↑Proinflammatory CD28-CD57+ senescent T cell phenotype 
Expansion of effector CD8+ T cells (e.g. specific for CMV and/or HIV) 
“shrinkage of immunological space” 
Shortened telomeres 
Thymic involution 
B cells Increased production of IgA and IgG 
Monocytes 
Increase in intermediate and non-classical subsets 
Impaired phagocytosis 
Shortened telomeres 
Increased plasma concentration of monocyte and macrophage-produced 
inflammatory cytokines and markers of activation (e.g. IL-6, sTNFR) 
Impaired TLR-1/2 response 
Impact of HIV on TLR response 
unknown 
NK cells 
Impaired cellular cytotoxicity (ADCC) 
Increased proportion of mature, 
CD56dim subset 
Increased number of activated, 
CD57+ senescent subset 
Dendritic 
cells 
Decreased number of circulating pDC 
Increased basal levels of intracellular proinflammatory cytokines 
Neutrophils Reduced function (chemotaxis and phagocytosis) 
Systemic ↑IL-6, TNF, hs-CRP, CXCL-10  ↑IL-6, TNF, hs-CRP, CXCL-10 
 
ADCC – antibody dependent cellular cytotoxicity; CMV - cytomegalovirus 
Adapted from (Hearps et al. 2011) 
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impaired replicative ability (associated with higher levels of the senescence differentiation 
marker CD57). Senescent T cells with shortened telomeres are expanded with age (Effros et 
al. 2005) and have an increased surface expression of proinflammatory receptors such as 
ICAM-1 and CCR2 (Kletsas et al. 2004; Acosta et al. 2008) and produce proinflammatory 
cytokines that may contribute to chronic inflammation (Rodier et al. 2009). Furthermore, 
both effector memory and cytotoxic CD8+ T cells from older individuals have higher basal 
intracellular levels of interferon (e.g. IFN-γ) and TNF in comparison to younger individuals, 
whilst memory CD8+ T cells have higher levels of IL-6 (Zanni et al. 2003). Therefore, the 
accumulation of these senescent, but inflammatory cells with age is thought to contribute 
to inflamm-ageing in older individuals (reviewed in (Davalos et al. 2010), discussed further 
in section 1.2.2).  
 
In addition to cellular senescence, thymic involution, which begins after the first year of 
birth and accelerates with age (Steinmann et al. 1985), further drives shrinkage of the T cell 
repertoire by reducing the production of new CD45RA+CD31+ naïve CD4+ T cells ((Douek et 
al. 1998; Kilpatrick et al. 2008), reviewed in (Steinmann 1986)). Therefore, expansion of 
highly differentiated CD8+ memory/effector T cells coupled with low production of naïve T 
cells skews the CD4+:CD8+ T cell ratio so that senescent, inflammatory CD8+ T cells 
represent a significant proportion of the T cell population. In addition to replicative 
senescence, this process can be exacerbated by bacterial and viral infection such as 
cytomegalovirus (CMV), whereby ligand specific T cells occupy large amounts of 
“immunological space” (discussed further in section 1.5.2.2). Thus, the expansion of highly 
differentiated senescent cells and impaired replenishment of naïve CD4+ T cells drives 
impaired immune function. 
 
HIV+ individuals receiving cART also have a higher proportion of senescent CD28- T cells 
which are an indicator of HIV-1 disease progression (Cao et al. 2009). Chronic HIV infection 
is also associated with an increase in CD8+ T cells expressing CD57+ (Brenchley et al. 2003), 
shortening of telomere length and loss of CD28 on CD8+ T cells (Effros et al. 1996) and 
reduction of the CD8+ T cell repertoire (Valenzuela and Effros 2002; Papagno et al. 2004), 
indicating loss of T cell function (Cao et al. 2009; Sauce et al. 2011). Furthermore, HIV+ 
individuals have lower numbers of naïve CD45RA+CD31+CD4+ T cells and CD45RA+CD31- 
CD4+ T cells with shorter telomere lengths than HIV- individuals (Table 1.1), with numbers   
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of these cells being similar to those of HIV- individuals aged approximately 17-28 years 
older (Rickabaugh et al. 2011). Furthermore, the loss of naïve T cell counts in HIV infection 
characterise immune ageing in these individuals (Appay et al. 2011). The proportion of 
activated CD8+ T cells with a CD38+HLA-DR+ phenotype is also increased in HIV+ individuals 
(Brenchley and Douek 2008). Plasma levels of IgA and IgG produced by B cells, known to 
increase with age (ListÌ et al. 2006), also are higher in HIV+ individuals compared to 
uninfected controls (Redgrave et al. 2005). Although HIV is also associated with thymic 
involution, this can be rescued with cART (Douek et al. 1998).  
1.2.1.2 Innate immune changes 
Although the above studies indicate that similar changes to adaptive immune function 
occur in both ageing and HIV infection, less is known about innate immune changes. Innate 
immune cells such as monocytes, dendritic cells (DCs), natural killer (NK) cells and 
neutrophils act as a first line of defence against pathogens. Limited evidence suggests that 
innate immune effector cell number, subset and function are also altered in HIV+ 
individuals (Boasso and Shearer 2008) and that these changes are similar to those observed 
with healthy ageing (reviewed in (Panda et al. 2009; Hearps et al. 2011; Hearps et al. 2014), 
Table 1.1). We have shown that monocytes from HIV+ individuals and the elderly share 
similar immunological properties which will be discussed in detail in section 1.4.4. The 
similar changes to DCs, NK cells and neutrophils are discussed below. 
1.2.1.2.1 Dendritic cells 
DCs are key antigen presenting cells that act as a bridge between the innate and adaptive 
immune system. As such, they play key roles in both ageing and HIV infection. Two major 
subsets of DCs are present in circulation; myeloid DCs (mDCs) derived from monocytes and 
respond to bacteria and plasmacytoid DCs (pDC) that have anti-viral functions resulting in 
the production of type I IFN. Both HIV+ individuals (Donaghy et al. 2001) and the elderly 
(Shodell and Siegal 2002) have lower circulating levels of pDCs than young, HIV- controls, 
possibly due to increased margination to the lymph node (Lehmann et al. 2008) or infection 
of pDCs in the case of HIV+ individuals ((Schmidt et al. 2004), Table 1.1). In addition to 
antigen presentation, DCs respond to bacterial and viral challenge via pattern recognition 
receptors (PRRs, discussed further in sections 1.4.3) resulting in the production of 
proinflammatory cytokines (e.g. IL-6 and TNF) and antiviral type I IFN (e.g. IFN-α). Basal 
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levels of intracellular cytokines (e.g. TNF) are higher in mDC and pDCs from the elderly with 
the latter DC subset also having higher Ievels of FN-α (Panda et al. 2010). DCs from HIV+ 
individuals also show high basal IFN-α levels in comparison to HIV- individuals (Lehmann et 
al. 2008) suggesting, that they are activated in both HIV infection and ageing.  
1.2.1.2.2 Natural killer cells 
NK cells are cytotoxic leukocytes that have anti-viral and anti-tumor functions. NK cells 
target pathogens for destruction by granzyme and perforin release, as well as by 
production of proinflammatory cytokines. NK cells are classified into two major subsets 
based on expression of the adhesion molecule CD56 (CD56bright or CD56dim, reviewed in 
(Cooper et al. 2001)). NK cells from older individuals have impaired cellular cytotoxicity 
(Ogata et al. 1997) and an expansion of senescent CD57+CD56dim NK subsets ((Campos et al. 
2014), reviewed in (Gayoso et al. 2011), Table 1.1). HIV+ individuals also show expansion of 
CD56dimCD16+ NK cells that have impaired cytolytic activity (Mavilio et al. 2005). We have 
shown that NK cell antibody-dependent cellular cytotoxicity (ADCC) is impaired in viremic 
HIV+ individuals in comparison to HIV- controls (Lichtfuss et al. 2011). Furthermore, NK cells 
were shown to be more activated in HIV+ individuals than uninfected controls and remain 
activated following HIV viral suppression (Lichtfuss et al. 2012), indicating that functionality 
of these cells is not restored by cART. Recently our laboratory has characterised a further 
subset of CD56dim NK cells that do not express FcR gamma-chain (FcRγ-), required for ADCC 
(Arase et al. 1997), which are expanded in HIV infection (Zhou et al. 2015). Whether this 
subset is also present in elderly HIV- individuals is unknown. 
1.2.1.2.3 Neutrophils 
Neutrophils are granulocytes that play a key role in the early immune response to bacterial 
and fungal infection by phagocytosis of pathogens and production of ROS, antibacterial 
peptides and granules (as reviewed in (Amulic et al. 2012)). Neutrophils from older 
individuals have impaired phagocytosis (Wenisch et al. 2000), lower surface expression of 
CD16, required for phagocytosis of antibody-opsonised targets, and increased production 
of superoxide ((Butcher et al. 2001), Table 1.1). Neutrophils from the elderly also have 
impaired chemotaxis (Wenisch et al. 2000) suggesting that recruitment to sites of infection 
is also impaired. Similar to those of the elderly, neutrophils from cART-treated HIV+ 
individuals have impaired chemotaxis in response to chemoattractants (i.e. IL-8, (Heit et al. 
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2006)). Recently, neutrophils from HIV+ individuals have been shown to have an 
immunosuppressive phenotype suggesting that HIV infection alters neutrophil function 
(Bowers et al. 2014). 
 
In summary, both HIV infection and ageing are associated with altered innate and adaptive 
immune function at the cellular level. Interestingly, many of these changes in young HIV+ 
individuals are similar to those of significantly older HIV- individuals, suggesting that the 
effects of HIV infection on immunity mimic those of healthy ageing.  
1.2.2 Chronic low level inflammation in HIV+ individuals and the elderly 
As mentioned above, ageing is associated with a chronic low level inflammatory state 
known as inflamm-ageing (Franceschi et al. 2000). Plasma inflammatory markers such as IL-
6 (Ershler et al. 1993; Harris et al. 1999), TNF (Bruunsgaard et al. 2003; de Gonzalo-Calvo et 
al. 2010), soluble TNF receptor (sTNFR, (Catania et al. 1997)) and activation markers such as 
CXCL-10 (Antonelli et al. 2006), CCL2 (Antonelli et al. 2006; Seidler et al. 2010) and 
neopterin (Catania et al. 1997) are present at elevated levels in healthy, elderly individuals 
in comparison to younger individuals (Table 1.1). As discussed in section 1.2.1.1, circulating 
cytokines are thought to be produced as a consequence of cellular senescence as well as 
due to innate activation following continual activation in responses to increased pathogen 
burden and redox stress ((Fagiolo et al. 1993), reviewed in (Jenny 2012)). 
 
Similar to the elderly, a chronic, low level inflammatory state characterised by elevated 
plasma levels of IL-6 (Shive et al. 2012) and TNF (Aukrust et al. 1999; Keating et al. 2011) is 
present in HIV+ compared to HIV- individuals of similar age and persists despite viral 
suppression with cART (Table 1.1). Increased levels of many of these markers of immune 
activation and inflammation such as sCD14 (Sandler et al. 2011), neopterin (Mildvan et al. 
2005) and hs-CRP (Lau et al. 2006) have been documented to be independent markers of 
HIV disease progression. Furthermore, our laboratory has showed that plasma levels of 
CXCL-10 and neopterin in young HIV+ individuals are present in similar levels to HIV- 
individuals approximately 30 years older and are not restored by cART (Hearps et al. 2012a).  
 
Taken together, these observations indicate that HIV infection and healthy ageing are 
associated with similar inflamm-ageing related changes. Whilst the pathologies of HIV 
12 
 
infection and ageing are different, chronic immune activation and inflammation is a 
common feature which may contribute to age-related disease pathogenesis.  
1.3 Age-related disease and inflammation in HIV infection and ageing 
Increasing evidence suggests that the leading causes of morbidity and mortality in both VS 
HIV+ individuals and the elderly are associated with biomarkers of inflammation (reviewed 
in (Hearps et al. 2014)). Inflammatory biomarkers such as IL-6 and TNF are independently 
associated with increased disease risk and worse disease outcomes in age-related diseases 
such as atherosclerosis (Amar et al. 2006; Tedgui and Mallat 2006), osteoporosis (Ginaldi et 
al. 2005), neurocognitive decline (Jenny et al. 2012) and frailty (Leng et al. 2011), 
suggesting that chronic inflammation in these individuals contributes to disease 
pathogenesis (Vasto et al. 2007). The relationships between inflammatory markers and age-
related disease in both HIV+ individuals and the elderly are discussed further below (Table 
1.2). 
1.3.1 Cardiovascular disease 
CVD is the leading cause of morbidity and mortality in both HIV+ individuals and the elderly 
(discussed further in section 1.9.1). Although generally known as a metabolic disease, CVD 
is influenced by inflammatory factors that are elevated in both HIV+ individuals and the 
elderly and are associated with disease pathogenesis (discussed further in section 1.9.4, 
Table 1.2). In HIV- individuals CVD is independently associated with increased levels of hs-
CRP (Empana et al. 2010; Schnabel et al. 2013), IL-6 (Jenny et al. 2012) and sTNFR (Schnabel 
et al. 2013). Higher plasma levels of TNF have been shown to be associated with higher 
rates of atherosclerosis (Bruunsgaard et al. 2000). Furthermore, hs-CRP levels are 
associated with cardiovascular events in the elderly with no symptoms of CVD, although 
levels are more strongly associated with events in elderly individuals with subclinical CVD 
(Tracy et al. 1997). The use of multiple inflammatory biomarkers in addition to traditional 
risk factors of CVD better predicts risk of death in elderly individuals than traditional risk 
factors alone measured by the Framingham risk score (Zethelius et al. 2008), highlighting 
the importance of inflammation in the pathogenesis of CVD. 
 
Similarly, cART treated HIV+ individuals also show an association between IL-6 (Duprez et al. 
2012) and hs-CRP levels (Duprez et al. 2012; De Luca et al. 2013) and cardiovascular  
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Table 1.2 Association of inflammatory markers with age-related disease 
Inflammatory 
disease/biomarker 
Association with disease 
 Ageing HIV 
Cardiovascular disease   
IL-6 ↑ (Volpato et al. 2001; Jenny et al. 
2012) 
↑ (Duprez et al. 2012; De Luca et 
al. 2013) 
TNF ↑ (Bruunsgaard et al. 2000) ↑ (Shikuma et al. 2014) 
hs-CRP ↑ (Empana et al. 2010; Schnabel et 
al. 2013) 
↑ (Duprez et al. 2012; Hsue et al. 
2012; De Luca et al. 2013) 
Frailty   
IL-6 ↑ (Ferrucci et al. 1999; Visser et al. 
2002; Leng et al. 2011; Jenny et al. 
2012) 
 
TNF ↑ (Visser et al. 2002) ↑ (Erlandson et al. 2013) 
hs-CRP ↑(Boxer et al. 2008; Jenny et al. 
2012) 
 
Neurocognitive decline   
IL-6 ↑ (Zuliani et al. 2007; Singh-
Manoux et al. 2014) 
↑ (Ancuta et al. 2008) 
TNF ↑ (Bruunsgaard et al. 1999b)  
hs-CRP ↑ (Komulainen et al. 2007; Noble 
et al. 2010) 
 
 
Adapted from (Hearps et al. 2014) 
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events that are independent of age. Furthermore, hs-CRP levels are predictive of 
progression of cIMT in HIV+ individuals (Hsue et al. 2012). 
1.3.2 Frailty 
Frailty is defined as a syndrome consisting of at least three of the following five properties: 
low grip strength, low energy and physical activity, decreased walking speed and weight 
loss (Fried et al. 2001). Traditionally associated with ageing, younger HIV+ individuals also 
show increased rates of frailty (reviewed in (Onen and Overton 2011)). Frailty is associated 
with increased IL-6 (Jenny et al. 2012), hs-CRP (Walston et al. 2002) and neopterin levels 
(Leng et al. 2011) in the elderly and also cART treated HIV+ individuals (Erlandson et al. 
2013). Furthermore plasma IL-6 and TNF inversely correlate with muscle mass in elderly 
men and women ((Visser et al. 2002), Table 1.2).  
1.3.3 Neurocognitive decline/dementia 
Neurocognitive decline and diseases such as dementia and Alzheimer’s disease occur more 
commonly with advanced age. HIV+ individuals also experience neurocognitive decline with 
approximately 40-60% of HIV+ individuals being diagnosed with HIV-associated neurological 
disorders (HANDs), despite viral suppression with cART ((Heaton et al. 2011), Table 1.2). In 
elderly individuals, plasma IL-6 levels predict cognitive decline (Weaver et al. 2002) and hs-
CRP levels are also associated with poorer neurological outcomes (Noble et al. 2010). 
Similarly IL-6 (Ancuta et al. 2008) and sTNFR (Ryan et al. 2001) are associated with 
neurocognitive decline in HIV+ individuals. 
 
Together, many age-related diseases have a strong association with plasma levels of 
markers of chronic inflammation and immune activation, suggesting that inflammation may 
contribute to disease pathogenesis. Many of the relationships between inflammatory 
factors and age-related disease also occur in cART treated HIV infection suggesting that 
these interactions may contribute to disease pathogenesis in this population also. 
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1.4 Monocytes in HIV infection and ageing 
1.4.1 Monocytes: an overview 
Monocytes are short lived (3-4 days), non-proliferating, circulating blood precursors of 
tissue macrophages (van Furth and Cohn 1968) and DCs that account for approximately 
10% of all leukocytes (reviewed in (Geissmann et al. 2010)). Known as mononuclear 
phagocytes, monocytes elicit immune responses to foreign antigens by recognising and 
responding to pathogens in the periphery by phagocytising targets and/or producing 
proinflammatory cytokines to initiate an immune response (mechanisms described in 
section 1.6). Monocytes may also have limited capacity to present antigen to T cells (Tacke 
et al. 2006), although this is not well defined. Monocytes play a role in maintaining 
homeostasis as well as tissue repair following injury (discussed in section 1.4.2) and 
emerging evidence suggests that monocytes may even have an immunological role in 
tissues without requiring differentiation to macrophage or DCs (Avraham-Davidi et al. 2013; 
Jakubzick et al. 2013). Monocytes migrate into tissue and blood vessel walls via adhesion 
and migration receptors and can influence disease pathogenesis (e.g. in atherosclerosis 
(reviewed in (Gautier et al. 2009), discussed further in section 1.9.2)).  
 
Monocytes are produced from CD34+ haematopoietic cells in the bone marrow and are 
recruited into blood, especially during infection, by interactions between surface CCR2 and 
monocyte chemoattractants, particularly monocyte chemoattractant protein-1 (MCP-1), 
also known as CCL2 (Serbina and Pamer 2006; Tsou et al. 2007). Alternatively, monocytes 
may also remain in the spleen forming a reservoir that can be rapidly recruited to sites of 
tissue damage, such as the heart (Swirski et al. 2009). Traditionally monocytes were 
thought to be essential for the replenishment of tissue macrophages under homeostatic 
conditions (van Furth and Cohn 1968); however, fate mapping in mice has revealed that 
macrophage populations can be maintained independently of monocyte 
migration/differentiation via proliferation of tissue macrophages originating from 
embryonic precursors ((Hashimoto et al. 2013), reviewed in (Ginhoux and Jung 2014)). 
Whether the yolk sac or fetal liver is the source of these precursor cells remains 
controversial, although it appears that tissue specific macrophages and DCs (e.g. microglia, 
Langerhans cells etc.) are derived from different sources (Ginhoux et al. 2010; Hoeffel et al. 
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2012; Schulz et al. 2012). However, further studies are required to confirm self-
replenishment of macrophages in humans. 
 
Although resident tissue macrophages may be partially self-replenishing, monocytes 
migrate into tissue, especially in the context of infection, and differentiate into classically 
(M1) or alternatively (M2) activated macrophages, which have a proinflammatory or anti-
inflammatory phenotype, respectively. It is of note that macrophages show high levels of 
plasticity and the phenotype of M1 and M2 macrophage may switch, or form a hybrid 
phenotype, based on environmental stimuli (reviewed in (Martinez and Gordon 2014)). 
Recent analysis of the transcriptome of human macrophages stimulated in vitro by TLR 
ligands (e.g. LPS) and other stimuli (e.g. oxLDL) has shown that macrophage activation may 
not only be characterised by specific patterns of gene changes induced by a particular 
stimulus, but also by a combination of changes that characterise specific conditions such as 
chronic inflammation or leukocyte activation (Xue et al. 2014). The stimulation of 
macrophages with a combination of 28 different stimuli resulted in 9 separate macrophage 
transcriptional programs characterised by 49 different clusters/modules of gene activation. 
Therefore a spectrum of macrophage activation exists whereby macrophages develop a 
particular phenotype with respect to host and environmental factors as well as in response 
to individual stimuli. As such macrophage ‘activation’ may be a more fitting description of 
macrophage ‘polarisation’ (as reviewed in (Murray et al. 2014)). 
 
Taken together, monocytes are important innate immune cells that play an important role 
in pathogen control and tissue repair. Altered monocyte phenotype and function in HIV 
infection and ageing may influence the responses of not only monocytes, but also those of 
macrophages and DC in tissues. 
1.4.2 Monocyte subsets 
Traditionally, human blood monocytes have been classified based on expression of the LPS 
binding receptor CD14 and Fcγ receptor IIIA (CD16A, herein referred to as CD16) and are 
known as CD14+CD16- (CD14+ ‘classical’) or CD14dimCD16+ (total CD16+) monocytes. CD14+ 
monocytes are hypothesised to be analogous to Gr1+ murine monocytes (CD11c-Ly6C/Ghigh) 
that display an inflammatory phenotype, have a high phagocytic capacity and are the major 
producers of TNF in response to bacterial infection (Belge et al. 2002). Conversely, total 
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CD16+ monocytes display similar properties to Gr1- murine monocytes that have a 
patrolling and repair phenotype (Auffray et al. 2007), but also produce high quantities of 
proinflammatory cytokines in response to viral and bacterial PAMPs (Cros et al. 2010). 
Recently, the total CD16+ subset has been reclassified into 2 subsets, CD14++CD16+ 
‘intermediate’ monocytes and CD14+ CD16++ ‘non-classical’ monocytes (Ziegler-Heitbrock et 
al. 2010). Intermediate monocytes are the major producer of proinflammatory cytokines in 
response to bacterial challenge and have higher surface expression of HLA-DR (major 
histocompatibility complex class two, (Cros et al. 2010)). Although the genesis of different 
monocyte subsets remains unclear, intermediate monocytes are assumed to be functional 
intermediaries of classical monocytes along a maturation pathway leading to non-classical 
monocytes (Weiner et al. 1994; Wong et al. 2011). However, this hypothesis is controversial 
as the intermediate subset has unique properties (Ziegler-Heitbrock and Hofer 2013), 
indicating that further studies are required to identify the genesis of intermediate 
monocytes.  
1.4.3 Soluble markers and products of monocyte activation  
Monocytes recognise pathogen-associated molecular patterns (PAMPs) and danger 
associated molecular patterns (DAMPs) by PRRs resulting in production of proinflammatory 
cytokines, type I IFNs, antimicrobial peptides and/or chemokines (Janeway and Medzhitov 
2002; Kumar et al. 2009). These products control the production of acute-phase proteins, 
endothelial permeability, recruitment of leukocytes to the site of infection as well as 
inflammatory cell death. Whilst the production of these inflammatory components aids the 
re-establishment of immunological homeostasis, chronic inflammation in HIV infection and 
ageing may result in aberrant PRR signalling leading to uncontrolled inflammation that can 
be harmful to the host.  
 
Currently five classes of PRRs have been most widely studied: plasma membrane or 
endolysosomal Toll-like receptors (TLRs, further discussed in section 1.6.1), plasma 
membrane C-type lectin receptors (CLRs, (Cambi and Figdor 2003)), cytoplasmic membrane 
NOD like-receptors (NLRs, (Chen et al. 2009)), pyrin and hemopoietic expression, IFN-
inducibility and nuclear localisation domain-containing protein family (PYHIN) members 
(Schattgen and Fitzgerald 2011) and retinoic acid-inducible gene (RIG)-1-like receptors 
(RLRs, (Loo and Gale Jr 2011)). TLRs are the best characterised class of PRRs and can 
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respond to extracellular or endolysosomal bacterial, viral, mycobacterial and fungal PAMPs. 
Interestingly, TLRs can also sense metal complexes as well as stress related DAMPs and 
modified lipid (Miller et al. 2003; Stewart et al. 2010). In response, monocytes produce 
cytokines, chemokines, ROS and granule enzymes to destroy the pathogen and stimulate an 
appropriate immune response. The major markers of monocyte activation are described 
below. 
1.4.3.1 sCD163 
sCD163, the soluble form of haemoglobin-haptoglobin scavenger receptor CD163, is shed 
from monocytes and macrophages following cellular activation, resulting in increased 
concentrations of sCD163 in circulation ((Davis and Zarev 2005), Table 1.3). CD163 is 
upregulated (Weaver et al. 2007) and shed from monocytes following stimulation of cells 
by TLR ligands such as LPS (Weaver et al. 2006) and following activation by oxidative stress 
(Timmermann and Högger 2005). We and others have shown that sCD163 levels are 
elevated in HIV infection (Burdo et al. 2011a) and in the elderly ((Hearps et al. 2012a), Table 
1.3). 
1.4.3.2 sCD14 
sCD14 is the soluble form of the LPS co-receptor CD14 ((Wright et al. 1990), further 
discussed in section 1.6). CD14 is produced and shed from monocytes following LPS 
stimulation (Bazil and Strominger 1991) and can act on other cells such as endothelial cells 
that have TLR-4 (LPS co-receptor, discussed further in section 1.6) to induce LPS signal 
transduction (Pugin et al. 1993), making it a potent immune activator. sCD14 levels are 
significantly higher in HIV+ individuals (Brenchley et al. 2006b) than HIV- individuals and are 
not normalised following viral suppression with cART ((Méndez-Lagares et al. 2013), Table 
1.3). sCD14 levels are also increased with age in HIV- individuals (Steele et al. 2014). 
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Table 1.3 Soluble markers of monocyte activation in HIV infection and ageing 
  Plasma levels1 
Markers Description Ageing HIV infection 
sCD14 Surface co-receptor for LPS on 
monocytes/macrophage shed following activation 
↑ (Reiner et al. 2013; 
Steele et al. 2014) 
↑  (Brenchley et al. 
2006b; Martin et al. 
2013) 
CXCL-10 IFN-γ-inducible protein and chemoattractant of T 
cells 
↑ (Hearps et al. 2012a; 
Martin et al. 2013) 
↑ (Hearps et al. 2012a; 
Kamat et al. 2012)  
Neopterin Acute phase reactant ↑ (Hearps et al. 2012a; 
Hearps et al. 2012b) 
↑ (Hearps et al. 2012a) 
sCD163 Haemoglobin-haptoglobin receptor shed from 
activated monocytes following stimulation 
↑ (Hearps et al. 2012a; 
Martin et al. 2013) 
↑ (Burdo et al. 2011a; 
Hearps et al. 2012a; 
Martin et al. 2013) 
CXCL-10 – C-X-C motif chemokine 10; IFN – interferon; sCD14 – soluble CD14; sCD163 – soluble CD163 
1
In comparison to young HIV- individuals  
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1.4.3.3 CXCL-10 
C-X-C motif chemokine 10 (CXCL-10), also known as IFN-γ-inducible protein 10 (IP-10), is a 
chemokine produced by macrophages and other cells in response to IFN-γ stimulation that acts as 
a chemoattractant primarily for T cells following binding to the chemokine receptor CXCR3 (Xie et 
al. 2003). In addition to being produced by macrophages, CXCL-10 is also produced by monocytes 
following infection with Leishmania braziliensis (Vargas-Inchaustegui et al. 2010) and HIV 
(Simmons et al. 2013), and is present in higher levels in inflammatory diseases such as 
atherosclerosis (Mach et al. 1999) and rheumatoid arthritis (RA, (Patel et al. 2001)). We have 
previously shown that CXCL-10 levels are elevated in both HIV+ individuals and the elderly and 
that plasma levels are similar in both groups (Hearps et al. 2012a). 
1.4.3.4 Neopterin 
Neopterin is a low molecular weight pteridine that is associated with monocyte activation in 
various inflammatory conditions (reviewed in (Murr et al. 2002)). Similar to CXCL-10, neopterin is 
produced by monocytes/macrophages following IFN-γ stimulation (Huber et al. 1984); however, 
stimulation of monocytes by LPS and/or TNF can also induce neopterin production 
(Schroecksnadel et al. 2010). We have previously shown that neopterin levels are significantly 
higher in plasma from both HIV+ individuals and the elderly (Hearps et al. 2012a).  
 
In summary, markers of monocyte activation are present in higher levels in both HIV+ individuals 
and the elderly. It is of note that as these biomarkers are also produced by other cells types, 
measuring a combination of these markers, or measuring them in conjunction with cellular 
markers of monocyte activation, may provide the best insight into monocyte activation in disease 
states. 
1.4.4 Altered monocyte phenotype and function in HIV infection and ageing 
1.4.4.1 Age-associated changes to monocytes 
Elderly individuals show an expansion of the proportion (Sadeghi et al. 1999) and absolute 
number (Seidler et al. 2010) of total CD16+ monocytes in comparison to younger individuals 
(Table 1.1), although the impact of age on the function of this subset is less clear. We have further 
shown that non-classical and intermediate monocyte subsets are individually expanded in both 
elderly men (Hearps et al. 2012b) and women (Martin et al. 2013), and that expansion of these 
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subsets is accompanied by a decrease in the proportion of classical monocytes. Furthermore, 
phagocytosis is also impaired in monocytes from the elderly (Hearps et al. 2012a). 
 
Monocytes are important in the clearance of pathogens and tissue repair both on and within 
blood vessel walls, involving monocyte adherence to endothelium via expression of adhesion 
receptors whose expression are known to be altered in the elderly. However, the adhesion and 
migratory capabilities of monocytes from the elderly is unclear, as conflicting evidence has 
reported both higher and lower surface expression of key adhesion molecules and integrins. One 
study found that monocytes from the elderly have increased surface expression of adhesion 
molecules CD54 (ICAM-1), CD29 (β1-integrin), as well as the low affinity IgG binding antibody 
receptor CD32 (Fcγ receptor-II) in comparison to monocytes from younger individuals (Stohlawetz 
et al. 1998), suggesting that they have enhanced binding ability to endothelium. However, in this 
study, monocyte adherence and migration through endothelial cells ex vivo did not differ 
between young and older monocytes. The absolute number of total circulating monocytes and 
the percentage of CD50+ (ICAM-3) and CD62L+ monocytes are significantly decreased in the 
elderly in comparison to controls (De Martinis et al. 2004), supporting our observations that the 
surface expression of CD62L on classical monocytes decreases with age (Hearps et al. 2012b). 
Classical monocytes from elderly individuals also show decreased surface expression of the 
attachment/migration molecule CX3CR1 in comparison to the young (Seidler et al. 2010), 
suggesting that the migratory capabilities of these monocytes may be impaired in the elderly. 
Conversely, we found that CD11b levels, an adhesion molecule, are increased with age on CD16 
expressing intermediate and non-classical monocytes (Hearps et al. 2012b). 
 
The effect of ageing on the ability of monocytes to produce proinflammatory cytokines is also ill-
defined with conflicting reports of both increased and decreased production following LPS 
stimulation. Monocytes from the elderly have been shown to have higher basal levels of IL-6 
(Roubenoff et al. 1998) and IL-1β in comparison to young controls, however following LPS 
stimulation IL-1β levels, which are produced by monocytes following LPS stimulation, were 
significantly lower than younger individuals (Sadeghi et al. 1999). Monocytes from elderly 
individuals also show impaired secretion of IL-1β in response to tumour targets which resulted in 
impaired cytolytic activity compared to monocytes from young individuals (McLachlan et al. 1995). 
However, stimulation of monocytes from the elderly with LPS ex vivo in whole blood showed 
higher production of IL-1β, IL-6 and IL-8 compared to young controls but this was not replicated 
when PBMCs from the same donors were incubated with LPS, suggesting that serum factors may 
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influence response to LPS in the elderly (Gabriel et al. 2002). Therefore, conclusively determining 
the ability of monocytes from the elderly to respond to LPS requires further investigation using 
whole blood assays that incorporate serum factors, especially in the context of individual 
monocyte subsets. 
1.4.4.2 Changes to monocytes in HIV infection 
Monocytes are largely resistant to productive infection by HIV; requiring maturation into 
macrophages or mDCs before efficient viral replication can occur (reviewed in (Bergamaschi and 
Pancino 2010)). However, our laboratory has previously shown that total CD16+ monocytes are 
more permissive to HIV infection in vivo compared to CD16- monocytes and that this subset 
contains HIV DNA even in patients with undetectable viral load (Ellery et al. 2007), suggesting that 
this monocyte subset may act as a persistent reservoir during cART. Despite their low level of 
infection with HIV, monocytes from HIV+ individuals show significant phenotypic and functional 
changes possibly due to the inflammatory environment and bystander effects of HIV-derived 
proteins such as Tat (Debaisieux et al. 2015). We and others have recently shown that viremic 
HIV+ individuals have a higher percentage of intermediate and non-classical monocyte subsets 
than HIV- individuals which is associated with a lower proportion of classical monocytes (Hearps 
et al. 2012a); however, proportions are normalised in cART treated individuals. Monocytes also 
show functional changes in HIV infection. CD14+ monocytes from viremic HIV+ individuals have 
impaired phagocytosis and both CD14+ and total CD16+ monocytes (containing both intermediate 
and non-classical subsets) have shorter telomere lengths than monocytes from HIV- controls 
(Hearps et al. 2012a), suggesting that monocytes in HIV+ individuals are undergoing changes 
associated with cellular senescence. These findings are supported by animal studies in simian 
immunodeficiency virus (SIV) infected CD8+ T cell depleted rhesus macaques, that show increased 
recruitment of monocytes from the bone marrow which is associated with increased monocyte 
turnover (Burdo et al. 2010), suggesting that new monocytes are produced to account for 
functionally inept cells. 
 
Thus, healthy ageing and HIV infection show similar increases in monocyte activation, expansion 
of proinflammatory CD16+ monocyte subsets and impaired phagocytosis that may promote age-
related disease. However, monocyte migration may differ between these groups, indicating that 
further studies are required to identify the mechanisms driving changes to monocytes in these 
individuals.  
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1.4.5  Role of monocytes in age-related disease in HIV+ individuals and the 
elderly 
A number of inflammatory diseases are associated with increased markers (i.e. sCD14, sCD163) 
and drivers (i.e. LPS) of monocyte activation, suggesting a critical role for monocyte activation in 
the pathogenesis of these diseases. This evidence is summarised below.  
1.4.5.1 Cardiovascular disease 
Monocytes and macrophages play a major role in atherosclerosis in HIV+ individuals (reviewed in 
(Crowe et al. 2010)) and ageing (further discussed in section 1.9). As discussed above, both HIV 
infection and ageing are associated with an increased proportion of intermediate and non-
classical monocyte subsets which are significant producers of proinflammatory cytokines. 
Epidemiological studies show that the proportion of intermediate monocytes independently 
predicts cardiac events in HIV+ individuals (Rogacev et al. 2012). Cellular changes to monocytes, 
including increased surface expression of tissue factor on intermediate monocytes, are associated 
with increased carotid intima media thickness (cIMT: a surrogate measure of coronary artery 
thickening and atherosclerosis) in HIV+ individuals (Funderburg et al. 2012; Kelesidis et al. 2012). 
Recently, increased soluble levels of monocyte activation markers (sCD163, sCD14 and CCL2) in 
cART treated HIV+ men were associated with atherosclerosis (McKibben et al. 2014), indicating 
that monocyte activation is associated with higher levels of inflammation and atherosclerosis in 
these individuals. Furthermore, sCD14 (Longenecker et al. 2014) and sCD163 (Burdo et al. 2011b) 
levels in cART treated HIV+ individuals correlate with coronary calcium (a measure of 
atherosclerotic plaque) and non-calcified plaques, respectively.  
 
Surprisingly, less is known about the relationship between monocyte activation and CVD in the 
elderly (i.e. >65 yrs.). The percentage of intermediate monocytes is higher in CAD patients than 
controls and the percentage of intermediate monocytes correlates with serum levels of TNF in 
CAD patients with the highest percentage of intermediate monocytes (Schlitt et al. 2004), 
suggesting that these cells may be a major source of TNF and influence atherogenesis. This is 
supported by findings from Calvert and colleagues who found that monocytes from CAD patients 
secreted more IL-6 and MCP-1 at baseline, and more IL-6, MCP-1 and TNF following LPS 
stimulation than age- and sex-matched individuals without CAD (Calvert et al. 2011). Furthermore, 
monocytes from these donors had shorter telomere lengths than controls, which were shown to 
influence cytokine secretion following experimentally induced telomere dysfunction representing 
cellular senescence (Calvert et al. 2011). Plasma neopterin levels independently predict coronary 
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events or death in acute coronary syndrome patients (Ray et al. 2007) and are also present in 
higher levels following ischemic stroke (Cojocaru et al. 2007). Plasma levels of sCD163 (Aristoteli 
et al. 2006) and sCD14 (Reiner et al. 2013) are also independently associated with cardiovascular 
disease in patients with CAD, suggesting that monocyte activation is associated with 
atherogenesis. 
1.4.5.2 Neurocognitive decline 
Monocytes are thought to migrate across the blood brain barrier (BBB) into the brain in response 
to chemokines derived from microglia activated by PAMPs/DAMPS (D'Mello et al. 2009). HIV 
infection is associated with increased monocyte migration into the brain and higher levels of 
monocyte activation (indicated by IL-6, sCD14) that are associated with increased dementia 
((Ancuta et al. 2008), reviewed in (Williams et al. 2014)). CD16+ (non-classical and intermediate) 
monocytes preferentially migrate into the brain and have been shown to co-localise with HIV p24 
antigen (Fischer-Smith et al. 2001), suggesting that these subsets are potential reservoirs of HIV in 
the brain. Furthermore, markers of monocyte activation are also higher in HIV+ individuals with 
neurological decline as these authors showed that sCD14 levels in cerebral spinal fluid (CSF) were 
higher in HIV+ individuals and associated with worse disease outcomes, indicating that sCD14 
levels may act as a biomarker for loss of neurocognitive function in these individuals (Fischer-
Smith et al. 2001). Higher CXCL-10 levels are also present in the CSF of HIV+ individuals with HAD 
in comparison to HIV+ individuals without HAD (Mehla et al. 2012), and sCD163 levels in plasma, 
but not CSF, are also higher in HIV+ individuals with minor neurological decline (Burdo et al. 2013). 
In addition to a proinflammatory phenotype, monocytes from HIV/HCV co-infected patients 
express a type I IFN phenotype (consisting of six IFN related genes) which correlates with 
neurological decline (Rempel et al. 2013). 
 
Less is known regarding the role of monocytes in neurological decline in humans who are HIV-. 
However, mouse studies show that monocyte migration into the brain is associated with 
neurological diseases such as Alzheimer’s disease (AD, (Malm et al. 2005)) and meningitis (Djukic 
et al. 2006), possibly in order to replenish microglia or phagocytose β-amyloid containing plaque. 
Monocytes from AD patients show an inflammatory phenotype expressing higher IL-6 levels, and 
an higher percentage of classical monocytes, in comparison to individuals without AD (Saresella et 
al. 2014). CD163 has been reported as a marker of perivascular monocytes/macrophage (Kim et 
al. 2006b) and levels are higher in AD patients than controls (Pey et al. 2014). Interestingly, CD163 
levels accumulate in areas of β-amyloid plaque, suggesting that monocytes migrate to these 
locations to phagocytose plaque. 
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Taken together, monocytes are associated with the pathogenesis of CVD and neurological decline 
and markers of monocyte activation are associated with worse disease outcomes. Due to 
increased monocyte activation in HIV infection and ageing, altered monocyte phenotype and 
function may exacerbate the role of these cells in inflammatory age-related disease. 
1.5 Potential mechanisms of monocyte activation 
Chronic low level endotoxaemia has been hypothesised to be a major cause of immune activation 
in HIV+ individuals; however, a growing body of evidence suggests that reactivation of latent viral 
infections, resulting in IFN production, may also play an important role. Although each of these 
mechanisms may individually contribute to immune activation and inflammation in both HIV+ 
individuals and the elderly, it is most likely that a combination of these and/or other factors result 
in the outcomes observed. 
1.5.1 Microbial translocation and low level endotoxaemia 
Microbial translocation, the passage of bacterial products across the mucosal layer of the gut into 
the bloodstream, has been proposed as a key contributor to the increased levels of bacterial 
products found in the blood of both HIV+ individuals and the elderly. LPS is a structural cell wall 
component of Gram-negative bacteria that is a potent immune activator and is significantly 
increased in the plasma of both cART experienced and naïve HIV+ individuals (Brenchley et al. 
2006b; Rajasuriar et al. 2010) as well as the elderly (Goto et al. 1994; Hearps et al. 2012a). Our 
laboratory has shown that LPS levels are elevated in the elderly to levels similar to young HIV+ 
individuals (Hearps et al. 2012a). Due to the potent inflammatory nature of LPS and other 
bacterial products, it has been suggested that increased microbial products in these individuals 
may promote monocyte activation contributing to heightened immune activation and 
inflammation (Brenchley 2006). The mechanisms leading to increased LPS in both HIV+ and 
elderly individuals are discussed below.  
1.5.1.1 Increased mucosal permeability in HIV infection and ageing 
Due to the propensity of HIV to infect activated CCR5+CD4+ T cells, and the fact that intestinal T 
cells have relatively high expression of CCR5 (Poles et al. 2001), significant infection occurs in the 
gut associated lymphoid tissue (GALT) of the gastrointestinal tract (Schneider et al. 1995; 
Brenchley et al. 2004). Sixty percent of memory CD4+ T cells in the lamina propria of the 
gastrointestinal tract are depleted within the first two weeks of HIV infection resulting in reduced 
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mucosal integrity (Mehandru et al. 2004) and the numbers of these cells are not completely 
restored by cART (Guadalupe et al. 2003). Reduced integrity of the mucosal layer is thought to 
allow bacterial products to translocate across the epithelial cell layer, and enter the blood stream 
via the hepatic portal vein. Indeed, depletion of CD4+ T cells within the GALT and decreased 
mucosal integrity is associated with the presence of bacteria and microbial products (e.g. LPS) in 
the blood and sustained immune activation and inflammation ((Brenchley et al. 2006b), reviewed 
in (Marchetti et al. 2013)). Furthermore, HIV+ individuals with AIDS have increased permeability 
(as measured by 3-O-methyl-D-gluscose absorption), suggesting barrier dysfunction in these 
individuals (Sharpstone et al. 1999). Initiation of cART does reduce plasma levels of bacterial 16S 
ribosomal DNA (rDNA), a marker of bacterial products, in HIV+ individuals, however, 16S rDNA 
levels correlate with both plasma LPS levels and the percentage/proportion of activated 
CD8+CD38+HLA-DR+ T cells in VS HIV+ individuals (Jiang et al. 2009), indicating that bacterial 
products may drive immune activation in these individuals. Furthermore, the level of bacterial 
products in plasma remains high despite virological suppression with cART and patients initiating 
cART at lower CD4 T cell counts (i.e. <200 cells/mL) show high plasma levels of LPS and sCD14 and 
altered bacterial microbiota after 12 months of cART (Merlini et al. 2011). Studies in pigtail 
macaques, an animal model of pathogenic HIV infection, have shown that damage to tight 
junctions between intestinal epithelial cells is associated with increased microbial translocation 
and immune activation (Klatt et al. 2010). Similar findings have been observed in HIV+ individuals 
where proteins associated with tight junctions in the descending colon are lower in VS HIV+ 
individuals (Chung et al. 2014), suggesting impaired integrity of tight junctions in these individuals. 
Furthermore a trend to an inverse relationship between tight junction proteins and sCD14 and 
LPS suggests that HIV induced degradation of tight junctions may drive immune activation (Chung 
et al. 2014). 
 
The elderly also display increased mucosal permeability which is known as ‘leaky gut’. Originally 
identified in alcoholics due to its association with chronic liver disease progression (Keshavarzian 
et al. 1999), a ‘leaky gut’ is believed to allow the translocation of pathogenic components such as 
LPS from the gastrointestinal tract due to the disruption of tight junctions. Plasma from elderly 
individuals contains increased levels of markers of microbial translocation (Goto et al. 1994) and 
elevated LBP levels. However, although the leaky gut phenomenon is thought to occur in the 
elderly, there is little mechanistic evidence conclusively describing the processes involved.  
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Taken together, both HIV+ individuals and the elderly have increased microbial products such LPS 
in the bloodstream thought to be due to enhanced microbial translocation. Despite the 
observation of enhanced plasma LPS levels, the mechanisms of microbial translocation are still ill-
defined, especially in the elderly. However, increased LPS levels may contribute to inflammation 
and immune activation in these individuals. 
1.5.1.2 Chronic low level endotoxaemia in HIV and ageing 
Chronic low level endotoxaemia (plasma levels of LPS approximately 30-100 pg/mL) is distinct 
from severe endotoxaemia (≥300 pg/mL (Opal et al. 1999)) observed in cases of septicaemia in 
which high levels of LPS rapidly enter the bloodstream, resulting in up to 100 fold increase in 
proinflammatory cytokine production (Gårdlund et al. 1995). The low, but significantly elevated 
levels of LPS and microbial products shown by ourselves and others to be associated with ageing 
(40 pg/mL, (Hearps et al. 2012a)) and chronic HIV infection (30-100 pg/mL, (Rajasuriar et al. 2010; 
Hearps et al. 2012a)), are thought to lead to persistent immune activation and a proinflammatory 
cytokine response (Krabbe et al. 2001; Bukh et al. 2011). Furthermore, in HIV+ individuals 
microbial translocation and associated immune activation is not completely restored by cART 
(Cassol et al. 2010). 
 
Although increased microbial translocation may be a significant cause of chronic, low level 
endotoxaemia, HIV+ individuals and the elderly may also have defects in the removal of LPS and 
other microbial products from the blood via the liver. This is particularly evident in individuals 
with liver damage (e.g. HCV co-infection related cirrhosis (Balagopal et al. 2008)), however there 
is limited evidence for this assertion in both HIV infection and ageing alone. One study in HIV-
infected humanised mice showed impaired clearance of LPS following dextran sodium sulphate 
induced bacterial translocation, which was caused by impaired phagocytosis by macrophages 
(Hofer et al. 2010). However, as HIV infected humanised mice are not a generally accepted model 
of HIV infection, further work is required to confirm this in primate models. 
1.5.1.3 Implications of chronic endotoxaemia on inflammation and immune activation 
Chronic endotoxaemia is thought to be an important driver of immune activation and 
inflammation in HIV infection independent of HIV viremia (Brenchley et al. 2006a). Plasma factors 
associated with chronic low level endotoxaemia such as LPS, (Brenchley et al. 2006b; Cassol et al. 
2010; Rajasuriar et al. 2010)), LPS-binding protein (LBP, (Brenchley et al. 2006b)) and sCD14, 
(Sandler et al. 2011)) are all associated with increased monocyte activation and levels are 
elevated in HIV+ individuals in comparison to HIV- controls. Plasma LPS levels positively correlate 
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with sCD14 and TNF levels in HIV+ individuals, supporting the theory that microbial translocation 
may be driving innate immune activation/inflammation (Jiang et al. 2009; Cassol et al. 2010). 
Furthermore, plasma LBP, sCD14 and LPS positively correlate with the percentage of activated 
CD38+HLA-DR+CD8+ T cells in HIV+ individuals, suggesting that microbial products may be a key 
factor driving immune activation and inflammation in HIV+ individuals. Interestingly, serum IL-6 
levels in HIV+ individuals correlate with plasma sCD14, but not HIV RNA, suggesting that 
mechanisms other than HIV replication drive increased IL-6 levels in HIV+ individuals (Shive et al. 
2012). These observations are supported by a key study by Brenchley and colleagues who found 
that SIV+ sooty mangabeys, a natural host of SIV who control infection and do not progress to 
AIDS, do not have chronic endotoxaemia, suggesting that LPS may drive inflammation, immune 
activation and disease pathogenesis in HIV+ individuals (Brenchley et al. 2006b). Subsequent 
studies have shown that treatment of SIV infected macaques with sevelamer, a LPS sequestering 
drug, dramatically reduces plasma levels of sCD14, hs-CRP, d-dimer and IL-1β levels as well as the 
percentage of activated HLA-DR+CD38+CD4+ T cells (Kristoff et al. 2014), further indicating that LPS 
contributes to immune activation and inflammation in these animals. This is of note as LPS, and 
markers of monocyte activation involved with LPS recognition such as sCD14, are also associated 
with age-related non-AIDS comorbidities (previously discussed in section 1.4.5), suggesting that 
chronic endotoxaemia may also promote age-related disease pathogenesis in HIV+ individuals.  
 
Similar to HIV+ individuals, we and others have shown that LPS levels are elevated in the elderly 
(Goto et al. 1994; Hearps et al. 2012a). Furthermore, levels of LBP (Gonzalez-Quintela et al. 2013) 
and sCD14 (Steele et al. 2014) increase with age. Despite these observations, the influence of 
ageing on other biomarkers of monocyte activation associated with endotoxaemia is unclear, and 
the mechanisms driving chronic endotoxaemia in the elderly are ill-defined (see section 1.5.1.1). 
However, recent findings show that age correlates with intestinal fatty acid-binding protein, a 
marker of intestinal cell damage, and sCD14 and LPS (Steele et al. 2014), suggesting physical 
damage to the gastrointestinal tract of older individuals may play a role in endotoxaemia. 
Furthermore, endotoxaemia is associated also associated with age-related disease as patients 
have a higher risk of atherosclerosis (Wiedermann et al. 1999), and older individuals injected with 
a bolus of endotoxin have a hyper-responsive initial response and a prolonged immune response 
than younger individuals (Krabbe et al. 2001), suggesting that endotoxaemia can promote 
immune activation and inflammation. 
 
29 
 
In summary, HIV+ individuals and the elderly have impaired mucosal integrity leading to higher 
levels of markers of microbial translocation and chronic low level endotoxaemia, albeit via 
different mechanisms. Endotoxaemia in these individuals is associated with higher levels of 
monocyte activation such as sCD14 which may contribute to age-related disease pathogenesis. 
Interestingly, these changes are not normalised following cART. Therefore, increased microbial 
translocation and resultant inflammation may contribute to chronic inflammation and age-related 
diseases in both HIV+ individuals and the elderly.  
1.5.2 Latent viral reactivation 
1.5.2.1 Latent HIV infection 
Whilst cART supresses HIV viral replication, most cART treated individuals have HIV viremia 
detectable by high sensitivity viral load assays (≥1 copy per mL) in blood for at least 7 years 
following cART initiation (Palmer et al. 2008). Latent infection is common to many viruses, such as 
herpes simplex one virus and CMV and allows the virus to lie dormant in cellular reservoirs until 
reactivation (see below). HIV resides in a latent state in tissues in VS HIV+ individuals and can 
quickly re-establish a fulminant infection following interruption of cART (El-Sadr et al. 2006), 
possibly due to stimulation by external factors or simply due to the lack of cART to inhibit 
replication. Therefore, although cART effectively suppresses HIV replication and prevents 
progression to AIDS, cART cannot clear viral infection completely. Reservoirs of HIV persist in 
latently infected cells and residual viral replication from these cells may contribute to persistent 
immune activation in cART treated individuals (Chun et al. 1997; Furtado et al. 1999; Chomont et 
al. 2009). Several cell types such as monocytes/macrophages (Crowe et al. 2003), naïve CD4+ T 
cells (Bukrinsky et al. 1991; Finzi et al. 1997; Ostrowski et al. 1999), CD34+ hematopoietic 
progenitor cells (Carter et al. 2010), DCs and brain microglia/macrophage (Persidsky and 
Gendelman 2003) are known to harbour latent reservoirs of HIV in treated individuals. 
Interestingly, latent HIV infection is thought to be harboured across multiple cellular reservoirs as 
cART reduces plasma HIV RNA levels to approximately one copy per mL over three phases during 
a 7 year period (Palmer et al. 2008). These findings suggest that individual latent compartments 
respond to therapy differently (e.g. first phase: CD4+ T cells, second phase: possibly 
monocytes/macrophage third phase: unknown) and that the compartment responsible for the 
final phase of decay are long-lived. Therefore, it is hypothesised that continuous residual viral 
reactivation and replication may contribute to persistent immune activation and inflammation. 
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Monocytes are recognised as sites of latent HIV infection even in cART treated individuals and 
show slower rates of decay than resting and activated CD4+ T cells (Zhu et al. 2002). This is of 
importance due to the migratory role of monocytes throughout the body which may lead to 
dissemination of the virus. Furthermore, due to monocytes ability to form macrophage and DC, 
latent infection in monocytes may be transferred following differentiation, therefore replenishing 
other reservoirs (reviewed in (Coleman and Wu 2009)). Of note, our laboratory has shown that 
total CD16+ monocytes are preferentially infected with HIV (Ellery et al. 2007), which may 
influence monocytes role in latent infection.  
1.5.2.2 Cytomegalovirus 
CMV is arguably the major chronic viral pathogen in humans. CMV infection is widespread and 
increases with age such that in the elderly >90% of people ≥80 years old are seropositive (CMV+) 
in the United States (Staras et al. 2006). Asymptomatic infection is generally maintained by host 
immune responses, although this is associated with significant expansion of CMV specific CD4+ 
and CD8+ T cells accounting for approximately 10-27% of the total CD4+ and CD8+ T cell pool 
(Sylwester et al. 2005; Arora et al. 2010). Therefore accumulation of senescent CD8+CD28-CD57+ T 
cells specific for CMV antigens (Olsson et al. 2001) reduces the ‘immunological space’ available 
for CD4+ T cells specific for other pathogens. Furthermore, the expansion of terminally 
differentiated CMV-specific CD8+ T cells contributes to the reduction of the CD8 clonal repertoire 
(Hadrup et al. 2006) and the inverted CD4+:CD8+ T cell ratio (ratio <1) characteristic of 
immunosenescence in the elderly ((Ferguson et al. 1995), previously described in section 1.2.1.1), 
and is associated with increased two year mortality (Wikby et al. 1998). In a model of short-term 
latency, HCMV infection of monocytes in vitro also elicit higher production of IL-6, TNF, CXCL-10 
and IFN-α (Noriega et al. 2014), suggesting that monocytes latently infected with CMV may 
contribute to inflammation. As observed with HIV infection (Hunt et al. 2011), ageing is also 
associated with a decrease in T cell repertoire due to an expansion of effector T cell subsets 
specific for virus such as CMV (Sylwester et al. 2005; Appay et al. 2011) that may drive 
immunosenescence and subsequent immune activation (Khan et al. 2002). CMV infection is 
thought to be a significant driver of immunosenescence however it is of note that a recent 
longitudinal study showed that increases in serum hs-CRP, IL-6 and TNF levels, indicative of 
inflamm-ageing, over a 10 year follow up in CMV negative individuals were similar to levels in 
CMV+ individuals, suggesting that CMV infection does not solely drive inflamm-ageing in the 
elderly (Bartlett et al. 2012). These findings indicate that CMV infection and inflamm-ageing may 
be parallel, but discrete processes contributing to immunological ageing, but further studies are 
required to delineate the contribution of CMV infection on age-related disease. However, 
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measuring the discrete effect of CMV infection is difficult due to limited methods to detect virus 
both in the latent state and following reactivation.  
 
CMV infection is also a significant burden in HIV+ individuals: approximately 90% of HIV+ 
Individuals attending the Alfred Infectious Diseases Unit are CMV+ (unpublished data). In addition 
to the CMV specific effects on immune activation, HIV co-infection may potentiate these effects. 
Recently, CMV+HIV+ individuals were shown to have a 50% increased risk of non-AIDS 
comorbidities compared to CMV seronegative HIV+ individuals, and that CMV seropositivity is 
associated with increased cardiovascular events (Lichtner et al. 2015), suggesting that CMV co-
infection may in fact potentiate age-related disease pathogenesis in HIV+ individuals.  
 
Taken together, CMV infection is associated with an expansion of CD8+ effector T cells that invert 
the CD4+:CD8+ T cell ratio, therefore, restricting “immunological space” in both HIV infection and 
ageing. Therefore, CMV may drive immunosenescence and subsequent immune activation in both 
HIV+ individuals and the elderly contributing to increased risk of inflammatory age-related 
disease. 
1.5.2.3 Interferon-alpha 
IFN-α is a potent antiviral IFN that has been suggested to drive monocyte activation in HIV+ 
individuals (Rempel et al. 2010; Benlahrech and Patterson 2011). Predominately produced by 
pDCs in humans in response to viral RNA and immune complexes (Siegal et al. 1999), other 
immune cells such as monocytes can also produce minor quantities (Francis and Meltzer 1993). 
IFN-α forms a key host immune response to viral infection (Kadowaki et al. 2000) and is elevated 
in viremic HIV+ individuals in comparison to HIV- controls (Hardy et al. 2013). Furthermore, IFN-α 
levels correlate with activated (CD38+) CD8+ T cells in viremic patients (Hardy et al. 2013). Surface 
IFN-α/β receptor (IFNAR) levels are lower in monocytes from HIV+ individuals in comparison to 
HIV- controls and loss correlates with disease progression markers such as CD4+ T cell levels 
(Hardy et al. 2009). Monocytes from HIV+ individuals are also desensitised to IFN-α stimulation 
(Hardy et al. 2009), possibly in response to chronically elevated IFN levels suggesting that IFN-α 
may be a biomarker of immune activation in HIV+ individuals. Interestingly, despite viral 
suppression over six years of cART, IFN-α levels remain higher than those in HIV- controls (French 
et al. 2009), suggesting that IFN-α may influence immune responses in cART treated individuals. 
In vitro stimulation of monocytes with IFN-α produces a gene expression profile similar to that of 
monocytes from HIV+ individuals as determined by whole genome microarray analysis (Rempel et 
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al. 2010). The influence of IFN-α on inflamm-ageing is less clear as elderly individuals, regardless 
of CMV infection, do not show elevated plasma IFN-α levels (Lee et al. 2012).  
1.6 Monocyte immune sensing, TLRs and pathogens 
1.6.1 Toll-like receptor structure and function in monocytes 
As discussed in section 1.4, monocytes recognise and respond to PAMPs via TLRs. TLRs are named 
after their structural similarities to Toll-receptors in Drosophila, which initiate signalling that 
produces antimicrobial peptides in response to fungal or Gram-positive bacteria (Valanne et al. 
2011). Ten TLRs are expressed in human monocytes, each having specific ligands such as 
lipoprotein (TLR-2), flagellin (TLR-5, (Hayashi et al. 2001)), diacylated lipoproteins (TLR-6, (Nakao 
et al. 2005)) and single stranded negative sense viral RNA such as HIV-1 (TLR-7/8, (Heil et al. 2004; 
Meier et al. 2007), reviewed in (Takeda and Akira 2005)). Whilst human monocytes exhibit low 
expression of TLR-9 (specific for unmethylated –cytosine – phosphate – guanine (CpG) 
oligodeoxynucleotides, (Hornung et al. 2002)), isolated monocytes are unresponsive to 
unmethylated CpG in vitro unless co-cultured with pDCs, suggesting that monocytes require 
signals from pDCs to recognise ligand with TLR-9.  
 
TLRs contain an extracellular N terminal domain consisting of leucine rich repeats and a 
conserved cytoplasmic Toll/IL-1 receptor (TIR) domain that is essential for signal transduction 
(reviewed in (Krishnan et al. 2007)). Whilst TLR-1, 2 and 4 detect extracellular PAMPs/DAMPs; 
TLR3, 7 and 8 detect PAMPs/DAMPs that are present within endolysomes, therefore, exposing 
these receptors to uncoated viral genomic material. Most TLRs recruit myeloid differentiation 
primary response gene 88 (MyD88) to their cytoplasmic TIR domain ((Medzhitov et al. 1998), 
reviewed in (Janssens and Beyaert 2002)) following binding of PAMPs/DAMPs. However, TLR-3 
recruits TIR domain-containing adaptor protein-inducing IFN-β (TRIF) which is essential for MyD88 
independent signalling and the production of type I IFNs (Yamamoto et al. 2003). TLR-4 is the only 
TLR family member that recruits and signals via both the MyD88-dependent and -independent 
pathways ((Kawai et al. 2001), Figure 1.1). 
1.6.2 Toll-like receptor 4 recognition of plasma LPS 
TLR-4 is the best characterised of the TLRs and is primarily known for its ability to recognise and 
respond to LPS (Figure 1.1). Macrophages from TLR-4(-/-) mice are unresponsive to LPS challenge 
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as measured by TNF-α production, supporting the key role of TLR-4 in the recognition and 
response to LPS (Hoshino et al. 1999).  
 
Heterodimers of TLR-4 and MD-2 specifically recognise LPS bound in a complex of LBP and either 
membrane bound CD14 (a glycophosphatidyl inositol (GPI)-linked receptor) or sCD14 that is shed 
from the surface of monocytes and macrophages following activation (Wright et al. 1990; Fenton 
and Golenbock 1998; Meng et al. 2011). Activation of TLR-4 signalling by sCD14 is called trans-
signalling. Due to high surface expression of CD14 on monocytes, trans-signalling is not needed to 
activate monocyte TLR-4 response, however sCD14 is important in the response of non-CD14 
expressing cells such as epithelial cells (Pugin et al. 1993). LPS presented by the LBP/CD14 
complex is specifically recognised by MD-2 bound to TLR-4 (Viriyakosol et al. 2001) and results in 
the formation of a multimer of two LPS/MD-2/TLR-4 complexes that are arranged symmetrically 
(Park et al. 2009). This complex subsequently recruits and triggers signal transduction of either 
the MyD88 dependent or independent pathway ((Shimazu et al. 1999), Figure 1.1). 
1.6.3 TLR-4 signalling in response to LPS 
The MyD88 dependent pathway is the most common signal transduction response to PAMPs by 
the different TLRs (Figure 1.1). This pathway specifically activates mitogen associated protein 
kinase (MAPK) and NF-κB pathways that converge to induce the production of proinflammatory 
cytokines such as IL-1, IL-6 and TNF (depending on the stimulus and TLR). MyD88 is an adaptor 
protein that contains both an N-terminal death domain and a C-terminal Toll/Interleukin-1 
Receptor (TIR) domain (Bonnert et al. 1997). The recruitment of MyD88 to TLR-4 is regulated by 
TIR domain-containing adaptor protein (TIRAP); also known as MyD88 adaptor like (MAL) protein 
that is essential in signal transduction (Fitzgerald et al. 2001). MyD88 deficiency leads to 
unresponsiveness to LPS stimulation in mice (Kawai et al. 1999) and severe pyogenic bacterial 
infection in humans (von Bernuth et al. 2008), highlighting its key role in TLR response to bacterial 
PAMPs. In response to ligand binding, MyD88 in complex with TIRAP/MAL recruits interleukin-1 
receptor (IL-1R) associated kinase 4 (IRAK-4, (Fitzgerald et al. 2001)).   
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Figure 1.1 Human monocytes respond to LPS via MyD88-dependent and -independent TLR-4 
pathways 
TLR-4/MD-2 recognition of LPS in complex with LBP and either soluble or membrane bound CD14 
triggers signal transduction resulting in the production of proinflammatory cytokines (e.g. IL-6 and 
TNF) via the MyD88-dependent signalling pathway or type I IFNs (e.g. IFN-α) via the MyD88-
independent pathway. TLR-4 signal transduction is either upregulated (green dashed line) or 
down-regulated (red solid line) at the receptor, signalling intermediate and post-transcriptional 
level by distinct miRNAs.  
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Following its recruitment to the receptor complex, IRAK-4 is autophosphorylated through 
interactions via its hydrophobic death domain which in turn activates its kinase activity. The 
MyD88-pIRAK-4 helical complex recruits IRAK-1 (Lin et al. 2010), co-localising the kinase domains 
of IRAK-1 and -4 thus triggering the phosphorylation of IRAK-1 (Li et al. 2002). Phosphorylation of 
TNF-associated factor 6 (TRAF-6) results in the phosphorylation of MAPKs, specifically p-38 MAPK 
as well as the NF-κB transcription factor family including NF-κB p65 via the canonical pathway 
(reviewed in (Lawrence 2009)). Phosphorylation of NF-κB p65 results in translocation into the 
nucleus and transcription of proinflammatory cytokines such as IL-1β, IL-6 and TNF as well as anti-
inflammatory cytokines such as IL-10 (de Waal Malefyt et al. 1991). Conversely, phosphorylation 
of p-38 MAPK results in activation of the AP-1 transcription factor which is translocated into the 
nucleus (reviewed in (Chang and Karin 2001)), facilitating cytokine production. 
 
LPS also activates signal transduction in monocytes in a MyD88-independent manner that results 
in the production of antiviral type I IFNs ((Kawai et al. 2001), Figure 1.1). In response to TLR 
ligands such as poly(I:C) (TLR-3 agonist) or LPS, TRIF is recruited to TLR-4 by TRIF-related adaptor 
molecule (TRAM) activating the MyD88-independent pathway (Tanimura et al. 2008). This 
pathway is unique to TLR-3 and TLR-4. These IFN regulatory factors (IRF) -3 and -7 translocate into 
the nucleus where they upregulate the production of IFN-α and IFN-β, however little type I IFN 
are produced via this mechanism in response to LPS in unprimed monocytes (Hayes et al. 1991; 
Richez et al. 2009). 
1.7 TLR-4 regulation: Priming, tolerance and miRNAs 
Due to the potency of the interaction between LPS and TLR-4, and the potential downstream 
roles of TNF and IL-6 in inflammation and disease pathogenesis, TLR signalling is highly regulated 
via feedback loop mechanisms (reviewed in (Kondo et al. 2012)). Regulatory mechanisms exist at 
all levels of signal transduction; however, the full extent of the mechanisms involved in regulation 
has not been fully defined. Recently, microRNAs (miRNAs), small regulatory segments of RNA, 
have also been found to have a profound effect on inflamm-ageing (reviewed in (Olivieri et al. 
2013), discussed below, section 1.7.2) and chronic inflammation in HIV infection (reviewed in 
(Swaminathan et al. 2014)). Therefore, regulation of TLR pathways can result in hyper- (primed) 
or hypo- (tolerised) responsiveness to further challenge and enhance or inhibit signal 
transduction and the production of cytokines and IFNs (see section 1.7).  
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1.7.1 Priming and Tolerance to LPS stimulation 
TLR signalling is influenced by the type and amount of ligand present and the simultaneous 
recognition of ligands by other TLR receptors (Bagchi et al. 2007). These conditions can have a 
hyper-responsive (defined in this thesis as priming) or hypo-responsive (tolerant) effect on signal 
transduction. Priming and tolerance may be caused by either extrinsic (i.e. ligand effects) or 
intrinsic (e.g. intracellular signalling intermediates) factors.  
 
The phenomenon of cellular priming has been documented in various cell types such as pDCs (Dai 
et al. 2004), T cells (Pufnock et al. 2011) and macrophages (Li et al. 2011; Ruiz-Alcaraz et al. 2011) 
and may represent either a defect in normal immune regulation or a protective biological 
mechanism to rapidly produce cytokines or chemokines in response to further challenge with 
ligand. Therefore, the biological implication of altered monocyte signalling by either tolerance, 
synergy or priming is significant. 
 
TLR-4 signalling in murine macrophages is influenced by the type of signalling an agonist triggers 
when recognised by its cognate receptor (i.e. MyD88 independent or dependent); when TLR-4 
expressed on murine macrophages was presented either in vitro or in vivo with MyD88-
dependent TLR agonists followed by a MyD88-independent agonist, a synergistic state ensued 
(Bagchi et al. 2007). Furthermore, pre-incubation of murine macrophages with TLR-2 agonist 
(peptidoglycan associated lipoprotein) before an LPS challenge increased TLR-4 signal 
transduction suggesting that signalling via TLR-2 primes TLR-4 responses. Conversely, when the 
MyD88 dependent agonist LPS was repeatedly added to murine macrophages, macrophages were 
desensitised (tolerised) to further LPS challenge (Bagchi et al. 2007). LPS tolerance is a well 
document phenomena in vivo in disease states such as sepsis in which a response to further LPS 
challenge is reduced in an attempt to limit widespread immune activation, and has been 
documented in the response of monocytes and neutrophils isolated from septic patients (Munoz 
et al. 1991; McCall et al. 1993). However, in contrast to septicaemia, HIV+ individuals and the 
elderly have significantly low, but still elevated levels in comparison to young controls, levels of 
LPS which may have a different effect to that of higher concentrations. This is of note as LPS 
challenge of monocytes that have been pre-stimulated with LPS in vitro is generally associated 
with tolerance. Recently investigators have shown that pre-stimulation of monocytes with 
physiological levels of LPS (0.1-100 pg/mL) for 5 days primes/trains monocytes/macrophages to 
further challenge with LPS resulting in higher IL-6 and TNF production (Ifrim et al. 2014). 
Therefore, the strength and perhaps timing of stimulation influences the development of primed, 
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synergistic or tolerised responses. This suggests that under conditions of chronic low levels of LPS 
in HIV+ individuals and the elderly, monocytes might produce primed responses. 
 
Epigenetic changes to monocytes have recently been suggested to influence macrophage 
priming/training or tolerance. Comparison of unactivated, β-glucan trained (primed) or LPS 
stimulated (tolerised) monocyte-derived macrophages identified significant epigenetic 
differences with each condition, altering cellular function and phenotype (Saeed et al. 2014), 
indicating that activation by either stimuli or differentiation alters monocytes at a genetic level 
predisposing these cells to a particular response. 
 
Collectively, these findings indicate that the response to TLR ligands may be dependent on the 
order, and strength of stimulation of the cell. Significant discrepancies exist between in vitro and 
in vivo findings regarding the addition of different TLR agonists, suggesting that the use of cell 
lines and isolated primary cells may not be truly representative of the in vivo environment. 
Therefore, whole blood models of priming and tolerance may provide the most representative 
environment to accurately investigate the condition present in aged and HIV+ individuals. Finally, 
limited studies show that activation or differentiation elicits epigenetic changes to monocytes 
that predispose different cells types for specific responses. Therefore, identifying these changes 
in HIV infection and ageing is of importance. 
1.7.2 Regulation of LPS signalling by microRNAs 
Previous findings evaluating monocyte response in HIV+ individuals have implicated post-
translational modifications of signal transduction proteins induced by LPS (Tilton et al. 2006). 
Recently, microRNAs (miRNA) have been identified to play a key role in controlling responses to 
LPS. miRNAs are short, 19-25 base pair single-stranded non-coding RNA sequences that are 
usually encoded within introns of plant and animal genes and possess immunoregulatory 
properties ((Lagos-Quintana et al. 2001), reviewed in (Bartel 2004)). It has been predicted that 
approximately 60% of protein coding genes in the human genome are regulated by miRNAs 
(Friedman et al. 2009). The full impact of miRNAs in regulating human gene expression is not well 
defined, however, several miRNAs have been found to play a role in TLR signalling (reviewed in 
(Nahid et al. 2011b)) and are altered with ageing (reviewed in (Chen et al. 2010)) and HIV 
infection (Houzet et al. 2008).  
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miRNAs act by forming a complex with miRNA-bound RNA-induced silencing complex (miRISC) 
which hybridises to the 3’ untranslated region (UTR) of target mRNA, resulting in translational 
repression, deadenylation and finally degradation of the target (reviewed in (Wilczynska and 
Bushell 2015)). Conversely, miRNAs can enhance signal transduction by binding to and stabilising 
their target mRNA and increasing its half-life ((Bala et al. 2011), reviewed in (Fabian et al. 2010)). 
Following transcription of the primary miRNA transcripts (pri-miRNA), processing occurs by the 
Type II endonucleases Drosha and Dicer (Gregory et al. 2004). Firstly, Drosha acts in the nucleus 
by binding to double stranded RNA binding domains and cleaving the pri-miRNA into 60-70 
nucleotide segments. These segments form hairpin structures known as pre-miRNA. Following 
formation, these structures are transported out of the nucleus by exportin 5 and are bound by 
Dicer which further processes pre-miRNA into 19-25 base pair RNA duplexes of miRNA-miRNA* 
(miRNA* being the complimentary strand which is generally degraded). The newly formed miRNA 
can then act on its target like the synthetically derived small molecular weight silencing RNAs 
(siRNA) to repress translation and inhibit signal transduction.  
 
The effects of ageing on miRNA expression have been briefly evaluated through global miRNA 
screening and comparison using PBMCs from young (30 years old) and older (60 years old) 
individuals. Comparison of miRNA expression identified 9 miRNAs that are highly down-regulated 
with age, whilst the majority of the 800 tested were also slightly decreased (Noren Hooten et al. 
2010). Similarly in vitro infection of HeLa cells with the HIV-1 laboratory strain NL4-3 was also 
found to be associated with a generalised down-regulation of many miRNA species (Yeung et al. 
2005). Furthermore, primary monocytes infected ex vivo with the macrophage-tropic laboratory 
strain of HIV, HIV-1 BaL displayed significantly higher expression of anti-HIV miRNAs (miRNA28, -
150, -223 and – 382) that decreased as monocytes differentiated into macrophages. This implies 
that expression of specific miRNAs negatively correlate with cell permissibility to HIV-1 (Wang et 
al. 2009).  
1.7.2.1 miR-146a 
As previously discussed many miRNAs have been linked to TLR-4 signal transduction; the best 
studied of which is miR-146a. miR-146a has been shown to down-regulate TLR-4 signalling 
responses to LPS via interactions with the 3’ UTR of IRAK-1 and TRAF-6 genes (Taganov et al. 2006) 
and therefore play a key role in endotoxin tolerance ((Nahid et al. 2009), Figure 1.1). The 
abundance of miR-146a is regulated following LPS-mediated signal transduction in an NF-κB 
dependent manner (Taganov et al. 2006). TLR-3, -4 and -5 activation are also associated with an 
upregulation of miR-146a (Nahid et al. 2011a). Furthermore miR-146a/b is also upregulated in 
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senescent fibroblasts resulting in decreased IRAK-1 expression and IL-6 and IL-8 production, 
therefore, acting as a feedback mechanism to suppress inflammation (Bhaumik et al. 2009). 
Whilst global miRNA responses within HIV+ individuals has been investigated (Houzet et al. 2008), 
the exact effect of these miRNA on cell function is not known.  
1.7.2.2 miR-155 
miR-155 expression also increases following LPS stimulation and exerts both positive and negative 
effects on immune responses via regulation of NF-κB mediated TNF production (Tili et al. 2007). 
miR-155 may enhance TNF translation by releasing inhibitory proteins binding the 3’UTR of TNF 
mRNA ((Tili et al. 2007), Figure 1.1), however, as this work was conducted using HEK-293 cells 
further studies in primary human cells are required to determine the relevance of this 
observation. Furthermore, overexpression of miR-155 in monocytes from RA patients promotes 
TNF and IL-6 production, indicating miR-155 can promote proinflammatory cytokine production 
(Kurowska-Stolarska et al. 2011). miR-155 expression also been shown to be 2 fold higher in 
human atherosclerotic plaque compared to healthy tissue, suggesting miR-155 may play a role in 
atherosclerosis.  
 
Taken together, TLR signalling may be strictly regulated at the post-transcriptional level by miRNA. 
It is of note that other regulatory proteins also modulate, generally negatively, TLR-4 response to 
LPS (not discussed in this introduction (reviewed in (Kondo et al. 2012))). However, previous 
observations in HIV+ individual and the elderly suggest that miRNA may influence TLR-4 signalling 
in these individuals. 
1.8 Primed TLR-4 responses to LPS in HIV infection and ageing 
1.8.1 Monocyte priming in inflammatory disease 
Monocytes are primed for LPS response in many inflammatory diseases; however, whether 
monocytes are primed in HIV+ individuals and the elderly is unknown. Monocytes from HCV+ 
individuals stimulated with LPS ex vivo secrete more TNF in comparison to monocytes from HCV- 
controls (Dolganiuc et al. 2003). The increased response observed in vitro may be physiologically 
significant since HCV+ individuals have increased TNF concentrations in their blood. Cytokine 
production to viral infection, such as IFN-γ production in response to HCV, may also contribute to 
priming since monocyte tolerance to LPS in vitro was abolished following the addition of IFN-γ 
(Dolganiuc et al. 2007). IFN-α stimulation of mDCs in vitro upregulated TNF-α production in 
response to LPS by up-regulating TLR-4 expression in a model of atherosclerosis (Niessner et al. 
40 
 
2007). This has also been shown in vitro in primary monocytes primed with IFN-γ for 40 hours 
(Hayes and Zoon 1993). Primed monocyte and mDC TLR-4 responses have also been reported in 
individuals with RA (Roelofs et al. 2009) as well as TLR-9-stimulated macrophages in 
atherosclerotic plaques (Niessner et al. 2007). Murine studies have also shown that oxLDL, an 
inflammatory lipoprotein implicated in atherosclerotic plaque formation, acts synergistically with 
LPS to increase proinflammatory cytokine production (Wiesner et al. 2010) and foam cell 
formation (lipid-laden macrophage, discussed further in section 1.9.2) in peritoneal macrophages 
from mice in a TLR-4 dependent manner (Howell et al. 2011). THP-1 cells (a human monocytic cell 
line expressing CD14) have a primed response to LPS challenge when co-stimulated with 
attenuated HIV-1 AT-2 ssRNA as measured by proinflammatory cytokine production (Mureith et 
al. 2010). 
 
Despite the observations of primed cellular responses to TLR ligands by monocytes and DCs in a 
number of in vivo and in vitro settings, the mechanism and regulatory factors controlling cellular 
priming have not been conclusively identified. However, many of the observations summarised 
above suggest cross-talk between viral and bacterial ligands may exacerbate inflammation and be 
implicated in disease pathogenesis.  
1.8.2  Primed monocyte response to LPS in HIV infection and ageing 
As chronic stimulation of monocytes in vitro leads to tolerance, we hypothesised that chronic low 
levels of LPS in the elderly and HIV+ individuals may lead to desensitised monocytic TLR-4 
response to further LPS challenge, resulting in a decreased production of proinflammatory 
cytokines. However, in previous work conducted during a Master’s by Coursework minor thesis 
project, it was observed using whole blood phosphorylated flow cytometry (Phosflow) assays that 
increased LPS signalling (as indicated by p-38 MAPK phosphorylation) occurred in monocytes 
from both HIV+ individuals and the elderly as compared to young HIV- controls (Angelovich et. al., 
Master’s Thesis 2010). Although few studies have directly evaluated monocyte responses to LPS 
in HIV+ individuals and the elderly, our observation was consistent with studies that showed that 
PBMC from viremic HIV+ individuals were primed to produce more TNF in response to ex vivo LPS 
challenge than HIV- controls (Lester et al. 2008; Lester et al. 2009). Furthermore, TLR-2 expression 
is elevated on circulating monocytes from HIV-infected patients (Hernandez et al. 2012), 
suggesting that these cells may also be primed in their responses to other bacterial PAMPs.  
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The responsiveness of monocytes from elderly individuals to LPS stimulation has been less well 
studied. Early studies found that monocytes in whole blood from elderly individuals stimulated 
with LPS produced significantly less TNF than that those of younger individuals (Bruunsgaard et al. 
1999a), suggesting that cells from the elderly are tolerised to LPS challenge. Conversely, more 
recent studies have shown that monocytes from older individuals share higher basal levels of 
secreted TNF and MCP-1 than those from younger individuals (Pinke et al. 2013). It is of note that 
these authors also showed that the proinflammatory profile of monocyte response to LPS in vitro 
is influenced by the presence of lymphocytes (Pinke et al. 2013), suggesting future studies should 
use whole blood to accurately determine the effect of stimulation on monocyte function in the 
elderly. One reason for the discrepancy between findings may be that Bruunsgaard et al. used 
levels of LPS (1 µg/mL) approximately 20,000 times physiological concentrations (~20-50 pg/mL), 
suggesting that high levels may have masked subtle effects of altered monocyte response to LPS.  
 
Taken together, these data suggest that monocytes from HIV+ individuals and the elderly may be 
primed to LPS challenge ex vivo possibly due to the presence of other TLR ligands. However 
whether monocyte subsets are differentially primed to LPS challenge, whether primed responses 
persist following viral suppression with cART, and whether primed monocyte responses are 
driven by similar mechanisms in ageing and HIV infection, are unknown.  
1.9 Role of monocyte activation and priming in atherosclerosis 
1.9.1 Atherosclerosis: an overview 
CVD is the major cause of morbidity and mortality in HIV+ individuals and the elderly, of which 
atherosclerosis is a leading cause. Atherosclerosis results in the formation of plaques, cellular and 
lipid aggregates encased by a fibrous cap, in medium and large arteries, which may be degraded 
resulting in rupture, coagulation and thrombosis contributing to myocardial infarction and stroke 
(reviewed in (Insull 2009)). Plaques form from fatty streaks composed of deposited lipid and 
monocytes/macrophage, and are generally associated with a state of hyperlipidaemia 
characterised by high circulating LDL levels that promote fatty streak formation. However, 
components of the inflammatory milieu also contribute to disease pathogenesis (discussed below, 
reviewed in (Angelovich et al. 2015a)). Lipid-laden macrophages, known as foam cells, are 
thought to form from migrated monocytes responding to oxidation of lipoprotein deposited 
within the intima (Swirski et al. 2007; Ley et al. 2011) and are important in disease pathogenesis. 
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1.9.2 Role of monocytes in atherosclerosis 
As macrophage precursors recruited to sites of lipid deposition and inflammation in medium to 
large arteries, monocytes play a major role in atherosclerotic plaque formation (Figure 1.2). 
Circulating lipids accumulate in areas of reduced blood flow around the aortic arch and 
bifurcations and induce endothelial activation, upregulating expression of adhesion molecules (i.e. 
VCAM-1 and P-selectin) and monocyte chemotactic proteins (e.g. CCL-2) that facilitate monocyte 
recruitment (Mestas and Ley 2008). Monocytes are activated by unmodified LDL and modified 
LDL (i.e. oxidised LDL (oxLDL), which may be produced from LDL by activated endothelial cells or 
interactions with free radicals and metal ions. In response to oxLDL, monocytes upregulate 
adhesion molecules and chemokine receptors (i.e. CD11b, CX3CR1) which increase recruitment to 
the endothelium (Weber et al. 1995). In contrast to oxLDL mediated monocyte recruitment, 
under inflammatory conditions proinflammatory cytokines (i.e. IL-6 and TNF, (Clahsen and 
Schaper 2008)) and potentially even pathogen/endothelial interactions (Zeuke et al. 2002) 
independently promote monocyte recruitment to the endothelium.  
 
Following adhesion, monocytes extravasate to the neointima where exposure to macrophage 
colony-stimulating factor (M-CSF/CSF-1) stimulates their differentiation to macrophages with 
increased surface and intracellular expression of scavenger receptor A (SR-A) and BIII (CD36) that 
facilitate ingestion of either acetylated LDL or native/oxidised LDL, HDL and anionic phospholipids, 
respectively ((Kunjathoor et al. 2002), Figure 1.2 A). Other scavenger receptors (e.g. SR-BI and BII) 
as well as TLRs also contribute to lipid uptake.  
 
OxLDL and other lipid species are hydrolysed in lysosomes within macrophages to liberate free 
cholesterol (FC) that is either exported via cholesterol efflux transporters such as ATP-binding 
cassette transporter 1 (ABCA1) and ABCG1 to apolipoprotein acceptors in the vasculature for 
delivery to, and further metabolism in, the liver (Attie et al. 2001) or stored in lipid droplets 
following esterification to cholesterol ester (CE) by Acyl-CoA:cholesterol acyltransferase-1 
(ACAT1). Monocytes and possibly macrophages may also egress from plaque to physically remove 
accumulated lipid (Llodrá et al. 2004). 
 
Cells which fail to egress from the plaque can ingest large quantities of lipid via SR-A and CD36 
(Kunjathoor et al. 2002) and potentially become resident foam cells although CD36(-/-)SR-A(-/-) 
apoE(-/-) mice form foam cells in the absence of these receptors (Moore et al. 2005), indicating 
that pathways independent of scavenger receptors contribute to foam cell formation.   
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Figure 1.2 Lipid and TLR-dependent inflammatory mechanisms of early atherogenesis 
Monocyte recruitment and foam cell formation at sites of deposited lipid (fatty streak, A). Circulating 
monocytes attach to endothelial cells following upregulation of adhesion molecules at sites of 
deposited lipid. Cells transmigrate into the intima where they differentiate into macrophages, up 
regulating scavenger receptors (SR-A/CD36) and LDLR which bind and subsequently internalise oxLDL 
to form foam cells. Metabolised LDL cholesterol is transported to HDL via the cholesterol efflux 
transporters ABCA1 and transported to the liver for excretion. In settings of chronic inflammation, 
monocytes with increased expression of adhesion molecules (i.e. CD11b, CX3CR1) are recruited to 
endothelial cells independent of accumulated lipid potentially due to the influence of circulating 
PAMPs and cytokines (i.e. IL-6, TNF, B). Cells transmigrate into the intima where they differentiate into 
macrophages and signals derived from native and oxLDL receptors and TLRs synergise to form foam 
cells. Cholesterol efflux and cell egress is impaired resulting in excess lipid accumulation which triggers 
necrotic pathways leading to cell death and release of lipid bodies. LDL accumulates in the intima 
triggering traditional monocyte recruitment and atherogenesis described in A.  
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Importantly, the factors governing the tendency of macrophages to remain in the intima and form 
foam cells are incompletely understood, although recent evidence suggests differentiation into 
proinflammatory M1 or anti-inflammatory M2 macrophages may be an important determinant, 
as M2 macrophages are more likely to form foam cells in vitro under inflammatory conditions (Oh 
et al. 2012) . These findings highlight the plasticity of macrophages to alter phenotype in different 
immunological environments. It is of note that M1/M2 macrophages generated in vitro may show 
different immune characteristics to their in vivo counterparts highlighting the requirement of 
further studies to identify the role of M1/M2 macrophages in physiologically relevant models of 
atherosclerosis. 
 
Under conditions where cholesterol influx exceeds cholesterol efflux, lipid droplets accumulate 
and necrotic and apoptotic pathways are ultimately activated in the foam cell resulting in cell 
death and the subsequent release of FC, CE and inflammatory cytokines that act on endothelial 
and immune cells in a positive feedback loop to induce further monocyte migration into the 
intima ((Woollard and Geissmann 2010), Figure 1.2).  
1.9.3 Monocyte subsets in atherogenesis 
As described in section 1.4.2, three subsets of monocytes have been defined in human circulation, 
however, studies of the role of individual monocyte subsets in atherogenesis have mostly been 
conducted using a mouse model of atherosclerosis, the “Western-Type Diet” fed hyperlipidaemic 
apoE deficient (apoE(-/-)) mouse model that readily forms atherosclerotic plaques in response to 
hyperlipidaemia. In apoE(-/-) mice, Gr1+ monocytes (equivalent to classical human monocytes, 
(Ingersoll et al. 2010)) expressing high levels of CCR2 and low levels of CX3CR1 take on an 
inflammatory role and migrate into fatty streaks to form foam cells (Swirski et al. 2007; Woollard 
and Geissmann 2010), while the Gr1- subset expressing high levels of CX3CR1 preferentially 
patrols the endothelium. Similarly, human non-classical monocytes have been demonstrated to 
have a patrolling phenotype when injected into mice, while intermediate and classical subsets 
have an inflammatory role (Cros et al. 2010). Gr-1+ monocytes are expanded in apoE(-/-) mice fed 
a high fat diet, suggesting hyperlipidaemia promotes higher circulating levels of ‘inflammatory’ 
monocytes (Swirski et al. 2007). While the role of individual human monocyte subsets in early 
atherogenesis have not been confirmed due to the lack of appropriate models of foam cell 
formation, cross-sectional studies have shown that numbers of intermediate monocytes 
independently predicted cardiovascular events in individuals undergoing elective coronary 
angiography (Rogacev et al. 2012) and the percentage of CD45RA+ (highly expressed on total 
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CD16+ subsets) monocytes correlates with serum LDL levels (Rothe et al. 1996). Total CD16+ 
monocytes are also associated with increased oxLDL uptake, whilst classical monocytes 
preferentially take up native LDL in patients with familial hypercholesterolemia (Mosig et al. 
2009), suggesting that monocyte subsets have different propensities to form foam cells. 
1.9.4 Influence of inflammation and PAMPs on atherogenesis 
Whilst there is a clear mechanistic link between hyperlipidaemia and atherogenesis, inflammatory 
factors associated with inflamm-ageing and HIV infection can promote foam cell formation and 
potentiate plaque development independent of hyperlipidaemia (reviewed in (Angelovich et al. 
2015a), Figure 1.2). Markers of inflammation including IL-6 (Amar et al. 2006), sTNFR (Elkind et al. 
2002), hs-CRP (Rost et al. 2001; Burke et al. 2002) and factors elevated in viral 
infection/autoimmune disorders including type I IFNs (IFN-α, IFN-β; (Somers et al. 2012)) are 
independently associated with adverse cardiac outcomes in people with atherosclerosis. As such, 
risk estimates such as the Reynolds risk score that incorporate measures of inflammation (plasma 
hs-CRP levels) in addition to traditional risk factors (age, smoking, blood pressure, LDL/HDL ratio), 
have been shown to better predict cardiac outcomes in both men (Ridker et al. 2008) and women 
(Cook et al. 2012) than risk scores such as the Framingham risk score which incorporate 
traditional risk factors alone. 
 
While fatty streaks are mainly composed of lipid deposits and monocytes/macrophages, other 
immune cells accumulate as the plaque matures (Stary et al. 1994). Lipid accumulation activates 
local immune cells (i.e. T cells and DCs) via stimulation of endothelial cells, smooth muscle cells 
and macrophages resulting in IL-1β, IL-6, TNF and IFN-γ production that contribute to localised 
inflammation as well as further monocyte recruitment (Bjorkbacka et al. 2004). Furthermore, 
murine macrophages incubated in vitro with oxLDL (Groeneweg et al. 2006) or FC produced 
following the blocking of macrophage cholesterol efflux (Zhu et al. 2008) have increased 
production of IL-6 and TNF in response to LPS, suggesting plaque resident macrophages exposed 
to lipid may have a primed inflammatory response to stimuli.  
 
Proinflammatory cytokines produced by foam cells within the plaque may also contribute to 
localised inflammation; the inflammatory nature of foam cells is supported by in vitro studies 
showing that human monocyte-derived M2 macrophages, which normally have an anti-
inflammatory phenotype, ingest high levels of oxLDL and produce proinflammatory factors (e.g. 
IL-6, IL-8, MCP-1) following their differentiation into foam cells, thus taking on a more M1-like 
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proinflammatory phenotype (van Tits et al. 2011). In contrast, other studies show that peritoneal 
foam cells produced in LDL receptor (LDLR) knockout mice (ldlr(-/-)) fed a western-type diet 
accumulate desmosterol. This sterol activates liver X receptor (LXR) pathways and suppresses 
TLR-4-dependent activation of NF-κB (Spann et al. 2012) that may dampen the response of these 
cells to inflammatory stimuli in the vessel wall. Further work, especially human studies, are 
required to fully characterise the inflammatory nature of foam cells and whether differences exist 
between foam cells in mature plaques and in fatty streaks.  
 
Although formation of foam cells was previously thought to occur solely via accumulation of 
exogenous modified LDL via scavenger receptors, Funk and colleagues first observed in vitro that 
incubation of RAW 264.7 cells with LPS resulted in foam cell formation in a dose dependent 
manner that was independent of the addition of exogenous LDL (Funk et al. 1993). Interestingly, 
foam cells formed under these conditions contain accumulated triglyceride-containing lipid 
droplets rather than esterified cholesterol, suggesting that these cells may differ biochemically 
from foam cells generated by incubation with modified cholesterol-containing lipoprotein 
particles. Atherosclerotic tissue from patients with CAD have 3-fold increased mRNA expression 
and protein levels of TLR-1/2 and -4 compared to tissue obtained from healthy control arteries in 
the same individuals, with expression in plaques largely restricted to macrophages and 
endothelial cells (Edfeldt et al. 2002), suggesting that plaque may be highly receptive to bacterial 
presence. Furthermore, circulating monocytes from patients with acute CAD also have increased 
surface expression of TLR-2 and -4 (Ashida et al. 2005; Kuwahata et al. 2010), suggesting that 
monocytes from CAD patients may be primed for responses to TLR-2 and -4 specific PAMPs (i.e. 
bacterial lipoprotein, LPS etc.). DNA analyses of resected mature plaques from individuals 
undergoing coronary atherectomy have identified a wide variety of bacteria, suggesting that 
bacterial products may mediate localised inflammation that drives plaque development (Ott et al. 
2006). These bacteria may also act by invading phagocytic cells localised within plaque, as it has 
been possible to culture viable bacteria from such tissue (Kozarov et al. 2005). 
 
Taken together, the above evidence suggests that inflammatory mechanisms acting on 
monocytes/macrophages promote atherosclerosis via proinflammatory foam cell formation 
which may be independent of hyperlipidaemia.  
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1.10 Influence of inflammation on foam cell formation 
Due to increased monocyte activation and PAMPS in HIV+ individuals and the elderly, these 
factors may contribute to monocytes propensity to form foam cells, therefore contributing to 
atherogenesis. However, despite many studies showing that TLR ligands stimulate foam cell 
formation by monocytes/macrophages, the mechanism driving increased lipid accumulation and 
storage for many of these molecules is unknown. TLR signalling may promote foam cell formation 
in three ways; 1) by upregulating lipid uptake, 2) by increasing lipid biosynthesis, and 3) by down-
regulating the processing and export of lipid following ingestion (Figure 1.3). In this section 
evidence supporting the role of TLRs, and PAMPs, in foam cell formation will be summarised. 
1.10.1 Enhanced lipoprotein uptake via LDL receptor 
While foam cells form following the ingestion of modified LDL via scavenger receptors, TLRs 
expressed on monocytes/macrophages also promote foam cell formation following uptake of 
unmodified LDL via the LDLR (Figure 1.3). In vitro incubation of human monocytic THP-1 cells with 
LPS stimulates uptake of unmodified, native LDL via LDLR resulting in cells morphologically similar 
to foam cells (Ye et al. 2009). LDLR transcription is regulated by sterol regulatory element binding 
protein-2 (SREBP-2) which is increased by activation of TLR-4 via MyD88 and IKK-dependent 
pathways (Li et al. 2013) and consequently, LPS enhances LDLR gene and protein expression and 
LDL uptake in THP-1 cells in vitro. LPS stimulation of macrophages in vitro also increases minimally 
modified LDL uptake by macropinocytosis (Choi et al. 2009). Thus, LPS may increase receptor and 
non-receptor-mediated uptake of unmodified LDL and stimulate foam cell formation independent 
of exogenous modified lipoproteins or scavenger receptors.  
1.10.2 Biosynthesis of lipids by macrophages 
TLR signalling promotes de novo lipid biosynthesis in monocytes/macrophages. Monocytes 
synthesize cholesterol in the endoplasmic reticulum, and this biosynthesis is essential to allow 
differentiation to macrophages (Figure 1.3). The rate determining step of cholesterol biosynthesis 
is catalysed by HMG-CoA reductase, the primary target for the statin class of cholesterol-lowering 
drugs. Inflammatory factors such as LPS, TNF and IL-1β induce HMG-CoA reductase gene 
expression in THP-1 macrophages by activating NF-κB and SREBP-2 transcription factors (Li et al. 
2013). Newly synthesised or internalised, unesterified cholesterol either traffics to cholesterol 
efflux receptors for export (discussed in section 1.9.2) or is esterified by ACAT-1 and stored as CE 
in lipid droplets. TNF increases ACAT-1 expression in human monocytes resulting in accumulation 
of CE and foam cell formation (Lei et al. 2009). This ability is not shared by other proinflammatory   
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Figure 1.3 Potential mechanisms of PAMP-induced foam cell formation 
Signal transduction via multiple TLRs (pink section) up regulate foam cell formation by influencing 
cholesterol influx (green), synthesis (yellow) or efflux mechanisms (purple) in 
monocytes/macrophages. TLR signalling enhances uptake of oxLDL by increasing surface 
expression of LDLR, CD36 and SR-A and native LDL by macropinocytosis (green). Free cholesterol, 
liberated from oxLDL, promotes further cholesterol synthesis, esterification to CE for storage in 
lipid droplets or is transported to cholesterol efflux transporters. TNF up regulates HMG-CoA 
reductase and ACAT-1 expression promoting cholesterol accumulation (yellow). TLR signal 
transduction through NF-κB and interferon regulatory factor-3 (IRF-3) down regulates liver X 
receptor (LXR) pathways that regulate cholesterol efflux transporters (ABCA1) impairing 
cholesterol efflux to HDL and apolipoproteins (purple). Modulators of TLR signalling may be 
exploited to impair TLR-mediated foam cell formation by targeting TLR receptors (Chloroquine, 
RS-LPS) or signalling pathways (miR146a). 
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cytokines such as IL-1β, IFN-γ or IL-6, suggesting a unique property of TNF in both promoting 
cholesterol biosynthesis and esterification. Together, these findings show that cross talk between 
TLR signalling pathways and their products skew cholesterol metabolism within 
monocytes/macrophages towards lipid synthesis and foam cell formation. 
1.10.3 Impaired cholesterol efflux 
Monocytes/macrophages export FC to either lipoprotein acceptors (apoA1) or HDL via the 
cholesterol efflux regulatory proteins ABCA1 (Kennedy et al. 2005) and ABCG1 (Wang et al. 2004), 
respectively (Figure 1.3). The transcription of these proteins is upregulated by the LXR pathway 
(Venkateswaran et al. 2000) that, if dysregulated, can promote foam cell accumulation via 
decreased cholesterol efflux (Schuster et al. 2002).  
 
PAMP-mediated TLR signalling impairs cholesterol efflux in mouse macrophages by down-
regulating ABCA1 mRNA expression via NF-κB-dependent mechanisms (Baranova et al. 2002). 
However, it is likely that both MyD88-dependent and -independent mechanisms (Chen et al. 2008) 
through transcription factor IRF-3 (Castrillo et al. 2003) are responsible for ABCA1 down-
regulation in this setting. In contrast, one study using THP-1 cells stimulated with LPS in vitro has 
shown an increase of ABCA1 mRNA expression via the LXR pathway (Kaplan et al. 2002), 
indicating that further studies, especially in human cells, are required to elucidate the impact of 
TLR-mediated pathways on cholesterol efflux. Whether viral PAMPs also result in decreased 
ABCA1 by inhibiting LXR pathways is currently unknown, however, as TLR-7/8 results in increased 
signalling via IRF-3 this is possible. 
 
These in vitro studies are supported by in vivo data which showed that acute endotoxaemia in 
C57BL/6 standard chow-fed mice reduced cholesterol efflux from macrophages and altered 
hepatic gene expression involved in biliary transport of cholesterol (McGillicuddy et al. 2009). In 
this study, it was further shown that LPS stimulation of human MDM decreased cholesterol efflux 
and expression of proteins involved in cholesterol efflux and metabolism including ABCA1. These 
findings are further supported by studies of patients with Tangier’s disease that showed 
decreased ABCA1 expression and cholesterol efflux in macrophages resulting in foam cell 
formation and associated with increased cIMT (van Dam et al. 2002). Interestingly monocytes 
from HIV+ individuals with high viral load have been reported to have increased ABCA1 mRNA 
expression in comparison to HIV- controls and VS HIV+ individuals (Feeney et al. 2013) however 
how this affects the atherogenic properties of such monocytes remains to be determined. As 
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mentioned above, bacterial PAMPs such as LPS may be important in promoting foam cell 
formation since TLR-4 mRNA expression is increased in surgically extracted atherosclerotic plaque 
(Edfeldt et al. 2002) and on circulating monocytes from individuals with acute coronary syndrome 
in comparison to controls (Methe et al. 2005b). A role for TLR-4 in promoting atherosclerosis is 
supported by studies showing polymorphisms that reduce TLR-4 activity are associated with 
decreased cardiovascular risk in humans (Kiechl et al. 2002; Ameziane et al. 2003).  
 
In summary TLR signalling influences foam cell formation by targeting cholesterol influx, 
metabolism and efflux in monocytes/macrophages resulting in accumulation and retention of 
cholesterol within the cell. TLR signalling potentially affects cholesterol trafficking and 
metabolism pathways after monocytes migrate into the subendothelial neointima and 
differentiate into macrophages, however chronic exposure of peripheral monocytes to PAMPs 
may also alter cholesterol efflux pathways and predispose monocytes to form foam cells prior to 
their trans-endothelial migration. Whether monocytes from the elderly are prone to form foam 
cells more readily than those from younger individuals is not known. 
1.10.4 Atherosclerosis is more prevalent in HIV+ individuals and the elderly 
Atherosclerosis is a leading cause of morbidity and mortality in both HIV infection and healthy 
ageing and is the major underlying cause of CVD. Here we will examine the pathogenic 
mechanisms that may contribute to increased risk of atherosclerosis and hence CVD in both 
groups. 
 
CVD is a leading cause of mortality in older individuals, but while older age is associated with 
increased risk factors for atherosclerosis including hyperlipidaemia (Wang and Bennett 2012), age 
itself is a significant independent risk factor for atherosclerosis (Wilson et al. 1998). Ageing is 
associated with increased cIMT, muscular changes in the heart including arterial and aortic 
stiffness contributing to higher blood pressure (Mitchell et al. 2004) and plaque formation ((van 
Popele et al. 2001), reviewed in (Lakatta and Levy 2003)) and, as discussed above, elevated levels 
of plasma markers/mediators of inflammation (IL-6, TNF, hs-CRP and LPS) (Bruunsgaard et al. 
1999b; Bruunsgaard et al. 2000; Cesari et al. 2003) which are associated with atherogenesis. 
Interestingly, a recent longitudinal study has shown that cholesterol levels are less predictive of 
cardiovascular events in people at an older age with high hs-CRP (>2.0 mg/L) than with low hs-
CRP (<2.0 mg/L) (Whelton et al. 2013), suggesting that inflammatory processes may contribute 
more to atherosclerosis in elderly individuals with chronic inflammation than cholesterol levels. 
51 
 
There data support previous findings that the generally strong association of cholesterol levels 
with cardiac events in healthy individuals is attenuated at older age (Kronmal et al. 1993).  
 
While HIV infection and healthy ageing are both associated with increased risk and incidence of 
atherosclerosis, whether the propensity of monocytes to form foam cells (i.e. their atherogenic 
potential) is increased in these individuals has not been defined. Due to the difficulty in obtaining 
atherosclerotic plaque or fatty streak samples from HIV patients or healthy elderly subjects, it is 
extremely difficult to study the early events leading to atherosclerotic plaque formation in 
humans. Our laboratory has recently developed an in vitro model coupling monocyte trans-
endothelial migration to foam cell formation that utilises human monocytes purified from patient 
samples. Using this model (described in Methods section 2.7), we have shown that monocytes 
from HIV+ individuals have an increased propensity to form foam cells following trans-endothelial 
migration and that these cells have decreased ability to reverse migrate out of collagen gels that 
model the neointima (Maisa et al. 2015). In this thesis, this model is used to ask whether, like 
HIV+ individuals, monocytes from elderly individuals have altered foam cell forming and 
migratory properties.  
 
Taken together, atherogenic risk is increased in ageing and HIV infection, suggesting that 
atherogenesis may be driven by inflammatory mechanisms. While the causes of chronic 
inflammation differ, signals elicited by PAMPs are a common feature of both healthy ageing and 
HIV infection. Increased levels of PAMPs such as LPS in HIV+ individuals and the elderly may 
influence monocyte behaviour and atherogenesis in these populations, however further studies 
are required to delineate to contribution of PAMPs to atherosclerosis. 
1.11 Conclusions and hypothesis  
Healthy ageing and HIV infection are both associated with increased risk of developing age-
related conditions such as atherosclerosis. Untreated, viremic HIV infection is associated with a 
unique pathogenesis due to the high rate of HIV infection and destruction of CD4+ T cells. 
However chronic, cART-treated, VS HIV infection (which represents the majority of HIV+ 
individuals in Australia and the developed world) shares many immunological characteristics with 
inflamm-ageing in HIV- individuals. Age-related immune changes in both young HIV+ individuals 
and the elderly contribute to widespread immune activation and inflammation that may alter 
immune responses. Preliminary data suggest that heightened monocyte activation may be a 
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potential mechanism exacerbating immune activation, inflammation and possibly driving age-
related disease progression. However, this mechanism remains to be investigated.  
 
Therefore, the hypothesis underlying this thesis is that chronic low level endotoxaemia is 
associated with inflammation-related immunological changes in both the elderly and HIV+ 
individuals that increase monocyte responsiveness to TLR ligands and further exacerbates chronic 
inflammation that may contribute to age-related disease pathogenesis. 
 
To evaluate potential alterations in monocyte activation and function in elderly and HIV+ 
individuals, this study consists of the following major research aims:  
 
1) To determine if HIV infection potentiates inflamm-ageing induced changes to monocyte 
proportion and soluble markers of activation, and whether these changes are restored in 
virologically suppressed individuals; 
 
2) To determine whether inflamm-ageing alters the response of individual monocyte subsets 
to LPS, and if the mechanism driving these changes are conserved in inflamm-ageing and 
HIV infection;  
 
and, 
 
3)   To determine whether inflamm-aging related changes affect the atherogenic potential of 
monocytes from elderly individuals and their ability to form foam cells in an in vitro model 
of atherosclerosis. 
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2 CHAPTER 2 
2.1 Identification and characterisation of monocyte populations 
Throughout the Results sections of this thesis, monocytes are classified into three subsets based 
on their expression of CD14 and CD16, as per the nomenclature suggested by Ziegler-Heitbrock et 
al. (Ziegler-Heitbrock et al. 2010); Classical (CD14++CD16-), Intermediate (CD14++CD16+) and Non-
classical (CD14+CD16++). For all flow cytometric phenotyping, monocytes were first gated based 
on FSC and SSC (Figure 4.1 A). From this population monocyte subsets were defined based on 
their expression of CD14 and CD16 as shown in Figure 4.1 B. This gating structure was used for all 
monocyte phenotyping, unless otherwise specified. 
2.2 Cell isolation and culture 
 Peripheral blood mononuclear cell (PBMC) isolation 2.2.1
PBMC were isolated from 20 mL human blood collected in EDTA anticoagulant (BD Vacutainers) 
by density gradient centrifugation. Whole blood was centrifuged for 10 minutes at room 
temperature at 990 × g in a Beckman Coulter GS-6R, and plasma was collected and stored at -
140°C. Cells were resuspended with an equal volume of room temperature calcium and 
magnesium deficient 1 × Dulbecco’s phosphate buffered saline (DPBS-, GIBCO) and gently layered 
over 10 mL of Ficoll-Paque PLUS (GE Healthcare) and centrifuged at room temperature for 20 
minutes at 900 × g with no brake applied during the deceleration. Following centrifugation, 
PBMC were carefully transferred from the interface to a new 50 mL Falcon tube (BD Biosciences) 
and washed twice with 50 mL DPBS- via centrifugation for 10 minutes at 440 × g and 180 × g, 
respectively. Cells were suspended in 20 mL of room temperature DPBS- and counted using a 
haemocytomer to determine cell number and viability (using a 1:2 dilution with trypan blue) 
before being washed with 20 mL DPBS- and centrifuged for a further 10 minutes at 440 × g. 
Resultant cells were either used immediately or resuspended in newborn calf serum (CCS) 
containing 10% dimethyl sulfoxide (DMSO) and stored at a density of 1.0 × 107 cells per mL in 1.5 
mL cyro vials in liquid nitrogen at -190°C. 
 Total monocyte isolation by negative selection 2.2.2
Monocytes were isolated from either freshly prepared or frozen PBMCs using the Pan Monocyte 
isolation kit (Miltenyi Biotech) via negative magnetic bead separation as per the manufacturer’s 
recommendations. Briefly, isolated PBMCs were counted and diluted with 30 µL of cold 
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fluorescence-activated cell sorting wash (FACS wash, consisting of 1% CCS, 2 mM EDTA in DPBS-) 
per 107 cells. Ten µL of FcR Blocking reagent followed by 10 µL Biotin-Antibody cocktail was added 
and cells were incubated on ice for 10 minutes. Following incubation a further 30 µL of FACS wash 
was added plus 20 µL of anti-biotin microbeads and cells were incubated for 15 minutes on ice. 
Cells were washed by the addition of 800 µL of FACS wash and centrifuged at 300 × g for 10 
minutes at 4°C and the pellet was resuspended in 500 µL FACS wash. Depending on cell number 
MS (≤107 cells) or LS (>107 cells) columns (Miltenyi Biotech) were washed 3 times with 0.5 or 1 mL 
of FACS wash, respectively, before cells were passed drop-wise through the column. A further 3 
or 6 mL of FACS wash was passed through the column and monocytes were collected from the 
pooled eluate by centrifuging at 300 ×  g for 10 minutes. Cells were counted and used 
immediately. 
 Monocyte subset isolation by FACS sorting. 2.2.3
Due to the large numbers of total monocytes required for FACS sorting of subsets, total 
monocytes were purified by counter-current elutriation from PBMC prepared from buffy packs 
obtained through the Red Cross Blood Bank, Melbourne, Australia, using a Beckman J-6M/E 
centrifuge JE-5.0 rotor as previously described (Leeansyah et al. 2007). Cell fractions obtained by 
this method were tested for monocyte purity by flow cytometry, and fractions containing >85% 
monocytes (determined in real time by light scatter analysis using a FACS Calibur flow cytometer) 
were combined, and all cells were stained with CD14 and CD16 antibodies for 30 minutes on ice. 
Following cell surface labelling, cells were washed once with RF-10 media (Roswell Park Memorial 
Institute (RPMI) media supplemented with 2 mM glutamine, 100 units/mL penicillin G, 100 µg/mL 
streptomycin sulphate and 10% pooled human serum (pHS) prepared from serum sourced from 
the Red Cross Blood Bank, Melbourne, Australia (n=18 individual donors, median age [range]: 37 
[28-51], heat inactivated 56°C for 30 minutes), resuspended at 10 × 106 cells per mL, then 
classical, intermediate and non-classical monocytes were purified using a FACS Aria or Influx cell 
sorter (BD Biosciences) based on their CD14 and CD16 expression (see Figure 5.2 B). FACS was 
performed by staff at the AMREP Core Flow Cytometry facility. The purity of each monocyte 
subset population was determined by flow cytometry and the yield and viability determined by 
trypan blue cell counting, before cells were resuspended in appropriate media for downstream 
applications. 
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2.3 Flow Cytometry 
 Monocyte surface phenotyping 2.3.1
One hundred µL aliquots of human blood collected in the presence of EDTA anticoagulant (BD 
Vacutainers, BD Biosciences) were added to 5 mL polypropylene tubes (BD Biosciences) within 2 
hours of collection, and washed once with 2 mL cold FACS wash. Following centrifugation, 
supernatant was aspirated and 2 mL of 1× cell lysis buffer (BD Biosciences) was added to lyse red 
blood cells and the cells incubated on ice for 10 minutes to lyse red blood cells. Tubes were 
centrifuged (5 min, 4°C, 300 × g) and supernatant aspirated before cells were washed twice with 
cold FACS wash. Appropriate volumes of pre-titrated antibodies were added (Table 2.1) and cells 
were incubated on ice in the dark for 30 minutes. Following incubation, cells were washed once 
with 2mL FACS wash, fixed with a final concentration of 1% formaldehyde and stored at 4°C until 
analysis. FlowJo analysis software (TreeStar, Inc) was used for all flow cytometry analysis. 
 Whole blood monocyte intracellular cytokine staining 2.3.2
One hundred µL aliquots of human blood collected in the presence of heparin anticoagulant (BD 
Vacutainers, BD Biosciences) were added to 5 mL polypropylene round bottom tubes containing 
100 µL of RF10 media with 3 µg/mL Brefeldin A (eBiosciences) and 1 µg/mL monensin (GolgiStop; 
BD Biosciences) and were stored on ice until required. Cells were either stimulated with a final 
concentration of 10 ng/mL of LPS (E.coli strain O111:B4, Sigma-Aldrich) and incubated at 37°C for 
4 hours or left unstimulated (to determine basal cytokine levels) and processed immediately. 
Stimulation was terminated by the addition of 2 mL of cold FACS wash and tubes were briefly 
vortexed and centrifuged (5 min, 4°C, 300 × g). Surface markers were assessed as above (see 
section 2.3.1). Following cell surface staining, cells were washed once with FACS wash and 
resuspended in 2 mL of 1× cell lysis buffer and incubated on ice for 10 minutes in the dark. Cells 
were washed twice with 2 mL FACS wash and were fixed overnight with a final concentration of 
1% formaldehyde. The following day, cells were washed once with FACS wash and resuspended in 
2 mL 1× Perm/Wash Buffer I (BD Biosciences) and incubated on ice for 10 minutes in the dark. 
Cells were centrifuged and stained with directly conjugated antibodies specific IL-6 and TNF, or 
relevant isotype control antibodies as described above (Table 2.1). Cells were fixed and stored, as 
above, before analysis by flow cytometry using a BD FACSCalibur.  
 Whole blood phosphoprotein signalling specific flow cytometry (PhosFlow) 2.3.3
One hundred µL of whole blood collected into heparin blood collection tubes were stimulated 
with 0 or 10 ng/mL LPS in sterile 5 mL polypropylene FACS tubes for 10 minutes at 37°C. Cells  
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Table 2.1 Antibodies used for flow cytometry 
 
Antibody Manufacturer 
Catalogue 
number 
Clone Volume (µL)2 
Monocyte phenotyping     
    CD14 – PE BD Biosciences 555398 M5E2 7.5 
    CD14 – APC BD Biosciences 555399 M5E2 7.5 
CD16 – FITC  BD Biosciences 555406 3G8 5 
    CD16 – PE.Cy7 BD Biosciences 557744 3G8 5 
Monocyte activation     
TLR-4 – FITC 
1
 R&D Systems FAB6248F 610015 10 
Phospho-specific     
    p38 MAPK – 
Alexa647     
(pT180/pY182) 
BD Biosciences 612595 36/p36(pT180/pY182) 10 
    NF-κB p65 – Alex488   
(S529) 
BD Biosciences 558421 20/NF-κB/p65 10 
Inflammatory cytokines     
IL-6 – FITC  BD Biosciences 554544 MQ2-6A3 5 (1:10 H2O) 
TNF – PE BD Pharmingen 559321 MAb11 2 
Isotype controls     
Mouse IgG1 – FITC  BD Pharmingen 555909 MOPC-21  
Mouse IgG1 – PE BD Pharmingen 554680 MOPC-21  
Mouse IgG1 – APC BD Pharmingen 555751 MOPC-21  
Mouse IgG1 – A488 BD Pharmingen 557702 MOPC-21  
Mouse IgG1 – A647 BD Pharmingen 557714 MOPC-21  
Mouse IgG2A – FITC
1
 BD Pharmingen 555573 G155-178  
 
1 appropriate target and isotype controls, all other antibodies were mouse IgG1 derived 
2 same volume of target antibody used for respective isotype control 
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were fixed and red blood cells lysed by incubation with 20 volumes pre-warmed 1× lyse/fix buffer 
(BD Biosciences) for 10 minutes at 37°C. Cells were washed twice with 2 mL FACS wash as above. 
Cells were stained with anti-CD14 (Table 2.1) on ice for 30 minutes in the dark to identify 
monocytes. Cells were washed with 2 mL FACS wash and permeabilised with 2 mL 1× Perm/Wash 
buffer I for 10 minutes on ice. Cells were collected by centrifugation and stained with Alexa Fluor 
488 conjugated NF-κB p65 (pS529) and Alexa Fluor 647 p-38 MAPK (pT180/Y182) or appropriate 
isotype controls (Table 2.1) for 30 minutes on ice in the dark. Following intracellular staining, cells 
were washed with 1× Perm/Wash buffer 1 and fixed in a final concentration of 1% formaldehyde 
overnight at 4°C until analysed using a BD FACSCalibur. 
2.4 Analysis of gene expression in monocytes by qPCR 
 Monocyte stimulation and cDNA preparation 2.4.1
PBMC (8.0 - 10.0 x 106 cells stored at -190°C) were thawed and monocytes isolated by negative 
selection as previously described (see section 2.2.2). Purified monocytes (1.0 – 3.0 x 106 cells) 
were either stimulated with 10 ng/mL LPS or cultured unstimulated for 4 hours in RPMI 
supplemented as above and containing 20% pHS, and total RNA containing both small and large 
RNA fragments was isolated using a miRNA isolation kit (mirVana, Life Technologies). Potential 
genomic DNA contamination was removed via treatment with 5 U of DNase I (37°C for 20 minutes, 
75°C for 10 minutes, Roche). cDNA synthesis was performed using a combination (1:2) of oligo(dT) 
and random hexamer primers, respectively as per kit instructions (Transcriptor First Strand cDNA 
synthesis kit, Roche) and samples were stored at -80°C until used for quantitative PCR (qPCR) 
analysis.  
 qPCR 2.4.2
qPCR analysis was performed using FastStart Universal SYBR Green Master Mix (Roche) for 
amplification of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), TNF, ABCA1 and ACAT-1 
mRNA and Brilliant SYBR II Master Mix (Agilent Technologies) for IL-6, ABCG1 and HMG-CoA 
reductase on a MX3005P qPCR machine (Agilent Technologies). PCR conditions were 95°C for 10 
minutes and 40 cycles of 95°C for 15 seconds, 60°C for 1 minute with 280 nM of each primer and 
2µL of cDNA (1:4 diluted in qPCR grade water) in a 20 µL reaction volume. A melt curve was 
generated of amplified PCR products and evaluated to identify potential primer dimers (as 
indicated by a lower melting temperature); samples containing evidence of primer dimers were 
excluded from the analysis. Absolute values were quantified using standards consisting of pGEM-
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easy T plasmids of known copy number containing the PCR amplicon of interest, generously 
provided by Dr Anna Hearps. Gene expression was standardised to GAPDH and the effect of LPS 
stimulation was quantified by the ratio of LPS stimulated divided by unstimulated where 
appropriate. GAPDH was chosen as the sole house-keeping gene due to its high expression in 
isolated monocytes allowing for reliable quantitation with limited cDNA from donor samples 
(discussed further in section 4.4.5). Limited amounts of sample RNA precluded the measurement 
of multiple house-keeping genes as normalisation controls, which is the preferred protocol for 
PCR analysis. All Ct values were an average of at least two qPCR runs. Primers used for qPCR were: 
TNF: Fwd: 5′ CCC CAG GGA CCT CTC TCT AATC 3′, Rev: 5′ GGT TTG CTA CAA CAT GGG CTA CA 3′, IL-
6: Fwd: 5′ CAA TCT GGA TTC AAT GAG GAG AC 3′, Rev: 5′ CTC TGG CTT GTT CCT CAC TAC TC 3′, 
GAPDH: Fwd: 5’ CCA TGG CAC CGT CAA GGC 3′, Rev: 5’ CCA GCA TCG CCC CAC TTG 3’, ABCA1: Fwd: 
5’ GCA CTG AGG AAG ATG CTG AAA 3’, Rev: 5’ AGT TCC TGG AAG GTC TTG TTC AC 3’, ABCG1: Fwd: 
5’ CAG GAA GAT TAG ACA CTG TGG 3’, Rev: 5’ GAA AGG GGA ATG GAG AGA 3’, ACAT-1: Fwd: 5’ 
CAA GGC GCT CTC TCT TAG ATG AAC 3’, Rev: 5’ GAT AAA GAG AAT GAG GAG GGC AAT AA 3’ and 
HMG-CoA reductase: Fwd: 5’ GGG ACC AAC CTA CTA CCT CAG 3’, Rev: 5’ CGA CCT GTT GTG AAT 
CAT GTG ACT T 3’. 
 miRNA analysis of miR-146a and miR-155 expression 2.4.3
cDNA specific for miR-146a, miR-155 or the miRNA housekeeping gene RNU48 was synthesised 
from total RNA using the TaqMan miRNA Reverse transcription kit (Life Technologies). Briefly 7 µL 
of TaqMan miRNA RT master mix was added to 5 µL of neat total RNA (isolated using mirVana 
miRNA isolation kit, see section 2.4.1) and 3 µL of target specific 5 X RT miRNA TaqMan assays 
(containing appropriate primers and probes) and incubated at 16°C for 30 minutes, 42°C for 30 
minutes and 85°C for 5 minutes as per manufacturer’s recommendations. The expression of each 
miRNA was quantified using a MX3005p qPCR machine following the addition of 1.33 µL of 
specific cDNA and 1 µL of respective 20 X TaqMan miRNA assay to 10 µL of 2X TaqMan Universal 
Master mix with no uracil-N-glycosylase and 7.67 µL qPCR grade water (20 µL final volume). Cycle 
conditions were 95°C for 10 minutes and 40 cycles of 95°C for 15 seconds, 60°C for 1 minute. 
Expression of mRNAs in patient samples were standardised to RNU48 by the ΔΔCt method (Livak 
and Schmittgen 2001).  
2.5 Analysis of monocyte cholesterol efflux by flow cytometry 
PBMC (1.0 – 2.0 × 106 cells) from young (n=8) and older (n=8) individuals were incubated for one 
hour with RF-10 media containing BODIPY-cholesterol labelling solution (1.5 µM Bodipy-
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cholesterol (Avanti Polar Lipids), 6 µM cholesterol and 300 µM methyl-β-cyclodextrin (Sigma-
Aldrich)) to load the cells with fluorescently labelled cholesterol. Following cholesterol uptake, 
cells were washed twice with 1× DPBS- and incubated in RF-10 media with or without 30 µM of 
the cholesterol acceptor methyl-β-cyclodextrin for 30 minutes at 37°C to promote cholesterol 
efflux from cells. Cells were washed once with FACS wash and stained for surface CD14, as 
previously described (see Methods section 2.3.1). 
2.6 Soluble markers of monocyte activation 
Stored plasma samples were thawed and clarified by centrifuging for 10 minutes at 300 x g before 
plasma LPS (measured in plasma diluted 1:10 in endotoxin-free water and heat inactivated for 15 
minutes at 80°C; Limulus Amebocyte Lysate assay, Lonza), LBP (1/1000 plasma dilution; Hycult 
Biotech), sCD163 (1/500 dilution, IQ products), neopterin (neat, Brahms), TNF (neat; 
ELISAkits.com), CXCL-10 (neat), and sCD14 (1/400 dilution; both R&D Systems) were quantified 
using commercial kits, as per manufacturer’s instructions. Plasma hs-CRP was measured using the 
Abbott Architect ci16200 (Abbott laboratories) by the Alfred Pathology Service, the Alfred 
Hospital (Melbourne, Australia). Non-fasting plasma HDL, LDL or total cholesterol was measured 
using the HDL and LDL/very LDL (vLDL) cholesterol assay kit using manufacturer’s specifications 
(Cell Biolabs). 
2.7 In vitro model of early atherogenesis 
An established model of early atherogenesis that measures foam cell formation following trans-
endothelial migration (TEM) of purified monocytes or monocytes present in PBMC preparations 
from individuals recruited into this study was used to determine the atherogenic potential of 
donor monocytes and autologous serum (AS). This model was originally developed by Professor 
William Muller (Northwestern University, Chicago (Muller and Weigl 1992)), and has been further 
refined in our laboratory in collaboration with him (Westhorpe et al. 2009; Westhorpe et al. 2012; 
Maisa et al. 2015).  
 Human umbilical vein endothelial cell (HUVEC) isolation and culture 2.7.1
Human umbilical cords from vaginal or caesarean births were obtained on the day of birth (Alfred 
Ethics Approval #03/34, RMIT Ethics Approval ASEHAPP 17-15, see Ethics section) from the Royal 
Women’s Hospital, Melbourne. Cords were washed by immersing in cold PD buffer (1 × DPBS- 
containing 1% glucose). The lumen of the vein was washed by rinsing twice with 35 mL PD buffer 
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by means of a syringe connected to the vein using a sterile luer-lock stopcock (Cole Palmer 
Instruments). Fifteen mL of type II collagenase (Worthington) diluted to 10 mg/mL with M199 
media (Invitrogen) supplemented with 2 mM glutamine, 100 units/mL penicillin G and 100 µg/mL 
streptomycin sulphate was infused into the lumen and incubated at 37°C for 12 minutes in order 
to detach HUVEC from the vein wall. Twenty mL of M199 containing 10% FCS was passed into the 
cords, which were then rinsed with 15 mL of M199. All remaining fluid in the cords was collected 
into the receiving syringe, transferred to a 50mL tube and centrifuged for 10 minutes at 300 × g 
to collect the detached HUVEC. Cells were resuspended in 5 mL M20 media (M199 containing 
20% pHS) and cultured (37°C, 5% CO2, in a humidified incubator) in 25 cm
2 tissue culture flasks 
(pre-coated with 50 pg/mL fibronectin diluted in DPBS- at room temperature for 10 minutes to 
promote cell attachment) for two hours before media was replaced with 10 mL fresh media to 
remove contaminating red blood cells. HUVEC were grown to confluence (sub-culture 1 (SC-1), 
approximately 4-6 days), detached with trypsin (0.05% trypsin, 0.53 mM EDTA in M199, incubated 
at room temperature for 1-2 minutes) and washed once in 10 mL M199 before being frozen and 
stored (see Methods section 2.2.1) in 5.0 × 105 cells/mL aliquots in liquid N2 at -190°C until 
required. 
 Construction of in vitro model of early atherogenesis. 2.7.2
Previously isolated passage one HUVECs (1.0 × 106 cells) were cultured to confluence in a 10 cm 
diameter Petri dish coated with 50 pg/mL fibronectin (approximately 5 days), before being 
detached with trypsin (as above) and added onto collagen gels in 96 well plates at a 
concentration of 2.0 × 104 cells in 100 µL M20 media per gel (see Methods section 2.7.3). HUVEC 
were cultured on collagen gels for 3 days at 37°C (sufficient time to allow monolayer formation 
(Pawlowski et al. 1988; Muller and Weigl 1992), confirmed by silver nitrate staining; Figure 2.1 D) 
and stimulated as discussed below (see section 2.7.4).  
 Collagen gel preparation 2.7.3
Fifty µL collagen gels consisting of 34.4% type I fibrous collagen (R&D Systems) polymerised in 
3.6mM NaOH, 0.71 × M199 (Sigma-Aldrich), 4.58 mM acetic acid were formed in 96 well plates 
(Sigma-Aldrich). Gels were incubated at 37°C for two hours to allow complete polymerisation. 
Following polymerisation, gels were overlayed with 150 µL of 1 × M199 and incubated for 5 days 
until use.  
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 TEM and foam cell formation 2.7.4
HUVEC monolayers were activated with either TNF or LPS (10 ng/mL for both, four hours, 37°C) 
before being washed twice with M199 to remove residual TNF or LPS. 2.0 × 105 fresh or frozen 
PBMCs (Figure 2.1 A) or 5.0 × 104 freshly isolated monocytes or monocyte subsets (Figure 2.1 B 
and C, respectively) were added to HUVEC monolayers. Following the addition of cells, each well 
was incubated for one hour at 37°C to allow forward migration of monocytes into the gel ((Muller 
and Weigl 1992), Figure 2.1 E). Non-migrated cells were then washed twice with 1 mM EGTA in 1 
× DPBS- and once with M199 and counted using a Countess automatic cell counter (Life 
Technologies) in order to determine the number of forward migrated cells (Figure 2.1 F). The 
percentage of forward migrated cells was determined by: 
 
𝐹𝑜𝑟𝑤𝑎𝑟𝑑 𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 =  𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑎𝑑𝑑𝑒𝑑 −  𝑛𝑜𝑛 𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 
 
𝑁𝑜𝑛 𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 (%) = 100 ×  
𝑁𝑜𝑛 𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝑇𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑎𝑑𝑑𝑒𝑑
 
  
𝐹𝑜𝑟𝑤𝑎𝑟𝑑 𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 (%) = 100 − 𝑁𝑜𝑛 𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠 (%) 
 
Cells retained in the gel were incubated for 48 hours in M20 containing 20% AS (i.e. derived from 
the same donor as the monocytes or PBMC) or pHS as required to test the potential effect of 
serum factors on monocyte migration and foam cell formation. After 48 hours, gels were washed 
twice with 1 mM EGTA to remove reverse migrated cells and the number of cells recovered was 
determined by counting using a Countess automated cell counter (Figure 2.1 G). 
 
The percentage of reverse migrated cells was determined by: 
 
𝑅𝑒𝑣𝑒𝑟𝑠𝑒 𝑚𝑖𝑔𝑟𝑎𝑡𝑖𝑜𝑛 (%) =  100 ×  
𝑅𝑒𝑣𝑒𝑟𝑠𝑒 𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝐹𝑜𝑟𝑤𝑎𝑟𝑑 𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
 
 
Cells retained in the gel (macrophages/foam cells) were counted using brightfield microscopy (see 
section 2.7.5.1) or flow cytometry (see section 2.7.5.2, Figure 2.1 H and I, respectively).  
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Figure 2.1 An in vitro model of monocyte migration and foam cell formation.  
PBMC (A), total monocytes (B) or FACS-sorted monocyte subsets (C) were added to type I fibrous 
collagen gels formed in 96 well plates and overlayed with a monolayer of primary human 
umbilical vein endothelial cells (HUVEC, D) and allowed to migrate for 1 hour (E). Non-migrated 
cells were counted (F) and the gel was incubated for 48 hours. Following incubation, reverse 
migrated cells were counted (G) and the percentage of foam cells (H) vs. macrophage (I) in the gel 
was determined by either phase contrast microscopy following staining with Oil Red O as shown, 
or flow cytometry. 
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 Quantitation of foam cells and macrophages in a model of early 2.7.5
atherogenesis 
2.7.5.1 Brightfield Microscopy 
2.7.5.1.1 Oil Red O stain 
Following removal of reverse migrated cells, gels were fixed overnight in 100 µL of 2% 
formaldehyde, then were washed twice with 100 µL of methanol (50% for 5 minutes, 78% for 15 
minutes both diluted in distilled water) and stained with 100 µL of 0.2 % w/v Oil-red O (Sigma-
Aldrich) in water (one hour at room temperature). Excess stain was removed by 4 washes with 
100 µL of 78% methanol before cells were counterstained with 100 µL of Giemsa (15 minutes, 
1:10 in distilled water, Sigma-Aldrich). Gels were washed with water before being detached from 
the wells using a 21 gauge needle and mounted on a microscope side. Cells were examined using 
differential interference contrast brightfield microscopy on an Olympus X51 inverted microscope 
(40X objective). The HUVEC monolayer was first brought into focus for three distinct fields of view 
located at the edges of each well and foam cells/macrophages were counted throughout the 
entire depth of the gel at each location at 40× magnification. Cells were scored as either foam 
cells (defined as cells containing >1/3 of their cytoplasm as Oil-red O stained lipid droplets) or 
macrophages (Figure 2.1 H and I, and Appendix Figure 5.1 A and B). Six gels per condition were 
prepared and counted without being blinded to the operator and the percentage of foam 
cells/macrophages was determined.  
2.7.5.1.2 Silver nitrate stain 
The integrity of the HUVEC monolayer was determined by silver nitrate staining as previously 
discussed (Pawlowski et al. 1988). Following TEM, gels were washed once with M199 and four 
times with 5% glucose (diluted in water, 100 µL per wash). Gels were then stained with 100 µL of 
0.5% AgNO3 (ICN Biomedicals) for one second and washed three times with 5% glucose before 
gels were stained with 1% NH4Br (ICN Biomedicals) and 3% CoBr2 (Acros Organics), both for 30 
seconds with three 5% glucose washes after each stain. Finally gels were fixed with 5% 
formaldehyde for 5 minutes before being mounted as previously described (see section 2.7.5.1.1). 
The integrity of the HUVEC monolayer was evaluated using brightfield microscopy on an Olympus 
X51 inverted microscope (20× and 40× objectives). 
2.7.5.2 Analysis of foam cells by flow cytometry 
To allow for phenotypic characterisation of foam cells and macrophages following TEM, after 
removal of reverse migrated cells and two washes with M199, gels were digested for 20 minutes 
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with 1 mg/mL collagenase D (Worthington) in M199 at 37°C before being macerated with a 
pipette tip and digested for a further 20 minutes. Once fully digested, extracted cells were filtered 
through 30 – 50 µm polyester mesh, then washed with FACS wash before being fixed in 1% 
formaldehyde overnight. Standard flow cytometry protocols for either surface or intracellular 
targets were used (described in Methods section 2.3.2). Surface or intracellular anti-CD14-APC 
and anti-TNF-PE antibodies or appropriate isotype controls were used (Table 2.1). Events were 
acquired using a FACSCalibur flow cytometer.  
 Characterisation of TEM and foam cell formation by monocyte subsets  2.7.6
Monocytes were isolated from PBMC prepared from buffy packs (Australian Red Cross, 
Melbourne) by counter-current elutriation. Individual subsets were purified following labelling 
with anti-CD14-APC and anti-CD16-PE.Cy7 antibodies by FACS sorting (see Methods section 2.2.3). 
Cells from each monocyte subset (5.0 x 104 cells per gel) were added to collagen gels as described 
above, and data collected for forward and reverse migration and foam cell formation by 
microscopy as described in section 2.7.5.1. Purity of individual monocyte subsets was > 90% as 
determined by purity checks of the sorted populations (Figure 5.2 C-E). 
2.8 Statistical analysis 
 Basic statistical analysis 2.8.1
Statistical analysis was performed using GraphPad Prism version 6 (GraphPad software, Inc.), 
except for linear regression analysis which was performed using Stata 12 (StataCorp, see section 
2.8.2). Pairwise comparison of groups was determined using non-parametric Wilcoxon signed 
rank test, while non-pairwise comparisons were determined using a Mann-Whitney U test; 
correlation analysis was performed using a Spearman’s rank test.  
 Linear regression modelling 2.8.2
Linear regression analysis was performed to evaluate changes in soluble levels of monocyte 
biomarkers with age (presented in Chapter 3). Individual linear regression models associating 
monocyte biomarkers with age were fitted using either age (years) or specific biomarker 
(respective units) as the outcome and adjusted for sex, smoking status and viremic or VS HIV 
infection. To directly compare the effect of viremic or VS HIV infection on the outcome 
(biomarker or age), a model containing categorical variables for either viremic or VS HIV infection 
was fitted and the differences in coefficients compared to controls using a Student’s t test.  
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As an example, the regression equation was fitted for the data depicted for CXCL-10 expression in 
viremic HIV individuals (Figure 3.2 A): 
 
CXCL-10 (pg/mL) = 1.29[age] + 204[viremic HIV] + 62.2[sex] – 28.1[smoking] – 2.40. 
 
All parameters were tested for differences in slope between sample groups by comparing models 
fitted with or without an interaction term (likelihood ratio test). Where the slope differed 
between groups, the linear equations (viremic and VS) obtained were solved for median 
parameter/age for HIV- individuals, taking into account the interaction term. No interaction term 
is required when there was no significant difference in slopes. Correlation analysis between 
biomarkers of monocyte activation was performed using Spearman correlations. All statistical 
analysis was performed using Stata v.12 (STATA Corp). 
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CHAPTER 3 
HIV infection exacerbates age-related 
inflammatory changes that are 
incompletely resolved by cART 
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3 CHAPTER 3  
3.1 Abstract 
HIV infection elicits significant changes to innate immune function that may contribute to 
increased risk of inflammatory age-related comorbidity. Our laboratory has previously shown in 
several small cross-sectional studies that cellular and soluble markers of monocyte activation are 
significantly elevated in HIV+ individuals and that levels are similar to those present in elderly 
HIV- individuals, implying that HIV infection may accelerate or accentuate age-related disease 
pathogenesis. However, how these markers change with age in either HIV- or HIV+ people is 
unknown. In this chapter data were combined from multiple studies to allow age-dependent 
changes to monocyte proportion, and established soluble markers and drivers of monocyte 
activation, to be quantified using linear regression modelling to determine whether HIV infection 
accentuates or accelerates age-related changes to monocyte activation.  
 
Data on the proportion of individual monocyte subsets and levels of soluble markers (i.e. CXCL-10, 
neopterin, sCD14, sCD163) and drivers (i.e. LPS) of monocyte activation were combined from six 
independent studies from our laboratory. Linear regression models were used to 1) determine 
how these markers change with age in healthy HIV- adults, and 2) identify how viremic and VS HIV 
infection influences the relationship of these parameters with age. All parameters increased with 
age in HIV- adults (p<0.05 for all), except for sCD14 levels and classical monocyte percentage, 
which remained unchanged or decreased (p<0.001), respectively. This established these markers 
as age-related immunological parameters. Plasma levels of CXCL-10, sCD163 and neopterin from 
viremic HIV+ individuals increased with age at a similar rate to those from HIV- individuals; 
however, levels of all parameters were significantly different (p<0.05 for all), indicating that HIV 
infection accentuates age-related changes to these markers. Neopterin levels in viremic HIV+ 
individuals increased with age at a greater rate than HIV- individuals, suggesting that viremic HIV 
infection accelerates age-related changes. CXCL-10, sCD163 and neopterin levels in VS HIV+ 
individuals were lower than those present in viremic HIV+ individuals (p<0.05), but remained 
higher than in HIV- individuals, indicating that HIV-induced changes to these biomarkers were not 
fully restored by cART. Using statistical approaches to compare the chronological age (in years) at 
which HIV+ and HIV- individuals have similar values for each parameter, it was determined that 
viremic HIV+ individuals display levels of monocyte activation similar to HIV- individuals aged up 
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to 12 years older, whilst VS individuals showed levels similar to HIV- individuals up to 4 years 
older. Using multivariable analysis, CXCL-10 levels correlated with values for most of the other 
markers of monocyte activation, and was therefore concluded to be the best independent 
predictor of age-related changes to markers of monocyte activation. 
3.2 Introduction 
Despite cART reducing plasma viremia to clinically undetectable levels in the majority of HIV+ 
individuals, VS HIV+ individuals display increased risk of CVD, frailty and neurological decline 
(discussed in Introduction section 1.1.2.3). Due to the inflammatory aetiology of these conditions, 
we hypothesise that chronic inflammation and immune activation persisting in cART-treated HIV+ 
individuals (characterised by increased plasma levels of LPS (Rajasuriar et al. 2010), D-dimer 
(Levin et al. 2011), hs-CRP (Lau et al. 2006), CXCL-10 and activated T cell phenotypes (Hazenberg 
et al. 2003; Brenchley et al. 2004)) may contribute to the pathogenesis of these diseases 
(discussed in section 1.3). Similarly, healthy ageing is characterised by increased inflammation or 
‘inflamm-ageing’ that is associated with many of these age-related conditions (reviewed in 
(Pawelec et al. 2014), discussed in section 1.2.2). Furthermore, young HIV+ individuals have 
similar levels of inflammatory biomarkers (e.g. IL-6, TNF, hs-CRP) to those present in significantly 
older HIV- individuals (discussed in section 1.2.2). Due to the higher risk of inflammatory age-
related disease, and the strong links between age-related disease and markers of inflammation, it 
has been hypothesised that HIV infection may accelerate or accentuate age-related changes to 
immune function. However, whether HIV infection accelerates age-related disease, or whether it 
accentuates diseases pathogenesis, is unknown (reviewed in (Pathai et al. 2014)).  
 
Monocytes are key innate immune effectors that contribute to local and systemic inflammation 
by producing proinflammatory cytokines (e.g. IL-6, TNF) in response to pathogens. Furthermore 
monocyte activation is associated with the pathogenesis of age-related disease such as 
atherosclerosis (see section 1.4.5). We have previously shown that monocyte subset proportion 
and plasma concentrations of soluble markers (i.e. sCD14, sCD163, CXCL-10, neopterin) and 
drivers (i.e. LPS) of monocyte activation are increased in HIV+ and elderly males compared to 
young HIV- individuals (Hearps et al. 2012a). Furthermore, markers of monocyte/immune 
activation are increased in women in an age-dependent manner and this interaction is 
exacerbated in HIV infection (Martin et al. 2013). In this relatively small cross-sectional study, it 
was estimated by linear regression modelling that for some markers (i.e. total CD16+ monocyte 
proportion), HIV+ women displayed similar levels to HIV- women approximately 11 years older. 
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However the effect of cART was not evaluated. Furthermore, whether common cofounders such 
as smoking influences these relationships was not identified. 
 
In this chapter, age-related changes to markers of monocyte activation were determined by 
modelling changes to biomarkers with age in a large dataset, consisting of both men and women 
with and without HIV infection and cART (n=309). The effect of viremic and VS HIV infection on 
age-related changes of these biomarkers was measured using univariable and multivariable 
analyses. Finally, using complex linear regression modelling adjusting for traditional risk factors 
such as sex and smoking status, the estimated effect of viremic or VS HIV infection was 
determined in years to determine whether HIV infection accelerated or accentuated changes to 
monocyte activation. 
3.3 Results 
 Ageing is associated with an expansion of intermediate and non-classical 3.3.1
monocyte subsets and increased levels of soluble markers of monocyte 
activation 
Data on monocyte subsets and soluble plasma markers (i.e. CXCL-10, neopterin, sCD163, sCD14) 
and drivers (i.e. LPS) of monocyte activation from 169 HIV- (median age [range]: 48 [20-84] yrs., 
67.5% male), 52 viremic HIV+ (viral load (<1000 - >1000000 RNA copies/mL, median age: 40 [19-
63] yrs., 82.7% male) and 88 VS HIV+ (<50 RNA copies/mL, 97.7% receiving cART, median age: 48 
[20-69] yrs., 81.8% male)) were pooled from six independent studies previously conducted in our 
laboratory using standardised protocols for sample preparation and flow cytometric analysis of 
monocyte subsets and phenotype ((Hearps et al. 2012a; Lichtfuss et al. 2012; Martin et al. 2013; 
Westhorpe et al. 2014) and Angelovich et al. (Chapter 4 cohort), Table 3.1). HIV+ individuals were 
recruited from the Infectious Diseases Unit at The Alfred hospital (Melbourne, Australia) and the 
University of Illinois at Chicago Medical Centre and Rush University Medical Center Infectious 
Diseases clinics (Chicago, IL, USA), and healthy control individuals were recruited from the 
community as part of previously described cross-sectional studies. Ethical approval for these 
studies was obtained from the relevant Institutional Review Boards. The age/smoking and 
relevant immunological and virologic characteristics of subjects enrolled in this study are shown 
in Table 3.1. As an initial step, potential operator differences in the measurement of each  
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Table 3.1 Demographic and clinical information of cohort 
  HIV- Viremic HIV+   VS HIV+ 
      P value     P value 
Participants (n) 169 52     88  
Age (years)            
Median (IQR) 48 (36-66) 40 (35-47) <0.001
2
   48 (39-54) NS
2
 
Range 20-84 19-63     20-70  
Sex (% male) 67.5% 82.7% 0.034
3
   81.8% 0.015
3
 
Body Mass Index
1
            
Median (IQR) 24.5 (22.0-27.5) 24.1 (22.5-27.2) NS
2
   25.7 (22.7-29.5) NS
2
 
Range 16.1-42.0 16.0-37.1     16.0-43.9  
Missing data (n) 18 21     19  
Smoking status            
Current 6.5% 46.2% <0.001
3
   37.5% <0.001
3
 
Previous 26.0% 23.0%     30.7%   
Never 67.5% 30.8%     31.8%   
Viral load (copies/mL)     <0.001
4
   All <50 copies/mL   
≤1,000 median age 
(IQR) 
 17.6% (43.0 (39.5-44.0))       
1,001-20,000   25.5% (42.5 (34.8-55.5))        
20,001-100,000   31.4% (38.5 (36.3-44.8))        
>100,000   25.5% (38.0 (29.8-48.3))        
CD4 T cells (cells/µL)
1
             
Median (IQR)   416 (319-527) <0.001
4
   619 (402-846)   
Range   4-1092     129-1433   
Missing data (n)   2     6   
Nadir CD4 (cells/µL)
1
             
Median (IQR)   267 (64-395) NS
4
   203 (80-292)   
Range   1-688     8-593   
Missing data (n)   14     15   
Receiving cART n (%)   10 (19.2%)     86 (97.7%)   
Duration of cART 
(years)
1
 
            
Median (IQR)         4.8 (2.3-18.9)   
Range         0.2-22   
Missing data (n)         10   
 
1
 Participants with missing data are not included in the values listed.  
2
 As compared to HIV- controls by Mann-Whitney test. 
3
 As compared to HIV- controls by Chi-squared test. 
4
 As compared to Virologically Suppressed HIV+ participants by Mann-Whitney test. 
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parameter were tested using a Mann-Whitney U test. If significant differences were detected, the 
values of the parameter measured from that study were excluded from the analysis.  
 
To quantitate the relationship between biomarkers of monocyte activation and healthy ageing, 
linear regression models were fitted to evaluate changes in monocyte proportion (classical, 
intermediate, non-classical and total CD16+) and plasma levels of markers (i.e. CXCL-10, sCD14, 
sCD163, and neopterin) and drivers (i.e. LPS) of monocyte activation with age for HIV- individuals 
(Table 3.2). As viremic and VS HIV+ groups had a higher percentage of men in comparison to 
controls (viremic: 82.7% (p=0.034) and VS: 81.8% (p=0.015) vs HIV- 67.5%, Table 3.1), and HIV+ 
groups had a higher percentage of current smokers in comparison to HIV- individuals (viremic: 
46.2% (p<0.001); VS: 37.5% (p<0.001), vs HIV-: 6.5%, Table 3.1), the effect of sex and smoking on 
these relationships were also examined using linear regression analyses by adjusting for either 
sex or smoking status. Plasma levels of LPS decreased with age in women, whilst LPS levels 
increased with age in HIV- men (Figure 3.1). As the sex difference was too great to be adjusted, a 
combined cohort could not be analysed for changes with LPS and only data for men were 
assessed for LPS.  
 
The percentage of intermediate and non-classical monocytes and the plasma levels of CXCL-10, 
and sCD163 were significantly associated with sex (p≤0.003 for all), indicating that sex influenced 
the relationship of these markers with age (Table 3.2). Therefore, in all subsequent analyses, all 
markers were adjusted for sex as a categorical variable. Similarly, as tobacco use has also been 
associated with changes in immune activation biomarkers (Diamondstone et al. 1994; Fröhlich et 
al. 2003), and was significantly higher in HIV+ groups in our cohort, smoking status (current or 
never/previous) was adjusted for in the analysis. BMI was not significantly different between 
cohorts, and was therefore not adjusted for in these analyses. 
 
HIV- individuals showed an increase in the percentage of intermediate (p<0.001) and non-classical 
monocytes (p=0.035) with age, and a similar trend was observed when these two subsets were 
analysed as a single CD16+ subset (p<0.001, Table 3.2). As expected, increasing levels of CD16 
expressing monocytes with age was accompanied by a corresponding decrease in the proportion 
of classical monocytes (p<0.001, Table 3.2). Analysis of soluble markers also showed significant 
increases in plasma levels of CXCL-10 (p<0.001), sCD163 (p=0.012), LPS (p=0.019) and neopterin 
(p<0.001) with age in HIV- individuals. However, sCD14 levels did not show any change with age 
in HIV- individuals. Taken together, these findings establish the proportion of CD16 expressing  
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Table 3.2 Age-related changes to biomarkers of monocyte activation 
  Effect of Age   Effect of sex 
 Coefficient (95% CI) P value
1
   P value
2
 
Monocytes (%)         
Classical 
(CD14
++
CD16
-
) 
-0.11 (-0.17, -0.05) <0.001   NS 
Intermediate 
(CD14
++
CD16
+
) 
0.06 (0.03, 0.09) <0.001   <0.001 
Non-classical 
(CD14
+
CD16
++
) 
0.05 (0.01, 0.09) 0.035   0.003 
Total CD16
+
 0.12 (0.05, 0.18) <0.001   NS 
Soluble factors         
CXCL-10 (pg/mL) 1.29 (0.67, 1.92) <0.001   <0.001 
sCD14 (ng/mL) 2.18 (-1.18, 5.53) NS   NS 
sCD163 (ng/mL) 4.49 (0.99, 8.00) 0.012   <0.001 
Neopterin (nM) 0.05 (0.01, 0.04) <0.001   NS 
LPS (pg/mL) 0.29 (0.05, 0.54) 0.019   -
3
 
 
1 
P value <0.05 indicates the parameter changes significantly with age (i.e. slope of 
the regression was significantly different to zero). 
2 
P value indicates whether sex significantly contributed to age-related changes. 
3
 – only men were tested for LPS 
NS: not significant 
 
75 
 
  
 
 
 
Figure 3.1 Linear regression analyses of LPS with age in HIV- men and women. 
 
Linear regression analysis for LPS detected by the Limulus Amebocyte Lysate assay was 
performed for HIV- men and women. Lines of best fit shown. 
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monocytes and the levels of several markers/mediators of monocyte activation as age-related 
biomarkers. 
 
 HIV infection exacerbates age-related changes to markers of monocyte 3.3.2
activation which are partially restored by therapy 
Next, the relationship of the above biomarkers with age in viremic and VS HIV+ individuals was 
determined. Categorical variables for viremic and VS HIV+ groups were created allowing HIV-
induced changes to be directly compared to age-related changes in HIV- individuals (Column P vs 
HIV-, Table 3.3). The co-efficient of this comparison represents the difference in biomarker 
(measured in appropriate units for that biomarker) between HIV- and HIV+ (viremic or VS) 
individuals at any given age (i.e. difference between parallel lines, Figure 3.2 A). Therefore, 
significant values indicate that HIV infection alters the value of the y-intercept of the interaction 
and that HIV accentuates age-related changes to biomarkers. All analyses were also tested for an 
interaction term which determined whether biomarkers and HIV infection were associated 
independent of age and therefore that the rate of change was different to HIV- individuals (P 
value slope). The inclusion of an interaction term indicated that HIV infection accelerates age-
related changes, and therefore that the rate of change is different between HIV- and HIV+ 
individuals (diverging lines, Figure 3.2 B). Significant differences between viremic and VS HIV+ 
individuals are denoted in the ‘viremic vs VS’ column. 
3.3.2.1 Monocytes subsets 
Viremic HIV+ individuals had higher proportions of intermediate (p=0.002) and total CD16+ 
(p=0.021) monocytes and decreased proportions of classical monocytes (p=0.015) in comparison 
to HIV- individuals for any given age (Table 3.3). A trend to increased percentage of non-classical 
monocytes (p=0.077) was also observed. Significant differences between viremic and VS HIV+ 
groups were observed for all subsets with the exception of non-classical monocytes (p<0.05 for 
all), suggesting that cART restores age-related changes to levels similar to HIV- individuals. 
 
Interestingly, an interaction between the percentage of non-classical monocytes and HIV status 
was observed, indicating that non-classical monocytes are not altered with age at the same rate 
in viremic HIV+ individuals. To accommodate this, linear equations describing the relationships 
between non-classical monocytes and age for viremic and VS HIV+ individuals were solved for the 
median age of the cohort (46 yrs.). Solving the individual equations for HIV status (i.e. viremic or 
VS) identified that for the median age of the cohort, non-classical monocytes from viremic HIV+  
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Table 3.3 Regression analysis of each parameter with age or parameter as the outcome 
 n P value 
1
 
slope 
Coefficient (95% CI) P vs HIV-
2
 Viremic vs VS
3
 
Monocytes (%)          
Classical (CD14
++
CD16
-
) 264        
HIV+ Viremic     -3.96 (-7.13, -0.79) 0.015 0.013 
HIV+ VS    0.11 (-1.84, 2.05) 0.914   
Intermediate 
(CD14
++
CD16
+
) 264        
HIV+ Viremic     2.68 (1.01, 4.35) 0.002 0.049 
HIV+ VS    0.84 (-0.29, 1.97) 0.143   
Non-classical 
(CD14
+
CD16
++
) 264        
HIV+ Viremic    0.049 2.12 (-0.23, 4.47)
4
 0.077 0.108 
HIV+ VS   0.020 -1.05
 
(-2.13, 0.02)
4
 0.055   
Total CD16
+
 264        
HIV+ Viremic     3.86 (0.60, 7.13) 0.021 0.012 
HIV+ VS    -0.38 (-2.37, 1.61) 0.707   
Soluble factors      
CXCL-10 (pg/mL) 204        
HIV+ Viremic     204 (153, 255) <0.001 <0.001 
HIV+ VS    66.5 (30.5, 103) <0.001   
sCD14 (ng/mL) 246        
HIV+ Viremic     432 (189, 675) 0.001 0.208 
HIV+ VS    602 (421, 783) <0.001   
sCD163 (ng/mL) 246        
HIV+ Viremic     683 (513, 854) <0.001 <0.001 
HIV+ VS    324 (159, 490) <0.001   
Neopterin (nM) 251        
HIV+ Viremic    0.012 11.0 (6.83, 15.1)
4
 <0.001 0.031 
HIV+ VS    2.87 (1.36, 4.37) <0.001   
LPS (pg/mL)
5
 147        
HIV+ Viremic     9.20 (-1.17, 19.6) 0.082 0.524 
HIV+ VS    5.71 (-2.12, 13.5) 0.152   
 
Linear regression analysis of changes in biomarker levels with age due to viremic or virologically 
suppressed HIV infection adjusting for sex and smoking. The coefficient indicates the effect of HIV status 
on biomarker level in addition to the effect of age. 
1 
P value <0.05 indicates the rate of change of the parameter with age (i.e. slope) in HIV+ individuals is 
significantly different to controls. 
2
 P value reports direct effect of HIV status (viremic; V, virologically suppressed; VS) in comparison to HIV- 
controls, indicating the y intercept of the regression curve was significantly different to HIV- individuals. 
3 
P value indicates whether there was a significant difference in the y intercept between V and VS HIV+ 
individuals, as determined by Student’s t test. 
4
 Where the slope was significantly different to HIV- individuals, an interaction term was introduced. The 
resulting equation was solved for the median age of the entire cohort, and the coefficient and p value for 
that value shown.  
5
 Only males were included in analysis 
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Figure 3.2 Linear regression analysis of CXCL-10 and neopterin with age for HIV- and viremic and 
VS HIV+ individuals. 
 
Linear regression analysis for CXCL-10 (A) and neopterin (B) were performed adjusted for sex and 
smoking status for HIV- and viremic and virologically suppressed (VS) HIV+ individuals. Linear 
regression equations for viremic HIV infection were CXCL-10 = 1.29[age] + 204[viremic HIV] + 
62.2[sex] – 28.1[smoking] – 2.40. VS HIV infection were CXCL-10 = 1.29[age] + 66.5[VS HIV] + 
62.2[sex] – 28.1[smoking] – 2.40. 
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individuals increase with age at a greater rate (‘P value of slope’=0.049) than those of HIV- 
individuals, indicating that HIV accelerates age-related changes to the percentage of non-classical 
monocytes.  
 
Taken together, proportions of classical and intermediate monocytes are altered with age at a 
rate similar to HIV- individuals; however, these relationships are accentuated in viremic HIV 
infection. Conversely, non-classical monocytes are expanded with age at a significantly higher 
rate than in HIV- individuals, indicating that HIV infection accelerates the expansion of this subset. 
Interestingly, the proportion of all subsets were similar in HIV- individuals and VS HIV+ individuals 
showing that cART restores HIV-induced changes to monocyte subsets. 
3.3.2.2 Soluble biomarkers of monocyte activation 
In comparison to age-related changes in HIV- individuals, viremic HIV+ individuals showed 
increased plasma levels of CXCL-10 (Figure 3.2 A) and sCD163 with age (P vs HIV- column, p<0.001 
for both, Table 3.3), showing that viremic HIV infection accentuates age-related changes to these 
biomarkers of monocyte activation. These changes persisted in VS HIV+ individuals for CXCL-10 
and sCD163 (p<0.001 for both, Table 3.3); however, the difference was significantly lower than 
that between viremic HIV+ individuals and HIV- individuals (‘viremic vs VS HIV+’, p<0.001 for 
both), indicating that cART does reduce the impact of HIV infection on these biomarkers. 
Neopterin levels were also altered by HIV infection, however comparison of the slopes of the 
regression lines indicated that levels in viremic HIV+ individuals increased with age at a higher 
rate than in HIV- individuals (‘p value slope’=0.012, Table 3.3 and Figure 3.2 B). Neopterin levels 
were also significantly higher in VS HIV+ individuals than HIV- controls however no interaction 
was present, indicating that in cART treated HIV+ individuals, levels are accentuated, but not 
accelerated. 
 
sCD14 levels were increased in viremic HIV+ individuals in comparison to HIV- individuals 
(p<0.001, Table 3.3). However, as sCD14 levels did not increase with age for HIV- individuals, 
higher levels in HIV+ individuals suggests that sCD14 levels are altered in HIV+ individuals by a 
mechanism independent of ageing. These levels were also higher in VS HIV+ individuals, however 
there was no difference in levels between viremic and VS HIV+ individuals (p=0.208), indicating 
that cART did not reduce these levels.  
 
A trend to higher LPS levels in viremic HIV+ men was observed in comparison to HIV- individuals 
(p=0.082, Table 3.3). The relationship between LPS levels was similar for VS HIV+ and HIV- 
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individuals (p=0.152). Interestingly, when the adjustment for smoking status was removed from 
linear regression analyses, plasma LPS levels were elevated in viremic HIV+ (p=0.004) and VS HIV+ 
(p=0.084) individuals in comparison to uninfected controls, indicating that smoking status is an 
important factor in determining LPS levels in plasma. However, it is of note that as a trend to 
increased LPS levels were observed regardless of smoking status, a larger dataset may be 
required before a definitive conclusion can be drawn.  
 
Taken together, all markers of monocyte activation in HIV+ individuals except for sCD14 and 
neopterin were associated with age-related changes similar to those in HIV-individuals; however, 
levels of monocyte activation markers were higher in these individuals, indicating that HIV 
infection accentuates age-related changes. Conversely, neopterin levels increased with age at a 
higher rate than HIV- individuals, indicating that HIV infection accelerates age-related changes to 
neopterin. Although VS HIV+ individuals had monocyte proportions similar to HIV- individuals and 
significantly lower plasma levels of inflammatory markers in comparison to viremic HIV+ 
individuals, levels of soluble markers of monocyte activation remained higher than levels in HIV- 
individuals, indicating that cART does not reduce the effect of HIV infection on age-related 
changes to levels similar of HIV- individuals. 
 CXCL-10 levels correlate best with markers of monocyte activation 3.3.3
As most of the markers measured above were altered with age and HIV infection, we next asked 
whether any given marker may act as a surrogate biomarker of monocyte activation in HIV 
disease. Spearman correlations were performed in order to identify which markers best predicted 
age-related changes to monocyte activation. The percentage of intermediate monocytes 
correlated with CXCL-10 (rho=0.356, p<0.001), neopterin (rho=0.162, p=0.016) and sCD163 
(rho=0.158, p=0.025) levels (Table 3.4), while classical monocytes correlated with CXCL-10 levels 
(rho=-0.273, p<0.001) and non-classical monocytes did not correlate with any soluble marker of 
monocyte activation (Table 3.4). In addition to correlating with the percentage of classical and 
intermediate monocytes, CXCL-10 levels correlated with plasma neopterin (rho=0.547, p<0.001), 
sCD163 (rho=0.409, p<0.001) and LPS (rho=0.198, p=0.036) levels (Table 3.4).  
 
It was concluded that CXCL-10 correlated with all other age-related biomarkers (with the 
exception of non-classical monocyte proportions; sCD14 not being an age-related biomarker). 
Therefore, this biomarker may be used as a surrogate marker of monocyte activation in both HIV 
infection and ageing. 
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Table 3.4 Correlation of soluble and cellular monocyte activation biomarkers1. 
    CXCL-10  Neopterin  sCD163  sCD14  
Soluble markers           
CXCL-10  204 -       
Neopterin  160 0.547
***
 -     
sCD163  160 0.426
 ***
 0.375
 ***
 -   
sCD14  152 0.090 0.221
***
 -0.022 - 
LPS  109 0.198
*
 0.189 0.336
 ***
 -0.085 
Monocyte subsets         
Classical subset (%) 237 -0.273
***
 -0.095 -0.114 0.013 
Intermediate subset (%) 237 0.356
***
 0.162
*
 0.158
*
 -0.001 
Non-classical subset (%) 237 0.132 0.013 -0.095 0.001 
 
1
Determined by Spearman’s correlation; Rho values shown.  
Statistically significant correlations are shown in bold italic. * p value < 0.05, ** p value < 0.01, *** p value  
< 0.001. 
MFI=Mean fluorescence intensity.  
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 Viremic HIV infection is associated with an increase in monocyte 3.3.4
activation markers equivalent to an estimated 8-12 years of ageing, and 
this effect is 2-4 years in individuals with viral suppression 
Conceptually, if the lines describing the relationship of a given biomarker with age in HIV+ and 
HIV- subjects were parallel, it should be possible to determine the age-difference between the 
groups which gives the same level of that biomarker. This could be considered as the degree to 
which HIV infection “ages” the innate immune system. Linear regression modelling was used to 
predict the age difference between HIV- and HIV+ individuals for a given level of a marker of 
monocyte activation. In these analyses the linear regression equations were rearranged so that 
age was the outcome of models and like previous analyses, where biomarker level was the 
outcome, all analyses were adjusted for sex and smoking status. The coefficient obtained 
indicated the estimated age difference between HIV+ and HIV- individual for a given level of 
biomarker. This basic analysis is only valid where slopes are parallel; where HIV accelerates age-
related changes, an interaction term was included to account for the change in slope (previously 
described in Methods section 2.8.2). 
 
Viremic HIV infection was associated with plasma concentrations of markers of monocyte 
activation similar to HIV- individuals 11.6 – 12.9 years older (CXCL-10 (IQR): -12.0 (-18.9, -4.9) yrs., 
sCD163: -11.6 (-17.0, - 6.3) yrs., neopterin: -12.9 (-18.4, -7.4) yrs., Table 3.5). Despite treatment 
with cART, levels of markers of monocyte activation in VS HIV+ individuals were similar to HIV- 
individuals 1.8 – 4.0 years older (CXCL-10: -4.0 (-9.1, 1.1) yrs., sCD163: -2.5 (-6.6, 1.7), neopterin: -
1.8 (-6.1, 2.5), Table 3.5), indicating that HIV induced changes to biomarkers with age are not 
completely normalised by cART. Interestingly, all biomarkers showed similar estimated 
differences in terms of years further supporting the robust nature of the analysis method. As the 
relationship between monocyte populations and age did not differ in VS HIV+ individuals (Table 
3.3), this was not evaluated. 
 
Together, these findings show that VS and viremic HIV infection are associated with increased 
levels of monocyte activation that are similar to those found in HIV- individuals up to 4 or 12 
years older, respectively. Significantly, whilst monocyte activation in VS HIV+ individuals is 
reduced by viral suppression associated with cART, levels of these markers are not restored to 
those of HIV- individuals, indicating that changes to monocyte activation persist in treated HIV+ 
individuals. 
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Table 3.5 Difference in age between HIV+ individuals and controls for any given level of 
monocyte activation marker. 
 n   Estimated difference (Years)
1
 
      HIV+ Viremic HIV+ VS 
CXCL-10 204   -12.0 (-18.9, -4.9)
2
 - 4.0 (-9.1, 1.1)
2
 
sCD163  246   -11.6 (-17.0, -6.3) -2.5 (-6.6, 1.7) 
Neopterin  251   -12.9
 
(-18.4, -7.4)
2
 -1.8
 
(-6.1, 2.5)
2
 
 
1
 As determined by regression analysis, where the value of the coefficient estimates the difference in age 
between HIV+ individuals and controls for any given level of parameter. Median and 95% confidence 
intervals shown. 
2
 Where the slope was significantly different to HIV- individuals, an interaction term was introduced. The 
resulting equation was solved for the median marker level of the entire cohort, and the coefficient for that 
value shown.  
 
84 
 
3.4 Discussion 
In this chapter age-related changes to monocyte subsets and markers of monocyte activation 
were shown to be accentuated, and/or accelerated in some cases, by HIV infection using linear 
regression modelling. Furthermore, these changes were shown to persist in cART treated HIV+ 
individuals, indicating that these changes are incompletely restored by viral suppression. By 
quantifying the effect of HIV infection on age-related changes in year equivalents, viremic HIV+ 
individuals were shown to exhibit levels of monocyte activation similar to those of HIV- 
individuals up to 12 years older, while levels in VS HIV infection were equivalent to HIV- persons 
approximately 4 years older, indicating that cART does not completely normalise changes to 
monocyte activation. Finally CXCL-10 levels were shown to be the most robust, independent 
indicator of age-related changes to markers of monocyte activation in both HIV- and HIV+ 
individuals. To our knowledge this is the first time that the effect of viremic and VS HIV infection 
on age-related changes to monocyte activation have been determined and compared. These 
findings support the hypothesis that HIV infection accentuates age-related changes to monocyte 
activation that may contribute to higher risk of age-related diseases in these individuals. 
 
 Heightened monocyte activation in HIV+ individuals at earlier ages than 3.4.1
HIV- individuals may drive age-related disease 
Levels of CXCL-10, sCD14, neopterin and sCD163 all correlate with adverse inflammatory disease 
outcomes (previously discussed in section 1.4.5). These parameters may also be considered 
markers of monocyte activation, and monocytes are innate immune cells that are associated with 
chronic inflammatory disease pathogenesis. Furthermore, ageing is an independent risk factor for 
all of these diseases. The findings reported in this chapter of increased levels of markers of 
monocyte activation with age indicate that monocytes become more activated with age. 
Furthermore, HIV infection accentuates age-related changes to monocyte activation, possibly 
exacerbating the effect of monocytes in disease pathogenesis. It is of note that whilst cART 
treated HIV+ individuals did show reduced levels of many of these biomarkers, for most of the 
markers measured levels were still above those of HIV- individuals, indicating that cART does not 
effectively normalise levels of these markers most likely due to persistent activation by microbial 
products and potentiation/reactivation of viruses such as CMV following cART (previously 
discussed in section 1.5). Furthermore, recent findings show that treatment with anti-
inflammatory drugs such as rosuvastatin in combination with cART, decreases levels of plasma 
sCD14 and proportions of tissue factor expressing non-classical monocytes in HIV+ individuals 
without diagnosed CVD (Funderburg et al. 2014), suggesting that components of the 
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inflammatory milieu may contribute to monocyte activation. Therefore, correlating levels of these 
potential activators of monocytes with biomarkers of monocyte activation such as CXCL-10 are 
required to identify why these markers remain elevated in HIV+ individuals with effective viral 
suppression. Furthermore, the use of intervention studies may provide insight into the efficacy of 
specific antiretroviral or even anti-inflammatory drugs for the reduction of monocyte activation in 
these individuals.  
 
Epigenetic changes to monocytes/or monocyte precursors in HIV+ individuals may also potentially 
promote an activated state. Analysis of monocytes from VS HIV+ individuals for upregulation of 
genes regulating markers associated with activation such as IL-6 and TNF may provide insight into 
the mechanisms driving monocyte activation in these individuals. 
 
 CXCL-10 is the best marker of monocyte activation in HIV+ individuals and 3.4.2
the elderly 
As previously shown, HIV-induced monocyte activation persists in VS HIV infection, further 
highlighting potential effects of HIV on monocyte activation. Enhanced levels of CXCL-10 
(Kawamura et al. 2003) and sCD163 (Aristoteli et al. 2006) are associated with many chronic 
inflammatory diseases, such as atherosclerosis, suggesting that accentuated changes in HIV 
infection may further promote age-related disease pathogenesis. In this study, plasma 
concentrations of CXCL-10, followed closely by those of neopterin, were the strongest predictors 
of HIV-induced exacerbation of age-related immune changes. Although CXCL-10 correlates with 
other biomarkers of monocyte activation, these interactions were not that strong (i.e. rho=0.15-
0.58), suggesting that whilst these biomarkers are representative of monocyte activation, each 
biomarker may represent different processes in age-related changes to monocyte activation. 
Further studies are warranted using CXCL-10 as a surrogate marker of HIV-induced exacerbation 
of age-related changes to monocyte activation in large cohorts of HIV+ individuals powered to 
investigate their association with risk of age-related disease (i.e. atherosclerosis) which may 
provide key predictive power in age-related disease risk profiles. 
 
 Changes to monocyte activation are conserved across multiple biomarkers 3.4.3
The estimated age effect of HIV infection on different biomarker levels was similar for both 
viremic (11.6 – 12.9 years) and VS (1.8 – 4.0 years) HIV+ individuals. While a small difference of 
1.8 to 4 years difference was observed in VS HIV+ individuals, these values are consistent across 
the biomarkers measured, supporting the power of the analysis method used. However, 
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longitudinal studies confirming these findings using may be a better indicator of this age 
difference and provide insight into why the changes persist despite viral suppression. The effect 
of these HIV-related age differences may be significant given the well documented association 
between enhanced monocyte activation and age-related disease pathogenesis (discussed in 
section 1.4.5). Specifically, the proportion of CD16+ monocytes (intermediate and non-classical) 
are expanded in both acute (e.g. sepsis (Fingerle et al. 1993)) and chronic inflammatory 
conditions (e.g. chronic kidney disease (Lee et al. 2013), obesity (Poitou et al. 2011) and diabetes). 
Therefore, the observed increase in the percentage of CD16 expressing monocytes with age, and 
the exacerbation of these effects with viremic HIV infection, suggest that these changes may 
enhance the disease pathogenesis of conditions such as CVD (Rogacev et al. 2012) and 
neurocognitive decline which are leading causes of morbidity in these individuals. An increased 
proportion of intermediate monocytes expressing tissue factor and CD62P in HIV+ individuals has 
been compared to a similar phenotype for monocytes of HIV- individuals with acute coronary 
syndrome, suggesting HIV induced immune changes may drive pathology associated with 
cardiovascular diseases (Funderburg et al. 2012). This is also true of HAND in HIV+ individuals 
where increased proportions of CD16 expressing monocytes are associated with worse disease 
outcomes (Ancuta et al. 2008). 
 
 Sex influences LPS levels in HIV+ individuals and the elderly 3.4.4
Increased plasma levels of LPS in viremic and VS HIV+ individuals are thought to contribute to 
generalised monocyte activation via TLR-4 signalling (Brenchley et al. 2006b). While an increase in 
LPS levels with age was observed in the present study, LPS levels were not significantly altered by 
HIV infection contrary to the findings of several cross-sectional studies including one previous 
study from our laboratory (Brenchley et al. 2006b; Rajasuriar et al. 2010; Hearps et al. 2012a). 
The measurement of LPS can be problematic due to the presence of interfering substances for the 
LPS Limulus Amebocyte Lysate assay present in plasma providing false positive readings and the 
presence of inhibitory plasma components (Balagopal et al. 2012). Therefore, LPS may not be the 
most suitable indicator of factors leading to monocyte activation. Importantly in our hands, the 
relationship of plasma LPS levels with age were significantly different in men and women (Figure 
3.1) leading to the decision to exclude women from the analysis of age and HIV-related changes 
to LPS concentrations. As the majority of HIV+ individuals in Australia are men (86.9%, (Kirby 
2014)), it was felt that men were more representative of the major risk group for HIV infection. 
Exclusion of women in this analysis reduced the sample size and hence the power of analyses. 
While LPS levels were not significantly elevated in HIV infection, increases in other components of 
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TLR-4 signalling in response to LPS such as sCD14 provides indirect evidence of increased LPS in 
these patients. Plasma levels of sCD14 are commonly used as a surrogate marker of LPS (Kamat et 
al. 2012), and were elevated in both viremic and VS HIV+ individuals. Furthermore cross-sectional 
analysis of plasma LBP levels, a plasma LPS binding protein which mediates transfer of LPS to TLR-
4 (previously discussed in section 1.6.2), showed increased levels in viremic HIV+ individuals 
(p=0.02) and the elderly (p=0.04, Appendix Figure 3.2 A). As plasma LBP positively correlates with 
LPS levels (Appendix Figure 3.2 B), increased LBP in HIV+ people further supports the hypothesis 
of increased LPS in these individuals.  
 
Taken together, in this study LPS levels from men and women were unable to be combined for 
analysis due to opposite changes of plasma levels with age. Furthermore, we observed a 
significant influence of smoking status on LPS levels in both HIV+ individual and the elderly. 
Therefore, accounting for both sex and smoking status is essential for all future studies evaluating 
LPS in HIV+ individuals and the elderly. 
 
 Limitations of the study 3.4.5
CMV infection and reactivation has been suggested to drive immune activation, inflammation and 
immunosenescence in HIV+ individuals (reviewed in (Deeks 2011)) and the elderly, although the 
role of CMV in inflamm-ageing remains controversial ((Bartlett et al. 2012), see section 1.5.2.2). 
CMV viremia or seropositivity were not measured in the patient groups studied herein, which is a 
limitation of this study; however as over 90% of HIV+ individuals are CMV seropositive (Kim et al. 
2006a) and CMV viremia is generally only detected during acute infection, identifying the specific 
effects of CMV seropositivity/reactivation would not have been possible. Future studies recruiting 
a large number of HIV+ donors would be required to evaluate this question in order to match the 
power of this study (i.e. >1000 HIV+ individuals would yield >100 CMV- HIV+ individuals assuming 
a CMV seropositivity of 90%). HIV infection and ageing are also associated with increased risk of 
other infections (e.g. influenza etc.) that were not tested for in this study, however current 
medical treatments were noted and individuals with self-reporting illness were excluded. 
 
The linear regression analyses were not adjusted for the duration of viral suppression. Attempts 
were made to correlate “time on therapy” data for cART treated VS HIV+ individuals with levels of 
markers of monocyte activation, however, no significant association was observed for any of the 
biomarkers (p>0.05 for all, data not shown). Furthermore, no difference was observed between 
groups when VS HIV+ individuals were stratified by time on therapy (<5 years, 5-10 years and 10+ 
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years of therapy) for all biomarkers (p>0.05 for all, data not shown). Despite these observations, 
it is acknowledged that the time of virological suppression and duration of infection may affect 
some of the relationships evaluated in this study and that larger numbers of donors may be 
required to delineate these interactions. It is difficult to accurately determine the duration of 
cART treatment or viral suppression prior to blood analysis due to the fact that the HIV patients 
were not enrolled as part of a cohort study and ethical guidelines provided us with access to 
participant medical information at our sites only (i.e. the Alfred Hospital and Rush University 
Medical Centre). As donors may have initiated therapy at other sites prior to recruitment, the 
total time of viral suppression may be skewed as HIV+ individuals may have sought treatment at 
other sites. These analyses would also be complicated by the fact that time on therapy may not 
accurately reflect duration of virological suppression in patients who poorly adhere to treatment 
and experience periodic viral rebound. Some early antiretroviral regimens have also been 
associated with increased risk of age-related disease and may account for some changes to 
biomarkers measured. For these reasons, association of biomarkers with duration of viral 
suppression or time since infection were not included into the regression analyses. However, in 
general, VS HIV+ individuals showed lower levels of most of the biomarkers measured, with the 
exception of sCD14, in comparison to viremic HIV+ individuals indicating that cART is having a 
beneficial effect in lowering monocyte activation.  
 Future studies 3.4.6
The observation that HIV infection accentuates age-related changes to levels of monocyte 
activation similar to HIV- individuals approximately four year older indicates that further studies 
are required to identify the association of these changes with age-related disease in current 
groups of HIV+ patients receiving cART. CXCL-10 levels predict age-related changes to monocyte 
activation independent of other markers, indicating that this chemokine may have predictive 
value in assessing the risk of age-related disease in HIV+ individuals and the elderly. These 
findings provide evidence supporting the measurement of CXCL-10 to determine whether 
targeting monocyte activation reduces the risk of age-related disease. As an indicator of 
monocyte activation, CXCL-10 may be a useful prognostic indicator in other chronic inflammatory 
states such as hepatitis and RA; however, further studies are required to delineate to the 
contribution of monocyte activation in these diseases. 
89 
 
 Conclusion 3.4.7
In this chapter, the effect of viremic and VS HIV infection on age-related changes to monocyte 
activation was evaluated. Using linear regression analyses, we show for the first time that HIV 
infection exacerbates age-related changes to monocyte activation and that these changes are not 
completely restored by viral suppression. Monocyte activation in VS and viremic HIV+ individuals 
are similar to HIV- individuals approximately 4 to 12 years older, respectively, suggesting that 
immunological changes may drive the increased risk of age-related disease pathogenesis 
observed in these individuals. Furthermore, monocytes from these individuals showed an 
expansion of proinflammatory subsets which were associated with higher plasma levels of soluble 
markers. Therefore, the effect of chronic, exacerbated inflammation on age-related disease 
pathogenesis requires further investigation.  
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CHAPTER 4 
MONOCYTE RESPONSES TO LPS IN 
YOUNG HIV+ INDIVIDUALS AND THE 
ELDERLY 
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4 CHAPTER 4 
4.1 Abstract 
As shown in Chapter 3, monocytes from young viremic HIV+ individuals and the elderly show 
similar expansion of CD16+ monocyte subsets and elevated levels of markers of monocyte 
activation (neopterin, CXCL-10) compared to young HIV- individuals which may contribute to 
increased risk of inflammatory age-related disease in these individuals. LPS is a potent immune 
activator and stimulates monocytes via the TLR-4 receptor complex to produce proinflammatory 
cytokines such as IL-6 and TNF. Increased mucosal permeability in HIV+ individuals and the elderly 
is associated with increased translocation of bacterial products such as LPS which may drive 
monocyte activation. However, whether increased microbial translocation alters monocyte 
responses that further contribute to chronic inflammation in these individuals is unknown. In this 
chapter the effect of the inflammatory and endotoxin milieu present in HIV+ individuals and the 
elderly on monocyte production of IL-6 and TNF in response to LPS was investigated.  
 
The functional activation of monocytes in individual subsets (indicated by their basal and LPS-
induced intracellular IL-6 and TNF protein levels) from young cART-naïve viremic (median age 
[range]: 36 [26-43] yrs.) and VS (36 [29-43] yrs.) HIV+ donors was compared to young (30 [21-45] 
yrs.) and older HIV- controls (68 [66-74] yrs.; n=10 per group, all male). All three monocyte 
subsets from viremic and VS HIV+ individuals showed increased basal and LPS-induced levels of 
intracellular IL-6 and TNF in comparison to young HIV- individuals (p<0.05 for all comparisons) 
and similar levels to those found in a group of HIV- healthy men aged approximately 38 years 
older. LPS-induced IL-6 and TNF mRNA gene expression in total monocytes was higher in HIV+ and 
older HIV- men as compared to young controls. Surface TLR-4 expression on monocytes was also 
increased in HIV+ and aged individuals; however, surface TLR-4 expression correlated with IL-
6/TNF gene expression and plasma LPS levels in HIV-, but not HIV+ individuals. 
 
Taken together, although monocytes from both young HIV+ individuals and the elderly have 
higher basal levels of proinflammatory cytokines and increased responsiveness to LPS challenge 
ex vivo, the mechanisms governing primed responses appears to differ in these groups, indicating 
that chronic inflammation in HIV infection may result from a mechanism that is different to 
inflamm-ageing. 
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4.2 Introduction 
Due to the similar chronic inflammatory phenotype and expansion of proinflammatory 
immunosenescent cells in HIV+ individuals and the elderly, together with the high incidence of 
age-related disease in the HIV+ population, it has been suggested that HIV infection prematurely 
induces age-related immunological changes that drive chronic inflammatory disease in cART 
treated HIV+ individuals (Appay and Sauce 2008; Desai and Landay 2010). HIV+ individuals have 
increased markers of immunosenescence, such as impaired CD4+:CD8+ T cell ratios (Serrano-Villar 
et al. 2014b) and expansion of CD28- T cells with a proinflammatory Th1 phenotype (Cao et al. 
2009) highlighting intrinsic changes to immune cells in HIV infection which shift towards an ageing 
phenotype. Although the drivers of inflammation and immune activation in both inflamm-ageing 
and HIV+ individuals remain controversial, increased plasma concentrations of microbial products 
such as LPS, elevated in both of these populations, may be a common factor (discussed in section 
1.5.1.2). 
 
Monocytes are innate immune effector cells and the predominant cell type that recognises 
bacterial LPS via a complex of LBP, membrane bound CD14 and TLR-4. In response to LPS, and 
other bacterial and viral PAMPS, monocytes produce proinflammatory cytokines such as IL-6 and 
TNF and shed CD14 which aid the clearance of infection (discussed in section 1.4.3). Monocyte 
subsets (classical, intermediate and non-classical) respond differently to bacterial challenge, with 
the intermediate subset being the major producer of IL-6 and TNF in response to LPS in healthy 
individuals (Belge et al. 2002; Cros et al. 2010). Furthermore, in Chapter 3 evidence was 
presented that VS and viremic HIV infection accentuates age-related changes to levels of soluble 
markers of monocyte activation similar to HIV- individuals approximately 4–12 years older 
(Angelovich et al. 2015b).  
 
Although limited evidence suggests that PBMC from HIV+ individuals are hyper-responsive 
(primed) to LPS challenge (Lester et al. 2008; Lester et al. 2009), the impact of HIV infection and 
ageing on the response of monocytes and individual subsets to LPS is unknown. This is important 
since circulating IL-6 (Amar et al. 2006) and soluble TNFR (Elkind et al. 2002) levels, produced by 
monocytes in response to LPS, are independently associated with increased risk of atherosclerosis 
(discussed in section 1.3.1). Furthermore, the substantial evidence linking monocyte activation 
with inflammation and age-related disease (see section 1.4.5), including the expansion of CD16+ 
monocyte subsets (Heine et al. 2007; Rogacev et al. 2012), suggests that higher cytokine 
production in monocytes from these individuals may contribute to age-related disease 
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pathogenesis. However, whether HIV infection affects monocyte response to LPS, and whether 
this is reminiscent of changes which occur during healthy ageing, is unclear. Therefore, we 
hypothesised that as a result of elevated monocyte activation; their response to LPS is enhanced 
– thus contributing to chronic inflammation in HIV+ and elderly individuals via similar mechanisms.  
 
In this chapter, the inflammatory state of monocyte subsets from young HIV-infected men and 
their response to LPS was compared to two groups of healthy HIV- men of similar or significantly 
older age using whole blood flow cytometry techniques. Furthermore, the mechanisms driving 
altered monocyte response to LPS, and the potential of cART to restore these changes, were 
assessed to identify how monocyte activation may drive chronic inflammation in these individuals.  
4.3 Results 
 Monocytes from HIV+ men show increased basal proinflammatory 4.3.1
cytokine production ex vivo similar to monocytes from the elderly 
Healthy young (median age [range]: 30 [21-45] yrs.) and older (68 [66-74] yrs.) HIV- male controls, 
plus young viremic (36 [26-43] yrs.) and VS (36 [29-43] yrs.) HIV+ males (n=10 in each group) were 
recruited into a cross-sectional study approved by The Alfred Hospital Research and Ethics 
Committee, Melbourne, Australia (Project 168/08) and RMIT University Human Ethics Committee 
(see Ethics section, Table 4.1). Participants provided written informed consent and in order to 
maximise the likelihood that age-related changes observed to monocyte function were not due to 
underlying inflammatory disease, individuals with chronic diseases, a recent history of acute 
infection, recent use of anti-inflammatory medication or self-reported symptoms of acute 
infection in the past three weeks were excluded from participation in this study. As approximately 
86.9% of new HIV diagnosis in Australia were men (Kirby 2014), only men were recruited into this 
study. 
 
To test whether increased monocyte activation in HIV+ individuals and the elderly is associated 
with increased monocyte production of IL-6 and TNF, basal intracellular IL-6 and TNF protein 
levels in monocytes subsets from elderly men, identified using FSC/SSC gating and surface 
expression of CD14 and CD16 (Figure 4.1 A and B), were measured in whole blood using flow 
cytometry (see Methods section 2.3.2). In comparison to young healthy controls, all monocyte 
subsets (classical, intermediate and non-classical) from older individuals showed significantly 
elevated basal TNF levels (Figure 4.1 C-E). While classical and intermediate monocytes from 
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Table 4.1 Demographic and clinical information of cohort 
 HIV-   HIV+ 
 Young Older   Viremic VS 
Participants (n) 10 10   10 10 
Age  30 (21-45) 68 (66-74)   36 (26-43) 36 (29-43) 
Body Mass Index 25.74 (22.9, 28.7) 26.8 (24.5, 28.4)   22.9 (19.1, 23.8)  24.6 (23.6, 27.2) 
Smoking status       
Current 20% 0%   40% 20% 
Previous 0% 30%   10% 20% 
Never 80% 70%   50% 60% 
HIV Viral load 
(copies/mL) 
NA NA   
107, 949 
(4922, 165613) 
20 (20, 25.8) 
CD4 T cell count 
(cells/µL) 
NT NT   400 (386, 498) 532 (371, 917) 
Nadir CD4 
(cells/µL) 
NA NA   541 (310, 752) 459 (266, 700) 
Duration of cART  
(years) 
NA NA   NA 2.0 (0.3-5.3) 
Hepatitis C virus NT NT   10% 10% 
 
NT – not tested, NA – not applicable 
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Figure 4.1 Basal protein levels of IL-6 and TNF in monocyte subsets. 
Monocyte subsets were gated based on FSC/SSC (A) and CD14/16 expression (B). Basal 
intracellular TNF (C-E) and IL-6 (F-H) protein levels were measured using flow cytometry for 
monocytes subsets (classical, intermediate and non-classical) in young HIV+ (viremic/virologically 
suppressed (VS)) and age-matched and older HIV- individuals. Tukey plots represent the median 
and 1.5 IQR of each cohort. Mean fluorescence intensity (MFI) is plotted (target expression – 
isotype control). Groups were compared using non-parametric Mann-Whitney U tests (* p<0.05, 
** p<0.01, *** p<0.001). 
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elderly donors also showed a trend to higher basal levels of IL-6 (classical: p=0.06, intermediate: 
p=0.14, Figure 4.1 F and G, Appendix Table 4.1), no significant difference in IL-6 levels were 
observed in non-classical monocytes (p=0.54, Appendix Table 4.1). However, very low basal levels 
of IL-6 (as indicated by low mean fluorescence intensity (MFI)) were detected in all subsets, 
suggesting that limited sensitivity of the assay may have restricted the ability to detect small 
differences between groups (Appendix Table 4.1).  
 
Our previous observations of a similar monocyte phenotype and impaired phagocytosis in HIV+ 
individuals and the elderly (Hearps et al. 2012a) indicated that monocytes from these groups may 
also have a similar level of basal activation. In order to determine whether HIV infection elicits 
similar monocyte changes as observed in inflamm-ageing, basal intracellular IL-6 and TNF levels 
were measured in monocyte subsets from either viremic or VS HIV+ individuals. In comparison to 
men of a similar age, all monocyte subsets from both viremic and VS HIV+ individuals showed 
significantly elevated TNF (C-E) and IL-6 (Figure 4.1 F-H) levels. No difference was observed in 
cytokine levels between viremic and VS HIV+ individuals (Appendix Table 4.1).  
 
Taken together, these data suggest that monocytes in young HIV+ individuals regardless of viral 
suppression and older HIV- men are more inflammatory than young HIV- controls.  
 Monocytes from HIV+ men and the elderly produce more IL-6 and TNF in 4.3.2
response to LPS than those from young, HIV- males  
We and others have previously shown that ageing is associated with increased plasma levels of 
proinflammatory cytokines (IL-6, TNF, (Breen et al. 1990; Aukrust et al. 1999)), markers of 
monocyte activation (CXCL-10, sCD14, neopterin) and PAMPS such as LPS (Chapter 3, (Hearps et 
al. 2012b; Angelovich et al. 2015b). However whether these changes translate into, or are 
representative of, altered monocyte response to LPS remains unclear (as previously discussed in 
section 1.4). To determine whether the activated basal state of monocytes observed in the 
elderly and in young, HIV+ men affects their subsequent response to PAMPs such as LPS, the 
production of TNF and IL-6 following a LPS challenge (10 ng/mL, 4 hours) was evaluated. This time 
was chosen following experiments aimed at optimising the detection of these cytokines by 
intracellular cytokine staining following LPS stimulation (Appendix Figure 4.1 A-D). In response to 
ex vivo LPS challenge, intermediate and non-classical monocytes from elderly donors produced 
significantly more TNF (Figure 4.2 B and C) and IL-6 (Figure 4.2 E and F) compared to young 
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Figure 4.2 LPS-induced intracellular IL-6 and TNF production in monocytes subsets. 
Whole blood from viremic or virologically suppressed (VS) HIV+ and young or older HIV- 
individuals was stimulated with 0 or 10 ng/mL LPS for 4 hours. Intracellular TNF (A-C) and IL-6 (D-
F) protein levels were measured using flow cytometry for monocytes subsets (Classical, 
Intermediate and Non-Classical). Tukey plots represent the median and 1.5 IQR of each cohort 
and dots represent outliers. Delta mean fluorescence intensity (ΔMFI) is plotted (LPS stimulated - 
unstimulated). Groups were compared using non-parametric Mann-Whitney U tests (* p<0.05, ** 
p<0.01, *** p<0.001). 
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 controls, whilst classical monocytes showed a similar trend to increased cytokine production (IL-6: 
p=0.15, TNF: p=0.16, Figure 4.2 A, Appendix Table 4.1).  
To determine whether monocytes from HIV+ individuals had a greater response to LPS challenge 
than age-matched HIV- individuals, intracellular IL-6 and TNF production in response to LPS was 
evaluated in viremic and VS HIV+ individuals. Classical and intermediate monocyte subsets from 
viremic HIV+ individuals produced significantly more intracellular TNF (p<0.05 for both, Figure 4.2 
A and B) and all subsets produced more IL-6 (p<0.05 for all, Figure 4.2 D-F). Furthermore, all 
monocytes subsets from VS donors also had higher IL-6 and TNF production than age-matched 
controls (Figure 4.2, p<0.05 for all), suggesting viral suppression associated with cART does not 
mitigate HIV-associated heightened proinflammatory cytokine production in response to LPS.  
 
Of the three monocyte subsets, intermediate monocytes were the greatest producers of 
proinflammatory cytokines in response to LPS in both HIV- and HIV+ donors (Appendix Table 4.1), 
confirming that this subset is the most responsive to LPS. These findings suggest that monocytes 
from HIV+ individuals and the elderly are primed to LPS challenge, resulting in enhanced 
proinflammatory cytokine production ex vivo. 
 LPS-induced, but not basal IL-6 and TNF gene expression, is enhanced in 4.3.3
HIV+ and elderly individuals in comparison to young controls 
To determine whether increased proinflammatory cytokine production was driven by changes at 
the level of cytokine gene expression, IL-6 and TNF mRNA levels were evaluated by qPCR in 
isolated monocytes stimulated with either 0 or 10 ng/mL LPS for 4 hours (see Methods sections 
2.4.1 and 2.4.2). As all monocyte subsets from HIV+ individuals and the elderly showed primed 
responses to LPS, and because of limitations imposed by Ethics approvals preventing the 
obtaining of sufficient blood required to purify monocyte subsets by FACS (~200 mL), purified but 
unsorted monocytes were used for this analysis. Since monocytes were isolated from stored 
PBMC it was initially confirmed that priming of LPS-induced cytokine production from monocytes 
also occurs when frozen PBMC, instead of whole blood, is used. Therefore, intracellular cytokine 
staining was performed on LPS-stimulated PBMC from age-matched HIV- and viremic HIV+ 
individuals. Monocytes present in PBMC isolated from viremic HIV+ individuals displayed 
significantly increased intracellular TNF levels (p=0.026) and a trend to increased intracellular IL-6 
(p=0.179), confirming that priming occurs in this system (Appendix Figure 4.1 E and F, 
respectively). mRNA from one elderly donor showed poor GAPDH expression and was excluded 
from further analysis. Whilst basal TNF and IL-6 (Figure 4.3 A and C, respectively) gene expression 
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Figure 4.3 Basal and LPS-induced IL-6 and TNF gene expression in monocytes from HIV- and 
HIV+ individuals.  
Monocytes isolated from PBMC (n=10 per cohort, n=9 for older group) were stimulated with 0 or 
10 ng/mL LPS for 4 hours and cDNA prepared. Basal and LPS-induced TNF (A and B, respectively) 
and IL-6 (C and D, respectively) gene expression was determined by qPCR and standardised to 
GAPDH. LPS stimulated samples represent fold change over unstimulated conditions. Tukey plots 
represent the median and IQR of each cohort and dots represent outliers. Groups were compared 
using non-parametric Mann-Whitney U tests (* p<0.05, ** p<0.01, *** p<0.001). 
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 in monocytes from elderly donors was not different to young controls, monocytes from elderly 
donors showed higher induction of TNF and IL-6 gene expression in response to LPS (p<0.05 for 
both, Figure 4.3 B and D, respectively).  
 
To address whether similar changes to proinflammatory cytokine gene expression also occur in 
HIV+ men, total mRNA from viremic and VS HIV+ donors were quantified. Similar to the elderly, 
no difference in basal TNF or IL-6 (Figure 4.3 A and C, respectively) mRNA expression was 
observed between HIV+ individuals and young age-matched HIV- controls. However, following 
LPS stimulation, monocytes from both viremic and VS HIV+ individuals showed significantly higher 
TNF and IL-6 mRNA levels (p<0.05 for both, Figure 4.3 B and D, respectively). No difference was 
observed in TNF or IL-6 mRNA expression between HIV+ donors and elderly HIV- individuals, 
indicating that monocytes from these donors are primed for a similar level of gene expression 
following LPS stimulation. Furthermore, there was no difference in TNF or IL-6 gene expression 
between monocytes from viremic and VS HIV+ individuals, indicating that viral suppression by 
cART does not alter gene expression (TNF: p=0.98, IL-6: p=0.13). 
 
Taken together, LPS stimulation of monocytes induced IL-6 and TNF mRNA in young HIV+ men 
and the elderly that was higher in comparison to young controls, indicating that gene expression 
is altered in response to LPS in these donors. However, basal IL-6 and TNF mRNA expression in 
monocytes from HIV+ men and the elderly did not differ in comparison to young HIV- controls. 
Thus, mRNA expression does not account for the higher basal TNF and IL-6 levels observed in 
monocytes from elderly and HIV+ subjects (Figure 4.1). 
 Basal and LPS-induced NF-κB p65 and p-38 MAPK phosphorylation is not 4.3.4
significantly altered in monocytes from HIV+ individuals and the elderly 
The observations reported in 4.4.3 suggest that signal transduction in response to LPS may be 
enhanced in both young HIV+ individuals and the elderly. To determine whether increased LPS-
induced IL-6 and TNF mRNA expression in HIV+ individuals and the elderly is associated with 
enhanced TLR-4 signal transduction, phosphorylation of functional intermediaries of the TLR-4 
signalling pathway were evaluated. Following binding to LPS, TLR-4 recruits the adaptor protein 
MyD88 which results in the phosphorylation of both p-38 MAPK and NF-κB p65 through separate 
signalling pathways and results in the translocation of transcription factors that promote IL-6 and 
TNF production (see Introduction section 1.6.3, Figure 1.1). As a measure of these separate 
signalling pathways, the phosphorylation of p-38 MAPK and NF-κB p65 were measured in 
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monocytes following LPS challenge using a whole blood phosphorylated flow cytometry assay 
(PhosFlow, Appendix Figure 4.2, see Methods section 2.3.3). In contrast to traditional methods of 
analysing phosphorylation of signalling intermediates, such as western blotting, whole blood 
Phosflow allows the quantification of phosphorylation events at a single cell level (Appendix 
Figure 4.2 A). Furthermore, the analysis of monocytes within whole blood allows for a more 
physiologically relevant analysis than measuring LPS signalling in monocytes by western blotting, 
as it measures the combined influence of all soluble proteins present in blood and also indirect 
effects from other circulatory immune cells. 
 
PhosFlow analysis of signal transduction requires relatively harsh fixation conditions in order to 
rapidly stop signal transduction. For this reason, p-38 MAPK and NF-κB p65 phosphorylation in 
response to LPS could not be evaluated in individual monocyte subsets as the CD16 epitope 
defining the minor monocyte subsets did not survive fixation under conditions required for 
Phosflow (Appendix Figure 4.2 D). Due to low MFIs in basal conditions, basal levels of 
phosphorylated NF-κB p65 and p-38 MAPK were expressed as fold change of the target over 
isotype control to account for the potential impact of different batches of antibody on MFI. 
Neither HIV infection nor ageing were associated with significant basal p-38 MAPK and NF-κB p65 
phosphorylation in total monocytes from these donors (Figure 4.4 A and C respectively). 
Following stimulation of whole blood with saturating concentration of LPS for 15 minutes (10 
ng/mL, Appendix Figure 4.2 E and F), p-38 MAPK and NF-κB p65 phosphorylation did not differ 
between groups (Figure 4.4 B and D).  
 
Monocytes from elderly donors showed a trend to increased LPS-induced p-38 MAPK 
phosphorylation, no such trend was observed in HIV+ individuals. Conversely, monocytes from 
viremic and VS HIV+ individuals showed a trend to increased basal p-38 MAPK phosphorylation; 
however, no change in LPS-induced phosphorylation of p-38 MAPK was observed. Despite these 
trends, these results were limited by low the MFIs obtained (Appendix Figure 4.2 B and C), 
suggesting that the assay may have lacked the required sensitivity to identify differences in 
phosphorylation of p-38 MAPK and NF-κB p65 in monocytes from HIV+ individuals and the elderly. 
Therefore, these findings need to be confirmed using more sensitivity techniques.  
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Figure 4.4 Basal and LPS-induced p-38 MAPK and NF-κB p65 phosphorylation in total 
monocytes. 
Basal and LPS-induced p-38 MAPK (A and B) and NF-κB p65 (C and D) phosphorylation from total 
monocytes was determined by flow cytometry. Fold change is plotted (Basal: target 
expression/isotype control; LPS-induced: (LPS stimulated/Basal (target expression/isotype 
control)). Median and IQR shown (n=10). Groups were compared using non-parametric Mann-
Whitney U tests. 
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 Monocytes from young HIV+ individuals have increased surface TLR-4 4.3.5
expression that is similar to older, HIV- men. 
To determine if the increased response to LPS is due to increased surface expression of the 
receptors required for its recognition, surface expression of TLR-4 and CD14 on monocytes was 
measured by flow cytometry. As CD16 has been described to induce TLR-4 tolerance to the lipid A 
moiety of LPS in monocytes (Shalova et al. 2012), surface CD16 expression was also measured 
(see Methods section 2.3.1). In comparison to young HIV- controls, older donors had higher 
monocyte surface expression of TLR-4 (p=0.021, Table 4.2). Monocytes from viremic HIV+ 
individuals also had higher surface TLR-4 in comparison to controls (p<0.01, Table 4.2), however 
VS HIV+ donors did not. Surface CD14 and CD16 expression were not significantly different 
between groups.  
 
To determine whether increased surface TLR-4 expression on monocytes from older and viremic 
HIV+ individuals was associated with increased proinflammatory cytokine production, LPS-
induced TNF and IL-6 gene expression was correlated with surface TLR-4 expression. To evaluate 
the influence of ageing and HIV infection on these associations, data was stratified by HIV status 
(i.e. HIV- (young and older) and HIV+ (viremic and VS HIV+). Surface TLR-4 expression strongly 
correlated with LPS-induced TNF mRNA expression (rho 0.82, p<0.001, Figure 4.5 A) and IL-6 gene 
expression (rho 0.61, p=0.017, Figure 4.5 C) in monocytes from HIV- individuals. Interestingly, 
these relationships were not observed in HIV+ individuals for either TNF (p=0.86, Figure 4.5 B) or 
IL-6 (p=0.30, Figure 4.5 D), suggesting that factors other than increased TLR-4 expression drive the 
primed monocyte responses to LPS observed in monocytes from HIV+ individuals.  
 
These findings show that surface TLR-4 expression is important for age-associated priming of 
monocytes to LPS challenge. Conversely, surface TLR-4 levels do not appear to be rate 
determining for monocyte responses to LPS in HIV+ individuals, suggesting that primed monocyte 
responses to LPS in these people are driven by other mechanisms. 
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Table 4.2 Basal levels of surface TLR-4, CD14 and CD16 in age-matched viremic HIV+ and older HIV- individuals on total monocytes 
(median (IQR)). 
 HIV-  HIV+ 
 Young Older p*  Viremic p* VS p* 
TLR-4 (ΔMFI) 4.61 (3.85, 6.09) 8.87 (5.73, 15.1) 0.021  8.83 (7.35, 10.9) <0.01 6.44 (5.15, 9.54) ns 
CD14 (MFI) 22.2 (19.4, 29.2) 21.4 (18.08, 36.7) ns  18.9 (13.9, 23.3) ns 17.5 (12.3, 24.5) ns 
CD16 (MFI) 6.39 (5.24, 6.87) 7.06 (6.15, 8.05) ns  6.24 (5.26, 7.03) ns 6.14 (5.69, 6.71) ns 
 
* P values in comparison to young HIV- individuals using non-parametric Mann-Whitney U tests. 
ns = not statistically significant 
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Figure 4.5 Correlation analysis of LPS-induced TNF gene expression with surface TLR-4 protein 
levels in HIV- and HIV+ individuals. 
LPS-induced gene expression of TNF (A, B) and IL-6 (C, D) in total monocyte populations from HIV- 
(n=15, A and C) and HIV+ (n= 19, B, D) individuals were correlated with basal TLR-4 expression on 
total monocytes. Non-parametric Spearman’s rho and p values are reported. 
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 Plasma LPS levels are associated with increased surface TLR-4 expression 4.3.6
on monocytes from the elderly, but not monocytes from HIV+ individuals 
Given the observation of a strong correlation between surface TLR-4 levels and LPS-induced 
proinflammatory cytokine gene expression in HIV- individuals, the mechanisms driving increased 
TLR-4 surface expression were evaluated. While ex vivo stimulation of monocytes with LPS down-
regulates surface TLR-4 expression, sepsis patients exposed to high circulating LPS levels show 
higher surface TLR-4, suggesting a positive feedback loop contributing to higher proinflammatory 
cytokine production (Skinner et al. 2005). Therefore, plasma LPS levels were measured to 
determine whether higher LPS levels in these donors correlated with surface TLR-4 expression. 
 
In Chapter 3, evidence was presented that plasma LPS levels increase with age, and as expected, 
plasma LPS levels in elderly individuals recruited to this study were significantly elevated in 
comparison to young controls (median: 56.8 vs 52.6 pg/mL p=0.03, respectively, Appendix Table 
4.2). LPS levels were also elevated in VS HIV+ individuals as compared to young controls (p<0.05, 
Appendix Table 4.2), but not in viremic HIV+ individuals (p=0.21). To determine the relationship 
between plasma LPS levels and surface TLR-4 expression, and specifically to address whether HIV 
infection alters this relationship, the groups were combined into HIV- (young and older) and HIV+ 
(viremic and VS) groups for correlation analysis. Surface TLR-4 expression strongly correlated with 
plasma LPS levels in HIV- individuals (rho=0.798, p=0.002, Figure 4.6 A), but not in HIV+ 
individuals (p=0.197, Figure 4.6 B), indicating that elevated LPS levels are associated with 
increased TLR-4 expression on monocytes from the elderly that may facilitate increased 
proinflammatory cytokine production. The lack of correlation between plasma LPS and TLR-4 
expression in HIV+ individuals suggests that this TLR-4 dependent mechanism observed in 
inflamm-ageing is not likely to be responsible for primed responses to LPS in HIV+ donors. 
 Basal miR-155 expression is higher in elderly donors, but not HIV+ 4.3.7
individuals 
Although enhanced IL-6 and TNF mRNA induction by LPS was observed in HIV+ individuals and the 
elderly compared to young controls (Figure 4.3 B and D), supporting the intracellular 
proinflammatory cytokine measurements (Figure 4.2), no difference in basal mRNA levels was 
observed (Figure 4.3 A and C), suggesting that other post-transcriptional mechanisms may drive 
heightened basal proinflammatory cytokine levels. miRNAs are short post-transcriptional 
regulators that can influence mRNA expression by blocking, degrading or stabilising the 3’ UTR of 
target mRNA. Specifically miR-146a and miR-155 have been identified as key regulators of TLR-4
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Figure 4.6 Correlation analysis of plasma LPS levels with basal surface expression of TLR-4 on 
monocytes from HIV- and HIV+ individuals. 
Correlation of surface TLR-4 expression on classical monocytes and plasma LPS levels in A) HIV- 
(n=13) or B) HIV+ individuals (n=15). Non-parametric Spearman’s rho and p values are reported. 
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signalling and are produced following LPS stimulation of monocytes (see Introduction section 
1.7.2). Therefore, miR-146a and miR-155 expression in unstimulated monocytes from all study 
groups was measured by qPCR (see Methods section 2.4.3). In comparison to controls, monocytes 
from the elderly had higher basal levels miR-155 (p=0.025) and a trend towards higher levels of 
miR-146a (p=0.099, Figure 4.7 A and B, respectively). However, no difference in miR-155 or miR-
146 was observed in viremic and VS HIV+ individuals in comparison to controls, indicating that 
these miRNAs are not likely to be responsible for increased proinflammatory cytokine production 
in HIV+ patients. 
 
In summary, higher miR-155 levels and a trend to increased miR-146a in elderly individuals may 
be indicative of heightened signal transduction via TLR-4 dependent pathways. As this was not 
observed in HIV+ individuals, these findings further support the correlation analyses in Figure 4.5 
that priming in HIV+ individuals is not solely regulated via TLR-4 mechanisms and is most likely 
influenced by other signalling pathways, indicating that different mechanisms drive priming in HIV 
infection and ageing. 
4.4 Discussion 
In this chapter, monocytes from both young HIV+ and older HIV- men were shown to share the 
property of having increased basal and LPS-induced production of the proinflammatory cytokines 
IL-6 and TNF. This property was especially evident in the main proinflammatory cytokine 
producing monocyte subsets (intermediate and non-classical monocytes). These findings support 
the previous observations - reported in Chapter 3 and elsewhere - that monocytes from relatively 
young HIV+ individuals are similar in many respects (i.e. monocyte subset proportion, level of 
activation) to those from healthy, elderly individuals (Hearps et al. 2012a). However, contrary to 
the hypothesis that HIV infection mimics inflamm-ageing associated changes to monocytes, it is 
shown here that although monocyte activation in HIV+ individuals and elderly HIV- individuals is 
superficially similar, the mechanisms driving primed monocyte responses to LPS appear to differ. 
This is of importance as these findings indicate that the factors inducing these changes may also 
differ, and may not be due to elevated LPS levels alone. Primed LPS responses were associated 
with increased surface TLR-4 expression associated with increased circulating LPS levels in elderly 
HIV- individuals, although these associations were not present in HIV+ individuals. The high 
intracellular IL-6 and TNF protein levels and gene expression following LPS stimulation in HIV+ 
men were similar to older HIV- men, suggesting not only that TLR-4 dependent mechanisms may 
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Figure 4.7 Basal TLR-4 associated miRNA gene expression in monocytes. 
Basal gene expression of miR-155 (A) and miR-146a (B) and from isolated total monocytes from 
HIV- young and older donors and HIV+ viremic and virologically suppressed (VS) individuals 
standardised to the housekeeping miRNA RNU48 by the ΔΔCt method. Tukey plots show median 
and 1.5 IQR of each group (n=10). Groups were compared using non-parametric Mann-Whitney U 
tests. 
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be altered in these individuals, but that proinflammatory cytokine production may be induced by 
other pathways in HIV+ individuals. These findings provide mechanistic evidence that suggests 
although the shared property of primed monocyte responses might contribute to inflammatory 
disease pathogenesis in both HIV+ and elderly HIV- individuals, the mechanisms driving priming 
are different.  
 Primed monocyte responses to LPS may contribute to age-related disease 4.4.1
in young HIV+ men and the elderly 
As previously discussed (see Introduction section 1.1.2), relatively young HIV+ individuals and the 
elderly have increased risk and incidence of inflammatory age-related conditions such as 
atherosclerosis, frailty, renal and bone diseases and non-AIDS cancers. Soluble IL-6 and TNF have 
direct effects on the pathogenesis of these conditions in HIV- individuals and correlate with 
disease risk and outcomes (Table 1.2). As monocytes from HIV+ individuals and the elderly had 
increased responses to LPS, in comparison to young HIV- controls, and produce more 
proinflammatory cytokines, monocyte activation may further drive chronic inflammation in these 
donors and exacerbate disease pathogenesis. These findings support those of Liuzzo and 
colleagues who showed that basal and LPS-induced IL-6 levels in monocytes are higher in HIV- 
patients with chronic unstable angina who have high CRP levels (>0.3 mg/dL, (Liuzzo et al. 2001)), 
suggesting that primed responses may contribute to CVD. Identifying the contribution of primed 
monocyte responses to the pathogenesis of diseases, such as CVD, is important and the 
association between monocyte activation and atherosclerosis is addressed in Chapter 5. 
 
A heightened monocyte response coupled with increased proportions of intermediate and non-
classical monocytes in HIV infection and ageing (observed in Chapter 3, (Angelovich et al. 2015b)), 
may also partially explain the association of inflammatory monocyte subsets and age-related 
disease. The percentage of intermediate monocytes correlated with cardiovascular events in 
patients undergoing coronary angiography (Rogacev et al. 2012) and in chronic kidney disease 
patients (Rogacev et al. 2011). Furthermore, these findings support those of others, indicating 
that monocytes from HIV+ individuals are associated with a proinflammatory phenotype 
characterised by high surface expression of tissue factor that is similar to that of patients with 
CAD (Funderburg et al. 2012).  
 
Interestingly, patients who were virologically suppressed also had higher basal (Figure 4.1) and 
LPS-induced (Figure 4.2) levels of proinflammatory cytokines than HIV- men of a similar age, 
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suggesting that the mechanisms driving primed monocyte responses in these individuals is not 
solely driven by viremia. As these patients represent a random selection of HIV+ individuals in the 
community with well managed viremia, these findings are consistent with the observation that 
increased risk of inflammatory disease persists despite cART; however, larger studies associating 
monocyte phenotype with age-related disease events/outcomes are required to confirm this 
hypothesis. 
 
Taken together, primed monocyte responses to LPS may contribute to age-related disease 
pathogenesis in young HIV+ and older HIV- men, potentially explaining, in part, the higher risk of 
disease in these individuals. As VS HIV+ men also showed increased responsiveness of monocytes 
to LPS stimulation, these individuals may also have heightened risk for age-related diseases that 
persists despite cART. 
 
 TLR-4-dependent mechanisms are associated with enhanced monocyte 4.4.2
responsiveness to LPS in the elderly 
Previous studies have shown that TLR1/2 responses are impaired in all monocyte subsets from 
elderly individuals in comparison to younger controls (Nyugen et al. 2010); however, TLR-4 
responses in monocyte subsets from elderly donors has not been thoroughly evaluated. 
Monocytes from older donors had higher TLR-4 expression in comparison to young donors (Table 
4.2), consistent with primed monocyte responses to LPS observed in all subsets from these 
donors. While LPS-induced IL-6 and TNF gene expression correlated with basal surface TLR-4 
levels in HIV- men, basal gene expression was not elevated in these donors. This contrasts with 
the higher basal intracellular protein levels of these cytokines. The observation of elevated 
intracellular protein levels in the absence of increased gene expression suggests that post-
transcriptional steps may be altered in the elderly. However, it is of note that as low gene 
expression was detected by SYBR based qPCR, especially for IL-6 (Figure 4.3 C), these findings 
should be confirmed using larger study groups and more sensitive probe-based chemistries in 
order to conclusively rule out altered basal gene expression in these donors.  
 
Gene expression of miR-155 and miR-146a increased with LPS-induced TLR-4 signalling in healthy 
controls, presumably reflecting feedback loops following signal transduction (previously discussed 
in section 1.7.2). Therefore, higher levels of these miRNAs in monocytes from elderly donors are 
further evidence of activated TLR-4 signalling pathways in these donors. miR-155 stabilises target 
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mRNA species by binding to the 3’ untranslated region. In this way, miR-155 levels remain high 
independent of transcription (discussed in section 1.7.2). As higher basal TNF levels were present 
in monocytes from elderly donors, higher miR-155 levels may stabilise TNF mRNA, further driving 
primed monocyte responses. However, specifically designed studies are required to confirm this 
hypothesis. Enhanced half-life of TNF mRNA may partially explain why basal intracellular TNF 
protein levels are higher in elderly individuals while basal phosphorylation of p-38 MAPK and NF-
κB p65 in monocytes from the elderly were not different to young controls (Figure 4.4). 
 
The trend to higher p-38 MAPK phosphorylation in elderly donors following LPS stimulation 
supports our hypothesis that TLR-4 mediated signalling drives higher LPS-stimulated 
proinflammatory cytokine production in these donors. It is of note that due to the low expression 
of these genes, and NF-κB p65 phosphorylation at basal levels (Appendix Figure 4.2 B), larger 
studies and more sensitive techniques may be required to observe differences between groups.  
 
 Higher basal and LPS-induced proinflammatory cytokine levels are not 4.4.3
associated with surface TLR-4 in HIV+ individuals 
The observation that basal proinflammatory cytokine levels are higher in monocytes from HIV+ 
individuals supports findings by Tilton et al. who observed an increased percentage of monocytes 
containing proinflammatory IL-6 and TNF in PBMC isolated from both viremic and VS HIV+ 
individuals (Tilton et al. 2006). Recent work by Dutertre and colleagues - published after these 
experiments were done - also showed a higher percentage of monocytes containing intracellular 
TNF in viremic HIV+ individuals using whole blood studies (Dutertre et al. 2012). It is of interest 
that these investigators also identified that a significant percentage of TNF-expressing cells 
following LPS stimulation were CD16++CD14+Slan+ (M-DC8+) DCs, which co-localise with non-
classical monocytes in a CD14/CD16 scatter plot, and were not evaluated in the current study. 
The identification of this DC subset using eight colour flow cytometry highlights advances in 
identifying the functional characteristics of monocytes, and this subset should be evaluated in 
future studies. 
 
Total monocytes from viremic HIV+ individuals expressed more surface TLR-4 compared to young 
HIV- controls (Table 4.2), although this was not observed in cART-treated VS HIV+ individuals, 
supporting previous findings by Lester et al. (Lester et al. 2008). Furthermore, the finding of a lack 
of correlation between surface TLR-4 expression and plasma LPS levels in HIV+ individuals 
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supports those of Lester et al. who reported a similar lack of association measuring TLR-4 levels in 
monocytes in PBMC (Lester et al. 2009). While HIV+ individuals showed primed LPS cytokine 
responses that did not appear to be associated with increased TLR-4 expression or cytokine 
mRNA induction, no difference was found in basal miR-146a and miR-155 expression in 
monocytes from either viremic or VS HIV+ individuals (Figure 4.7). This suggests that other 
pathways or ligands may play a more dominant role than TLR-4 in instigating priming in these 
individuals.  
 Potential mechanisms driving primed monocyte responses to LPS in HIV+ 4.4.4
individuals 
4.4.4.1  Role of HIV viral RNA and proteins in monocyte priming 
Although evidence was presented in this chapter that factors associated with HIV infection induce 
primed monocyte responses to LPS via a different mechanism to that found in healthy ageing, the 
mechanism governing HIV-induced changes was not identified. TLR ligands, present in HIV+ 
individuals due to microbial translocation and latent bacterial/viral reactivation (i.e. CMV, 
tuberculosis), as well HIV ssRNA may cross-prime TLR-4 signalling pathways to influence 
proinflammatory cytokine responses (discussed in section 1.8.2). Stimulation of CD14 expressing 
THP-1 cells and primary human monocytes with ssRNA from the attenuated HIV viral strain AT-2 
has been shown to prime TLR-4 responses to LPS (Mureith et al. 2010), suggesting that viral HIV 
present in plasma may drive heightened monocyte responses in viremic HIV+ individuals. 
Furthermore, stimulation of monocytes in vitro with IFN-γ also primes LPS-induced monocyte TNF 
production (Hayes and Zoon 1993), suggesting that type I and II IFNs produced in response to HIV 
viremia, as well as other viruses such as CMV, may be a significant contributor to monocyte 
priming (previously discussed in Introduction section 1.8.1). This is of note as monocytes isolated 
from viremic HIV+ individuals have been suggested to have a transcriptional signature similar to 
monocytes from HIV- individuals stimulated in vitro with type I IFN-α (Rempel et al. 2010). 
However, our finding that proinflammatory cytokine levels remain elevated in monocytes from 
cART treated HIV+ individuals indicates that the mechanism of priming is not solely dependent on 
viral components or responses to virus associated with viremia (e.g. IFN-α), at least in this cohort. 
Therefore, mechanisms independent of viremia likely contribute to primed monocyte responses 
in cART treated HIV+ individuals. Despite the above-mentioned studies identifying a primed 
monocyte response or IFN-like signature, the mechanism of primed monocyte responses to LPS in 
HIV+ individuals remains elusive at the molecular level. The findings presented in this chapter 
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provide a novel insight that priming is most likely downstream of TLR-4 expression, as surface 
TLR-4 levels did not correlate with either IL-6 or TNF gene expression.  
 
Due to growing evidence implicating inflammasome activation as a significant contributor to 
monocyte activation and also foam cell formation (Li et al. 2014), inflammasomes may influence 
monocyte responses to LPS downstream of surface TLR-4. Expression of the nod-like receptor 
family, pyrin domain containing 3 (NLRP3) protein is upregulated by TLR ligands, such as LPS 
(Bauernfeind et al. 2009; Schroder et al. 2012), thus priming the NLRP3 inflammasome for 
subsequent apoptosis-associated speck-like protein containing a C-terminal caspase-recruitment 
domain (ASC) clustering and caspase activation (Fernandes-Alnemri et al. 2013). However, 
whether subsequent activation of the NLRP3 inflammasome can have a reciprocal effect on TLR 
function is unknown. TLR-8 recognition of HIV viral proteins can activate the NLRP3 
inflammasome resulting in the production of IL-1β (Chattergoon et al. 2014). Interestingly, NLRP3 
activation has also been shown to be independent of TLR activation as IRAK-1 can bypass TLR 
mediated activation resulting in direct activation of the inflammasome (Lin et al. 2014) and recent 
studies in mice suggest that inflammasomes may also recognise LPS independent of TLR-4 
(Kayagaki et al. 2013); however, this finding is yet to be replicated in human cells. As there was no 
correlation between surface TLR-4 expression and proinflammatory cytokine protein or mRNA 
expression in HIV+ individuals, activation of inflammasomes by other TLR ligands or by direct 
interaction with inflammasome may indirectly activate cytokine production via an alternate 
pathway not involving TLR-4 signal transduction, although IL-6 and TNF are not thought to be 
direct inflammasome targets. Therefore, further studies evaluating inflammasome activation are 
required to determine whether inflammasome activation/priming contributes to higher 
proinflammatory cytokines production in HIV+ individuals. 
 
4.4.4.2  Role of other chronic viruses in primed monocyte responses to LPS 
Monocytes from HCV+ individuals are also primed to LPS challenge (Dolganiuc et al. 2003), which 
is induced by HCV core protein (Dolganiuc et al. 2007) and miR-155 induced signalling changes 
(Bala et al. 2012). Bala and colleagues identified that both monocytes and serum from HCV+ 
patients contained higher levels of miR-155 than those from HCV- individuals and that these 
levels correlated with TNF production following LPS stimulation (Bala et al. 2012). The HCV status 
of the young and elderly HIV- participants in the present study was not tested, although no 
donors self-reported as seropositive for HCV in our recruitment questionnaire. Although HCV is a 
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common co-infection associated with HIV, only one of our HIV+ donors was HCV seropositive, 
ruling out potential bias by HCV co-infection in this study group.  
 
CMV is a significant immune activator in the setting of HIV infection and ageing (discussed in 
section 1.5.2.2). Although the effects of CMV infection on monocyte responses are not well 
characterised, monocytes stimulated with UV inactivated CMV virions in vitro have been shown 
to produce IL-6 in a CD14 dependent manner (Compton et al. 2003), possibly via TLR-2 dependent 
mechanisms, as HEK-293 cells transfected with CD14 and TLR-2 produce IL-6 and IL-8 via NF-κB 
following stimulation with the same ligand. Although CMV DNA is recognised by TLR-9, human 
monocytes have limited TLR-9 expression in the steady state, and there is no evidence showing 
TLR-9 dependent recognition of CMV by monocytes. Furthermore, CMV infection is largely latent 
in healthy individuals and CMV viremia in serum is usually undetectable by standard assays, 
except in the case of fulminant CMV infection, arguing against a significant direct effect of CMV 
viral products on TLR priming.  
4.4.4.3 Contribution of circulating lipids to monocyte priming 
In addition to binding to LPS, the TLR-4/MD-2 complex can also recognise lipids such as oxLDL and 
other fatty acids contributing to proinflammatory cytokine production (i.e. TNF, (Jovinge et al. 
1996)) and lipid uptake (Howell et al. 2011). Since the data reported in this chapter was obtained, 
exposure of monocytes to oxLDL in vitro has been shown to prime monocyte production of TNF in 
response to LPS (Bekkering et al. 2014). Furthermore, oxLDL has recently been reported to be 
present at higher levels in HIV+ individuals in comparison to HIV- controls and to correlate with 
markers of monocyte activation (i.e. sCD14 and IL-6, (Zidar et al. 2015)), therefore, evaluating 
oxLDL levels in HIV+ individuals may provide insight into its contribution to primed monocyte 
responses.  
 
Bekkering and colleagues further showed that priming of monocytes by oxLDL upregulates 
trimethylation of histone 3 at lysine 4 (H3K4me3) expression, a chromatin modification, on the 
TNF and IL-6 promoters as well as those of other proinflammatory and proatherogenic markers 
not tested in the present study (e.g. IL-18, MCP-1 and CD36, (Bekkering et al. 2014)). Interestingly, 
blocking TLR-4 and TLR-2 surface expression of monocytes in vitro with appropriate antagonists 
only elicited partial reduction in primed responses, whilst incubation with PI3K and ERK inhibitors 
had a greater effect, suggesting that other, MyD88 independent pathways may play a more 
significant role in primed responses to LPS than TLR-4 dependent pathways alone. Studies in 
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HEK293 cells indicate that recognition of oxLDL by CD36 induces a TLR-6-TLR-4 heterodimer that 
is independent of the common TLR-4 co-receptor MD-2, which may explain the MyD88-
independent priming of TLR responses in response to oxLDL (Stewart et al. 2010). These findings 
may provide insight into the observation reported in this chapter of a lack of correlation between 
surface TLR-4 and gene expression of IL-6 and TNF in HIV+ individuals (Figure 4.5). 
 Limitations of the study 4.4.5
CMV status was not determined for the individuals recruited to this study, which is a limitation 
due to the potential role of CMV as a contributor to chronic inflammation and possibly primed 
monocyte responses (discussed in section 4.4.4.2). There is no consensus, however, as to what 
constitutes the most appropriate measure of CMV infection or reactivation. CMV infection is 
prominent in both HIV+ individuals (occurring in ~90% of HIV patients recruited to The Alfred 
Hospital) and the elderly (approximately 90.8% of people ≥80 years old are seropositive in the 
United States (Staras et al. 2006)). CMV is a latent infection, but it causes immune activation 
following periodic reactivation in tissues, although such reactivation is not usually manifest as 
CMV viremia in the periphery. The extent of CMV-specific immune activation is difficult to 
estimate and it is not clear how CMV antibody titres or CMV DNA in peripheral blood cells relate 
to this. CMV also induces a stable imprint on the expression of KIR inhibitory and activating 
receptors on NK cells (Béziat et al. 2013) and, as our laboratory has shown, expands a novel 
CD56dim NK subset that lacks the signalling protein FcRγ (Zhou et al. 2015), further highlighting its 
role in immune activation. Whether CMV infection primes monocyte responses to TLR-4 in vivo is 
unknown, however, as both elderly and HIV+ individuals show higher seropositivity for CMV, this 
question is relevant. Linear regression analysis adjusting for CMV status or viral load may provide 
some insight into the effect of CMV on primed monocyte responses; however, due to the large 
prevalence of CMV infection in both elderly and young HIV+ men, large cohorts would be 
required to address this. 
 
As shown in Chapter 3, the proportion of intermediate and non-classical monocytes are 
significantly expanded in both HIV+ infection and ageing. Due to the limitations on the amount of 
blood that could be obtained from our HIV+ patients by the conditions of our Ethics approval, IL-6 
and TNF gene expression analysis in individual monocyte subsets was not practical. Attempts 
were made to determine monocyte subset gene expression using SmartFlare nanoparticles 
(Merck Millipore) which quantify mRNA expression by flow cytometry, thereby requiring fewer 
cells. This method utilises gold nanoparticles expressing primers for the target gene of interest 
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(i.e. IL-6 or TNF) and fluorophores that are activated following annealing to target genes. Beads 
are cultured with cells for 16 hours to enable the endocytosis and subsequent annealing of 
primers to target mRNA. Following bead uptake, cells of interest are labelled via standard flow 
cytometry protocols with appropriate surface markers. Unfortunately due to the high, but 
variable phagocytic activity of monocyte subsets, this technique was abandoned due to non-
uniform uptake of the beads between subsets (Appendix Figure 4.3 A and B). Other flow 
cytometry-based techniques for quantifying mRNA at the single cell level, such as ViewRNA or 
FlowRNA (Affymetrix), were considered but these technologies were not available in Australia at 
the time. Therefore, unless these technologies become available, further studies with access to 
larger volumes of HIV patient blood are required to conclusively identify gene expression in 
individual monocyte subsets. Although evaluating potential differences driving primed responses 
to LPS between each monocyte subset would be of interest in terms of characterising these cells 
in HIV infection and ageing, as monocytes subsets from both the elderly and HIV+ donors showed 
similar trends in increased production of proinflammatory cytokines in response to LPS, it was not 
felt that analysis of mRNA in individual monocyte subsets was required.  
 
Similarly, p-38 MAPK and NF-κB p65 phosphorylation were only evaluated in CD14+ monocytes as 
differentiation of CD16+ subsets was not possible due to the requirement of harsh fixatives to 
stop phosphorylation of signalling intermediates, which destroyed the epitope of CD16 (Appendix 
Figure 4.2 D). While other fixative methods compatible with PhosFlow were attempted (10-40% 
formaldehyde (Sigma-Aldrich), data not shown), these also resulted in loss of CD16 detection, 
making identification of intermediate and non-classical subsets impossible. However, as 
proinflammatory cytokine production was increased in all three monocyte subsets, the evaluation 
of total monocyte cell signalling properties was deemed an appropriate surrogate for total 
monocyte response to LPS. Due to the low MFIs obtained following LPS stimulation for NF-κB p65 
phosphorylation by PhosFlow, these findings should be confirmed using conventional methods 
such as measuring NF-κB activation by western blotting. Alternatively, analysis of other signalling 
intermediates not evaluated in this study, such as MyD88 expression and IRAK1/4 
phosphorylation, may also provide insight into TLR-4 mediated signal transduction due to their 
crucial role in signal transduction in response to LPS (discussed in Introduction section 1.6.1, 
Figure 1.1). However due to the lack of antibodies for the measurement of MyD88 expression and 
IRAK1/4 phosphorylation by flow cytometry, and the large number of cells required for western 
blotting (~1.0 × 106 isolated monocytes per condition), specifically designed studies with access 
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to larger volumes of blood are required to determine the effect of HIV infection on 
phosphorylation of these signalling intermediates in response to LPS.  
 
Gene analysis of IL-6 and TNF expression in monocytes was standardised to a single house-
keeping gene (GAPDH). As previously discussed (section 2.4.2), standardising gene analysis to 
multiple house-keeping genes was not feasible as limited amount of cDNA was transcribed from 
donor monocytes due to the precious nature of stored samples. Therefore, GAPDH was chosen 
for standardisation due to its high expression in monocytes and its widespread use in studies 
evaluating monocyte response to LPS. Although LPS stimulation altered GAPDH gene expression 
in monocytes in comparison to unstimulated conditions, no difference in the median fold change 
of GAPDH expression (+LPS/-LPS) was observed between donor groups (p>0.05 for all 
comparisons, data not shown), indicating that these changes did not influence comparisons of IL-
6 and TNF gene expression between cohorts. Furthermore, as LPS stimulation induced large 
changes in TNF and IL-6 gene expression in monocytes (Figure 4.3 B and D, respectively), 
differences in GAPDH gene expression between unstimulated and LPS-stimulated conditions had 
little effect on the results reported in this study. 
 Conclusion 4.4.6
In summary, monocytes from HIV+ individuals contain higher basal proinflammatory cytokine 
intracellular concentrations, and produce more proinflammatory cytokines in response to LPS 
than age-matched HIV- individuals, and this was observed in both viremic and VS HIV+ donors. 
Furthermore, the levels observed in HIV+ individuals are similar to significantly older HIV- 
individuals, but unlike the latter, are not associated with increased TLR-4 surface expression. This 
study provides some of the first evidence that the mechanism driving heightened cytokine 
production is different in HIV infection and ageing. Due to the important role of proinflammatory 
cytokines in immune homeostasis and disease pathogenesis, primed monocyte responses may 
drive proinflammatory disease pathogenesis such as atherosclerosis. Therefore, it is of interest to 
determine whether changes to monocytes in HIV+ individuals and the elderly influence 
inflammatory disease pathology such as atherosclerosis and other inflammatory age-related 
diseases (addressed in Chapter 5). 
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CHAPTER 5 
ATHEROGENIC POTENTIAL OF 
MONOCYTES IN THE ELDERLY 
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5 CHAPTER 5 
5.1 Abstract 
Ageing is the strongest independent predictor of CVD, which is the leading cause of morbidity and 
mortality in Australia. Monocytes play a key role in atherogenesis - the major cause of CVD - as 
both phagocytes of lipid, leading to the formation of foam cells (lipid-laden macrophages), and 
producers of proinflammatory cytokines, which are independently associated with atherosclerotic 
risk. As shown in Chapter 3, monocytes from the elderly have a higher proportion of 
inflammatory intermediate and non-classical subsets in comparison to those from young men. 
Furthermore, monocytes from elderly men have higher basal- and LPS-induced expression of the 
proinflammatory cytokines IL-6 and TNF (Chapter 4), indicating that they are primed to LPS 
challenge, which may contribute to chronic inflammation. These changes are similar to those of 
monocytes from young HIV+ individuals, albeit caused by different mechanisms. Using an in vitro 
model of early atherogenesis, our laboratory recently showed that monocytes from HIV+ 
individuals have an increased propensity to form foam cells. These cells also had impaired 
cholesterol efflux that may contribute to foam cell formation and higher CVD risk in these 
individuals (Maisa et al. 2015). However, whether monocytes from the elderly are also primed for 
foam cell formation, and share similar atherogenic characteristics to those of young HIV+ men, is 
unknown.  
 
The foam cell forming abilities of monocytes from elderly men (median age [range]: 75 [58-85] 
yrs.) were compared to those of younger men (32 [23-46] yrs.). Monocytes from elderly men 
formed foam cells more readily in our atherogenesis model than those from younger donors 
(p<0.05). Expression of regulators of cholesterol synthesis and esterification (HMG-CoA reductase 
and ACAT-1, respectively) and the cholesterol efflux transporter ABCA1 was significantly lower in 
monocytes from elderly individuals in comparison to younger men (p<0.05 for all), and ex vivo 
cholesterol efflux was also impaired in monocytes from the elderly. Foam cell formation was 
influenced by soluble factors present in serum from elderly donors, as incubation of five different 
sera from elderly men with monocytes from younger men increased foam cell formation in 
comparison to matched monocytes incubated with pHS from young men (p<0.05 for all). 
However, foam cell formation did not correlate with plasma levels of lipid (i.e. HDL/LDL) and 
markers (i.e. hs-CRP and TNF) or drivers of inflammation (i.e. LPS, LBP), suggesting other 
lipid/inflammatory components prime monocytes from the elderly for foam cell formation. 
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Therefore, using an in vitro model of early atherogenesis, it is shown here that monocytes from 
older men are primed for foam cell formation via both intrinsic and extrinsic mechanisms.  
5.2 Introduction 
CVD is the leading cause of mortality in Australia and atherosclerosis is the major causative agent. 
Atherosclerosis involves the progressive recruitment of immune cells such as monocytes and DCs 
to sites of lipid deposition and inflammation, resulting in the formation of plaque in medium to 
large coronary arteries (previously discussed in Introduction section 1.9.1). Monocytes migrate 
into the neointima of the blood vessel and form foam cells (lipid-laden macrophages) following 
the uptake of unmodified (e.g. LDL) or modified (e.g. oxLDL) lipid via LDL and scavenger receptors, 
respectively (reviewed in (Angelovich et al. 2015a), Figure 1.2). In the neointima, macrophages 
and possibly foam cells phagocytose cellular debris and produce cytokines and 
metalloproteinases, which destabilise the protective fibrous layer of mature plaque resulting in 
rupture, recruitment of platelets and formation of thrombi, potentially leading to myocardial 
infarction and stroke (reviewed in (Woollard and Geissmann 2010), Figure 1.2 A). Although 
typically characterised as a metabolic disease, inflammatory mechanisms also contribute to the 
pathogenesis of atherosclerosis and proinflammatory factors are independently associated with 
atherosclerotic risk (reviewed in (Angelovich et al. 2015a), Figure 1.2 B). Ageing is associated with 
increased incidence of coronary heart disease, which is influenced by traditional risk factors such 
as smoking, hypercholesterolemia, high blood pressure and diabetes; however, ageing itself is 
also a major independent risk factor for the development of atherosclerosis (Wilson et al. 1998). 
Despite the significant effect of age on atherogenesis, few studies have evaluated the 
mechanisms governing increased risk of age-related disease independent of traditional risk 
factors. As previously described (Introduction 1.2.2), ageing is associated with systemic chronic 
inflammation and activation known as inflamm-ageing (Franceschi et al. 2000), which is thought 
to contribute to lipid-independent mechanisms elevating cardiovascular risk. Due to the 
inflammatory nature of plaque formation, chronic inflammation and immune activation may play 
a significant role in exacerbating plaque formation in the elderly.  
 
A crucial step in plaque formation in atherogenesis is the formation and accumulation of foam 
cells derived from monocytes and tissue resident macrophages, which take up and store lipid in 
lipid droplets (reviewed in (Woollard and Geissmann 2010)). Monocytes may egress from the 
plaque following lipid uptake and deliver this lipid via cholesterol efflux proteins, such as ABCA1 
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to lipoprotein acceptors to physically transport lipid to the liver for further metabolism ((Llodrá et 
al. 2004), discussed in Introduction section 1.9.2, Figure 1.2). Foam cells may arise from an 
imbalance of the lipid uptake/efflux equilibrium where excess unmodified or modified lipid 
accumulates in the cell, or hyperactive lipid biosynthesis. Ultimately apoptotic/necrotic pathways 
are induced in foam cells resulting in cell death and spillage of metabolised lipid to surrounding 
tissue, which can activate other plaque-resident cells (discussed in Introduction section 1.9.2). 
Production of proinflammatory cytokines and chemokines in the plaque promotes monocyte 
recruitment in a positive feedback loop, although the inflammatory properties of foam cells 
remain controversial (discussed in Introduction section 1.9.4).  
 
We have previously shown that monocytes from HIV+ individuals have increased propensity to 
form foam cells independent of the addition of oxLDL using a novel in vitro model of early 
atherogenesis (Maisa et al. 2015). Increased foam cell formation may be due to reduced gene 
expression of the cholesterol efflux transporter ABCA1 and impaired cholesterol efflux, which we 
observed in monocytes from HIV+ individuals in comparison to HIV- controls of similar age (Maisa 
et al. 2015). Interestingly, in HIV+ individuals a trend to increased foam cell formation with age 
was observed; however, whether monocytes from elderly individuals also have an increased 
propensity to form foam cells, and whether the mechanisms governing this are similar in these 
donors, is unknown.  
 
In Chapters 3 and 4, we showed that CD16 expressing intermediate and non-classical monocytes 
were expanded in elderly individuals and produce higher levels of proinflammatory cytokines IL-6 
and TNF (Hearps et al. 2012b). IL-6 and TNF activate endothelial cells and promote recruitment to, 
and migration into, atherosclerotic plaques (Wassmann et al. 2004) and are significantly 
associated with the presence of plaque and cIMT (Amar et al. 2006) - a well-established surrogate 
measure of coronary artery thickening and atherosclerosis. Monocytes from CAD patients also 
secrete more IL-6 and TNF following LPS stimulation and more IL-6 at baseline than controls 
(Calvert et al. 2011). As TNF can promote foam cell formation by stimulating ACAT-1 expression, 
which drives cholesterol esterification of FC to CE for storage as lipid droplets (Lei et al. 2009), 
increased production of proinflammatory cytokines in the elderly may contribute to increased 
foam cell formation and risk of CVD in these individuals. Establishing an association between 
activated circulating monocytes in the elderly and foam cell formation may indicate that 
monocytes are a useful prognostic of, and a therapeutic target to reduce, CVD risk in these 
individuals. 
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In this chapter, the propensity of monocytes from healthy, elderly men to form foam cells, and 
the mechanisms governing foam cell formation, were evaluated using a human in vitro model of 
early atherogenesis.  
5.3 Results 
 Monocytes from older men have an increased propensity to form foam 5.3.1
cells compared to those from younger individuals 
Using our optimised in vitro human model of early atherogenesis, we have shown that monocytes 
from relatively young HIV+ men have higher percentages of monocyte-derived foam cells in 
comparison to age-matched HIV- controls (Maisa et al. 2015). As shown in Chapter 4, monocytes 
from HIV+ individuals were primed to LPS challenge and produced similar levels of 
proinflammatory cytokines to those of older HIV- men; however, whether monocytes from 
elderly donors also have a higher propensity to from foam cells is unknown. Therefore monocytes, 
purified from whole blood of elderly men via negative selection (to minimise alterations in cell 
activation by antibodies used for cell isolation), were added to our model in the presence of AS 
and foam cell formation was assessed (see Methods section 2.7). 
 
Healthy young (n=20, median age [range]: 32 [23-46] yrs.) and older (n=20, 75 [58-85] yrs.) men 
were recruited into a cross-sectional cohort with ethics approval from The Alfred Human Ethics 
committee and RMIT Ethics committees (#36/02, ASEHAPP 16-15 Table 5.1, see Ethics section). 
Donor groups were matched for smoking and BMI and had no previous history of CVD. Volunteers 
undergoing anti-inflammatory (i.e. low-dose aspirin) or cholesterol altering (i.e. statins) therapy 
were excluded from participation in this study. In comparison to younger men, monocytes from 
older individuals formed a higher percentage of foam cells (Young; median (IQR): 34.0 (18.5, 
46.3)% vs Older; 51.5 (39.0, 67.0)%, p=0.003 Figure 5.1 A), indicating that foam cell formation is 
increased in monocytes from the elderly. To determine whether foam cell formation was 
accompanied by enhanced forward migration of monocytes into collagen gel, the percentage of 
total monocytes that migrated into the collagen was determined. No difference in forward 
migration was observed between monocytes from young and older men, with 94.5% (IQR: 89.7%, 
95.3%) and 95.0% (87.8%, 96.4%) of monocytes migrating into gels, respectively (Figure 5.1 B). 
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Table 5.1 Demographic and clinical information of cohort (median (range)) 
 Young Older P value 
Participants (n) 20 20 n.s 
Age  32 (23-46) 75 (58-85)  
Body mass index 23.7 (21.2-25.6) 24.8 (21.9-38.1) n.s 
Smoking    
Current 
Previous 
Never 
0% 
40% 
60% 
0% 
35% 
65% 
n.s 
n.s 
n.s 
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Figure 5.1 Propensity of monocytes from young and older individuals to forward migrate, form 
foam cells and reverse migrate. 
The percentage of foam cells in collagen (A) and the percentage of forward and reverse migrated 
cells (B) were determined for young and older individuals using our in vitro model. Monocytes 
were added to HUVEC in the presence of autologous serum (n=20 per group). The percentage of 
foam cells was determined by manual counting of foam cells and macrophages in gels by 
brightfield microscopy (x40) following Oil Red O staining. Percentage of forward migrated cells = 
100 – (cell counts of top chamber / total number of cells added x 100). The percentage of reverse 
migrated cells = cell counts reverse migrated / forward migrated cells X 100. Tukey plots show 
median and 1.5 IQR for each group. Comparisons were made using Mann-Whitney U test (* 
p<0.05, ** p<0.01). 
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However, more cells from older individuals remained in gels 48 hours post-migration as only 8.54 
(7.37, 10.3)% of forward migrated cells from older men reverse migrated in comparison to 11.8 
(7.24, 16.1%, p=0.04) from young men, indicating that cells from the elderly have impaired 
reverse migration properties. 
 
Taken together, monocytes from older individuals had a higher propensity to form foam cells in 
comparison to monocytes from younger men. Whilst forward migration was not different 
between groups, reverse migration out of gels was impaired in monocytes from the elderly. As 
foam cells are thought to be less motile following lipid uptake (Zerbinatti and Gore 2003), the 
greater number of foam cells in comparison to macrophages produced by monocytes from the 
elderly may account for their impaired migration out of gels.  
 Foam cells have a proinflammatory phenotype and inflammatory 5.3.2
intermediate monocytes form foam cells more readily than other subsets 
Monocyte subsets have different atherogenic potentials and roles in atherogenesis based on 
surface expression of attachment and adhesion molecules (Tacke et al. 2007). As shown in 
Chapter 3, elderly men have a higher proportion of proinflammatory cytokine producing 
intermediate and non-classical monocyte subsets (Hearps et al. 2012b; Angelovich et al. 2015b), 
which have been associated with higher risk of atherosclerosis in chronic CAD patients (Rogacev 
et al. 2012). In vitro and vivo mouse studies show that classical (CD14++CD16+) or patrolling 
(intermediate (CD14++CD16++) and non-classical (CD16++CD14+)) monocyte subsets have different 
migratory properties that may influence foam cell formation. However these findings are limited 
by the lack of a corresponding subset of intermediate monocytes in mice. Furthermore, human 
studies comparing the behaviour of different subsets following TEM are restricted to using highly 
artificial trans-well models. To determine the migratory and foam cell forming properties of 
individual subsets using primary human cells, individual monocytes subsets from young donors 
were purified to a high degree of purity by FACS following monocyte enrichment by elutriation 
(see Methods section 2.7.6, Figure 5.2 A-E). Purified monocyte subsets were separately added to 
TNF-activated HUVEC.  
 
Following addition of monocytes from each subset to the model, forward migration was not 
different between intermediate and classical monocyte subsets, however non-classical 
monocytes did not forward migrate as readily as the other two subsets (paired Wilcoxon test, 
p<0.05, Figure 5.2 F). However intermediate monocytes formed foam cells more than classical 
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Figure 5.2 Foam cell forming and migration properties of monocyte subsets.  
Individual monocyte subsets were isolated from elutriation-purified monocytes by FACS sorting 
based on FSC/SSC (A) and CD14/CD16 expression (B) using monocytes prepared from buffy packs 
(n=8). Representative CD14/CD16 plots of classical ((C), C), intermediate ((I), D) and non-classical 
((NC), E) purified monocyte subsets. The ability of monocyte subsets to forward migrate (F), form 
foam cells (% G) and reverse migrate (H) were assessed in the model, then differences 
determined by paired non-parametric Wilcoxon tests (median and IQR shown * p<0.05, ** 
p<0.01). 
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and non-classical subsets (intermediate median % (IQR): 49.3 (42.9, 66.5) vs classical: 32.5 (27.3, 
46.3) vs non-classical: 25.42 (22.7, 46.25), p<0.05 for both, Figure 5.2 G). No difference in foam 
cell formation was observed between classical and non-classical subsets (p=0.31). Reverse 
migration did not differ between the three monocyte subsets (Figure 5.2 H). 
 
To determine how increased foam cell formation may impact localised inflammation in plaque, 
the intracellular content of the proinflammatory cytokine TNF in cells extracted from collagen gels 
was measured by flow cytometry (Figure 5.3). Cells were extracted from gels following 48 hours 
of incubation of monocytes from young HIV- donors with pHS and stained with antibodies specific 
for intracellular TNF and appropriate isotype controls (see Methods section 2.7.5.2). Cells were 
analysed using a method optimised elsewhere of gating on CD14+ cells and discriminating large 
granular foam cells (red gate) from smaller less granular macrophages (black gate) based on FSC 
and SSC that was validated to identify foam cells from macrophages ((Maisa et al. 2015), Figure 
5.3 A). Large, granular CD14low cells, characterised as foam cells, showed higher intracellular TNF 
levels than smaller, less granular CD14+ ‘macrophage-like cells’, suggesting that foam cells are 
proinflammatory (Figure 5.3 B).  
 Monocytes from older men have decreased gene expression of 5.3.3
cholesterol efflux and metabolism intermediates. 
Monocytes from people with chronic inflammatory disease such as HIV infection (Maisa et al. 
2015) as well as CAD (Sivapalaratnam et al. 2012) have altered ability to efflux cholesterol, 
properties which may promote foam cell formation. To determine whether altered efflux activity 
may underlie increased monocyte-derived foam cell formation in the elderly, expression of the 
cholesterol efflux transporters ABCA1 and ABCG1 were measured by qPCR (see Methods sections 
2.4.1 and 2.4.2). ABCA1 and ABCG1 traffic processed cholesterol to plasma acceptors (i.e. HDL, 
apoA-1 respectively) resulting in efflux of cholesterol from stores within the cell (see Introduction 
section 1.9.2). ABCA1 expression was significantly lower in monocytes from elderly individuals in 
comparison to younger men (p=0.01, Figure 5.4 A). However, ABCG1 was expressed at very low 
levels and was not significantly altered in monocytes from elderly men (Figure 5.4 B), suggesting 
that ABCA1 may have a more significant role in cholesterol efflux in monocytes and changes to its 
expression a more significant driver of altered monocyte atherogenicity in these individuals.  
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Figure 5.3 Inflammatory phenotype of foam cells vs macrophage in an in vitro model of early 
atherogenesis. 
Foam cells and macrophage were gated by FSC/SSC (A). Large, highly granular cells were denoted 
foam cells (red) and smaller less granular cells, macrophages (black). Intracellular basal TNF levels 
were determined by flow cytometry (n=6 donors) (B). Median and interquartile ranges shown. 
Differences were tested using non-parametric Mann-Whitney U test (** p<0.01). 
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Figure 5.4 Basal expression of cholesterol metabolism and efflux genes in total monocytes from 
young and older individuals. 
Basal gene expression of genes involved in cholesterol efflux (ABCA1 (A) and ABCG1 (B)), 
cholesterol synthesis/esterification (HMG-CoA reductase (C) and esterification ACAT-1 (D)) in 
total monocytes of young and older individuals was determined by qPCR (n=10 per cohort). Genes 
were standardised to GAPDH controls. Tukey plots show median and 1.5 IQR and outliers as dots. 
Mann-Whitney U test (* p<0.05, ***p<0.001). 
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Next, to determine whether monocytes from elderly men may store more cholesterol from de 
novo synthesised sources in comparison to those of younger individuals, expression of key 
regulators of cholesterol synthesis and esterification were measured. HMG-CoA reductase, the 
rate-determining step in cholesterol synthesis via the mevalonate pathway, and ACAT-1, which 
esterifies FC for storage as CE, have both been shown to be key components in foam cell 
formation (reviewed in (McLaren et al. 2011)). In comparison to monocytes from younger men, 
gene expression of both HMG-CoA reductase and ACAT-1 were lower in monocytes from the 
elderly (p<0.05 for both, Figure 5.4 C and D, respectively), suggesting cholesterol 
synthesis/esterification gene transcription is switched off, possibly in response to large 
intracellular stores of cholesterol due to impaired efflux mechanisms. 
 
Taken together, gene expression of the cholesterol efflux transporter ABCA1 was significantly 
lower in monocytes from older donors in comparison to those from younger men. Interestingly, 
gene expression of regulators of cholesterol synthesis/esterification were also lower in 
monocytes from the elderly, suggesting that while cholesterol efflux may be impaired by 
decreased production of ABCA1 protein, monocytes from elderly donors may produce less 
cholesterol, possibly in response to higher accumulated cholesterol levels within the cell. 
 Cholesterol efflux is impaired in monocytes from older men. 5.3.4
To determine the functional consequences of decreased ABCA1 gene expression in monocytes 
from the elderly, efflux of BODIPY-labelled cholesterol by monocytes was measured by flow 
cytometry (see Methods section 2.5). Following one hour of loading with BODIPY-labelled 
cholesterol, monocytes from elderly individuals showed no difference in the total BODIPY-
cholesterol content (Figure 5.5 A). BODIPY-cholesterol loaded monocytes were then incubated for 
30 minutes with or without the cholesterol acceptor methyl-β-cyclodextrin. Efflux of cholesterol 
in the presence of acceptor was then compared between the groups. In comparison to young 
donors, monocytes from older men had significantly lower percentages of cholesterol efflux 
(p<0.05, Figure 5.5 B), showing that decreased expression of ABCA1 is associated with lower 
cholesterol efflux in monocytes from these individuals.  
 
In summary, efflux of cholesterol from monocytes from elderly individuals is significantly impaired 
in comparison to that of younger individuals, which may contribute to lipid accumulation in 
monocytes from the elderly. These findings represent intrinsic changes to monocytes from the 
elderly, indicating that they are primed for foam cell formation whilst in circulation.  
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Figure 5.5 Efflux of BODIPY labelled cholesterol from monocytes from young and older 
individuals. 
Monocytes from young and older individuals (n=8 per cohort) were incubated with BODIPY 
labelled cholesterol for one hour and cholesterol uptake in CD14+ monocytes determined by flow 
cytometry (A). The percentage of cholesterol efflux from monocytes following 30 minutes 
incubation with the cholesterol acceptor methyl-β-cyclodextrin as a percentage of total loaded 
cholesterol was determined after subtracting background efflux (no methyl-β-cyclodextrin added) 
(B). Tukey plots show median and 1.5 IQR for each group. Comparisons made using Mann-
Whitney U test (* p<0.05). 
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 Soluble factors contribute to foam cell formation in the elderly 5.3.5
Markers of hyperlipidaemia and inflammation are independently associated with increased risk of 
CVD in the elderly (see Introduction section 1.3.1). Although the findings above show that 
monocytes from the elderly have intrinsic atherogenic changes, extrinsic soluble factors may also 
contribute to foam cell formation. To determine whether soluble components present in serum 
from the elderly also contribute to foam cell formation, in addition to intrinsic changes to 
monocytes, monocytes from elderly men were added to the model in medium containing either 
pHS or AS. Incubation of monocytes with AS enhanced foam cell formation in comparison to the 
same monocytes incubated with pHS (Figure 5.6 A), suggesting that serum factors are present or 
elevated in elderly donors that stimulate foam cell formation. Incubation with AS did not 
influence forward migration of monocytes from the elderly, however monocytes incubated with 
AS showed significantly impaired reverse migration in comparison to pHS controls (Figure 5.6 B) 
consistent with their increased propensity for foam cell formation.  
 
In the experimental design used above, individual serum samples were tested on their autologous 
monocytes. To determine whether serum factors in the elderly promote foam cell formation 
independent of intrinsic changes to monocytes, stored sera from five elderly donors were 
individually incubated with monocytes isolated from six young individuals, and foam cell 
formation compared to that obtained using pHS (Figure 5.7 A). To control for the potential of 
serum components to influence monocyte attachment and migration, forward migration was 
conducted in the presence of pHS, and serum from older men was only added post-migration 
after thorough washing to remove pHS. Each of the sera from the elderly donors (1-5), when 
incubated with monocytes from younger donors, increased foam cell formation in comparison to 
monocytes incubated with pHS from younger donors, indicating that components in the sera of 
elderly men enhance foam cell formation independent of intrinsic changes to monocytes (p<0.05 
for all, Figure 5.7 B).  
 
Taken together, whilst a higher propensity of monocytes from elderly donors to form foam cells is 
associated with intrinsic changes to cholesterol efflux and synthesis/esterification, other soluble 
factors in serum from the elderly also promote foam cell formation independent of intrinsic 
changes to monocytes.  
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Figure 5.6 Effect of autologous serum on cell migration and foam cell formation from 
monocytes from elderly men. 
Foam cells (%) in collagen (A) and forward and reverse migrated cells (%) was determined (B) for 
monocytes from older individuals incubated with either serum from young individuals (pooled 
human serum (pHS) pooled from 18 donors with a median age of 37 yrs.) or autologous serum 
(AS) in our in vitro model (n=20). The percentage of foam cells determined by manual counting of 
foam cell and macrophage in gels by microscopy (x40). Percentage of forward migrated cells = 
100 – (cell counts of top chamber / total number of cells added x 100). The percentage of reverse 
migrated cells = cell counts reverse migrated / forward migrated cells X 100. Tukey plots show 
median and 1.5 IQR and outliers as dots for each group. Comparisons were made using paired 
Wilcoxon tests (** p<0.01, **** p<0.0001). 
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Figure 5.7 Effect of serum from elderly men on foam cell formation by monocytes from young 
donors. 
Monocytes from young donors (n=6, median age [range]: 32 [27-34] yrs.) were incubated with 
sera from 5 elderly donors (with the indicated age) or pooled human serum (pHS, from 18 
different donors median age: 37 yrs.) following forward migration across TNF activated HUVEC 
and the percentage of foam cells vs. macrophages determined by brightfield microscopy (A). 
Foam cell formation in the presence of serum from elderly donors (1-5) or pHS is shown. 
Comparisons made using paired Wilcoxon tests (* p<0.05, ** p<0.01, ***p<0.001) Median and 
IQR shown (B). 
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 The foam cell forming abilities of monocytes from elderly men do not 5.3.6
correlate with plasma lipid, TNF or hs-CRP levels. 
Soluble LDL levels and LDL/HDL ratios are measured as indicators of hyperlipidaemia and are 
associated with increased risk for atherosclerosis (Tarchalski et al. 2003). Furthermore, LDL levels 
are generally elevated in the elderly; however, reports of the relationship between LDL levels and 
atherosclerosis in the elderly are conflicting (Zimetbaum et al. 1992; Chyou and Eaker 2000; 
Tikhonoff et al. 2005). To determine whether plasma LDL/HDL levels contribute to enhanced 
foam cell formation by monocytes from elderly donors, plasma LDL and HDL were measured 
using non-fasting donor serum (see Methods section 2.6). Though generally measured on fasting 
blood samples, non-fasting lipid levels from control donors are predictive of CVD and are not 
significantly altered by normal food intake (Langsted et al. 2008). In comparison to younger men, 
no difference in plasma LDL and HDL levels were observed between young and older donors 
(Figure 5.8 A and C, respectively), suggesting that the levels of these lipoproteins did not 
confound the comparison made above of the atherogenic properties of serum from young and 
elderly subjects. To determine whether there was any relationship between plasma lipid levels 
and foam cell formation, young and older donors were grouped and linear regression analysis was 
performed. No association between autologous plasma LDL, HDL (Figure 5.8 B and D, respectively) 
or LDL/HDL ratio (data not shown) and the percentage of foam cell formation by respective 
monocytes from young and older men was observed, suggesting that plasma lipid levels did not 
influence monocyte-derived foam cell formation in this cohort.  
 
Inflammatory cytokines (i.e. IL-6, TNF) and TLR ligands (i.e. LPS) are also known to influence foam 
cell formation (reviewed in (Angelovich et al. 2015a)). To determine whether soluble levels of 
inflammatory markers were elevated in the elderly and whether plasma levels correlated with 
foam cell formation, plasma hs-CRP and TNF levels were measured due to their strong 
independent associations with atherogenesis ((Bruunsgaard et al. 2000; Burke et al. 2002; Kablak-
Ziembicka et al. 2011), Table 1.2). A trend to higher plasma TNF existed in older individuals in 
comparison to younger men (p=0.14), however this did not reach significance and no association 
with foam cell formation was observed by linear regression analysis (Figure 5.9 A and B, 
respectively). Furthermore hs-CRP levels did not differ between groups and were also not 
associated with foam cell formation (Figure 5.9 C and D, respectively).  
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Figure 5.8 Influence of plasma lipid levels on foam cell formation in young and older individuals. 
Plasma LDL (A) and HDL (C) levels were determined using a plasma lipid assay kit specific for 
LDL/vLDL and HDL. Bars represent median and IQR. Linear regression analysis between matched 
foam cell and plasma LDL (B) and HDL (D) data was performed in a combined cohort of young and 
older donors (n=40). 
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Figure 5.9 Influence of inflammatory markers on foam cell formation in young and older 
individuals. 
Plasma TNF (A) and hs-CRP (C) levels were determined using ELISA based assays. Bars represent 
median and IQR. Linear regression analysis between matched foam cells (conducted in the 
presence of autologous serum) and plasma TNF (B) and hs-CRP (D) was performed in a combined 
cohort of young and older donors (n=40). 
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Taken together, monocyte-derived foam cell formation was not associated with plasma lipid (LDL, 
HDL, LDL/HDL ratio) and inflammatory levels (TNF, hs-CRP), suggesting other soluble components 
contribute to foam cell formation. 
 LPS stimulation of HUVECs or monocytes promotes foam cell formation 5.3.7
independent of TNF 
PAMPs have been shown to influence foam cell formation independent of lipid dependent 
mechanisms by either directly interacting with monocytes/macrophages to promote cholesterol 
influx/synthesis or impair cholesterol efflux, or with plaque resident cells such endothelial cells 
((Angelovich et al. 2015a), discussed in Introduction section 1.7). As plasma levels of LPS were 
shown to be elevated in elderly donors in Chapter 3 and 4 (Hearps et al. 2012a), the effect of LPS 
stimulation of HUVEC on foam cell formation was evaluated. Incubation of HUVEC with increasing 
concentrations of LPS, before adding monocytes to the model, resulted in increased monocyte-
derived foam cell formation (Figure 5.10 A). Maximal foam cell formation was observed after 
stimulation of HUVEC with 1000 pg/mL LPS, which was similar to levels of foam cell formation 
observed when HUVEC were stimulated with 10 ng/mL TNF (LPS: 55% vs TNF: 53%, Figure 5.10 A). 
Interestingly, LPS stimulation with concentrations between 10-100 pg/mL elicited significant 
dose-dependent formation of foam cells, which is highly relevant given that we have shown 
concentrations between 25-100 pg/mL are found in plasma from elderly individuals ((Hearps et al. 
2012b), Appendix Table 4.2).  
 
Next, to determine the effect of LPS stimulation of monocytes on foam cell formation, monocytes 
were stimulated with 10 ng/mL LPS (chosen as a saturating concentration based on induction of 
proinflammatory cytokine production after four hours stimulation (see Chapter 4, Appendix 
Figure 4.1)) before being added to unactivated or TNF-activated HUVEC. In comparison to 
unstimulated or TNF-stimulated monocytes, LPS stimulated monocytes showed enhanced foam 
cell formation (unstimulated; average foam cell formation: 9.12% vs TNF stimulated; 16.9% vs LPS 
stimulated; 44.0%, Figure 5.10 B), suggesting that LPS can directly stimulate monocytes to adopt a 
foam cell morphology after TEM. LPS was a more potent inducer of foam cell formation than TNF 
(Figure 5.10 B). Next, plasma LPS levels were measured and correlated with foam cell formation 
by monocytes in the presence of AS from those donors. Contrary to our in vitro findings, no 
association with plasma LPS levels and foam cell formation was observed in a combined cohort of 
young and older donors (Figure 5.10 C). However, as levels obtained were significantly lower in 
this cohort than in previous assays measuring LPS (Chapter 4 Appendix Table 4.2), LBP levels were 
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Figure 5.10 Effect of LPS stimulation of HUVEC and/or monocytes on monocyte-derived foam 
cell formation. 
Monocytes were added to HUVEC stimulated for 4 hours with increasing concentrations of LPS or 
10 ng/mL TNF (dotted line) and foam cell formation (%) determined by brightfield microscopy (A). 
Data represent median and IQR of 3 independent experiments. Monocytes and/or HUVEC were 
stimulated with either LPS (10 ng/mL) or TNF (10 ng/mL) for 4 hours before addition to the 
model. After 48 hours incubation, foam cell formation (%) was determined by brightfield 
microscopy (B). Bars represent median foam cell formation from 3 independent experiments (%). 
Plasma LPS (C) and LBP (D) levels in young and older individuals were determined by LPS LAL and 
LBP ELISA and associations with foam cell formation tested by linear regression analysis. P values 
of association shown. 
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measured as a surrogate marker of LPS to confirm this interaction. Similar to our observations 
with LPS, plasma LBP levels from elderly donors were not associated with foam cell formation 
(Figure 5.10), suggesting that LPS most likely did not significantly contribute to the atherogenic 
properties of serum in this limited sample group.  
 
Taken together, preliminary studies show that activation of HUVEC with physiological levels of LPS 
can promote foam cell formation by monocytes. Activation of monocytes with LPS also promotes 
an increased propensity to form foam cells, suggesting that this may contribute to atherogenic 
properties of monocytes in the elderly; however, no association between foam cell formation and 
plasma LPS or LBP levels were identified in this cohort. However, as LPS levels varied significantly 
from our previous findings (Chapter 3 and 4), further studies determining the influence of LPS on 
the ability of monocytes from the elderly to form foam cells may better delineate the effect of 
plasma LPS on foam cell formation in the elderly. 
5.4 Discussion 
In this chapter monocytes from elderly men were shown to form foam cells more readily than 
those from younger men using an in vitro model of early atherogenesis. Monocytes from the 
elderly had lower expression of the cholesterol efflux transporter ABCA1 and impaired cholesterol 
efflux in comparison to younger donors, suggesting that dysregulated cholesterol efflux 
mechanisms may account for their higher propensity to form foam cells in vitro. Interestingly, 
increased foam cell formation possibly induced by impaired cholesterol efflux was also observed 
in a parallel study conducted by Dr Anna Maisa using monocytes from HIV+ individuals (Maisa et 
al. 2015), indicating that in addition to the findings of a similar phenotype shown in Chapter 3, 
and primed monocyte response to LPS shown in Chapter 4, monocytes from both HIV+ individuals 
and the elderly are also primed for greater foam cell formation (discussed further in section 5.4.7). 
Gene expression of key regulators of cholesterol synthesis and esterification were also lower in 
comparison to younger men, possibly in response to higher intracellular levels of cholesterol 
within cells.  
 
In addition to intrinsic atherogenic changes to monocytes from the elderly, soluble components in 
sera from the elderly had a proatherogenic effect on monocytes from young men as foam cell 
formation was increased following incubation with sera from elderly men. These findings indicate 
that soluble factors contribute, in part, to foam cell formation in these individuals. However foam 
cell formation did not correlate with traditional lipid markers (LDL and HDL) or inflammatory 
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markers (hs-CRP and TNF), suggesting that either other soluble components are responsible or 
that these inflammatory factors act together to increase the atherogenic properties of serum, and 
that this study was not adequately powered to detect the influence of any single factor on the 
atherogenic properties of monocytes. LPS was shown to influence foam cell formation in vitro, 
however, plasma LPS and LBP levels were not associated with foam cell formation in linear 
regression analysis. Finally, analysis of the foam cell forming activity of the three monocyte 
subsets showed that the intermediate subset, which is significantly expanded in the elderly (Table 
3.2), had a significantly higher propensity to form foam cells in comparison to the other subsets. 
To our knowledge this is the first evidence of an enhanced foam cell forming ability of this subset. 
Together, these findings indicate that monocytes from elderly men are primed for foam cell 
formation by both extrinsic and intrinsic changes, which may drive atherogenesis in these 
individuals. 
 Decreased cholesterol efflux, and not increased cholesterol 5.4.1
synthesis/esterification, contributes to foam cell formation by monocytes 
from the elderly. 
The finding of decreased ABCA1 gene expression and impaired cholesterol efflux in monocytes 
from elderly donors in comparison to those of younger men suggests that foam cell formation 
may be driven by increased retention of cholesterol. These findings are consistent with those of 
other inflammatory conditions, such as HIV infection where we and others have shown that 
monocytes from HIV+ individuals (Maisa et al. 2015), as well as patients with CAD 
(Sivapalaratnam et al. 2012), have lower ABCA1 gene expression than controls. Whilst the 
mechanism driving decreased gene expression of ABCA1 was not determined in this study, the 
immunological similarities of HIV infection and ageing described in Chapter 3 and 4 suggests that 
components of the inflammatory milieu may drive down regulation of these transporters 
(discussed further in section 5.4.2). Although monocytes from elderly men had lower levels of 
ABCA1 gene expression and cholesterol efflux in comparison to those of younger individuals, no 
difference was observed in ABCG1 expression (Figure 5.4 A and B, respectively). This observation 
may be due to extremely low gene expression detected by the qPCR assay, possibly suggesting 
that ABCG1 does not play an important role in cholesterol efflux in monocytes. However, as 
ABCG1 has been shown to be expressed at lower levels in monocytes from patients with early 
onset CAD (Sivapalaratnam et al. 2012), larger cohort studies with more sensitive probe based 
qPCR chemistry are required to determine ABCG1 expression in monocytes from elderly 
individuals.  
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Interestingly, gene expression of rate limiting enzymes of cholesterol synthesis and esterification 
(i.e. HMG-CoA reductase and ACAT-1, respectively) were also lower in monocytes from older men 
in comparison to younger donors (Figure 5.4 C and D). Lower gene expression may signify a 
response to high levels of accumulated lipid that would be associated with foam cell formation, 
therefore acting as a negative feedback mechanism to stop excess cholesterol production. 
However, further studies measuring intracellular lipid content, possibly by BODIPY staining or 
commercial cholesterol assays, are required to quantify intracellular lipid content from these cells 
in younger and older donors.  
 
The findings reported in this chapter are of interest in regards to treatment strategies for CVD risk 
in the elderly. Statins are prescribed to older individuals with moderate to high risk of CVD based 
on Framingham risk score (Alliance 2012) and act by impairing cholesterol synthesis regulated by 
HMG-CoA reductase (Harley et al. 2007) as well as having an anti-inflammatory role, which has 
been shown to target cholesterol efflux (Wang et al. 2013). Studies as a part of the Justification 
for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin 
(JUPITER) trial show beneficial effects in older individuals with moderate to high CVD risk based 
on higher hs-CRP levels (Glynn et al. 2010). However, our finding of decreased HMG-CoA 
reductase gene expression in monocytes from the elderly suggests that the anti-inflammatory 
properties of statin therapy may have a more crucial therapeutic benefit than specifically 
targeting this enzyme in individuals with low CV risk (based on hs-CRP levels) as HMG-CoA 
reductase gene expression is already down-regulated (Figure 5.4 C). Therefore, modifying the 
atherogenic potential of monocytes in elderly men with low CVD may be a more appropriate drug 
target in these individuals.  
 
Few cholesterol efflux modifying therapies are currently clinical available, however recent studies 
have identified potential drugs for clinical use. Anthocyanin, a flavonoid that protects LDL and 
HDL from oxidation, has been shown to improve LDL/HDL ratios and cholesterol efflux in 
hypercholesterolemic individuals supplemented for 24 weeks (Zhu et al. 2014). CSL112, a 
modified form of HDL derived from apoA-1, has also been shown to promote cholesterol efflux in 
patients with CVD regardless of patient HDL levels (Gille et al. 2014). These preliminary findings 
suggest that targeting cholesterol efflux may be a viable drug target, however further studies are 
required to validate these therapies for widespread clinical use so that these effect of these 
treatments can be determined in elderly individuals with low cardiovascular risk.  
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 Potential mechanisms of altered cholesterol efflux in monocytes from the 5.4.2
elderly. 
Increasing evidence supports the role of inflammation in foam cell formation (as reviewed in 
(Nicolaou and Erridge 2010; Angelovich et al. 2015a)). Incubation of sera from elderly individuals 
with monocytes from younger men promoted foam cell formation, suggesting that serum 
components promote cholesterol retention possibly by mechanisms such as down-regulation of 
ABCA1 gene expression on monocytes. ABCA1 expression is regulated by the LXR pathway 
(discussed in section 1.10.3) and has been shown to be down-regulated by LPS in an NF-κB 
dependent manner in mouse macrophages ((Baranova et al. 2002), Figure 1.3), although this 
mechanism needs to be confirmed in human monocytes. The higher surface TLR-4 expression on 
monocytes from the elderly, reported in Chapter 4, suggests that decreased ABCA1 expression on 
monocytes from the elderly may be a consequence of greater LPS-mediated signalling. Therefore, 
down-regulation of ABCA1 expression may be a by-product of primed monocyte responses, 
although further examination of the pathways regulating ABCA1 in the elderly are required to 
delineate this interaction. 
 
Chronic viral infections such as those caused by CMV or other herpes viruses, which are 
increased/reactivated in the elderly, may also influence ABCA1 gene expression. Sanchez and 
colleagues showed that human CMV infection of THP-1 derived macrophages in vitro decreases 
mRNA and protein levels of ABCA1, however infection also impaired oxLDL-stimulated foam cell 
formation (Sanchez and Dong 2010), suggesting further studies are required to elucidate the role 
of CMV in atherogenesis. While CMV viral load or antibodies were not measured in this study, 
based on our observations of increased foam cell formation in monocytes from the elderly, 
studies in collaboration with Professor Patricia Price are currently underway to evaluate the 
contribution of CMV infection to foam cell formation in the elderly. Therefore, correlating 
markers of CMV activation such as anti-CMV antibodies with monocyte-derived foam cell 
formation and ABCA1 gene expression in our model may provide further insight into the influence 
of CMV on monocyte cholesterol efflux and foam cell formation in the elderly. 
  
Taken together, serum components such as proinflammatory cytokines as well as PAMPs may 
down-regulate ABCA1 gene expression in monocytes from elderly individuals. Further studies are 
required to delineate the contribution of these mechanisms on foam cell formation in the elderly. 
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 Enhanced foam cell forming abilities of monocytes from elderly men is 5.4.3
independent of LDL/HDL levels 
The findings of an increased propensity of monocytes from the elderly to form foam cells 
reported in this chapter supports the few studies that have evaluated monocyte-derived foam 
cell formation in aged individuals. Friedman and colleagues showed that addition of acetylated 
LDL and 3H cholesterol to MDM from elderly donors resulted in the formation of 3H CE twice as 
readily as macrophages from younger donors (Friedman et al. 1997). However, this study was 
conducted using artificial experimental conditions where high, non-physiological levels of 
exogenous modified lipid were incubated with monocyte-derived macrophages independently of 
cellular migration. Our model of early atherogenesis couples migration of monocytes across an 
activated endothelium with foam cell formation in the absence of exogenous modified lipid 
(Westhorpe et al. 2012), thus providing a more physiological representation of lipid modification 
and uptake. Therefore, our findings extend previous studies to identify the contribution of lipid 
independent mechanisms on foam cell formation in the elderly.  
 Role of monocyte subsets in foam cell formation in the elderly 5.4.4
The finding of increased foam cell formation by the intermediate monocyte subset implies that 
the expansion of CD16 expressing monocytes in the elderly may promote atherogenesis in these 
individuals. Cross-sectional studies have shown that the proportion of intermediate monocytes 
correlates with cardiovascular events in CAD patients (Rogacev et al. 2012). The increase in foam 
cell formation by intermediate monocytes compared to other subsets was significant (~40%, 
(Figure 5.2 G)), thus the expansion of the intermediate subset indicates that this change may have 
a considerable impact on elderly individuals in vivo. 
 
Foam cells derived from migrated monocytes were also shown to express higher intracellular 
levels of TNF than macrophages in this model (Figure 5.3). As ageing is associated with an 
increase in CD16 expressing monocytes, which are primed to LPS challenge (Figure 4.2), a 
preferential differentiation of intermediate monocytes into foam cells within atherosclerotic 
plaques may enhance TNF production contributing to a positive feedback loop that promotes 
further foam cell formation. However, further studies are required to determine whether higher 
intracellular TNF levels and response to LPS in circulating monocyte subsets translates into a more 
inflammatory environment in plaque. 
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 Role of other lipids in foam cell formation 5.4.5
Recently, in vitro addition of oxLDL to monocytes has been shown to reprogram monocytes for a 
proinflammatory phenotype characterised by primed proinflammatory cytokine in response to 
LPS (Bekkering et al. 2014). These authors show that monocytes stimulated with oxLDL for 24 
hours up-regulated IL-6, TNF and MCP-1 production following LPS stimulation. Interestingly pre-
exposure to oxLDL also resulted in increased foam cell formation following incubation with high 
levels of oxLDL showing that monocytes are primed for foam cell formation by oxLDL. 
Furthermore, oxLDL down regulated ABCA1 gene expression in monocytes, inducing a phenotype 
similar to that described in this chapter for monocytes from elderly individuals. oxLDL was not 
measured in plasma from the donors used in this study, which is a major limitation. However, in a 
parallel study by Maisa et al., oxLDL levels were measured and did not correlate with foam cell 
formation by monocytes from HIV+ and age-matched HIV- individuals (Maisa et al. 2015).  
 LPS activation of monocytes and/or HUVEC promotes foam cell formation 5.4.6
PAMPs such as LPS are present in higher levels in the elderly ((Goto et al. 1994; Hearps et al. 
2012a), Chapters 3 and 4) and plasma LPS levels are associated with a threefold increased 
incidence of atherosclerosis independent of hyperlipidaemia (Wiedermann et al. 1999). The in 
vitro findings reported here that LPS influences the role of both monocytes and HUVEC in 
monocyte-derived foam cell formation (Figure 5.10) suggest that higher LPS levels may be a factor 
influencing foam cell formation in the elderly. These findings may also suggest LPS influences 
monocyte-derived foam cell formation in other chronic inflammatory diseases, such as HIV 
infection where donors experience levels of LPS that are similar to elderly individuals (Hearps et al. 
2012a); a higher risk of atherosclerosis independent of hyperlipidaemia; and higher atherogenic 
properties of monocytes in comparison to HIV- controls ((Maisa et al. 2015), reviewed in 
(Angelovich et al. 2015a)). Although no association between plasma LPS levels and the ability of 
monocytes from elderly men to form foam cells was observed in this study, the effect of serum 
components are likely to be multifactorial, suggesting that only a small proportion of serum 
effects may be due to any single driver of inflammation, such as LPS. Therefore, expanding these 
studies with larger numbers of study participants may be necessary to determine the relevance of 
plasma LPS to foam cell formation. Furthermore, the LAL endotoxin assay is not considered a 
robust assay for plasma LPS due to the presence of a number of proteins in plasma that can bind 
LPS and interfere in the assay (Balagopal et al. 2012). Therefore, using surrogate markers for 
plasma LPS such as sCD14 and endoCAB may be considered in determining the role of LPS in foam 
cell formation. 
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In addition to activating monocytes, LPS has been shown to activate TLR-4 expressing endothelial 
cells by trans-signalling via sCD14 and LBP (Pugin et al. 1993). LPS activation of human coronary 
artery endothelial cells (HCAEC) upregulates adhesion receptor expression (ICAM-1, VCAM) and 
enhances proinflammatory cytokine production (IL-6, IL-8 and MCP-1, (Zeuke et al. 2002)), which 
may explain our observations of heightened foam cell formation following incubation of HUVEC in 
our model with increasing concentrations of LPS (Figure 5.10 A). However, forward migration of 
cells added to HUVEC stimulated with LPS was not evaluated in this study, indicating further 
studies are required to identify the mechanisms governing LPS activation of endothelial cells on 
foam cell formation. 
 
Together, these findings suggest that circulating LPS levels may contribute to the atherogenic 
properties of both monocytes and serum from the elderly. 
 Primed foam cell formation by monocytes from HIV+ individuals and the 5.4.7
elderly may be driven by similar mechanisms 
We have shown in a parallel study that monocytes from VS HIV+ individuals more readily form 
foam cells compared to those from age-matched HIV- individuals (Maisa et al. 2015), however, 
whether monocytes from both elderly HIV- and younger VS HIV+ individuals are primed for foam 
cell formation by a similar mechanism is unknown. The percentage of foam cells formed by 
monocytes of elderly men could not be directly compared to those of VS HIV+ individuals 
measured by Dr Anna Maisa due to potential operator bias inherent with manual counting. 
However, monocytes from HIV+ individuals and the elderly formed approximately 80-100% more 
foam cells than their respective age-matched or young HIV- controls, suggesting that a similar 
increase in foam cell formation occurs in each group.  
 
Interestingly, monocytes from both populations had lower gene expression of ABCA1 and 
impaired cholesterol efflux, indicating that impaired cell mediated cholesterol efflux contributes 
to increased foam cell formation in both VS HIV+ individuals and the elderly. Furthermore, serum 
from elderly and VS HIV+ individuals promoted the formation of foam cells by monocytes from 
control donors, suggesting that both intrinsic changes to monocytes and soluble components can 
drive foam cell formation. Importantly, key differences were observed between the study 
reported in this thesis and the study by Dr Maisa on the foam cell forming properties of 
monocytes from HIV+ individuals. Plasma TNF levels were higher in VS HIV+ men in comparison to 
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controls and blocking of TNF receptors I and II impaired foam cell formation. Whilst plasma TNF 
levels are known to be elevated in the elderly (Bruunsgaard et al. 2000), we did not observe a 
difference in TNF levels in the individuals enrolled in this study, probably due to the relatively 
small size of the study group. Although a difference in TNF levels between VS HIV+ individuals and 
controls was observed in a similar number of donors, this is not surprising as it was shown in 
Chapter 3 that VS HIV+ individuals have higher levels of markers of monocytes activation than 
age-related changes in HIV- men and therefore may not have as high levels of plasma TNF. No 
difference in ACAT-1 expression was also observed in monocytes from HIV+ individuals, possibly 
suggesting that esterification and therefore cholesterol ester storage is more important in foam 
cell formation in the elderly than in HIV+ individuals. 
 
Together, comparison between these studies provides insight into the similar traits in the foam 
cells forming properties between HIV+ individuals and the elderly; however, specifically designed 
studies comparing the mechanisms driving foam cell formation in these groups are required to 
delineate discrete changes in both populations. 
 Limitations of the study 5.4.8
Foam cell formation was evaluated in healthy, asymptomatic individuals that may have led to 
unintentional recruitment bias. Individuals over 65 years old who had a history of heart disease or 
were currently taking anti-inflammatory and/or lipid altering medication were excluded from this 
study. As a significant proportion of older individuals are prescribed either one or both of these 
classes of medication, excluding individuals on the basis of these criteria may have inherently 
selected for donors with better cardiovascular health. Large variation in plasma LDL/HDL levels 
was observed in young men in comparison to the elderly, possibly suggesting that this elderly 
group may have taken more proactive steps to monitor cardiovascular risk and respond to 
elevated risk by modifications to lifestyle (e.g. diet, exercise etc.). Furthermore, due to relatively 
small numbers in each group, effects of plasma factors may be teased out using larger group sizes. 
Clinical or surrogate measures (e.g. cIMT) of atherosclerosis were not evaluated in this study. 
Therefore, evaluating the effect of lipid levels on foam cell formation in elderly donors with a 
range of cardiovascular risk and linking the propensity of monocytes from the elderly to form 
foam cells may better delineate the role of inflammation and lipids on foam cell formation.  
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 Future studies 5.4.9
This study shows a significantly higher propensity of monocytes from elderly men to form foam 
cells, possibly due to impaired cholesterol efflux mechanisms providing the basis to use this 
model in elderly men as a predictor of cardiovascular health. Future studies coupling monocyte-
derived foam cell formation with clinical outcomes of atherosclerosis such as cIMT, 
Framingham/Reynold’s risk score or CVD incidence will identify the sensitivity of this assay to 
predict CV events. Importantly, as foam cell formation was higher in ‘healthy’ asymptomatic 
elderly individuals in comparison to younger men and was independent of plasma hs-CRP levels 
(albeit in a small cross-sectional study), the findings obtained using this model suggest that this 
method may be a better indicator of cardiovascular health than current risk score estimates such 
as the Reynold’s score, which incorporates plasma hs-CRP to the standard risk factors 
encompassed in the Framingham risk score. Therefore, linking donor monocytes’ propensity to 
form foam cells ex vivo with clinical measures of CVD (i.e. cIMT, incidence of cardiovascular 
events) will form the basis of research into early monocytic events in atherogenesis in not only 
the elderly, but also in HIV+ individuals. Furthermore, expanding these studies into longitudinal 
cohorts may delineate age-related risk of foam cell formation in asymptomatic men, highlighting 
when these individuals may have greater cardiovascular risk that is not detected by standard 
clinical measures. Finally, identifying the contribution of plasma LPS levels, and other PAMPs in 
foam cell formation, may provide insight into how foam cell formation is altered in inflammatory 
disease.  
 Conclusion 5.4.10
In summary, monocytes from healthy elderly men were shown to be primed for foam formation 
via both intrinsic and extrinsic mechanisms. Monocytes from the elderly had lower expression of 
the cholesterol transporter ABCA1 and impaired cholesterol efflux in comparison to young 
controls. Intermediate monocytes were shown to have a significantly greater potential to form 
foam cells following TEM and foam cells themselves are proinflammatory, producing TNF, 
suggesting that the proatherogenic changes to monocytes in the elderly may predispose them to 
form foam cells. Finally, enhanced formation of foam cells was independent of LDL and HDL 
lipoprotein levels, suggesting that components of the inflammatory milieu, and possibly other 
lipid species, may contribute to foam cell formation in these individuals. These findings provide 
the basis for further studies evaluating atherogenic risk in asymptomatic elderly individuals.  
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CHAPTER 6 
GENERAL DISCUSSION 
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6 GENERAL DISCUSSION 
Chronic inflammation and immune activation is a common hallmark of both HIV infection and 
ageing (Hearps et al. 2011; Hearps et al. 2014). We have previously shown that monocytes from 
HIV+ individuals have a similar phenotype to those of a comparison group of older HIV- 
individuals (Hearps et al. 2011; Martin et al. 2013). Furthermore, monocytes from HIV+ men have 
a greater potential to form foam cells compared to HIV- controls of similar age (Maisa et al. 2015). 
This thesis expands on these observations, identifying that in addition to phenotypic changes and 
impaired phagocytic ability, monocytes from HIV+ men and the elderly contain elevated basal 
levels of proinflammatory cytokines and are hyper-responsive to LPS challenge. Furthermore, 
monocytes from older HIV- men have a higher propensity to form foam cells in comparison to 
those from younger HIV- men. This observation is similar to findings from a parallel study of HIV+ 
individuals conducted in our laboratory, and adds to our data showing that monocytes from HIV+ 
individuals have phenotypic and functional similarities to those of older HIV- individuals. Finally, 
this thesis shows for the first time that the mechanism driving increased monocyte 
responsiveness to LPS is different in HIV+ individuals and the elderly, thus providing evidence that 
HIV infection does not prematurely induce age-related mechanisms that prime monocytes to LPS, 
but acts in a different manner. 
 
In Chapter 3, linear regression analysis was used for the first time to quantify the impact of both 
viremic and VS HIV infection on age-related changes to markers of monocyte activation. These 
analyses were adjusted for the important confounders of smoking status (Bakhru and Erlinger 
2005) and sex (Martin et al. 2013), which can significantly impact markers of monocyte activation. 
Soluble markers of monocyte activation (i.e. CXCL-10, neopterin) and percentages of monocyte 
subsets from HIV+ individuals showed a similar age-dependence as in HIV- individuals; however, 
levels were significantly different in HIV+ individuals, indicating that HIV infection accentuates 
age-related changes to monocyte activation. Of the markers tested, plasma CXCL-10 levels were 
the best independent predictor of age-related changes to monocytes in both HIV infection and 
ageing which suggests that this marker may be used as a surrogate of monocyte activation in 
these chronic inflammatory settings. By quantifying changes to levels of CXCL-10 and the other 
markers it was predicted that viremic HIV+ individuals have levels of monocyte activation 
comparable to HIV- individuals approximately 12 years older. Furthermore, and particularly 
relevant to the largely cART treated population in Australia and other Western countries, VS HIV+ 
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individuals also had higher levels of these markers, which were comparable to HIV- individuals 
approximately four years older. These findings provide the first estimates comparing the effects 
of HIV infection and chronological age on monocyte activation. Heightened levels of monocyte 
activation may have functional implications in these individuals, promoting age-related disease 
pathogenesis. Quantifying changes in monocyte activation in “year equivalents” may inform the 
magnitude of increased risk of age-related diseases developing in HIV+ individuals.  
 
In addition to similarly altered levels of soluble markers of monocyte activation, the results 
presented in Chapter 4 showed that monocytes from HIV+ men had higher basal and LPS-induced 
production of IL-6 and TNF in comparison to young HIV- controls, which were similar to 
monocytes from a group of elderly HIV- donors approximately 30 years older. Importantly, the 
mechanism governing primed monocyte responses in HIV- and HIV+ men was shown to be 
different. These findings are the first indicating that monocytes from HIV+ men are not primed by 
premature induction of age-related changes and must therefore be taken into account in future 
studies comparing these populations. 
6.1 Primed monocyte responses to LPS and altered monocyte subset 
proportion may contribute to inflammatory age-related disease 
Age-related diseases such as atherosclerosis, frailty and neurocognitive decline/dementia are 
associated with chronic inflammation. Altered monocyte subset proportion and primed responses 
to LPS may influence the pathogenesis of these age-related diseases. In Chapter 5 monocytes 
from elderly men were found to have a higher propensity to form foam cells, an indicator of 
atherosclerotic plaque development (see Chapter 5 section 5.3.1). Furthermore, intermediate 
monocytes, the major producers of proinflammatory cytokines, were identified to be the major 
foam cell forming subset in comparison to classical and non-classical monocytes (see Chapter 5 
section 5.3.2). As this subset is expanded in all of the above mentioned inflammatory diseases 
(discussed in Introduction section 1.4), this finding may partially explain the higher risk of 
inflammatory disease in elderly and HIV+ individuals and supports studies evaluating 
measurement of monocyte subsets as prognostic markers for age-related diseases.  
 
In addition to the implications of altered monocyte phenotype/function on atherosclerosis in the 
elderly, which was evaluated in this study, primed monocyte responses to LPS, and possibly other 
PAMPS, may also influence other age-related diseases. Classical and non-classical monocytes 
expressing intracellular TNF have recently been shown to be expanded in frail elderly individuals 
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in comparison to younger individuals (Verschoor et al. 2014), suggesting that monocytes from 
these individuals have a heightened inflammatory state. These findings are supported by gene 
array analysis showing that LPS stimulated CD14+ monocytes from frail individuals have 4 fold 
higher CXCL-10 gene expression than age-matched non-frail controls (Qu et al. 2009a). 
Interestingly, CXCL-10 levels were also shown to correlate with IL-6 gene expression in monocytes 
from frail individuals (Qu et al. 2009b) which is not surprising given the results presented in 
Chapter 3 that plasma CXCL-10 levels are the best independent marker of monocyte activation of 
those examined (Chapter 3, Table 3.4). These findings suggest that primed monocyte responses 
to stimuli such as LPS may contribute to the pathogenesis of this disease. Frail individuals are 
highly susceptible to bacterial infection, suggesting that increased levels of bacteria-derived 
PAMPs may drive primed responses; however, studies evaluating the mechanisms driving primed 
monocyte responses in frailty are required to test this hypothesis. Furthermore, as HIV infection 
and ageing are associated with chronic low level endotoxaemia, in vitro experiments incubating 
monocytes with low, physiological levels of LPS are required to probe the mechanisms of 
monocyte hyper-responsiveness in frailty. 
 
With respect to HIV infection, LPS-driven monocyte activation, as measured by plasma sCD14 and 
CCL-2, has been associated with increased incidence of HAD in HIV+ individuals (Ancuta et al. 
2008). Moreover, sCD163 levels were higher in HIV+ patients with an impaired global deficit score, 
indicative of neurocognitive decline, than those who were not impaired (Burdo et al. 2013) 
providing indirect evidence for a role of monocytes in HAD.  
 
Together, primed monocyte responses to LPS may contribute to chronic inflammation in both 
HIV+ individuals and the elderly which may drive age-related disease. Developing treatments that 
specifically target TLR-4 signalling in HIV+ individuals and the elderly may reduce the effect of 
primed monocyte responses in these individuals, and therefore their contribution to chronic 
inflammation and age-related disease. 
6.2 HIV infection and ageing: intersecting epidemics 
It is estimated that by 2015 approximately 50% of HIV+ individuals in the Western world will be 
more than 50 years old ((Kirk and Goetz 2009), see Introduction section 1.1.2). Therefore, the 
potential burden of an ageing HIV+ population is significant. Due to the relatively short history of 
HIV infection (first identified in 1983 (Barresinoussi et al. 1983)) and the high mortality rate 
associated with AIDS-defining illnesses, little is known about the effects of HIV infection in 
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patients who have been HIV positive for over 30 years. Therefore studies evaluating incidence of 
co-morbidities with age are required to identify whether HIV+ individuals develop age-related 
diseases earlier than HIV- people or whether they are simply more prone to disease in general. 
These studies are likely to be very difficult to design as they will need to correct for the duration 
of infection with HIV, which may increase in people who are older with HIV infection, and for the 
fact that people infected early in the HIV epidemic are likely to have been treated with sub-
optimal antiretroviral regimens. The finding that the relationship between markers of monocyte 
activation (i.e. CXCL-10, neopterin) and age in HIV+ individuals are accentuated in comparison to 
age-related changes alone suggests that HIV may act as an additional risk factor that may 
promote age-related disease.  
 
The average age of people diagnosed with HIV is also rising in Australia (from 33 years to 37 for 
men in the last 10 years (Kirby 2014)). The findings presented in this thesis of monocyte hyper-
responsiveness to inflammatory stimuli indicates that HIV infection later in life may have 
significant effects on disease pathogenesis as age-related changes are already present. The 
combination of age and HIV-induced changes may have significant effects on monocyte function 
and therefore age-related disease; however this hypothesis needs to be tested in specifically 
designed cohorts.  
6.3 Primed TLR-4 responses to LPS in DCs may also contribute to PAMP 
mediated chronic inflammation  
Our observation of primed TLR-4 responses to LPS in monocytes from young HIV+ men and the 
elderly raises the possibility that other innate immune cells are similarly altered in these 
individuals. DCs are potent responders to PAMPs via TLRs and other PRRs. DCs present in 
peripheral blood consist of multiple subsets, mainly conventional mDCs and pDCs, that express 
similar TLR profiles to monocytes from HIV+ individuals and respond to LPS via TLR-4 (Hernández 
et al. 2011). Similar to our findings in monocytes, mDCs from HIV+ individuals have been recently 
shown to be primed to LPS stimulation (Camacho-Sandoval et al. 2014). Furthermore, a subset of 
Slan+ M-DC8+ cells, with phenotypic properties similar to non-classical monocytes, is expanded 
with HIV infection and primed to LPS challenge, producing high levels of TNF (Dutertre et al. 2012). 
In addition to primed responses to LPS, DCs from HIV+ individuals are also primed to respond to 
TLR-7/8 agonists, suggesting other viral and bacterial components may contribute to chronic 
inflammation in these individuals (Sabado et al. 2010). Due to the similar primed responses to LPS, 
it would be of interest to identify the mechanism of DC responses to LPS in HIV+ individuals. 
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Identifying the role of DCs in chronic inflammation in these inflammatory states is also of 
importance as, like monocytes, DCs also form foam cells ((Paulson et al. 2010), reviewed in 
(Niessner and Weyand 2010)). The precise mechanisms driving DC-derived foam cell formation is 
unclear, although our findings that foam cell formation by monocytes is influenced by soluble 
factors present in plasma suggests that these factors may also act on DCs. While our in vitro 
model has been optimised for the study of monocytes in early atherogenesis, this technology may 
potentially be adapted to study foam cell formation by DCs. Circulating DCs migrate into plaques 
using similar chemokine receptors to monocytes (i.e. CX3CR1, (Liu et al. 2008)), however as DCs 
are thought to be more important at later stages of plaque development (see Introduction 
section 1.9.2), specifically designed models may be required to identify their role in atherogenesis. 
 
Together, altered TLR responses in DCs from HIV+ individuals and the elderly may contribute to 
further chronic inflammation in these populations. Furthermore, whether these cells are primed 
to respond more to other PAMPs may provide insight into the general activation state of these 
cells. Therefore, elucidating the role of aberrant TLR signalling in DCs may help to explain chronic 
inflammation in young HIV+ men and the elderly as well as other chronic inflammatory diseases.  
6.4 Is cART driving or inhibiting age-related diseases in HIV+ individuals? 
Advances in cART have led to better disease outcomes for HIV+ patients with the majority of 
patients on suppressive cART not developing AIDS-defining illnesses (discussed in Introduction 
section 1.1.2). Currently, standard treatment guidelines in Australia recommend a first round 
regimen consisting of efavirenz (NNRTI), tenofovir and emtricitabine (both NRTIs) for patients 
who are therapy naïve (Health 2014) which effectively reduces HIV viral load to clinically 
undetectable levels (<20 copies of HIV RNA per mL) in the majority of patients. However, our 
observations of primed monocyte responses to LPS, and higher basal levels of proinflammatory 
cytokines, in VS HIV+ individuals suggest that monocytes may still promote age-related non-AIDS 
disease pathogenesis in these individuals. This is especially possible considering that levels of 
monocyte activation in VS HIV+ individuals were similar to HIV- individuals four years older, 
indicating that cART does not completely reverse changes to monocyte activation in these 
individuals. Therefore, these findings raise questions regarding the efficacy of cART in preventing 
non-AIDS diseases in chronic HIV infection. The results presented in this thesis suggest studies are 
required to test the efficacy of adjunctive anti-inflammatory medication in HIV+ individuals to 
reduce age-related changes driven by inflammatory factors (discussed in section 5.4.2).The 
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phenotypic and functional parameters investigated in chapters 3, 4 and 5 might be useful in 
gauging the effectiveness of such therapies. 
 
While the toxicity of different antiretroviral drugs has been well studied, the long term effects of 
cART are unknown given that combination triple therapy was introduced only in 1995. 
Antiretroviral drugs themselves have been previously associated with morbidity in HIV+ 
individuals, especially early regimens containing zidovudine and stavudine which are associated 
with dyslipidaemia (Saint-Marc et al. 1999). Although improved cART regimens have reduced 
adverse side effects that may contribute to age-related disease pathogenesis, some therapies 
remain associated with increased risk of age-related diseases. Abacavir, an NRTI, is associated 
with increased risk of myocardial infarction (D:A:DStudyGroup 2008; Trevillyan et al. 2013) whilst 
lopinavir and ritonavir have also been shown to be associated with increased risk of CVD (Durand 
et al. 2011). Recently current use of protease inhibitor monotherapy has also been associated 
with increased monocyte activation and higher levels of markers of microbial translocation 
(Torres et al. 2014), indicating that the effects of these drugs driving monocyte activation also 
need to be evaluated. Furthermore, increased duration of cART was independently associated 
with cIMT thickness (Abd-Elmoniem et al. 2014) in HIV+ individuals, suggesting that drug related 
toxicity impacts CVD. HIV+ participants in our study had a median duration of cART therapy of 4.8 
years at enrolment (range = 2.3-18.9 yrs.), suggesting that the majority were never treated with 
more toxic drugs, such as zidovudine; however, donors were not stratified by therapy regimen 
due to the variety of medications used and relatively small numbers of donors. It is also of note 
that initiating cART at high nadir CD4+ T cell count and CD4+:CD8+ T cell ratio may reduce risk of 
age-related disease pathogenesis (Serrano-Villar et al. 2014a). Therefore, very early initiation of 
cART when the nadir CD4+ T count is higher may be effective at reducing rates of comorbidities in 
HIV+ individuals. This has been confirmed by recent findings of the Strategic Timing of 
Antiretroviral Therapy (START) trial which found that initiating therapy at a CD4+ T cell count 
higher than 500 cells per mm3 has greater beneficial effects against AIDS- and non-AIDS 
morbidities than delaying initiation of therapy until CD4+ T cell levels drop below 350 per mm3 
(Insight 2015), suggesting that HIV+ individuals should initiate cART on diagnosis regardless of 
CD4+ T cell count.  
 
However, the direct effects of early initiation of cART on monocyte activation have not been 
directly evaluated. Very early initiation of therapy may reduce the level of physical and 
immunological damage to the gastrointestinal tract during the acute phase of infection that is 
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responsible for microbial translocation of PAMPs that may contribute to a hyper-responsive state 
in monocytes. Furthermore, rapid reduction of viral load from recently infected individuals may 
reduce the development of reservoirs that may also influence primed monocytes responses to 
LPS. Intervention studies, measuring monocyte activation following the administration of cART at 
different time points such as the START trial, are required to conclusively determine whether 
early initiation of cART totally abolishes the hyper-responsive state of these cells. Therefore, 
identifying whether particular drug regimens are associated with increased or decreased 
monocyte responsiveness and activation would be of interest. 
 
Although intensive cART regimens have been found to have little effect on peripheral viremia 
(Dinoso et al. 2009; Gandhi et al. 2010), intensification of cART has recently been shown to have 
some success at reducing the effect of monocyte activation on age-related diseases such as HAND 
where monocytes play a key role. Intensive therapy with the CCR5-receptor antagonist maraviroc 
for 24 weeks, in addition to standard cART, reduced proportions of CD16 expressing monocytes, 
lowered plasma levels of markers of monocyte activation (sCD163), decreased levels of HIV DNA 
in monocytes and improved neurological test scores in HAND VS HIV+ individuals (Ndhlovu et al. 
2014), suggesting that this therapy may also have similar effects on other age-related diseases 
where monocytes are important (e.g. atherosclerosis). Further studies testing the effect of 
intensive maraviroc, and other antiretroviral drugs, treatment on the hyper-responsive state of 
monocytes from HIV+ individuals are warranted in order to identify the direct effects of this 
therapy regimen on monocyte activation.  
 
Taken together, although modern cART regimens effectively suppress HIV viral load in HIV+ 
patients, the presence of a hyper-responsive monocyte phenotype that is similar to HIV- 
individuals approximately four years older indicates that age-related inflammatory changes are 
not completely reversed by current therapy regimens. Therefore, incorporating additional, anti-
inflammatory therapies may be beneficial in the long term care of these individuals.  
6.5 Does HIV infection accelerate or accentuate age-related changes? 
Whether HIV infection prematurely induces age-related changes that drive inflammatory age-
related disease pathogenesis (i.e. accelerates the onset of disease development), or acts is a risk 
factor that accentuates risk of age-related disease at all ages, remains a point of contention 
(reviewed in (Pathai et al. 2014)).  
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Numerous studies have attempted to answer these questions by evaluating risk or incidence of 
inflammatory age-related disease in HIV+ individuals (discussed in Introduction section 1.1.2.3); 
however, few have mechanistically compared the similar immune changes present in young HIV+ 
individuals and the elderly that may drive disease pathogenesis. In this study, it was shown that 
HIV+ individuals had higher levels of biomarkers of monocyte activation using linear regression 
modelling, but that subsequent age-related changes occurred at the same rate as in HIV- 
individuals, supporting the hypothesis that HIV infection accentuates age-related changes. These 
observations, which are specific to monocytes at a cellular level, are supported by 
epidemiological evidence reported recently by a large multicentre longitudinal study that 
evaluated age of onset of myocardial infarction, end-stage renal disease and non-AIDS cancers in 
HIV+ individuals and controls (Althoff et al. 2015). These authors found that HIV+ individuals have 
increased risk of disease in comparison to controls; however, the median age of onset of these 
diseases is not different between HIV+ and HIV- individuals, suggesting that HIV infection 
accentuates, but does not accelerate, age-related disease pathogenesis (Althoff et al. 2015).  
 
These findings differ from those of a key cross-sectional study that found that the risk of age-
related disease (measured as polypathology) in HIV+ individuals was similar to HIV- individuals 
approximately 10-15 years older (Guaraldi et al. 2011), which the authors concluded is due to 
premature induction of age-related disease. However, due to the cross-sectional nature of this 
study, and the lack of analysis of incidence of disease with age, the observed 10-15 years 
difference may not be due to increased onset of age-related disease at all, but in fact heightened 
(accentuated) risk that cannot be delineated from the data unless the rate of increased markers 
are taken into account. Therefore, heightened risk of disease in HIV+ individuals may actually be 
driven by accentuated, and not accelerated, changes. 
 
Our observation that monocyte hyper-responsiveness to LPS in HIV infection and ageing is driven 
by different mechanisms (presented in Chapter 4) provides further evidence that suggests that 
HIV infection does not induce age-related changes earlier in life in HIV+ individuals. Therefore, 
these findings support those presented in chapter 3 that HIV infection may act as an additional 
risk factor in HIV+ individuals and accentuate immunological changes. 
 
In summary, regardless of whether HIV infection accelerates or accentuates changes associated 
with ageing, a higher burden of inflammatory age-related disease exists in both HIV+ individuals 
and the elderly. Due to the key role of monocytes in many age-related diseases, and their hyper-
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active and responsive state, modulating the potential down-stream effects of monocytes on age-
related disease pathogenesis is crucial to reducing age-related disease risk in both populations. 
Furthermore, as the mechanisms of monocyte hyper-responsiveness appear to be different in HIV 
infection and ageing, specifically tailored therapies may be required in ageing and HIV infection. 
6.6 Can anti-inflammatory medication modulate monocyte responses to 
LPS in HIV infection and ageing? 
The heightened inflammatory state of monocytes in HIV+ individuals and the elderly identified in 
this study supports the hypothesis that chronic monocyte activation contributes to chronic 
inflammation, which potentiates the development of age-related diseases. LPS levels correlated 
with surface TLR-4 expression in HIV- individuals (Chapter 4 section Figure 4.6), suggesting that 
PAMPS may drive primed monocyte responses in the elderly by upregulating molecules involved 
in TLR recognition/signalling. Furthermore, plasma IL-6 and TNF levels have been previously 
shown to correlate with cardiovascular events (Ridker et al. 2000; Amar et al. 2006; Jenny et al. 
2012). Although mechanisms of monocyte hyper-responsiveness in HIV+ individuals and the 
elderly appeared to differ, both groups produced high levels of IL-6 and TNF in response to LPS. 
Therefore, reducing systemic and cellular inflammation to levels of young, HIV- individuals may be 
an effective therapy target in both HIV+ individuals and the elderly.  
 
Few therapies directly target TLR-4 signalling; however, anti-inflammatory medication may 
reduce the contribution of end-point inflammatory factors including IL-6 and TNF to age-related 
disease pathogenesis. In addition to the anti-platelet properties of aspirin, aspirin’s anti-
prostaglandin activity has anti-inflammatory effects. Prophylactic treatment with low-dose aspirin 
is common in elderly individuals and is associated with decreased risk of CVD (Antithrombotic 
Trialists 2009). For this reason participants who were taking low-dose aspirin therapy were not 
recruited in this study in order to identify ‘natural’ immunological changes. Recently, it was 
shown that treatment of VS HIV+ individuals for one week with low-dose aspirin (81 mg daily) 
reduced levels of activated CD4+ T cells (CD38+HLA-DR+), plasma levels of sCD14 and a trend to 
decreased plasma IL-6 levels, highlighting the potential immunomodulatory effects of aspirin in 
VS HIV+ individuals (O’Brien et al. 2013). However, the use of aspirin as a continuous anti-
inflammatory therapy in HIV+ individuals is highly underutilised as Burkholder and colleagues 
identified that just one in five VS HIV+ individuals who qualify for low-dose aspirin therapy based 
on guidelines set for the general population, are prescribed this regimen (Burkholder et al. 2012). 
Interestingly, the authors conclude that the low prescription rates of low-dose aspirin is most 
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likely because no guidelines currently exists for low-dose aspirin treatment in HIV+ individuals 
and many HIV clinicians are not familiar with the guidelines set for the general population. 
Therefore, clinical trials identifying the benefit of low-dose aspirin therapy in HIV+ individuals is 
essential to inform treatment guidelines in HIV+ individuals and gauge the effect of anti-
inflammatory therapy on chronic inflammation in these patients. Furthermore, as aspirin is also 
associated with increased risk of gastrointestinal ulcer formation and bleeding (Derry and Loke 
2000), identifying whether low-dose aspirin is safe for use in HIV+ individuals with compromised 
GALT integrity is required. 
 
Drugs specifically targeting TLR-4 signalling are also currently being trialled in mouse and human 
clinical studies with limited success. Treatment with Eritoran, which blocks LPS binding TLR-4-MD-
2 complexes, lowers plasma cytokine levels (i.e. IL-6, TNF) in persons with experimental 
endotoxaemia and shows a trend to decreased mortality rates in sepsis patients (Lynn et al. 2003; 
Tidswell et al. 2010). However, no clinical improvement in 28 day mortality was observed in 
severe sepsis patients in a large phase three clinical trial (Opal et al. 2013), suggesting that 
Eritoran treatment may have limited ability to reduce outcomes in these patients. Further studies 
are required to determine the efficacy of Eritoran treatment in VS HIV+ individuals and the elderly 
with low level endotoxaemia. In vivo mouse studies have also shown that treatment of diabetic 
apoE(-/-) mice with the TLR-4 antagonist RS-LPS reduces foam cell formation and atherosclerotic 
lesion size in comparison to untreated diabetic mice (Lu et al. 2013). While inhibition of TLR-4 
with RS-LPS is athero-protective in mouse models, the efficacy of RS-LPS in human atherosclerosis, 
and/or any human disease state, is yet to be assessed. As RS-LPS is a competitive inhibitor of LPS 
binding to TLR-4 it is predicted that this would impair LPS-induced IL-6 and TNF production, 
however further human clinical trials are required to evaluate its effectiveness in HIV+ individuals 
and the elderly.  
 
In contrast to TLR-4 specific therapy, human trials evaluating the anti-malarial drug Chloroquine, 
an intracellular TLR-7/8 antagonist, are currently underway with the Atheroma Reduction with 
Chloroquine in the Metabolic Syndrome (ARCH-MS) trial nearing completion (late-2015). The 
results of this trial will provide insight into whether directly targeting TLRs in vivo influences 
inflammatory atherogenesis in high risk individuals. A positive result in this trial will further 
increase interest in the development of TLR modulators for human trials, therefore, allowing 
future studies to test whether blocking TLR action in vivo reduces chronic inflammation and 
immune activation in these populations. 
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Therapies targeting microbial translocation, thought to drive higher LPS levels, are also currently 
being evaluated in HIV+ individuals. Treatment with sevelamer, a phosphate/LPS binding drug 
generally used to lower LPS levels in patients with chronic kidney disease on haemodialysis, 
reduces LPS and sCD14 levels in SIV infected pig-tailed macaques, and with it associated markers 
of inflammation, immune activation and coagulation (Kristoff et al. 2014). However, a recent 
study in HIV+ individuals found that sevelamer has no effect on markers of microbial 
translocation in viremic HIV+ individuals, although its use did lead to lower oxLDL levels (Sandler 
et al. 2014), suggesting it may have some athero-protective properties in these individuals. 
Rifaximin, a non-absorbable antibiotic designed to target bacteria in the gastrointestinal tract, has 
also been shown to reduce LPS levels in patients with cirrhosis (Vlachogiannakos et al. 2009). 
Currently, the effect of rifaximin in reducing levels of chronic immune activation in HIV+ 
individuals associated with microbial translocation is being tested in phase two clinical trials with 
conclusion of the Rifaximin for Chronic Immune activation in People With HIV trial estimated at 
2017. Preliminary results from a similar study found that in a limited group of HIV+ individuals 
who do not progress to AIDS, despite being therapy naïve, no significant decrease in plasma LPS 
or sCD14 levels were observed following 28 day therapy with rifaximin (Tenorio et al. 2015). 
Therefore, due to the early stages of clinical trials, further studies are required in patients with 
HIV to conclusively identify whether sevelamer and rifaximin have any beneficial value lowering 
markers of microbial translocation in these individuals.  
 
Finally, in addition to modulating cholesterol synthesis, statins also have anti-inflammatory 
properties (previously discussed in Chapter 5 section 5.4.1). Recently, the Stopping 
Atherosclerosis and Treating Unhealthy Bone With Rosuvastatin in HIV (SATURN-HIV) trial found 
that daily treatment (10 mg) reduced plasma sCD14 levels and the percentage of tissue factor 
expressing non-classical monocytes in comparison to a placebo control group (Funderburg et al. 
2014). Furthermore, treatment of monocytes with simvastatin and atorvastatin in vitro decreases 
TLR-4 mediated response to LPS (Methe et al. 2005a). Therefore, the use of statins may provide 
the dual purpose of targeting both monocyte activation and foam cell formation in both HIV+ 
individuals and the elderly. 
 
In summary, several anti-inflammatory drugs are currently in development that may modulate 
the influence of inflammatory factors on monocyte activation, and subsequent age-related 
disease pathogenesis. Importantly, our identification of CXCL-10 as a soluble biomarker of age-
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related changes to monocyte activation may provide a useful indicator of the effects of these 
drugs on monocyte activation. Therefore, due to the relative ease of measuring CXCL-10 levels in 
plasma by ELISA, measurement of this chemokine should be incorporated in future clinical trials 
of drugs targeting monocyte activation. 
6.7 Conclusion 
In summary, the findings presented in this thesis provide key insight into how monocytes 
contribute to chronic inflammation and immune activation in young viremic and VS HIV+ 
individuals and the elderly, which may drive age-related disease pathogenesis. The fact that 
differences in monocyte activation, and the ability of monocytes to form foam cells, could be 
detected in a relatively small number of donors without age-related disease is striking, suggesting 
that changes to monocytes are most likely greater in individuals with increased risk of disease. 
Therefore, these findings provide the basis for much larger longitudinal studies that associate 
clinical end-point measurements with markers of monocyte activation, which may further 
delineate the effect of changes to monocytes in age-related disease.  
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Appendix Figure 3.1. Plasma LBP levels in young HIV+ and older HIV- individuals.  
Plasma levels of LBP from young HIV- (n=25) were compared to age-matched HIV+ (viremic 
(n=28); VS (n=17)) and older HIV- individuals (n=18) by ELISA (A). Median and interquartile range 
of each cohort is shown and p values determined by Mann-Whitney U test. The relationship 
between plasma LBP and LPS levels in HIV- individuals (n=23) was determined by non-parametric 
spearman correlation (B). 
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Appendix Table 4.1 Basal and LPS-induced IL-6 and TNF levels in age-matched HIV+ and older HIV- individuals 
(median MFI (IQR)). 
 HIV-  HIV+ 
 Young Older p
1
  Viremic p
1
 VS p
1
 p
2
 
Basal          
IL-6 (MFI)          
Classical 3.34 (2.87, 3.65) 3.71 (3.42, 4.36) 0.06  4.66 (4.40, 5.44) <0.001 5.06 (4.82, 5.17) <0.001 0.519 
Intermediate 3.69 (3.01, 4.03) 3.94 (3.66, 4.57) 0.14  5.05 (4.71, 6.04) <0.001 5.43 (5.26, 6.00) <0.001 0.447 
Non-classical 3.64 (2.90, 4.05) 6.66 (3.89, 4.49) 0.54  4.87 (4.37, 5.91) 0.004 4.85 (4.55, 5.24) 0.004 0.896 
TNF (MFI)          
Classical 5.17 (4.39, 5.96) 7.54 (6.68, 8.29) 0.030  8.60 (7.55, 9.57) <0.001 9.28 (8.95, 10.2) <0.001 0.172 
Intermediate 6.42 (5.28, 7.59) 9.89 (9.50, 11.1) 0.029  11.2 (10.3, 14.0) <0.001 12.5 (11.5, 15.9 <0.001 0.215 
Non-classical 7.22 (5.72, 8.06) 9.86 (8.43, 11.5) 0.024  10.4 (9.65, 13.0) 0.007 10.6 (9.85, 13.9)  <0.001 0.541 
LPS stimulated          
IL-6 (ΔMFI)          
Classical 4.04 (3.19, 5.44) 4.76 (4.41, 7.31) 0.145  9.20 (7.56, 11.0) <0.001 8.36 (6.24, 10.1) 0.002 0.429 
Intermediate 13.9 (11.5, 15.5) 19.6 (16.1, 31.1) 0.033  21.7 (15.6, 25.7) 0.035 22.2 (17.8, 30.8) 0.006 0.671 
Non-classical 6.76 (4.85, 7.92) 11.3 (8.86, 16.0) 0.005  10.7 (7.93, 13.5) 0.046 12.4 (9.85, 16.0) <0.001 0.164 
TNF (ΔMFI)          
Classical 62.1 (50.2, 79.6) 88.4 (52.9, 143) 0.164  178 (121, 230) <0.001 136 (103, 162) 0.013 0.142 
Intermediate 304.6 (257.5,460.1) 733.1 (467.0, 1242) 0.013  774.1 (503.5, 1003) 0.016 958.2 (571.0, 1286) 0.002 0.311 
Non-classical 218 (89.1, 318) 420 (333, 674) 0.003  295 (219, 453) 0.423 440 (274, 762) 0.016 0.164 
 
1
 P values in comparison to young HIV- individuals using Kruskal-Wallis one way ANOVA 
2 P value shows difference between viremic and VS HIV+ individuals using Mann-Whitney U test 
Bold p values < 0.05, IQR - Interquartile range 
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Appendix Table 4.2 Surface and soluble markers of monocyte response to LPS challenge in age-
matched HIV+ and older HIV- individuals (median (IQR)). 
 HIV-  HIV+ 
 Young Older p1  Viremic p1 VS p1 p2 
Surface proteins           
TLR-4 (ΔMFI)          
Classical 4.61 (3.91, 6.21) 8.29 (5.69, 15.1) 0.026  8.53 (6.95, 10.7) 0.019 6.54 (4.61, 9.25) ns ns 
Intermediate 7.55 (5.54, 8.69) 11.5 (10.2, 21.2) 0.043  17.5 (10.3, 20.9) 0.025 17.4 (7.29, 26.6) 0.031 ns 
Non-classical 3.69 (3.22, 9.13) 11.1 (8.40, 22.5) 0.033  14.1 (7.56, 23.1) 0.026 11.9 (4.79, 15.6) ns ns 
CD14 (MFI)          
Classical 26.2 (23.1, 39.5) 29.3 (21.8, 50.3) ns  24.8 (17.1, 29.5) ns 24.2 (16.4, 38.2) ns ns 
Intermediate 22.1 (18.9, 27.8) 22.8 (18.7, 46.2) ns  20.8 (13.3, 26.0) ns 18.1 (12.6, 34.9) ns ns 
Non-classical 4.64 (4.10, 5.75) 4.03 (3.08, 6.41) ns  4.56 (2.73, 5.17) ns 3.49 (3.06, 6.35) ns ns 
CD16 (MFI)          
Classical 5.32 (4.87, 5.90) 6.05 (5.23, 6.43) ns  5.69 (4.75, 6.10) ns 5.84 (5.17, 6.11) ns ns 
Intermediate 35.65 (27.2, 44.1) 41.2 (36.1, 58.0) ns  25.15 (22.1, 38.1) ns 32.2 (25.6, 41.8) ns ns 
Non-classical 52.1 (30.8, 64.5) 51.3 (46.4, 80.4) ns  28.7 (23.4, 51.7) ns 40.0 (25.6, 55.1) ns ns 
Soluble factors          
LPS (pg/mL) 52.6 (48.6, 56.3) 56.8 (53.9, 75.6) 0.033  63.08 (48.9, 71.3) ns 65.92 (53.7, 74.2) 0.045 ns 
LBP (µg/mL) 33.0 (27.9, 43.7) 39.0 (30.7, 50.0) ns  27.0 (24.4, 48.6) ns 30.9 (22.4, 40.8) ns ns 
sCD14 (pg/mL) 3527 (3369, 4017) 4509 (3553, 5072) ns  4485 (3602, 4916) ns 5510 (4449, 6864) 0.003 ns 
CXCL-10 (pg/mL) 41.4 (27.9, 48.4) 161.3 (63.2, 299) 0.001  161 (100, 222) 0.001 74.02 (54.9, 170) 0.029 ns 
 
1
 P values in comparison to young HIV- individuals using Kruskal-Wallis one way ANOVA  
2 P value shows difference between viremic and VS HIV+ individuals 
Bold p values < 0.05 
ns - not statistically significant  
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Appendix Figure 4.1 Optimisation of intracellular cytokine staining by flow cytometry. 
Whole blood monocytes (A) were stimulated for 4 hours with 0 or 10 ng/mL LPS and intracellular 
TNF (B) and IL-6 (C) levels were determined by flow cytometry in comparison to unstimulated 
controls. Time course of LPS stimulation using 10 ng/mL LPS was performed (bars represent 
average of two experiments) (D). Intracellular TNF (E) and IL-6 (F) production following LPS 
stimulation was compared in isolated monocytes from HIV- and HIV+ individuals (n=6 per group) 
incubated with RPMI containing 20% pooled human serum. Median and IQR shown. Comparisons 
made by Mann-Whitney U test. 
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Appendix Figure 4.2 Optimisation of whole blood phosphorylated flow cytometry. 
Whole blood monocytes (A) were stimulated for 15 minutes with 0 or 10 ng/mL LPS and 
phosphorylation of NF-κB p65 (B) and p-38 MAPK (C) were determined by flow cytometry in 
comparison to appropriate isotype controls. CD16 expressing intermediate and non-classical 
monocytes were not assessed for p-38 MAPK and NF-κB p65 phosphorylation due to shedding of 
CD16 (D). Concentration (E) and time course (F) of LPS stimulation was performed (n=3 
respectively). Median values plotted. 
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Appendix Figure 4.3 Optimisation of SmartFlare mRNA uptake beads for monocyte subsets. 
Uptake of SmartFlare control uptake beads (Merck Millipore) by monocyte subsets were 
measured following incubation of beads with PBMCs cultured in RMPI + 20% FCS for 16 hours and 
measured by flow cytometry (n=3, A). The rate and saturation of bead uptake was investigated 
following incubation of beads for the indicated time points with PBMC (n=1, B). 
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Appendix Figure 5.1 Morphology of foam cells and macrophage in collagen gels. 
Foam cells (black arrow) and macrophages (white arrows) were manually counted based on 
morphology following Oil red O staining using an Olympus BX-51 inverted microscope (A). One 
field of view, at one z-section of gel at 40X magnification shown. Scale bar represents 20 µm. 
Figure 5.1 A zoomed in at 150% showing a macrophage (left) and foam cell (right, B). 
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Viremic and Virologically Suppressed HIV Infection
Increases Age-Related Changes to Monocyte Activation
Equivalent to 12 and 4 Years of Aging, RespectivelyAU1
Thomas A. Angelovich, MSc,*† Anna C. Hearps, PhD,*‡ Anna Maisa, BSc,*
Genevieve E. Martin, MBBS,* Gregor F. Lichtfuss, BSc,*‡ Cheng Wan-Jung,* Clovis S. Palmer, BSc,*§
Alan L. Landay, BSc,k Suzanne M. Crowe, MBBS,*‡¶ and Anthony Jaworowski, BSc*‡#AU2
Background: Chronic inflammation and immune activation occur
in both HIV infection and normal aging and are associated with
inflammatory disease. However, the degree to which HIV influences
age-related innate immune changes, and the biomarkers which best
reflect them, remains unclear.
Methods and Results: We measured established innate immune
aging biomarkers in 309 individuals including 88 virologically
suppressed (VS) and 52 viremic (viral load # and .50 copies per
milliliter, respectively) HIV+AU5 individuals. Levels of soluble (ie,
CXCL10, soluble CD163, neopterin) and cellular (ie, proportions of
inflammatory CD16+ monocytes) biomarkers of monocyte activation
were increased in HIV+ individuals and were only partially
ameliorated by viral suppression. Viremic and VS HIV+ individuals
show levels of age-related monocyte activation biomarkers that are
similar to uninfected controls aged 12 and 4 years older, respec-
tively. Viremic HIV infection was associated with an accelerated rate
of change of some monocyte activation markers (eg, neopterin) with
age, whereas in VS individuals, subsequent age-related changes
occurred at a similar rate as in controls, albeit at a higher absolute
level. We further identified CXCL10 as a robust soluble biomarker
of monocyte activation, highlighting the potential utility of this
chemokine as a prognostic marker.
Implications: These findings may partially explain the increased
prevalence of inflammatory age-related diseases in HIV+ individuals
and potentially indicate the pathological mechanisms underlying
these diseases, which persist despite viral suppression.
Key Words: HIV, innate immune activation, monocyte, aging
(J Acquir Immune Defic Syndr 2015;00:1–7)
INTRODUCTION
The advent of effective combination antiretroviral
therapy (cART) has made HIV infection a manageable
chronic condition for HIV+ individuals who maintain long-
term viral suppression. However, as this population ages, it is
becoming increasingly apparent that even virologically sup-
pressed (VS) HIV+ individuals suffer ongoing immune
activation and dysfunction, which is not reflected by tradi-
tional biomarkers of HIV disease such as viral load and CD4+
T-cell count. HIV infection induces immunological changes
that are characteristic of the normal aging process including
increased inflammation (as indicated by inflammatory
markers such as TNF and IL-6, reviewed in Deeks et al1),
an expansion of senescent T cells with shortened telomeres,2,3
and an increase in markers of adaptive and innate immune
activation.4 Beyond being simply biomarkers of aging or HIV
infection, many of these age-related parameters are of clinical
significance and are increasingly being shown to be predictive
of inflammatory age-related morbidities that HIV+ individu-
als are at heightened risk of developing.1,5 Markers of
inflammation such as IL-66 and high-sensitivity C-reactive
protein7 are associated with increased risk of cardiovascular
disease (CVD) in HIV+ individuals and the general popula-
tion (reviewed in Hearps et al8). Monocytes/macrophages
play critical roles in the pathogenesis of inflammatory disease
such as CVD,9 and we have previously shown that monocyte
activation markers increase during aging10 and in both VS and
viremic HIV infection.5,11 Elevated levels of monocyte
activation biomarkers including the proportion of inflamma-
tory CD16+ monocytes and levels of soluble (s)CD163 and
sCD14 (shed from activated monocytes) are associated with
indices of CVD including noncalcified plaques,12 arterial
inflammation,13 coronary artery calcification,14 and progres-
sion of carotid intima-media thickness (a surrogate clinical
measure of atherosclerosis).15
Although adaptive immune parameters such as CD4+
T-cell counts may be useful prognostic markers in untreated
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HIV infection, it is becoming increasingly clear that innate
markers of inflammation and monocyte activation may more
accurately predict morbidity and mortality than T-cell param-
eters in cART-treated individuals.16–18 However, the relative
contributions of both aging and HIV infection on these
immunological changes are unclear.
Studies investigating the link between monocyte acti-
vation and clinical outcomes in HIV infection use various
cellular and soluble markers of monocyte activation including
the proportions of monocyte subsets (particularly the “inflam-
matory” CD16+ subsets), expression of activation markers
such as CD11b or tissue factor, and plasma levels of
molecules either shed from or secreted by activated mono-
cytes/macrophages (eg, sCD14, sCD163, CXCL10, MCP-1).
Importantly, it remains unclear which of these parameters best
indicates monocyte activation and to what extent these
biomarkers may overlap and indicate common underlying
immunological mechanisms.
Here, we evaluated a combined dataset of commonly
tested biomarkers associated either directly or indirectly with
monocyte activation to (1) identify the most robust and
indicative markers of monocyte activation and (2) quantitate
the individual effects of aging and viremic and VS HIV
infection on changes to monocyte activation, which are
thought to underpin development of inflammatory diseases
in these populations.
METHODS
Participant Recruitment
HIV+ individuals were recruited from the Alfred
Hospital Infectious Diseases Unit with informed consent
and institutional review board approval. Blood collected into
EDTA-coated tubes was used for fresh whole-blood immu-
nophenotyping of monocytes, whereas plasma was prepared
and stored for future analysis as previously described.5
Healthy controls were recruited from the community. This
study used data from newly recruited individuals (n = 31) plus
biomarker data from previously published cross-sectional
cohort studies.5,11,19,20
Experimental Procedures and
Statistical Analysis
Monocyte subsets and soluble plasma markers of innate
immune activation/inflammation including CXCL10, neo-
pterin, sCD163, sCD14, and LPS were determined as pre-
viously described.5,11,19 To evaluate the continuous effect of
aging on the biomarkers tested, data from cross-sectional
studies were combined with additional patient recruitment for
analysis. Linear regression analysis was used to identify
monocyte biomarkers that were significantly altered with age
and determine the influence of sex, current smoking status,
and either viremic or VS HIV infection on this relationship.
Spearman’s correlation analysis was used to determine the
association between individual monocyte activation bio-
markers. To quantitatively estimate the impact of viremic
and VS HIV infection on monocyte activation in the context
of aging, linear regression modeling was used to estimate the
age difference between VS and viremic HIV+ individuals
with HIV2 controls for a given level of each biomarker.
Differences in coefficients due to HIV status were analyzed
using a Student t test (P , 0.05 considered significant),
whereas differences in slope between sample groups were
determined by comparing models fitted with or without an
interaction term (likelihood ratio test). Where the slope
differed between groups, the linear equations were solved
for a given parameter level taking into account the interaction
term. Linear regression analysis was performed using Stata
v.11 (StataCorp), and correlations were assessed using
GraphPad Prism (version 6.02).
RESULTS
Data from a total of 309 participants were analyzed
including 169 HIV-seronegative controls [median age (range):
48 (20–84) years, 67.5% male], 88 VS HIV+ individuals with
undetectable viral load [,50 RNA copies per milliliter, 97.7%
receiving cART, median age: 48 (20–70) years, 81.8% male],
and 52 viremic HIV+ individuals with detectable viral load
[VL . 50 copies per milliliter (range: 80 to .100,000
copies per milliliter), 19.2% receiving cART, median age: 40
(19–63) years, 82.7% male]. Clinical and demographic
information is detailed in T1Table 1.
To identify markers of monocyte activation that altered
significantly with age, we performed linear regression model-
ing on all biomarker data and adjusted for HIV infection, sex
(which we have previously shown influences a number of
these biomarkers10), and current smoking status. Plasma levels
of CXCL10, sCD163, neopterin, and the proportions of
monocyte subsets (defined as classical, CD14++CD162; inter-
mediate, CD14++CD16+; and nonclassical, CD14+CD16++)
were all significantly altered with age independent of HIV
infection (P , 0.05 for all, see Table S1, Supplemental
Digital Content, http://links.lww.com/QAI/A642), confirming
and extending our previous findings using age as a categorical
variable that these parameters represent biomarkers of age-
related monocyte activation.10 Although routinely used as
biomarkers of monocyte activation in HIV studies, neither
sCD14 nor LPS levels were significantly associated with age
in this study. Sex affected the relationship between a number
of the biomarkers analyzed (including monocyte subsets,
CXCL10, sCD163 and LPS, see Table S1, Supplemental
Digital Content, http://links.lww.com/QAI/A642) and age,
confirming the need to adjust for sex in these analyses,
although adjustment for smoking did not alter the relationship
between any of the biomarkers and age in the control cohort
(data not shown).
We have previously shown in a small cross-sectional
study that younger HIV+ individuals (aged , 45 years)
exhibit higher levels of monocyte activation than age-
matched controls, and this effect is only partially ameliorated
by viral suppression.5 We thus used linear regression to
extend these findings in an expanded cohort of HIV+ and
HIV-seronegative individuals aged 19–84 years using statis-
tical analysis that allowed appropriate adjustment for the
effect of sex and smoking status (due to the increased
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prevalence of current smokers in many HIV+ cohorts
including ours; Table 1). We also sought to determine
whether the impact of HIV on monocyte activation is
amplified at older ages. Biomarkers that were significantly
altered with age in controls showed a similar trend in HIV+
individuals (data not shown).T2 Table 2 shows the impact of
HIV infection in addition to age-related changes on each
parameter and indicates that proportions of intermediate
monocytes were significantly increased and the proportions
of classical monocytes consequently decreased, in viremic
HIV infection (P = 0.002 and 0.015, respectively, column
“P value vs HIV2”) but not in VS individuals. In contrast,
levels of soluble age-related monocyte activation markers
CXCL10, neopterin, and sCD163 were significantly elevated
in both viremic (P # 0.001 for all, column “P value vs
HIV2”) and VS individuals (P, 0.001 for all). Although it was
not significantly altered by age, sCD14 was increased in both
viremic and VS HIV+ individuals as compared with controls
(P # 0.001 for both). We also determined whether the slope
of the regression curve, which indicates the rate at which
these parameters change with age, differed between HIV+
and control individuals (column “P value slope”; Table 2).
The rate of change for nonclassical monocytes was altered in
HIV+ individuals; however, the overall effect of HIV
infection on this parameter was not significant. There was
a significant difference in the slope of the regression curve
between viremic and control individuals for neopterin
(P = 0.012, Table 2; F1Fig. 1), indicating age-related changes
to neopterin occur at a greater rate in those with uncontrolled
HIV replication. However, no such differences in slope were
detected for soluble biomarkers in VS HIV+ individuals
(P . 0.05, Table 2; Fig. 1; Note similar slope of the
regression curves for VS HIV+ and uninfected individuals),
indicating that although HIV increases the overall level of
TABLE 1. Demographic Details of Study Participants
HIV2
Viremic HIV+ VS HIV+
P P
Participants (n) 169 52 88
Age (yrs)
Median (IQR) 48 (36–66) 40 (35–47) ,0.001* 48 (39–54) NS*
Range 20–84 19–63 20–70
Sex (% male) 67.5% 82.7% 0.034† 81.8% 0.015†
Body mass index‡
Median (IQR) 24.5 (22.0–27.5) 24.1 (22.5–27.2) NS* 25.7 (22.7–29.5) NS*
Range 16.1–42.0 16.0–37.1 16.0–43.9
Missing data (n) 18 21 19
Smoking status
Current 6.5% 46.2% ,0.001† 37.5% ,0.001†
Previous 26.0% 23.0% 30.7%
Never 67.5% 30.8% 31.8%
Viral load (copies/mL) ,0.001§ All ,50 copies/mL
#1000 median age (IQR) 17.6% [43.0 (39.5–44.0)]
1001–20,000 25.5% [42.5 (34.8–55.5)]
20,001–100,000 31.4% [38.5 (36.3–44.8)]
.100,000 25.5% [38.0 (29.8–48.3)]
CD4 T-cells (cells/mL)‡
Median (IQR) 416 (319–527) ,0.001§ 619 (402–846)
Range 4–1092 129–1433
Missing data (n) 2 6
Nadir CD4 (cells/mL)‡
Median (IQR) 267 (64–395) NS§ 203 (80–292)
Range 1–688 8–593
Missing data (n) 14 15
Receiving cART n (%) 10 (19.2) 86 (97.7)
Duration of cART (yrs)‡
Median (IQR) 4.8 (2.3–18.9)
Range 0.2–22
Missing data (n) 10
*As compared with HIV2 controls by Mann–Whitney test.
†As compared with HIV2 controls by x2 test.
‡Participants with missing data are not included in the values listed.
§As compared with virologically suppressed HIV+ participants by Mann–Whitney test.
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these markers, subsequent age-related changes occur at the
same rate in VS HIV+ individuals as in uninfected controls.
These data confirm that HIV significantly alters age-related
changes to monocytes independent of sex and smoking and
that viral suppression associated with cART does not
normalize the levels of soluble monocyte activation markers.
To assess the level of redundancy of each marker and
determine whether 1 or more markers could be used to
accurately predict other markers of monocyte activation, we
next analyzed the associations between each of the monocyte
activation markers. CXCL10 levels significantly correlated
with all other soluble monocyte activation markers measured
except sCD14 and also with proportions of classical and
intermediate monocyte subsets ( T3Table 3). Neopterin levels
also correlated significantly with a number of soluble markers
(CXCL10, sCD163, and sCD14) and intermediate but not
classical monocyte subsets. In this cohort, sCD14 showed
a significant association with only neopterin and not with
monocyte subsets. Taken together, these data indicate that
CXCL10, and to a lesser extent neopterin, levels are
TABLE 2. Effect of HIV Infection on Biomarkers of Monocyte Activation in Addition to Age-related Changes
n
Viremic HIV+ Virologically Suppressed HIV+
Viremic vs
Virologically
Suppressed
P
Slope* Coefficient (95% CI)
P vs
HIV2†
P
Slope* Coefficient (95% CI)
P vs
HIV2† P‡
Monocyte subsets
Classical (CD14+
+CD162)
264 NS 23.96 (27.13 to 20.79) 0.015 NS 0.11 (21.84 to 2.05) 0.914 0.013
Intermediate (CD14+
+CD16+)
264 NS 2.68 (1.01 to 4.35) 0.002 NS 0.84 (20.29 to 1.97) 0.143 0.049
Nonclassical
(CD14+CD16++)
264 0.049 2.12 (20.23 to 4.47)§ 0.077§ 0.020 21.05§ (22.13 to 0.02) 0.055§ 0.108
Total CD16+ 264 NS 3.86 (0.60 to 7.13) 0.021 NS 20.38 (22.37 to 1.61) 0.707 0.012
Soluble factors
CXCL10 204 NS 204 (153 to 255) ,0.001 NS 66.5 (30.5 to 103) ,0.001 ,0.001
sCD14 246 NS 432 (189 to 675) 0.001 NS 602 (421 to 783) ,0.001 0.208
sCD163 246 NS 683 (513 to 854) ,0.001 NS 324 (159 to 490) ,0.001 ,0.001
Neopterin 246 0.012 11.0 (6.83 to 15.1)§ ,0.001§ NS 2.87 (1.36 to 4.37) ,0.001 0.031
LPS 220 NS 5.71 (24.51 to 15.9) 0.272 NS 9.06 (20.07 to 18.2) 0.052 0.491
Linear regression analysis of changes in biomarker levels with age due to viremic or virologically suppressed HIV infection adjusting for sex and smoking. The coefficient indicates
the effect of HIV status on biomarker level in addition to the effect of ageAU10 .
*P , 0.05 indicates the rate of change of the parameter with age (ie, slope) in HIV+ individuals is significantly different to controls.
†P value reports direct effect of HIV status compared with HIV2 controls, indicating that the y intercept of the regression curve was significantly different to HIV2 controls.
‡P value indicates whether there was a significant difference in the y intercept between V and VS HIV+ individuals, as determined by the Student t test.
§Where the slope was significantly different to HIV2 individuals, an interaction term was introduced. The resulting equation was solved for the median age of the entire cohort and
the coefficient and P value for that value shown.
FIGURE 1. Regression analysis of plasma levels of CXCL10 (A) and neopterin (B) in viremic (black circles and line) and virologically
suppressed (gray triangles and line) HIV+ individuals and uninfected controls (open squares, dashed line) and age. Curves were
fitted to unadjusted data. Adjusted regression equations for CXCL10 including adjustment for viremic or virologically suppressed
HIV infection were CXCL10 = 1.29[age] + 204[viremic HIV] + 62.2[sex] 2 28.1[smoking] 2 2.40 and CXCL10 = 1.29[age] + 66.5
[VS HIV] + 62.2[sex] 2 28.1[smoking] 2 2.40, respectively, where HIV status, smoking, and sex were categorical variables.
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indicative of other soluble monocyte activation markers and
monocyte subset proportions.
To determine whether CXCL10 also correlated with
other commonly measured cellular markers of monocyte
activation, in a subset of participants, we measured the
association between CXCL10 levels and expression of
functional/activation markers including CD38,21 which is
upregulated on monocytes from HIV+ individuals irrespec-
tive of cARTAU6 (unpublished data). We found that CXCL10
levels correlated significantly with expression of the activa-
tion markers CD11b and CD38 and the procoagulant protein
tissue factor on classical and intermediate monocyte subsets
(Table 3). The sCD14 levels did not correlate with any of
these markers, whereas neopterin and sCD163 correlated with
CD11b and tissue factor levels only. Taken together, these
data suggest that CXCL10, but not sCD14, is a robust and
easy to measure plasma marker of monocyte activation that
can be used to indicate other soluble and importantly the more
difficult to analyze cellular markers of monocyte activation
under both healthy and inflammatory states.
To quantify the effect of HIV infection on monocyte
activation and estimate the age at which HIV+ individuals
reach a given level of monocyte activation, we used a similar
regression model as above but where age was the outcome of
the regression equation. We selected CXCL10 to use in this
analysis, having established it above as a robust biomarker of
age and HIV-related monocyte activation and an accurate
indicator of other monocyte activation markers. In this
analysis, the coefficient for the viremic or VS HIV
adjustment term indicated the difference in age between
HIV+ individuals and uninfected controls for any given
level of CXCL10. In VS HIV+ individuals, the value of the
coefficient was 24.0 [95% confidence interval (CI): 29.1
to 1.1, see Table S2, Supplemental Digital Content,
http://links.lww.com/QAI/A642], indicating that VS HIV+
individuals exhibit the same level of CXCL10 4 as
seronegative controls aged approximately 4 years older.
The coefficient for viremic HIV+ individuals indicated
a more dramatic effect, in that these individuals reached
this level of activation 12.0 (95% CI: 218.9 to 24.9) years
earlier than uninfected controls. We validated this statistical
approach using other biomarkers shown to be elevated in
HIV infection and found strikingly similar coefficient values
(ranging from 29.7 to 212.9 and 21.8 to 23.7 years for
viremic and VS HIV infection, respectively, see Table S2,
Supplemental Digital Content, http://links.lww.com/QAI/A642).
In summary, these data indicate that viremic HIV+ individ-
uals exhibit levels of monocyte activation markers similar to
those seen in seronegative controls aged up to 12 years older,
and although viral suppression significantly reduces this
effect, VS HIV+ individual still experience levels of mono-
cyte activation similar to those observed in controls aged up
to 4 years older.
DISCUSSION
Although HIV infection is known to be associated with
innate immune dysfunction and the premature appearance of
age-related changes, the extent to which age and HIV
contribute to these changes in HIV+ individuals, and whether
these effects are completely reversed by cART, has remained
unclear. We report that viremic HIV+ individuals display
a similar level of monocyte activation to HIV2 controls aged
12 years older, and although viral suppression significantly
reduced the level of biomarkers such as CXCL10, VS HIV+
individuals still show an equivalent level of monocyte
activation 4 years earlier. Strikingly similar estimated effects
of HIV in year equivalents were observed for a range of
soluble and cellular markers of monocyte/innate immune
activation, supporting the validity of this analysis. These
findings suggest that in addition to the effects of aging,
viremic and VS HIV infection have an additional burden of
innate immune activation equivalent to up to 12 and 4 years
of normal aging, respectively.
In addition to increasing the absolute level of monocyte
activation biomarkers, viremic HIV infection was associated
with an accelerated rate of change of the biomarker neopterin
with age, indicating a potentiation of age and HIV viremia on
factors driving the production of this biomarker. For all other
biomarkers, our analysis revealed that HIV infection height-
ened monocyte activation but did not accelerate the rate
of subsequent age-related changes (indicated by parallel
regression curves in Fig. 1). This suggests that HIV infection
TABLE 3. Correlation of Soluble and Cellular Monocyte
Activation Biomarkers*
CXCL10 Neopterin sCD163 sCD14
Soluble markers
CXCL10 204 —
Neopterin 246 0.547*** —
sCD163 246 0.409*** 0.375*** —
sCD14 246 0.090 0.221*** 20.022 —
LPS 220 0.175* 0.078 0.336*** 20.085
Monocyte subsets
and phenotype
Classical
monocytes
% Classical
subset
237 20.273*** 20.095 20.114 0.013
CD38 (MFI) 221 0.162* 0.114 0.093 0.016
CD11b (MFI) 225 0.346*** 0.188** 0.276*** 0.101
Tissue factor
(MFI)
78 0.319** 0.412*** 0.399*** 0.163
Intermediate
monocytes
% Intermediate
subset
237 0.356*** 0.162* 0.158* 20.001
CD38 (MFI) 219 0.161* 0.137 20.021 0.014
CD11b (MFI) 223 0.300*** 0.186** 0.234*** 0.079
Tissue factor (MFI) 68 0.422*** 0.334** 0.318** 0.229
Nonclassical
% Nonclassical
subset
237 0.132 0.013 20.095 0.001
Statistically significant correlations are shown in bold. *P , 0.05; **P , 0.01;
***P , 0.001.
*Determined by Spearman correlation; r values shown.
MFI, mean fluorescence intensity.
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is associated with a higher absolute level of monocyte
activation irrespective of age but that age-related changes
continue to occur at a rate similar to uninfected controls.
Although cross-sectional studies such as these are
a useful, predictive way of estimating likely age-associated
effects, the observations made here require confirmation in
a longitudinal study of individuals infected at a similar age.
However, due to the decade-long follow-up period required to
conduct such analyses, a retrospective study design will likely
be required.
Initiating cART early after infection (within 6 months)
has been shown to reduce the extent of T-cell activation as
compared with those who initiate cART later,22 although
whether early cART initiation would similarly reduce sub-
sequent innate immune activation has not been determined.
Duration of HIV infection and viral suppression are both
likely to impact the degree of innate immune activation,
although the former cannot usually be determined with
accuracy in cross-sectional studies. Nadir CD4 T-cell count
is often used in VS individuals as a surrogate marker for the
extent of immune damage incurred before cART initiation. In
our cohort, there was no significant difference in CXCL10 or
neopterin levels in VS HIV+ individuals with nadir CD4
T-cell counts above versus below 200 cells per microliter
(P . 0.05 for both, data not shown). The estimated median
duration of cART for VS patients in this study was 4.8 years;
however, this only included treatment received at the
attending clinic, thus we did not adjust for duration of
therapy in our study. We consider that the effect of both
early cART initiation and duration of therapy on immune
activation is best investigated using a contemporary cohort of
well-characterized patients receiving optimal cART regimens.
In this analysis, we adjusted for sex, which we have
shown affects monocyte activation biomarkers levels,10 and
also determined the effect of current smoking status, due to its
established effects on inflammation.23 Although smoking
status did not alter the relationship between the biomarkers
and age in control individuals, it did influence levels in HIV+
individuals; plasma LPS levels were significantly elevated in
viremic and VS HIV+ individuals as compared with controls
before but not after adjustment for smoking (data not shown),
demonstrating the necessity to control for smoking status
when comparing LPS levels in HIV studies. Although BMI
was not significantly different between HIV+ and seronega-
tive individuals, concurrent illness including hepatitis C
coinfection (more prevalent in HIV+ individuals), socio-
demographic differences, and other lifestyle factors may also
affect our results.
Cytomegalovirus (CMV) infection significantly impacts
immunosenescence associated with aging,24 and CMV sero-
positivity is ubiquitous in most HIV+ populations, making it
difficult to delineate the discrete effects of CMV and HIV.
CMV reactivation can occur during HIV infection and healthy
aging, but it is not known how the timing and/or frequency of
reactivation impacts on immune activation. For these reasons,
CMV status was not adjusted for here, and although these
results clearly demonstrate that immune dysfunction occurs in
HIV+ individuals, it is entirely possible that this may result
from the combined effects of HIV and CMV.
Studies investigating monocyte activation in HIV
infection typically measure plasma levels of sCD14, LPS,
or the proportion of monocyte subsets (or a combination of)
as biomarkers of monocyte activation. Accurate determina-
tion of plasma LPS levels can be influenced by inhibitory
binding proteins in plasma25 and a lack of robustness in the
analytical assays used, and is therefore a less reliable
biomarker. sCD14 is produced after monocyte stimulation
and is thus considered indicative of monocyte activation;
however, it can act systemically to inhibit LPS responses,26
complicating the interpretation of elevated plasma sCD14
levels. We have shown both here and previously10 that
although monocyte activation biomarkers such as CXCL10
and neopterin are increased during aging, sCD14 levels are
not, suggesting that these soluble biomarkers may indicate
different types of monocyte activation. Indeed, in our
analysis, sCD14 levels correlated only with neopterin levels
but no other soluble biomarkers or proportions of monocyte
subsets. CD16+ monocyte subsets are often considered
“inflammatory”27 and thus a marker of inflammation-
induced monocyte activation as they produce large amounts
of proinflammatory cytokines after stimulation28 and are
present at elevated levels in various inflammatory settings,29
including viremic HIV infection. The lack of correlation
between sCD14 levels and proportions of inflammatory
monocyte subsets shown here suggest that sCD14 levels
may only partially predict the extent of monocyte activation
and should therefore be interpreted with caution. In contrast,
CXCL10 levels were associated with all other soluble
biomarkers measured (except sCD14 as discussed above),
with proportions of intermediate and classical (although not
nonclassical) monocyte subsets, and also with other cellular
markers of monocyte activation/coagulation (ie, CD11b,
CD38, and tissue factor). These data suggest that CXCL10
can be used to indicate a range of monocyte activation
outcomes and is thus a useful biomarker warranting inclusion
in studies of monocyte activation. CXCL10 can be produced
from many different cell types including neutrophils and
endothelial cells after IFNg stimulation and is therefore not an
exclusive marker of monocyte/macrophage activation. How-
ever, our data suggest that CXCL10 levels may be a more
sensitive marker than monocyte-specific factors such as
sCD14 in this setting. Furthermore, monocytes are the
primary source of CXCL10 from PBMC in HIV+ individuals,
and plasma CXCL10 levels correlate significantly with
CXCL10 mRNA levels in monocytes.30 In the general
population, plasma CXCL10 levels are increased in individ-
uals with a range of conditions including colorectal cancer,31
frailty,31,32 hypertension, and coronary heart disease and
correlate significantly with traditional CVD biomarkers
including CRP, IL-6, and fibrinogen.33,34 Plasma CXCL10
levels are increased in HIV infection (including in HIV
controllers35) and are associated positively with T-cell activa-
tion and negatively with CD4 T-cell counts.35,36 CXCL10 is
a neurotoxic factor that is elevated in the cerebrospinal fluid of
HIV+ individuals and is further increased in those with AIDS-
related dementia37,38; further work is required to assess the
predictive value of plasma CXCL10 levels in morbidities such
as frailty and CVD in HIV infection.
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Although it has been speculated that HIV may accel-
erate biological aging, this is likely an oversimplification of
the diverse and incompletely understood mechanisms that
contribute to immunological aging. The data presented here
indicate that HIV infection heightens age-related changes
such that levels of monocyte activation reflect those observed
in HIV2 individuals who are significantly older and that this
effect is only partially ameliorated by cART. Given the
established associations between these activation biomarkers
and inflammatory disease, this likely confers increased disease
risk, although this requires investigation. Determining the
pathological consequences of these changes, and the mecha-
nism underlying them, is required to prevent inflammatory
diseases in the increasingly aging VS HIV+ population.
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REVIEW
Inflammation-induced foam cell formation in
chronic inflammatory disease
Thomas A Angelovich1,2, Anna C Hearps1,3 and Anthony Jaworowski1,3,4
Atherosclerosis is the leading cause of cardiovascular disease and is both a metabolic and inflammatory disease. Two models
describe early events initiating atherosclerotic plaque formation, whereby foam cells form in response to hyperlipidaemia or
inflammation-associated stimuli. Although these models are inextricably linked and not mutually exclusive, identifying the unique
contribution of each in different disease settings remains an important question. Circulating monocytes are key mediators of
atherogenesis in both models as precursors to lipid-laden foam cells formed in response to either excess lipid deposition in
arteries, signalling via pattern-associated molecular patterns or a combination of the two. In this review, we assess the role of
monocytes in each model and discuss how key steps in atherogenesis may be targeted to enhance clinical outcomes in patients
with chronic inflammatory disease.
Immunology and Cell Biology advance online publication, 10 March 2015; doi:10.1038/icb.2015.26
Atherosclerotic plaque formation is typically associated with a state of
hyperlipidaemia characterised by high levels of circulating lipid-
containing oxidised low-density lipoproteins (oxLDL) that promote
fatty streak formation. Fatty streaks form mainly in medium to large
arteries and may progress to form plaques encased by a fibrous cap
that may be degraded, resulting in rupture, coagulation and throm-
bosis contributing to myocardial infarction and stroke. Lipid-laden
macrophages, known as foam cells, are thought to form from migrated
monocytes responding to oxidation of lipoprotein deposited within
the intima.1,2 In this scenario, the progression of asymptomatic fatty
streaks to atherosclerotic plaques depends upon lipid levels in
circulation, which determine the extent of deposition of lipid into
arteries and the inflammatory milieu that promotes endothelial
activation and lipid oxidation.3 For convenience, we will term this
the lipid-centric model of foam cell formation. However, a growing
body of literature indicates that soluble and cellular immune factors
associated with chronic inflammation can promote atherogenesis
independent of hyperlipidaemia. This is evident by the increased risk
of atherosclerosis in a number of inflammatory conditions such as
sepsis (threefold),4 human immunodeficiency virus (HIV) infection
(threefold),5,6 healthy ageing,7 systemic lupus erythematosus (SLE)8
and rheumatoid arthritis (RA) (twofold),9 which is independent of
traditional cardiovascular risk factors including lipid levels. Further,
emerging data suggest that the role of monocytes/macrophages in
atherosclerosis is not simply that of a passive acceptor of oxidised
lipid. Monocytes, circulating blood precursors of tissue macrophages
and myeloid-derived dendritic cells (DCs) influence plaque develop-
ment following recruitment into the intima and differentiation to
foam cells. Although the mechanisms governing inflammation-derived
foam cell formation by monocytes remain ill-defined, recent evidence
suggests that recognition of inflammatory pattern-associated molecu-
lar patterns (PAMPs) by pattern recognition receptors (PRRs) may
have a key role. For the purposes of this review, we will term this the
inflammation-centric model.
In this review, we discuss the role of inflammatory components in
monocyte/macrophage-derived foam cell and atherosclerotic plaque
formation through PRRs and the implication of this for cardiovascular
risk in the setting of inflammatory diseases.
ROLE OF MONOCYTES IN THE LIPID-CENTRIC MODEL OF
ATHEROGENESIS
As macrophage precursors recruited to sites of lipid deposition,
monocytes have a major role in changes to fatty streak composition
that can lead to atherosclerotic plaques (Figure 1a). High levels of
circulating lipid accumulate in areas of oscillatory blood flow around
the aortic arch and bifurcations and induce endothelial activation,
upregulating the expression of adhesion molecules (i.e. vascular cell
adhesion molecule-1 and P-selectin) and monocyte chemotactic
proteins (e.g. CCL2) that facilitate monocyte recruitment. Monocytes
are activated by oxLDL, which may be produced from LDL by
activated endothelial cells10 or interactions with free radicals and metal
ions. In response, monocytes upregulate adhesion molecules and
chemokine receptors (i.e. CD11b, CCR2, CX3CR1), which increase
recruitment. The differential expression of these receptors has a key
influence on the role of individual monocyte subsets in atherogenesis.
Three subsets of monocytes have been defined in human circula-
tion, which are characterised by the expression of lipopolysaccharide
(LPS) coreceptors CD14 and FcγRIIIA (CD16). The majority of
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monocytes are classical monocytes (CD14++CD16−, ~ 80%), whereas
intermediate (CD14++CD16+, ~ 8%) and non-classical (CD16++
CD14+, ~ 5%) monocytes make up minor populations in healthy
individuals. Studies of the role of individual monocyte subsets in
atherogenesis have mostly been conducted using mouse models, in
particular 'western diet'-fed hyperlipidaemic apoE-deficient (apoE
(− /− )) mice that readily form atherosclerotic plaques. In contrast
to humans, mouse monocytes are usually characterised as having only
two subsets roughly equivalent to classical (Gr1+/Ly6C+) and non-
classical (Gr1–/Ly6C–) monocyte subsets as determined by gene
expression analysis. In apoE(− /− ) mice, Gr1+ monocytes expressing
high levels of CCR2 and low levels of CX3CR1 take on an
‘inflammatory’ role and migrate into fatty streaks to form foam
cells,2 whereas the Gr− subset expressing high levels of CX3CR1
preferentially ‘patrols’ the endothelium. Similarly, human non-classical
monocytes have been identified to be ‘patrolling’, whereas intermedi-
ate and classical subsets have an inflammatory role.11 Ly-6C-hi(Gr-1+)
monocytes are expanded in apoE(− /− ) mice fed a high fat diet,
suggesting that hyperlipidaemia promotes higher circulating levels of
‘inflammatory’ monocytes.2 Although the role of individual human
monocyte subsets in early atherogenesis has not been confirmed owing
to the lack of appropriate models of foam cell formation, cross-
sectional studies showed that the number of intermediate monocytes
independently predicted cardiovascular events in individuals under-
going elective coronary angiography,12 and the percentage of CD45RA
+ (highly expressed on CD16+ subsets) monocytes correlates with
serum LDL-cholesterol levels.13
Following adhesion, monocytes extravasate to the neointima where
exposure to macrophage colony-stimulating factor stimulates their
differentiation to macrophages with increased surface and intracellular
expression of scavenger receptor A (SR-A) and -B (CD36) that
facilitate ingestion of either acetylated LDL or native/oxLDL, high-
density lipoprotein (HDL) and anionic phospholipids, respectively
(Figure 1a).14 Other scavenger receptors (e.g. SR-BI and -BII) as well
Figure 1 Traditional and alternate inflammatory mechanisms of early atherogenesis. Monocyte recruitment and foam cell formation at sites of deposited lipid
(fatty streak). (a) Circulating monocytes attach to endothelial cells following the upregulation of adhesion molecules at sites of deposited lipid. Cells
transmigrate into the intima, where they differentiate into macrophages, upregulating scavenger receptors (SR-A/CD36) and LDLR, which bind and
subsequently internalise oxLDL to form foam cells. Metabolised LDL-cholesterol is transported to lipoprotein acceptors (e.g. HDL) via cholesterol efflux
transporters (e.g. ABCA1) and transported to the liver for excretion. (b) In settings of chronic inflammation, monocytes with increased expression of adhesion
molecules (i.e. CD11b, CCR2 and CX3CR1) are recruited to endothelial cells independent of accumulated lipid potentially because of the influence of
circulating PAMPs and proinflammatory cytokines (i.e. IL-6, TNF). Cells transmigrate into the intima where they differentiate into macrophages and signals
derived from native and oxLDL receptors and TLRs synergise to form foam cells. Cholesterol efflux and cell egress is impaired resulting in excess lipid
accumulation, which triggers necrotic pathways leading to cell death and release of lipid bodies. LDL accumulates in the intima triggering traditional
monocyte recruitment and atherogenesis described in (a).
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as Toll-like receptors (TLRs) also contribute to lipid uptake. Alter-
natively, monocytes may differentiate to myeloid-derived DCs that can
be activated by bacterial ligands via TLRs, potentially contributing to
lipid accumulation. However, the ability of DCs to take up lipid and
the role of TLRs in this process remains controversial.15
OxLDL and other lipid species are hydrolysed in lysosomes within
macrophages to liberate free cholesterol (FC) that is either exported
via cholesterol efflux transporters such as ATP-binding cassette
transporter 1 (ABCA1) and ABCG1 to apolipoproteins acceptors in
the vasculature for delivery to, and further metabolism in, the liver or
stored in lipid droplets following esterification to cholesterol ester
(CE) by acyl-CoA:cholesterol acyltransferase-1 (ACAT-1). Monocytes
and possibly macrophages or DCs may also egress from plaque to
physically remove accumulated lipid.16
Cells that fail to egress from the plaque can ingest large quantities of
lipid mainly via SR-A and CD36 and potentially become resident foam
cells, although CD36(− /− )SR-A(− /− )apoE(− /− ) mice form foam
cells in the absence of these receptors,17 indicating that pathways
independent of scavenger receptors contribute to foam cell formation.
Importantly, the factors governing the tendency of macrophages to
remain in the intima and form foam cells are incompletely under-
stood, although recent evidence suggests differentiation into classically
activated (LPS-stimulated) proinflammatory M1 or alternatively
activated (IL-4-stimulated) anti-inflammatory M2 macrophages may
be an important determinant, as M2 macrophages are more likely to
form foam cells in vitro under inflammatory conditions.18 These
findings highlight the plasticity of macrophages to alter phenotype in
different immunological environments. It is of note that M1/M2
macrophages generated in vitro may show different immune char-
acteristics to their in vivo counterparts, highlighting the requirement of
further studies to identify the role of M1/M2 macrophages in
physiologically relevant models of atherosclerosis.
Under conditions where cholesterol influx exceeds cholesterol
efflux, lipid droplets accumulate and necrotic and apoptotic pathways
are ultimately activated in the foam cell, resulting in cell death and the
subsequent release of FC, CE and inflammatory cytokines that act on
endothelial and immune cells in a positive feedback loop to induce
further monocyte migration into the intima.
INFLUENCE OF INFLAMMATION ON ATHEROGENESIS
Although there is a clear mechanistic link between hyperlipidaemia
and atherogenesis, inflammatory factors can promote foam cell
formation and potentiate plaque development independent of hyper-
lipidaemia (Figure 1b). Markers of inflammation (interleukin-6 (IL-6),
tumour necrosis factor (TNF) receptor, high-sensitivity C-reactive
protein (hsCRP)) and viral infection/autoimmune disorders (type I
interferons (IFN-α, IFN-β)) are independently associated with adverse
cardiac outcomes in people with atherosclerosis.19 Although these
markers have not been clinically validated, they may provide insight
into mechanisms of atherogenesis. As such, risk estimates that
incorporate the impact of inflammation (plasma hsCRP levels) on
atherogenic risk in addition to traditional risk factors (e.g. Reynolds
risk score) have been shown to better predict cardiac outcomes in
healthy individuals than risk scores, which rely on traditional risk
factors alone (i.e. smoking status, blood pressure, HDL/LDL, and so
on).20
In contrast to lipid-mediated atherogenesis where accumulated
oxLDL promotes initial monocyte recruitment, under inflammatory
conditions proinflammatory cytokines (i.e. IL-6 and TNF) and
potentially even pathogen/endothelial interactions independently pro-
mote monocyte recruitment to the endothelium. Bacterial products
may also directly influence atherogenesis as mouse J774 macrophages
stimulated in vitro with bacteria commonly identified in atherosclero-
tic plaques form foam cells via TLR-dependent mechanisms indepen-
dent of hyperlipidaemia.21 Human monocytes are particularly efficient
at responding to PAMPs and express 10 different TLRs responsible for
identifying non-host PAMPs such as LPS (TLR-4) and lipoprotein
(TLR-2) components of bacterial cell walls as well as viral nucleic acids
(TLR-7/8) and endogenous ligands. Through conserved myeloid
differentiation factor-88 (MyD88)-dependent (MyD88/nuclear fac-
tor-κB (NF-κB)) or -independent (TRIF/IFN regulatory factors
(IRFs)) signalling pathways, TLRs induce production of both proin-
flammatory (IL-1β, IL-6, TNF) and anti-inflammatory cytokines
(IL-10), as well as type I interferons (IFNα and β).
Following extravasation, monocyte/macrophage TLR responses to
PAMPs present in the neointima enhance uptake of LDL increasing
foam cell formation, in part, by upregulating LDL receptor (LDLR)
expression (Figure 1b, discussed further below). Evidence that loss of
SR-A and CD36 does not abolish foam cell formation in hyperlipi-
daemic mice is consistent with this, suggesting that other lipid-
independent pathways are involved.22 These lipid-independent pro-
cesses promote further monocyte recruitment and foam cell formation
by mechanisms described in the lipid-centric model, therefore linking
inflammatory processes to lipid oxidation and uptake.
Although fatty streaks are mainly composed of lipid deposits and
monocytes/macrophages, other immune cells accumulate as the
plaque matures. High serum cholesterol levels are associated with
macrophage activation, resulting in IL-1β, IL-6, TNF and IFN-γ
production that contribute to localised inflammation and monocyte
recruitment.23 Furthermore, murine macrophages incubated in vitro
with oxLDL24 or FC produced following the blocking of macrophage
cholesterol efflux25 have increased the production of IL-6 and TNF in
response to LPS, suggesting plaque-resident macrophages exposed to
lipid may have a heightened inflammatory response to stimuli,
therefore indicating crosstalk between the lipid- and inflammation-
centric models. Proinflammatory cytokines produced by foam cells
within the plaque may also contribute to localised inflammation: their
inflammatory nature is supported by in vitro studies showing that
human monocyte-derived M2 macrophages, which normally have an
anti-inflammatory phenotype, ingest high levels of oxLDL and
produce proinflammatory factors (IL-6, IL-8, MCP-1) following foam
cell formation, thus taking on a more M1-like proinflammatory
phenotype.26 In contrast, other studies show that peritoneal foam cells
produced in LDLR knockout mice (ldlr(− /− )) fed a western-type
diet accumulate desmosterol. This sterol activates liver X receptor
(LXR) pathways and suppresses TLR-4-dependent activation of NF-κ
B,27 which may dampen the proinflammatory response of these cells
to inflammatory stimuli in the vessel wall. Further work, especially
human studies, are required to fully characterise the inflammatory
nature of foam cells and whether differences exist between foam cells
in mature plaques and in fatty streaks.
Taken together, the above evidence suggests that inflammatory
mechanisms acting on monocytes/macrophages promote atherosclero-
sis via proinflammatory foam cell formation, which may be indepen-
dent of hyperlipidaemia.
ATHEROSCLOSIS IS INCREASED IN INFLAMMATORY
CONDITIONS
Atherosclerosis is a leading cause of morbidity and mortality in many
acute and chronic inflammatory conditions such as sepsis/endotox-
aemia, HIV, RA, SLE and ageing; however, the precise causal
relationships between atherosclerosis and these inflammatory states
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are unclear (Table 1). Despite the efficacy of combination antiretro-
viral therapy (cART), which lowers the viral load of HIV+ individuals
to levels undetectable by standard clinical assays (o50 copies of viral
RNA per ml) and reduces progression to acquired immune deficiency
syndrome (AIDS), HIV-infected individuals have an estimated 1.75
relative risk of acute myocardial infarction compared with matched
HIV-uninfected individuals, which is independent of traditional risk
factors such as dyslipidaemia.28 Although the HIV accessory protein
Nef may increase cardiovascular disease (CVD) risk by impairing
macrophage cholesterol efflux,29 virologically suppressed HIV+ indi-
viduals still experience threefold higher risk of atherosclerosis inde-
pendent of traditional risk factors,28 suggesting a role for factors other
than HIV-encoded proteins. Early combination antiretroviral therapy
regimens containing protease inhibitors were associated with dyslipi-
daemia and increased CVD risk; however, current cART regimens are
less likely to induce dyslipidaemia (except those containing some
nucleoside reverse transcriptase inhibitors such as Abacavir), and
despite the reduction of HIV-associated dyslipidaemia in virologically
suppressed individuals,30 increased CVD risk persists. CVD is a
leading cause of mortality in older individuals, but while older age
is associated with increased risk factors for atherosclerosis including
hyperlipidaemia, age itself is a significant independent risk factor for
atherosclerosis.7 Ageing is associated with chronic low-level inflam-
mation, increased carotid intima–media thickness (cIMT) and mus-
cular changes in the heart as well as elevated levels of plasma markers/
mediators of inflammation (IL-6, TNF, hsCRP and LPS), which are
associated with atherogenesis.31,32
Autoimmune disorders such as RA33 and SLE8 are also indepen-
dently associated with increased risk of CVD. Chronic inflammation
within the synovium of RA patients results in the recruitment of
multiple cell types including monocytes/macrophages, further poten-
tiating localised inflammation via the production of IL-1β, IL-6, IL-8
and TNF that results in joint destruction and functional impairment.
This also leads, however, to systemic increases in inflammatory
cytokines, which are associated with a twofold increase in
atherosclerosis.9 Similarly, duration of SLE disease is an independent
predictor of atherosclerosis and patients o40 years old have 5.6-fold
higher prevalence of atherosclerotic plaque to controls.8 SLE disease is
associated with high plasma levels of proinflammatory cytokines and
IFN, as well as hyperlipidaemia, which is thought to drive atherogen-
esis. SLE patients are also prone to infection and have high levels of
circulating LPS34 and autoimmune complexes that may promote foam
cell formation via TLR-mediated mechanisms, although further
studies are required to identify the role of TLRs in atherosclerosis in
SLE patients.
Taken together, atherogenic risk is increased in chronic inflamma-
tory disease settings independent of traditional risk factors such as
hyperlipidaemia, suggesting that atherogenesis may be driven by
inflammatory mechanisms. Although the causes of chronic inflamma-
tion differ, signals elicited by PAMPs are a common feature of these
conditions.
Increased presence of PAMPs in chronic inflammatory disease
HIV+ individuals have increased plasma levels of PAMPS such as LPS
because of increased mucosal permeability in the gut.35 These PAMPs
may exacerbate the role played by monocytes in atherogenesis as
predicted by the inflammation-centric model described above as
plasma sCD14 levels were associated with increased cIMT in HIV+
individuals36 (Figure 1b). High systemic levels of bacteria and bacterial
products, which occur during sepsis in HIV− individuals, also lead to
widespread immune activation and inflammation and is an indepen-
dent risk factor for atherosclerosis.4 Although LPS levels found in the
plasma of HIV+ individuals are not as high as those observed in sepsis
patients (⩾300 vs 40–60 pgml− 1 for virologically suppressed HIV+
individuals), chronically elevated plasma levels of LPS above 50
pgml− 1 (referred to as chronic endotoxaemia) are associated with a
threefold increased risk of atherosclerosis.4 This finding is significant,
as our laboratory has found that elderly individuals show similar levels
of LPS to younger, HIV+ individuals.37 This increase in the elderly is
possibly caused by increased permeability between tight junctions of
epithelial cells in the gut. SLE patients also have high plasma LPS levels
that are thought to dysregulate the transcriptome of monocytes.34
Furthermore, studies in patients with chronic kidney disorders
requiring dialysis, who are continuously exposed to bacterial products,
show increased cardiovascular risk associated with increased LPS levels
in the blood, suggesting that bacterial components may enhance
atherogenesis in this setting.38
The presence of bacterial cell wall components such as lipoprotein
and LPS is commonly caused by respiratory infections (Chlamydia
pneumoniae), bacterial contamination of dialysis tubing (Escherichia
coli) and periodontitis (Porphyromonas gingivalis) triggering general-
ised immune activation and inflammation via TLR signalling.
Furthermore, patients with concurrent vascular disease and chronic
periodontitis show higher bacterial load and bacterial diversity than
matched donors with vascular disease as determined by 16S rDNA
analysis of vascular biopsies.39 Interestingly, a recent longitudinal study
Table 1 Inflammatory disease risk factors associated with monocyte-derived atherosclerosis
Disease mRisk of
atherosclerosis
PAMPS Monocytes (%) TLR expression
on monocytes
Markers of inflammation Correlation with
atherosclerosis
Sepsis ↑ 3x4 LPS, lipoprotein ↑CD16+57 ↑ TLR-2, TLR-4 ↑ IL-6, TNF, sCD14 TF
HIV ↑ 3x5,6 HIV, LPS, lipoprotein,
CMV
↑CD16+37 ↑ TLR-2 ↑ IL-6, TNF, hsCRP, IFN, CD14,
neopterin
Intermediate
monocytes (%),59 TF,61
hsCRP
Ageing ↑ 1.057 a LPS, CMV lipoprotein ↑CD16+54 ↑ TLR-2, TLR-4 ↑ IL-6, TNF, hsCRP, d-dimer TNF, TNFR
Rheumatoid
arthritis
↑ 2x9 LPS, CMV, lipoprotein ↑CD14++CD16+
56
↑ TLR-2,44
TLR-4
↑ hsCRP, sCD14, IL-6, TNF hsCRP, IL-6, TNF9
SLE ↑ 4.88 b LPS ↑CD16++CD14+
53
↑ TLR-2,
TLR-445
↑ IFN-α, IL-6, TNF Unknown
Abbreviations: CMV, cytomegalovirus; hsCRP, high-sensitivity C-reactive protein; HIV, human immunodeficiency virus; IL-6, Interleukin 6; LPS, lipopolysaccharide; sCD14, soluble CD14; SLE,
systemic lupus erythematosus; TF, tissue factor; TLR, toll-like receptor; TNF, tumor necrosis factor.
aHazard ratio.
bOdds ratio.
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has shown that improvement in oral health is associated with a lower
rate of progression of cIMT in otherwise healthy individuals,40 further
suggesting a role for bacterial PAMPs on atherogenesis.
Viral PAMPs from cytomegalovirus (CMV) reactivation, hepatitis C
infection and residual HIV replication in cART-treated HIV-infected
individuals may be associated with atherogenesis. Recent findings
show that CMV-seropositive HIV-infected individuals have a 50%
increased risk of non-AIDS comorbidities compared with CMV-
seronegative HIV+ individuals, and that CMV seropositivity is
associated with increased cardiovascular events.41 CMV specific IgG
antibody has also been detected within atherosclerotic plaques42 and is
associated with increased systemic inflammation. Furthermore, in vivo
studies in MCMV-infected apoE(− /− ) mice identified that CMV-
induced atherosclerosis occurred without changes in circulating
cholesterol, HDL or triglycerides, but was associated with increased
IFNγ levels, consistent with inflammation-driven pathogenesis.43
CMV infection is widespread in the elderly ( ~90.8% of people ⩾ 80
years old are seropositive in the United States). CMV is associated with
increased CVD-related mortality, especially in those individuals with
increased inflammation as measured by plasma hsCRP. Endogenous
proteins found within arthritic joints such as heat-shock protein-60,
fibrinogen and fibronectin act as the major source of TLR activation in
RA patients, although the influence of these proteins on TLR-mediated
atherogenesis is unknown.
Immune activation and inflammation in chronic inflammatory
diseases influence atherogenesis independent of hyperlipidaemia via
both increased levels of PAMPS and increased circulating cytokines
that can influence the atherogenic potential of monocytes/
macrophages.
MONOCYTE ACTIVATION IN INFLAMMATORY DISEASE
Many chronic inflammatory diseases are associated with altered
monocyte phenotype and function, which may alter the potential of
these cells to influence atherogenesis (Table 1). Inflammatory diseases
are associated with increased plasma markers (sCD14, sCD163) and
drivers (LPS) of monocyte activation that are used as surrogate
markers of these processes, although few human studies have
evaluated the contribution of monocyte activation in inflammatory
disease on atherogenesis. Although individual chronic inflammatory
conditions may activate monocytes via different mechanisms, stimula-
tion of monocytes via TLRs and other PRRs is a common factor.
TLR-2 expression is elevated on circulating monocytes from RA,44
SLE45 and HIV-infected patients,46 suggesting that these cells may be
primed in their responses to bacterial PAMPs. This is also true of
healthy, older individuals who show age-related increases in systemic
inflammation termed 'inflamm-ageing'.31 In addition to responding to
inflammatory PAMPs, monocytes/macrophages also produce IL-1β,
IL-6 and TNF via TLR-4 recognition of oxLDL.47,48 Murine studies
have shown that oxLDL acts synergistically with LPS to increase
proinflammatory cytokine production49 and foam cell formation in
peritoneal macrophages from C3H/NeN mice in a TLR-4-dependent
manner.50 This shows that monocytes bridge the lipid-centric and
inflammatory models of atherosclerosis. Monocytes from HIV+
individuals,37,51 RA52 and SLE patients53 and the elderly54 show
increased response to LPS, which may exacerbate the interaction
between bacterial PAMPs and oxLDL. Furthermore, HIV
infection,37,55 RA,56 ageing54 and sepsis57 are all associated with an
increased proportion of intermediate and non-classical monocyte
subsets, which are significant producers of proinflammatory cytokines.
This is supported by epidemiological studies showing that increases in
the proportion of intermediate monocytes independently predict
cardiac events in HIV+ individuals12 and people with chronic kidney
disease58 and that cellular changes to monocytes including increased
surface expression of tissue factor on intermediate monocytes is
associated with increased cIMT in HIV+ individuals.36,59 In addition
to a shift towards CD16+ subsets, monocytes from HIV+ individuals
share phenotypic characteristics to those of HIV− individuals with
acute coronary syndrome (elevated surface CD11b60 and tissue
factor61 expression) and produce more proinflammatory cytokines
in response to LPS.51 As CD16-expressing monocytes have higher
surface expression of CD11b and CX3CR1 compared with classical
monocytes, this may result in enhanced monocyte adhesion to
endothelial cells; however, further human studies are required to
evaluate the significance of this mechanism to atherosclerosis.
Thus, the activation of monocytes by PAMPS and the expansion of
proinflammatory CD16-expressing monocyte subsets in the setting of
inflammatory disease may promote atherosclerosis by promoting
recruitment of proatherogenic monocytes into blood vessel walls.
Furthermore, activation of monocytes via inflammatory signalling
pathways may also enhance lipid uptake promoting monocyte
differentiation to foam cells.
TLR ACTIVATION IN ATHEROSCLEROSIS
Atherosclerotic tissue from patients with coronary artery disease has
been shown to have threefold increased mRNA expression and protein
levels of TLR-1/2 and -4 compared with tissue obtained from healthy
control arteries with expression in plaques largely restricted to
macrophages and endothelial cells.62 Furthermore, circulating
monocytes63 and DCs64 from patients with acute coronary artery
syndrome also have increased surface expression of TLR-2 and -4.
TLRs recognising both bacterial (TLR-2, -4, -5) and viral and
endogenous ligands (TLR-7/8, -9) have been identified to influence
atherogenic risk in both mouse and human studies. Evidence
summarised below shows that TLR signalling can drive foam cell
formation from macrophages independent of hyperlipidaemia, sug-
gesting that monocytes with increased TLR expression may form foam
cells more readily.
Bacterial-driven atherogenesis
As mentioned above, certain bacterial infections such as C. pneumo-
niae and E. coli are associated with increased risk of atherosclerosis and
foam cell formation, and the titre of IgA antibodies to C. pneumoniae
has been associated with carotid and femoral atherosclerosis.65 The
relationship between bacterial infection and atherosclerosis has been
demonstrated in animal models: rabbits fed a diet containing modest
levels of cholesterol and infected with C. pneumoniae experienced
accelerated atherosclerosis as measured by cIMT in comparison with
uninfected controls fed a similar diet.66 Similarly, inoculation of C.
pneumoniae into the carotid artery of ldlr(− /− ) mice enhanced
atherosclerosis and caused a twofold increase in cIMT.67 DNA analyses
of resected mature plaques from individuals undergoing coronary
atherectomy have identified a wide variety of bacteria, suggesting that
bacterial products may mediate localised inflammation that drives
plaque development.68 These bacteria may also act by invading
phagocytic cells localised within plaque, as it has been possible to
culture viable bacteria from such tissue.69
The potential importance of bacterial PAMPs such as LPS in
promoting foam cell formation is increased as TLR-4 mRNA expres-
sion is increased in surgically extracted atherosclerotic plaque62 and on
circulating monocytes from individuals with acute coronary syndrome
in comparison with controls.70 A role for TLR-4 in promoting
atherosclerosis is supported by studies showing that polymorphisms
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that reduce TLR-4 activity are associated with decreased cardiovascular
risk in humans.71 Animal models suggest that the mechanism of TLR-
mediated atherogenesis is independent of hyperlipidaemia as inhibi-
tion of TLR-4 signalling in LPS-stimulated apoE(− /− ) mice using
NF-κB inhibitors reduced LPS-induced plaque size by 50%, without
altering plasma levels of cholesterol or related lipids.72 Furthermore,
TLR-4 knockout in the apoE(− /− ) mouse results in a 75% decrease
in intimal lipid accumulation73 and reduced levels of MCP-1,74 a
soluble marker of immune activation associated with atherosclerosis,
without effects on serum cholesterol and triglyceride levels. Infection
of apoE(− /− ) mice with C. pneumoniae increased diet-induced
atherosclerosis in an MyD88-dependent manner that was abrogated
by deletion of either TLR-2 or TLR-4 showing the need for multiple
TLR pathways in infection scenarios.75 In this model, atherosclerosis
was enhanced in apoE(− /− )LXRα(− /− ) mice, suggesting that LXRα
modulates the effects of TLR ligands. One potential mechanism may
be increased expression of macrophage cholesterol exporters, which
are positively regulated by LXRα (see below). In vitro studies show that
incubation of RAW264.7 murine macrophages with purified C.
pneumoniae LPS causes foam cell formation;76 the pathways leading
to foam cell formation in these isolated cell systems need to be
assessed in vivo.
Although the lipid-centric atherogenesis model assumes that for-
mation of foam cells occurs via accumulation of exogenous modified
LDL via scavenger receptors, Funk et al.77 first observed in vitro that
incubation of RAW264.7 cells with LPS resulted in foam cell
formation in a dose- dependent manner that was independent of
the addition of exogenous LDL.77 Interestingly, foam cells formed
under these conditions contain accumulated triglyceride-containing
lipid droplets rather than esterified cholesterol, suggesting that these
cells may differ biochemically from foam cells generated by incubation
with modified cholesterol-containing lipoprotein particles. Lipoprotein
from Gram-positive bacteria, recognised by TLR-2, also promotes
foam cell formation independent of hyperlipidaemia.21 Infection of
RAW264.7 cells with C. pneumoniae promotes foam cell formation in
a TLR-2-dependent manner and foam cell formation is impaired in
peritoneal macrophages from TLR-2(− /− ) C57BL/6 mice incubated
with Pam3-cys or infected with C. pneumoniae.78
Taken together, evidence is accumulating that bacterial infection
and/or the presence of bacterial products may promote foam cell
formation via TLRs expressed on endothelial cells and macrophages
via mechanisms that do not require hyperlipidaemia.
Virus-driven atherogenesis
Although most research on the role of TLR-stimulated atherosclerosis
has focused on bacterial products, viruses and endogenous proteins
also influence atherogenesis. Individuals infected with HIV,6 CMV79
and hepatitis C80 also have increased CVD risk. Antigen-presenting
cells, particularly plasmacytoid DCs (pDCs), produce type 1 IFN in
response to viral ligands, which induces anti-viral response in
surrounding tissues and activating monocytes and macrophages.
While the role of pDCs in atherogenesis is not well characterised,
IFN-α mRNA gene expression is strongly associated with TNF
expression in surgically extracted human carotid plaque tissue
suggesting that activation of pDCs activate macrophages to produce
TNF in plaque.81 Furthermore, IFN-α produced by pDCs primes
macrophage responses to other PAMPs by upregulating TLR-4
expression, although further studies are required to identify conclu-
sively the contribution of pDCs to IFN-α production in vivo.81 Similar
studies in SLE patients also showed that IFN-inducible gene expression
correlated with SR-A mRNA expression, suggesting that IFN-α may
promote lipid uptake in plaque macrophages.82
Monocytes, particularly non-classical and intermediate subsets,
respond to viral PAMPs such as single-stranded RNA via TLR-7/8
and produce type I IFN and proinflammatory cytokines.11 A recent
study evaluating the role of HIV in foam cell formation found
that HIV RNA is recognised by TLR-8 and promotes foam cell
formation in human monocyte-derived macrophages via the produc-
tion of TNF.83 Conversely, TLR recognition of ssRNA may be
potentially protective against atherosclerosis by repressing macrophage
proinflammatory cytokine production; silencing of TLR-7 in apoE
(− /− ) mice accelerated atherogenesis and plaque vulnerability. In
contrast, macrophages from human plaques are reported to show
decreased response to TLR-2 and -4 ligands following TLR-7
stimulation.84 The role of TLR-7/8 in atherogenesis requires further
investigation.
Despite transducing common signalling pathways, TLR signalling
may have different roles in promoting or protecting against ather-
ogenesis. Further work is required to delineate the complex interac-
tions between these pathways.
POTENTIAL MECHANISMS OF TLR-DRIVEN FOAM CELL
FORMATION
Despite many studies showing that TLR ligands stimulate foam cell
formation by monocytes/macrophages, the mechanism driving
increased lipid accumulation and storage for many of these molecules
is unknown. TLR signalling may promote foam cell formation in three
ways: (1) by upregulating lipid uptake, (2) by increasing lipid
biosynthesis and (3) by downregulating the processing and export of
lipid following ingestion (Figure 2).
Enhanced lipoprotein uptake via LDL receptor
Although foam cells form following the ingestion of modified LDL
and other phospholipids via scavenger receptors, lipoprotein and TLRs
expressed on monocytes/macrophages also promote foam cell forma-
tion following uptake of unmodified LDL. In vitro incubation of
human monocytic THP-1 cells with LPS stimulates uptake of
unmodified, native LDL via LDLR, resulting in cells morphologically
similar to foam cells.85 Whether increased LPS levels in HIV+
individuals and the elderly specifically promotes foam cell formation
in these individuals via this mechanism is yet to be determined. LDLR
transcription is regulated by sterol regulatory element binding protein
2, which is increased by the activation of TLR-4 via crosstalk between
MyD88/IKK pathways,86 and consequently, LPS enhances LDLR gene
and protein expression and LDL uptake in THP-1 cells in vitro. LPS
stimulation of macrophages in vitro also increases minimally modified
LDL uptake by macropinocytosis.87 Thus, LPS may increase receptor
and non-receptor-mediated uptake of unmodified LDL and stimulate
foam cell formation independent of exogenous modified lipoproteins
or scavenger receptors.
Biosynthesis of lipids by macrophages
TLR signalling promotes de novo lipid synthesis by macrophages.
Monocytes synthesise cholesterol in the endoplasmic reticulum, and
this biosynthesis is essential to allow differentiation to macrophages.
The rate-determining step of cholesterol synthesis is catalysed by
HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-CoA reductase),
the primary target of the statin class of cholesterol-lowering drugs.
Inflammatory factors such as LPS, TNF and IL-1β induce HMG-CoA
reductase gene expression in THP-1 macrophages by activating NF-κB
and sterol regulatory element binding protein 2 transcription factors.86
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Treatment of monocytes from RA patients with simvastatin ex vivo
decreased TLR-2 responses to Staphylococcus aureus peptidoglycan via
inhibition of RhoA, indicating that statins also inhibit TLR-mediated
cytokine production via their anti-inflammatory properties.88 Newly
synthesised or internalised, unesterified cholesterol either traffics to
cholesterol efflux receptors for export (discussed below) or is esterified
by ACAT-1 and stored as CE in lipid droplets. TNF increases ACAT-1
expression in human monocytes resulting in the accumulation of CE
and foam cell formation.89 This ability is not shared by other
proinflammatory cytokines such as IL-1β, IFNγ or IL-6, suggesting a
unique property of TNF in both promoting cholesterol biosynthesis
and esterification. Taken together, these findings show that cross-talk
between TLR signalling pathways and their products skew cholesterol
metabolism within monocytes/macrophages towards lipid synthesis
and foam cell formation.
Impaired cholesterol efflux
Monocytes/macrophages metabolise FC to facilitate export to either
lipoprotein acceptors (apoA1) or HDL via the cholesterol efflux
regulatory proteins ABCA1 and ABCG1, respectively (Figure 2). The
transcription of these proteins is upregulated by the LXR pathway that,
if dysregulated, can promote foam cell accumulation via decreased
cholesterol efflux.90
PAMP-mediated TLR signalling impairs cholesterol efflux in mouse
macrophages by downregulating ABCA1 mRNA expression via NF-
κB-dependent mechanisms.91 However, it is likely that both MyD88-
dependent and -independent mechanisms,92 through transcription
factor IRF-3,93 are responsible for ABCA1 downregulation in this
setting. In contrast, one study using THP-1 cells stimulated with LPS
in vitro has shown an increase of ABCA1 mRNA expression via the
LXR pathway,94 indicating that further studies, especially in human
Figure 2 Mechanisms of TLR-induced foam cell formation. Signal transduction via multiple TLRs (pink) upregulate foam cell formation by influencing
cholesterol influx (green), synthesis (yellow) or efflux mechanisms (purple) in monocytes/macrophages. TLR signalling enhances uptake of oxLDL by
increasing surface expression of LDLR, CD36 and SR-A and native LDL by macropinocytosis (green). FC, liberated from oxLDL, promotes further cholesterol
synthesis, esterification to CE for storage in lipid droplets or is transported to cholesterol efflux transporters. TNF upregulates HMG-CoA reductase and
ACAT-1 expression promoting cholesterol accumulation (yellow). TLR signal transduction through NF-κB and IRF-3 downregulates LXR pathways that regulate
cholesterol efflux transporters (e.g. ABCA1) impairing cholesterol efflux to HDL and apolipoproteins (purple). Modulators of TLR signalling may be exploited to
impair TLR-mediated foam cell formation by targeting TLR receptors (chloroquine, RS-LPS) or signalling pathways (miR146a).
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cells, are required to elucidate the impact of TLR-mediated pathways
on cholesterol efflux. Whether viral PAMPs also result in decreased
ABCA1 by inhibiting LXR pathways is currently unknown; however,
as TLR-7/8 results in increased signalling via IRF-3, this may be
possible.
As mentioned above, LXRα modulates the proatherogenic effects of
C. pneumoniae infection.75 This was associated with the inhibition of
TLR-mediated NF-κB and IRF-3 activation when cells were stimulated
with LXR agonists. Thus, the LXR and TLR signalling pathways may
interact to mediate cross-talk between lipid- and inflammatory-
mediated foam cell formation. LXR downregulates proinflammatory
cytokine production in LPS-stimulated monocytes and reduces TNF
effects on cholesterol efflux.95 ABCA1 can also act as an exporter of
LPS from within macrophages and thereby decrease LPS-induced
tolerance.96 There is therefore a complicated interrelationship between
TLR and LXR signalling with cholesterol efflux and foam cell
formation on the one hand and cytokine secretion and inflammatory
pathways on the other.
These in vitro studies are supported by in vivo data, which showed
that acute endotoxaemia in C57BL/6 chow-fed mice reduced choles-
terol efflux from macrophages and altered hepatic gene expression
involved in biliary transport of cholesterol.97 In this study, it was
further shown that incubation of human monocyte-derived macro-
phages with LPS decreased cholesterol efflux and expression of
proteins involved in cholesterol efflux and metabolism including
ABCA1. These findings are further supported by studies of patients
with Tangier’s disease who show decreased ABCA1 expression and
cholesterol efflux in macrophages, resulting in foam cell formation
and is associated with increased cIMT.98 Interestingly, monocytes
from HIV+ individuals with high viral load have been reported to
have increased ABCA1 mRNA expression in comparison with HIV−
controls and virologically suppressed HIV+ individuals;99 however,
how this affects the atherogenic properties of such monocytes remains
to be determined.
In summary, TLR signalling influences foam cell formation by
targeting cholesterol influx, metabolism and efflux in monocytes/
macrophages, resulting in the accumulation and retention of choles-
terol within the cell. TLR signalling potentially affects cholesterol
trafficking and metabolism pathways after monocytes migrate into the
subendothelial neointima and differentiate into macrophages; how-
ever, chronic exposure of peripheral monocytes to PAMPs may also
alter cholesterol efflux pathways and predispose monocytes to form
foam cells before their transendothelial migration.
REGULATING TLR-INDUCED FOAM CELL FORMATION
TLR modulators
The influence of multiple TLRs, and the conserved nature of their
downstream signalling pathways, suggests that TLR pathway modula-
tors may provide a potential therapeutic option for treating
inflammation-driven atherogenesis. Chloroquine, an anti-malarial
drug which inhibits TLR activation by disrupting endosomal acidifica-
tion, reduced plaque lesion size induced by western-type diet in apoE
(− /− ) mice.100 Treatment of hyperlipidaemic apoE(− /− ) mice with
synthetic TLR-7 and -9 antagonists reduced foam cell formation by up
to 65%,101 while the TLR-4 antagonist RS-LPS (LPS from the
photosynthetic bacterium Rhodobacter sphaeroides) also reduced foam
cell formation and atherosclerotic plaques in diabetic apoE(− /− )
mice.102 While inhibition of TLR-4 and TLR-7 signalling is protective
in mouse models, the effectiveness of chloroquine or RS-LPS in
human atherosclerosis is currently unknown. Human trials evaluating
chloroquine are underway with the Atheroma Reduction with
Chloroquine in the Metabolic Syndrome (ARCH-MS) nearing com-
pletion (late 2015). The results of this trial will provide insight into
whether directly targeting TLRs in vivo influences inflammatory
atherogenesis in high-risk individuals.
MicroRNAs
Several microRNA species (miRNAs) have been linked to the
regulation of TLR signalling genes implicated in foam cell formation.
miRNAs act by binding in a sequence-specific manner to the
3′-untranslated region of mRNA, resulting in stabilisation or degrada-
tion of specific targets, thereby acting as either a positive or a negative
regulator of gene expression, respectively. The expression of miRNA-
-155, a positive regulator of TLR-4 signal transduction that upregulates
proinflammatory cytokine production, is increased following TLR-4
stimulation. miRNA-155 expression has recently been shown to be
twofold higher in human atherosclerotic plaque compared with
healthy tissue, and overexpression of miRNA-155 in C57BL/6 mouse
peritoneal macrophages is associated with decreased cholesterol
efflux.103 Knockout of miRNA-155 in apoE(− /− ) mice also decreases
CCL2 expression on monocytes, reduces their recruitment to the
endothelium, reduces proinflammatory cytokine production in
macrophages and reduces the size of atherogenic lesions via repression
of NF-κB.104 These observations suggest that miRNA-155 may have a
key role in atherogenesis at multiple levels by regulating monocyte
recruitment and differentiation into foam cells.103 In support of these
observations, it has been recently shown that antagomiR-155, an
inhibitor of miRNA-155, decreases oxLDL-induced foam cell forma-
tion in macrophages from apoE(− /− ) mice.105 Moreover, this study
also identified that miRNA-155 expression is increased in CD14+
monocytes from patients with coronary heart disease, suggesting a
role in response to injury. Although miRNA-155 appears to regulate
lipid-driven atherosclerosis in atherosclerosis—prone mice fed a high
fat diet—it is possible that it could also affect PAMP-driven athero-
sclerosis via similar mechanisms. However, the use of strategies to
silence miRNAs should be treated with caution, as they regulate many
genes. Stimulation of THP-1 cells with oxLDL increased miRNA-155
expression; however, silencing of miRNA-155 in vitro was associated
with enhanced lipid uptake and increased TNF production,106
suggesting that the mechanism of miRNA-155 regulation of TLR-4
signalling and atherogenesis is complex and remains to be fully
defined.
In contrast to miRNA-155, miRNA-146a is a negative regulator of
TLR-4 signalling reducing endothelial cell activation by repressing NF-
κB-dependent pathways and may therefore act in a negative feedback
loop to reduce LPS-induced inflammation.107 However, longitudinal
intervention studies evaluating miRNA-146a expression in peripheral
blood mononuclear cells from patients with coronary artery disease
before and after treatment with statins and angiotensin-converting
enzyme inhibitors identified that patients with higher baseline levels of
miRNA-146a have worse disease outcomes.108 Significantly,
miRNA-146a levels positively correlated with TLR-4 mRNA levels
that were independent predictors of cardiac events. Twelve-month
treatment with statins and angiotensin-converting- enzyme inhibitors
lowered miRNA-146a and TLR-4 levels, suggesting that altering
miRNA-146a levels may also contribute to the anti-inflammatory
effect of these therapies. This finding indicates that targeting
miRNA-146a may be an effective treatment option for
inflammation-induced CVD.
Limited data suggest that miRNAs may have an important role in
the regulation of TLR-mediated foam cell formation; however, further
work is required to elucidate these effects and identify which miRNAs
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may be potential therapeutic targets for regulating foam cell
formation.
CONCLUDING REMARKS
Although hyperlipidaemia stimulates atherogenesis by providing more
lipid for foam cell formation and an inflammatory milieu to increase
lipid oxidation, the observation that inflammatory stimuli such as
PAMPs can either synergistically or independently drive foam cell
formation from monocytes/macrophages raises new questions regard-
ing the mechanisms of plaque formation in chronic inflammatory
diseases. Inflammatory mechanisms may act as both a precursor to
mechanisms described in the lipid-centric model, while also promot-
ing atherogenesis via both oxidative and non-oxidative cholesterol
uptake and decreased cholesterol efflux. Therapeutically targeting
interactions between TLRs and foam cell formation may reduce
adverse cardiovascular outcomes in individuals with chronic inflam-
matory diseases. Some crucial questions remain to be answered
surrounding the roles of individual monocyte subsets in promoting
atherosclerotic plaque formation and which subset(s) are best able to
reverse the development of plaques from fatty streaks. Development of
more physiological models of fatty streak progression will provide us
with a better understanding of how inflammation may prime
monocytes for heightened foam cell formation in chronic inflamma-
tory disease.
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are reversed in antiretroviral treated individuals.
Design: A cross sectional study of monocyte ageing markers in viremic and virologi-
cally suppressed HIVþmales aged45 years and age-matched and elderly (65 years)
HIV-uninfected individuals.
Methods: Age-related changes to monocyte phenotype and function were measured in
whole blood assays ex vivo on both CD14þþCD16 (CD14þ) and
CD14variableCD16þ(CD16þ) subsets. Plasma markers relevant to innate immune acti-
vation were measured by ELISA.
Results: Monocytes from young viremic HIVþ males resemble those from elderly
controls and show increased expression of CD11b (p<0.0001 on CD14þ and
CD16þsubsets), and decreased expression of CD62L and CD115 (p¼0.04 and
0.001 respectively on CD14þ monocytes) when compared to young uninfected con-
trols. These changes were also present in young virologically suppressed HIVþ males.
Innate immune activation markers neopterin, sCD163 and CXCL10 were elevated in
both young viremic (p<0.0001 for all) and virologically suppressed (p¼0.0005, 0.003
and 0.002 respectively) HIVþ males with levels in suppressed individuals resembling
those observed in elderly controls. Like the elderly, CD14þ monocytes from young
HIVþ males exhibited impaired phagocytic function (p¼0.007) and telomere short-
ening (p¼0.03) as compared to young uninfected controls.
Conclusions: HIV infection induces changes to monocyte phenotype and function in
young HIVþ males that mimic those observed in elderly uninfected individuals,
suggesting HIV may accelerate age-related changes to monocytes. Importantly, these
defects persist in virologically suppressed HIVþ individuals.
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The increased life-expectancy of HIVþ individuals due
to combination antiretroviral therapy (cART) has
revealed an increased incidence of non-AIDS co-
morbidities more commonly seen in the elderly, such
as cardiovascular disease [1], frailty [2], bone and renal
disease [3] and neurocognitive decline [4]. While the
pathogenesis of age-related diseases is complex and
multifactorial, these conditions are associated with an
ageing and dysregulated immune system. The increased
prevalence of these diseases and their premature onset in
HIVþ individuals suggest HIV may induce premature
immune ageing.
Immune ageing results from a lifetime of pathogen
stimulation and is characterized by an increase in
senescent CD8þCD28T cells [5] and a state of chronic
inflammation which drives age-related immune dysfunc-
tion and disease [6,7]. Elevated plasma levels of
inflammatory markers (e.g. IL-6) predict age-related
diseases including cardiovascular disease, frailty and
mortality [8–12]. HIVþ individuals share many
immunological characteristics with the elderly including
chronic inflammation (reviewed in [13]), an increased
proportion of senescent T cells with shortened telomeres
[14,15] and increased risk of age-related disease. Similar
factors may drive chronic immune activation and
inflammation in HIVþ individuals and the elderly and
include a) increased pathogen burden due to impaired
immunity, b) chronic viral replication by viruses such as
cytomegalovirus, a well recognized driver of ageing
[16,17] and HIV and c) microbial translocation of
bacterial products across damaged mucosal surfaces e.g.
the gut [18,19].
In untreated HIVþ individuals, the level of T cell
activation is the strongest predictor of mortality [20], but
the predictive value of T cell activation markers in the
post-cART era is unclear. T cell activation in HIVþ
individuals is primarily driven by viral replication, which
is significantly suppressed by cART, although residual
activation persists [21]. In contrast, cART does not
normalize levels of innate immune stimulants such as LPS
[22], and innate immune activation persists in cART-
treated individuals [22,23]. A recent study of HIVþ
individuals (the majority being virologically suppressed,
VS) found levels of the monocyte/macrophage activation
marker soluble CD14 (sCD14) independently predict all
cause mortality [24]. In cART treated subjects, sCD14
levels correlate with inflammatory markers such as IL-6,
hsCRP and d-dimer [24] that predict cardiovascular
disease while elevated sCD163 levels are associated with
increased formation of non-calcified plaques [25]. Thus,
the persistence of innate immune stimuli in VS
individuals may contribute to HIV-related morbidity
and mortality in the post-cART era.pyright © Lippincott Williams & Wilkins. UnauthoLPS levels remain elevated in cART-treated individuals
with a decay half life of up to 13 years [22], yet the impact
of this on the phenotype and function of innate immune
cells remains unknown. Monocytes/macrophages are the
major responders to LPS due to their high expression of
the LPS-receptor TLR4 and its related signalling
molecule CD14 [26] and are primary producers of
pro-inflammatory cytokines like TNF and IL-6. Mono-
cytes have specific roles in the pathogenesis of age-related
diseases; e.g. in foam cell formation during the
development of atherosclerotic plaques [27] and in
HIV-associated dementia [28]. Given that the stimuli
to which monocytes respond remain elevated in cART-
treated individuals, monocyte activation may be an
independent predictor of age-related co-morbidities in
VS HIVþ individuals.
We sought to determine whether HIV infection
prematurely induces age-related changes to monocytes
by directly comparing the phenotype and function of
monocytes from young HIVþ individuals to both age-
matched and elderly HIV-uninfected controls. Our
findings confirm that HIV infection is associated with
a premature induction of age-related changes to
monocytes and support the hypothesis that HIV may
accelerate immune ageing and thus hasten the develop-
ment of age-related diseases.Methods
Participant recruitment and blood separation
Viremic (median viral load 41,600 RNA copies/ml,
range 80->100,000; median CD4 T cells 434/mL, range
11–1092) and VS (viral load <50 RNA copies/ml,
median CD4 T cells 695/mL, range 209–1199, median
time of viral suppression 2.8 years, range 0.7–7.6 years)
HIVþ individuals 45 years were recruited from the
Infectious Diseases Unit at The Alfred hospital,
Melbourne. Young (45 years) and aged (65 years)
HIV- controls were recruited from the community.
Ethical approval was obtained from The Alfred hospital
Research and Ethics Committee. Male participants were
exclusively recruited because HIVþ individuals in
Australia are predominantly male. Exclusion criteria
included current use of anti-inflammatory medication
and recent (3 weeks) vaccination or self-reported
illness/injury. Plasma separation and peripheral blood
mononuclear cell (PBMC) preparation (via Ficoll
gradient centrifugation) was performed within 2 hours
of blood collection.
Monocyte phenotyping
Blood collected into EDTA anticoagulant was mixed
with a 20x volume of 1x FACS lysing solution (BD
Biosciences) to lyse erythrocytes (shown not to signifi-
cantly alter expression of relevant surface markers),rized reproduction of this article is prohibited.
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FACS wash (1% heat-inactivated cosmic calf serum,
2mM EDTA in calcium- and magnesium-free phos-
phate-buffered saline (Invitrogen)). Cells were stained on
ice for 30minutes using pre-titrated volumes of the
following antibodies: CD14-APC, CD16-PE.Cy7,
CD38-PE, HLA-DR-FITC, CD11b-PE, CD62L-FITC
(BD Biosciences), TLR4-FITC (R&D Systems) and
CD115-PE (eBiosciences), or appropriate isotype control
antibodies. Cells were washed once in FACS wash and
fixed in 1% formaldehyde. Samples were analysed on a
dual-laser BD FACSCalibur flow cytometer.
Assessment of monocyte phagocytosis
Phagocytic capacity of monocytes was determined using
heat-killed E.coli labelled with the pH–dependent dye
pHRODO (Invitrogen) as per manufacturer’s instruc-
tions. 2 108 labelled E.coli were added to 100ml of
whole blood collected into heparin anticoagulant and
incubated either at 378C or on ice for 10minutes. Red
blood cells were lysed and monocytes labelled with
CD14-APC and analysed as described above.
Analysis of telomere length
Telomere length in monocyte subsets was determined via
immunophenotyping and FISH-Flow using modification
of a previously described protocol [29]. PBMCs were
labelled with anti-CD14-Qdot 800, anti-CD3-Alexa-
Fluor 405 (both from Invitrogen) and anti-CD16-
AlexaFluor 647 (Biolegend) and cross-linked with
4mM bis(sulfosuccinimidyl)suberate. Telomeres were
stained with the FITC FISH-Flow telomere labelling
kit (Dako) as per manufacturer’s instructions using a
7AADDNA stain (0.1mg/ml). Samples were analysed on
a LSRII flow cytometer and relative telomere length of
monocyte subsets determined as a percentage of the
internal control cell line 1301 [30].
Measurement of soluble markers of innate
immune activation
Plasma protein and endotoxin measurements were
performed using frozen EDTA plasma (subjected to only
one freeze-thaw), that was clarified via centrifugation at
10,000 x g for 10minutes prior to analysis. LPS levels
were determined in plasma diluted 1:10 and heat
inactivated (808C for 10min) using the chromogenic
Lonza LAL kit (Cat # 50–647U). Commercial ELISA
kits were used to determine levels of sCD163 (IQ
products, Cat. #IQP-383), neopterin (Screening EIA,
Brahms, Cat. # 99R.096), sCD14, CXCL10/IP-10 and
M-CSF (Cat. #DC140, DIP100 and DMC00B respect-
ively, all from Quantikine, R&D Systems) as per
manufacturer’s instructions.
Data and statistical analysis
Analysis of flow cytometric data was performed using
GateLogic software (Inivai). Graphing and statistical
analysis was performed using GraphPad Prism versionCopyright © Lippincott Williams & Wilkins. Unaut5.0. Mann-Whitney U test was used to detect significant
differences between sample groups (for non-parametric
data) and significant correlations detected via Spearman’s
correlation analysis.Results
Monocyte subsets
Peripheral blood monocytes were gated as
CD14variableCD16þ (referred to as CD16þ) and
CD14þþCD16- (referred to as CD14þ) subsets
(Fig. 1a). There was a significant increase in the
proportion of CD16þ monocytes in elderly individuals
(p¼ 0.003, Fig. 1b). An expansion of this population was
also observed in young viremic (p¼ 0.003) but not in VS
(p¼ 0.47) HIVþ males (Fig. 1b). In addition to the
expansion of total CD16þ monocytes, the CD14þ
monocyte subset (typically negative for CD16) in both
viremic and VS HIVþ males exhibited an increased
expression of CD16 (exemplified in Fig. 1c; p¼ 0.001 for
both, Fig. 1d).
Changes to monocyte phenotype induced by age
and HIV
A panel of monocyte phenotypic markers that reflect
immune activation and monocyte function was initially
screened using blood from healthy young and elderly
individuals to identify biomarkers of monocyte ageing
(see Supplementary data). We used ex vivo whole blood
analyses in this study, since we and others have shown that
PBMC preparation can alter surface expression of certain
monocyte receptors [31,32]. Monocytes from elderly
individuals had significantly altered expression of the
adhesion molecules CD62L (CD14þ monocytes,
p¼ 0.02) and CD11b (CD16þ and CD14þ monocytes,
p¼ 0.002 and 0.0005, respectively), the LPS-receptor
TLR4 (CD16þ monocytes, p¼ 0.007) and the M-CSF
receptor CD115 (CD14þ monocytes, p¼ 0.03) as
compared to young men. Expression of HLA-DR and
CD38 was high on all monocytes, but was not
significantly altered by age in our cohort (data not
shown) thus was not further analysed.
Age-related changes to monocyte phenotype were then
analysed in young HIVþ individuals. The same pattern of
phenotypic change was found in young viremic HIVþ
males as in the elderly, but the magnitude of these changes
was greater. Compared to young controls, monocytes
from viremic HIVþ subjects had significantly decreased
expression of CD62L (CD14þ monocytes, p¼ 0.04,
Fig. 2a), decreased expression of CD115 (CD14þ
monocytes, p¼ 0.001, Fig. 2b) and increased expression
of CD11b (p¼<0.0001 for both monocyte subsets,
Fig. 2c and d). Surface expression of CD11b on
monocytes from young viremic HIVþ subjects was
significantly higher than seen in the elderly (p¼ 0.003horized reproduction of this article is prohibited.
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Fig. 1. Proportions of monocyte subsets and CD16 expression levels. a) Peripheral blood monocytes were gated initially via
forward and side scatter then separated into subsets based on expression of CD14 and CD16. Monocyte subsets were analysed as
either CD14variableCD16þ (CD16þ) or CD14þCD16 (CD14þ). b) The proportion of monocytes expressing CD16 calculated as
[CD16þ monocytes]/[CD16þ þ CD14þ monocytes] in young healthy controls (closed circles), elderly healthy controls (open
circles), young viremic HIVþ (closed triangles) and young cART-treated virologically suppressed HIVþmales (open triangles).
Median ages and ranges for each group are shown below the relevant group label on the x axis. Median values and
interquartile ranges are shown. P values were calculated by Mann-Whitney analysis. c) Expression of CD14 and CD16 on
monocytes from a representative HIVþmale. d) Expression of CD16 (MFI, geometric mean fluorescence intensity) on the CD14þ
monocyte population in young and elderly healthy controls and young HIVþ males (viremic and virologically suppressed) as
detailed in (b).and 0.0003 for CD14þ and CD16þ monocytes
respectively) whilst expression of CD62L and CD115
was not significantly different between young HIVþ
individuals and the elderly. Monocytes from young
HIVþ individuals did not show significantly altered
expression of TLR4 (data not shown).
Similar age-related changes in monocyte phenotype were
also observed in young VS HIVþ individuals (Fig. 2a-d).
Their monocytes showed significantly increased expres-
sion of CD11b (p¼ 0.002 for both CD14þ and CD16þ
monocytes) and decreased expression of CD62L (CD14þ
monocytes, p¼ 0.03) and CD115 expression (CD14þ
monocytes, p¼ 0.03) as compared to age-matched
controls; expression levels were not significantly different
to the elderly. VS HIVþ individuals showed reduced
CD11b expression as compared to viremic patients,
however changes in expression of CD62L or CD115 with
treatment were not observed. These data indicate that
monocytes from young HIVþ individuals exhibit a
phenotype that mimics changes seen in elderly healthy
HIV- individuals and that these defects persist in cART-
treated individuals.pyright © Lippincott Williams & Wilkins. UnauthoSoluble mediators and markers of innate immune
activation
To compare the impact of ageing and HIV on innate
immune activation, we measured plasma levels of
candidate innate immune activation markers. Neopterin
(p¼ 0.0001), CXCL10 (p¼ 0.001) and sCD163
(p¼ 0.004) were significantly elevated in the elderly
compared to young individuals (Fig. 3a-c) whilst levels of
sCD14 and M-CSF were not significantly altered (data
not shown). In young viremic HIVþ individuals, plasma
levels of neopterin, CXCL10 and sCD163 were
significantly elevated when compared to both young
(p< 0.0001 for all) and elderly (p< 0.0001 for neopterin
and CXCL10 and 0.005 for sCD163) controls (Fig. 3a-c).
Plasma levels of these markers were significantly reduced
in VS as compared to viremic HIVþ individuals, but
remained elevated above those of age-matched HIV-
uninfected controls (p¼ 0.0005, 0.004 and 0.003 for
neopterin, CXCL10 and sCD163 respectively) and were
not significantly different to elderly controls. We also
measured plasma levels of the innate immune stimulant
LPS and found significantly elevated levels in elderly
controls (p¼ 0.006), viremic (p¼ 0.005) and VSrized reproduction of this article is prohibited.
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Fig. 2. Expression of CD62L, CD11b, CD115 on monocytes. Phenotyping of surface receptors was performed on peripheral
monocytes in whole blood from young healthy controls (closed circles), elderly healthy controls (open circles), young viremic
HIVþ (closed triangles) and young cART-treated virologically suppressed HIVþmales (open triangles). Median ages and ranges for
each group are shown below the relevant group label on the x axis. Expression of (a) CD62L and (b) CD115 on CD14þ monocytes
and CD11b on (c) CD14þ and (d) CD16þ monocytes measured as DMFI (geometric mean fluorescence intensity of stain minus
fluorescence of isotype control) is shown. Median values and interquartile ranges are shown. P values were calculated by Mann-
Whitney analysis and are shown for values <0.05.(p¼ 0.02) HIVþ individuals as compared to young
controls (Fig. 3d). These findings support the use of these
markers as biomarkers of innate immune ageing and show
that they are elevated in young HIVþ individuals
irrespective of viral load.
LPS binding to TLR4 receptors on monocytes leads to
production of pro-inflammatory cytokines like TNF;
thus we hypothesised that elevated LPS levels may be
associated with increased production of TNF by
monocytes. Basal intracellular levels of TNF in both
CD14þ and CD16þ whole blood monocytes from
elderly and HIVþ individuals were significantly higher
than young controls (see Supplementary data), suggesting
increased plasma LPS is associated with increased basal
production of pro-inflammatory cytokines by mono-
cytes.
We performed regression analyses between soluble innate
immune activation markers and phenotypic markers of
monocyte ageing and found a significant correlation
between CXCL10 and all identified phenotypic markers
(Table 1). Plasma levels of neopterin were significantly
associated with all phenotypic markers except the
proportion of CD16þ monocytes; sCD163 levels
correlated with expression of CD11b on CD16þCopyright © Lippincott Williams & Wilkins. Unautmonocytes and plasma LPS levels correlated with the
proportion of CD16þ monocytes.
Monocyte function
To determine whether monocyte function is altered by
ageing or HIV infection, we examined the phagocytic
ability of peripheral blood monocytes (Fig. 4a). The
percentage of phagocytic monocytes was significantly
reduced in elderly (p¼ 0.04) and young viremic HIVþ
males (p¼ 0.007) as compared to young controls with the
proportion of phagocytic cells not differing significantly
between elderly controls and HIVþ individuals (p¼ 0.6).
Monocyte telomere length
HIV infection is associated with accelerated telomere
shortening in CD8þ T cells [33,34] and in B cells [35].
The impact of HIV infection on telomere length in innate
immune cells is unknown. Using a multicolour FISH-
Flow protocol, we demonstrated that both CD14þ and
CD16þ monocytes from young HIVþ individuals
contain significantly shorter telomeres than young
controls (p¼ 0.03 and 0.02 for CD14þ and CD16þ
respectively, Fig. 4b and c) which were not significantly
different to elderly controls (p¼ 0.3 and 0.4 for CD14þ
and CD16þ monocytes respectively). In contrast, whilst
age was associated with a significant decrease in telomerehorized reproduction of this article is prohibited.
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Fig. 3. Plasma levels of innate immune activation markers. Plasma levels of (a) neopterin, (b) CXCL10 and (c) sCD163 were
determined via ELISA and (d) LPS determined by the Limulus Amoebocyte Lysate assay. Values are shown for young healthy
controls (closed circles), elderly healthy controls (open circles), young viremic HIVþ (closed triangles) and young cART-treated
HIVþ individuals (open triangles). Median ages and ranges for each group are shown below the relevant group label on the x axis.
Median values and interquartile ranges are shown. P values were calculated via Mann-Whitney analysis and are shown for values
<0.05.length in CD3þ T cells, telomere length in T cells from
young HIVþ individuals was not different to young
controls (p¼ 0.5, Fig. 4d). These data indicate that HIV
infection is associated with telomere shortening
in monocytes.Discussion
Increasing evidence suggests HIV infection induces
premature ageing of the adaptive immune system. Ageing
also hastens the development of age-related diseases with
inflammatory aetiologies, yet the impact of HIV on age-
related changes to innate cells critical for regulatingpyright © Lippincott Williams & Wilkins. Unautho
Table 1. Correlation of soluble and monocyte phenotypic markers of age
Neopterin CXCL10
rho p value rho
% CD16þ monocytes 0.09 NS (0.53) 0.405
CD11b on CD14þ monocytes 0.300 0.03 0.675
CD11b on CD16þ monocytes 0.418 0.002 0.653
CD62L on CD14þ monocytes 0.36 0.01 0.584
CD115 on CD14þ monocytes 0.291 0.03 0.37
Plasma levels of soluble markers of innate immune activation were correla
samples tested using Spearman’s rank correlation coefficient (rho, showninflammation (eg. monocytes) is unknown. Here we
directly compared monocytes from young HIVþ males
with young and elderly healthy controls and found that
young HIVþ individuals show changes to monocyte
phenotype, function and telomere length that closely
resemble those observed in elderly controls aged
approximately 30 years older. Furthermore, our data
suggest these immune defects are not fully restored
by cART.
We found that similar to elderly controls, the proportion
of CD16þ monocytes (considered inflammatory due to
their high production of TNF [36]) was increased in
young viremic HIVþ individuals. An increase in this
subset has been reported in other inflammatoryrized reproduction of this article is prohibited.
ing.
sCD163 LPS
p value rho p value rho p value
0.009 0.098 NS (0.55) 0.317 0.032
<0.0001 0.151 NS (0.36) 0.177 NS (0.24)
<0.0001 0.318 0.05 0.024 NS (0.88)
<0.0001 0.084 NS (0.63) 0.177 NS (0.26)
0.02 0.011 NS (0.95) 0.115 NS (0.45)
ted with age-related changes to monocyte phenotypic markers for all
in Table). NS¼not statistically significant.
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Fig. 4. Monocyte function and telomere length. a) The phagocytic function of monocytes was determined by whole blood flow
cytometry using pHRODO labeled E.coli phagocytic target. Values shown indicate % CD14þ monocytes that had phagocytosed
the target for young healthy controls (closed circles), elderly healthy controls (open circles), young viremic HIVþ (closed triangles)
individuals. Median ages and ranges for each group are shown below the relevant group label on the x axis. Median values and
interquartile ranges are shown. P values were calculated via Mann-Whitney analysis. b-d) Telomere length of CD14þ (b) and
CD16þ (c) monocyte subsets and CD3þ T cells (d) was determined via FISH-Flow and immunophenotyping. Values represent
Relative Telomere Length (RTL) expressed as a percentage of the internal control cell line 1301 for young healthy controls (closed
circles; median age 28, range 20–32 years), elderly healthy controls (open circles; median age 72, range 70–82 years), young
viremic HIVþ (closed triangles; median age 39, range 27–45 years). Median values and interquartile ranges are shown. P values
were calculated via Mann-Whitney analysis.conditions [37–39], in association with ageing [40] and in
patients with HIV-related dementia [28]. Our finding of
increased CD16þ monocytes in viremic but not cART-
treated individuals is consistent with data from ourselves
and others [41,42]. Distinct from the increased pro-
portion of CD16þ monocytes, we also observed an
increase in CD16 expression on the CD14þ monocyte
population seen specifically in HIVþ individuals. Whilst
the functional implications of this novel finding remain to
be defined, CD14þ monocytes are thought to be
precursors for the mature CD16þ subsets and an increase
in double positive (CD14þCD16þ) monocytes is a
preliminary step in M-CSF-induced expansion of
CD16þ monocytes in vivo [43]. This is consistent with
our finding of significantly increased plasma M-CSF
levels in viremic (median 177 pg/ml, p¼ 0.0002) and VS
(median 141, p¼ 0.04) HIVþ individuals but not elderly
individuals as compared to young controls (median
115 pg/ml, data not shown), suggesting increased CD16
expression on CD14þ monocytes may reflect an
increased rate of monocyte maturation induced by
cytokines such as M-CSF in HIVþ individuals. The
fact that increased expression of CD16 on CD14þCopyright © Lippincott Williams & Wilkins. Unautmonocytes persists in VS individuals while the proportion
of CD16þmonocytes is normalised suggests that different
factors may drive these two processes, but the net effect of
these changes on the inflammatory potential of monocyte
subsets remains to be determined.
Monocytes from young HIVþ individuals exhibited
other age-related changes including increased surface
expression of CD11b (a component of the b2-integrin
MAC-1) and decreased expression of the adhesion
molecule CD62L. CD11b is a marker of monocyte
activation; MAC-1 is involved in migration of monocytes
into atherosclerotic plaques [44] and increased CD11b
expression has been associated with atherosclerosis in a
mouse model [45]. Exposure of monocytes from healthy
donors to either TNFa, LPS or immune complexes
reduces CD62L expression and increases CD11b
expression [46,47], suggesting that changes in monocyte
phenotype observed here may be in part due to a pro-
inflammatory state present in both the elderly and HIVþ
individuals. CD62L and CD11b are required for
endothelial attachment and migration of monocytes,
and HIV infection of monocytic cell lines increaseshorized reproduction of this article is prohibited.
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[48]. Reduced expression of the M-CSF receptor CD115
was also found on monocytes from the elderly and
viremic HIVþ individuals, which in HIVþ individuals
may be a consequence of elevated M-CSF levels leading
to increased CD115 internalization and degradation [49].
Alternatively, LPS has been shown to reduce M-CSF
receptor expression on mouse macrophages [50]. The
functional implications of reduced CD115 expression are
not known, but may alter the ratio of M-CSF-stimulated
‘anti-inflammatory’ M2 monocytes and GM-CSF-
stimulated ‘inflammatory’ M1 macrophages [51].
We have confirmed and extended previous findings of
elevated plasma levels of neopterin, sCD163 and
CXCL10 in HIVþ individuals [23,52,53] by identifying
that levels of these innate immune activation markers in
VS HIVþ individuals were similar to those in elderly
controls and are linked with age-related changes to
monocyte phenotype. Elevation of these markers in VS
HIVþ individuals suggests factors other than HIV
viremia may drive persistent innate immune activation,
although the contribution of residual viral replication
cannot be excluded. Neopterin and CXCL10 are
implicated in frailty, atherogenesis and neurological
defects in elderly individuals [54–56] whilst in HIVþ
individuals, elevated neopterin is associated with
impaired cognitive function and AIDS-related dementia
[57] and elevated sCD163 with non-calcified coronary
plaques [25]. The neurotoxic chemokine CXCL10 is also
up-regulated in patients with HIV-associated neurocog-
nitive disorders [58,59] and was the only plasma marker
that correlated with all the observed age-related changes
to monocyte phenotype, supporting its use as a robust
biomarker of monocyte ageing. CXCL10 is produced by
monocytes, endothelial cells and fibroblasts in response to
IFNg [60] and our finding of elevated CXCL10 in elderly
and HIVþ individuals suggests elevated IFNg levels in
these individuals. LPS directly stimulates monocytes and
is elevated in both the elderly and HIVþ individuals
irrespective of viral load. Our finding of increased basal
levels of the pro-inflammatory cytokine TNF in
monocytes from both elderly and HIVþ individuals
suggests that persistent innate immune activation by
factors such as LPS may contribute to chronic
inflammation in both groups. The significant association
of innate immune activation markers with age-related
HIV co-morbidities warrants further work to elucidate
the drivers of persistent innate immune activation in
VS individuals.
Our data showing telomere shortening in monocytes
from both young HIVþ individuals and the elderly was
surprising. Human monocytes do not undergo significant
cell division, thus shortened telomeres are unlikely to
reflect enhanced peripheral cell division. These data morepyright © Lippincott Williams & Wilkins. Unautholikely reflect telomere shortening in bone morrow
precursor cells, suggesting HIV infection drives increased
precursor cell turnover. This hypothesis is consistent with
the findings of Burdo et alwho show increased monocyte
turnover in SIV-infected macaques which correlated with
increased levels of sCD163 and severity of encephalitis
[61]. Increased monocyte turnover during HIV infection
may be due to persistent immune activation (e.g.
secondary to microbial translocation) causing increased
monocyte mobilisation from the bone marrow. Reduced
activity of the telomere repair enzyme telomerase in
CD34þ haematopoietic progenitor cells from HIVþ
individuals [62] may also contribute. Despite the small
sample size, telomere length of CD14þ monocytes
correlated with plasma levels of CXCL10 in our study
(p¼ 0.03, Spearman’s rho -0.475, data not shown),
supporting a link between monocyte activation and
telomere shortening. The functional implications of
shortened telomeres in monocytes/macrophages are not
known but telomere shortening of leukocytes is
associated with age-related diseases including cancer
and cardiovascular disease [63]. HIV infection is
associated with telomere shortening in CD8þ but not
CD4þ T cells [33,34], which may explain why significant
telomere shortening was not detected in total CD3þ T
cells in this study. Our data showing HIV infection also
induces age-related changes to monocyte phagocytosis is
consistent with our previous findings [64,65]. Given the
observed similarities in monocyte activation and pheno-
type, it would be of interest to compare the gene
expression profiles of monocytes from young and elderly
HIV-uninfected and young HIVþ individuals, which to
date has not been done.
In summary, we have shown that young HIVþ men
exhibit age-related changes to monocyte phenotype and
levels of innate immune activation that resemble those
observed in elderly HIV-uninfected individuals. Impor-
tantly, age-related changes to plasma and phenotypic
markers of monocyte activation (eg. neopterin,
CXCL10, sCD163 and CD11b expression) are not
normalised by cART, which may have implications for
the development of co-morbidities involving activated
monocytes (e.g. atherosclerosis) in VS HIVþ individuals.
Given the strong links between chronic inflammation and
age-related co-morbidities, our findings have important
clinical implications. Future longitudinal studies are
required to investigate the impact of time of viral
suppression on innate ageing biomarkers and determine
whether the rate of ageing is increased by HIV.
Elucidating the mechanisms driving age-related changes
in the absence of overt viremia is required to prevent co-
morbidities in this population. This study has identified
biomarkers which may be useful for monitoring immune
activation and disease risk in HIVþ individuals and may
also represent new targets for interventional strategies.rized reproduction of this article is prohibited.
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Summary
Chronic inflammation in older individuals is thought to contribute
to inflammatory, age-related diseases. Human monocytes are
comprised of three subsets (classical, intermediate and nonclassi-
cal subsets), and despite being critical regulators of inflammation,
the effect of age on the functionality of monocyte subsets remains
to be fully defined. In a cross-sectional study involving 91 healthy
male (aged 20–84 years, median 52.4) and 55 female (aged 20–
82 years, median 48.3) individuals, we found age was associated
with an increased proportion of intermediate and nonclassical
monocytes (P = 0.002 and 0.04, respectively) and altered pheno-
type of specific monocyte subsets (e.g. increased expression of
CD11b and decreased expression of CD38, CD62L and CD115).
Plasma levels of the innate immune activation markers CXCL10,
neopterin (P < 0.001 for both) and sCD163 (P = 0.003) were signifi-
cantly increasedwith age.Whilst similar age-related changeswere
observed in both sexes, monocytes from women were phenotypi-
cally different tomen [e.g. lower proportion of nonclassical mono-
cytes (P = 0.002) and higher CD115 and CD62L but lower CD38
expression] and women exhibited higher levels of CXCL10 (P =
0.012) and sCD163 (P < 0.001) but lower sCD14 levels (P < 0.001).
Monocytes from older individuals exhibit impaired phagocytosis
(P < 0.05) but contain shortened telomeres (P < 0.001) and signifi-
cantly higher intracellular levels of TNF both at baseline and
following TLR4 stimulation (P < 0.05 for both), suggesting a dysre-
gulation of monocyte function in the aged. These data show that
aging is associated with chronic innate immune activation and
significant changes in monocyte function, which may have impli-
cations for the development of age-related diseases.
Key words: aging; innate immunity; monocytes; phagocyto-
sis; phenotype; TLR4.
Introduction
Aging is associated with a decline in immune function and increased
susceptibility to infections, which is juxtaposed with inflammation and an
increased risk of chronic disease. Chronic inflammation and immune
activation are pathogenically linked with immune senescence, and the
development of inflammatory age-related diseases and pro-inflammatory
cytokine levels are sensitive predictors of disease and mortality in older
adults. Increased levels of TNF and ⁄ or IL-6 are associated with mortality
(Bruunsgaard et al., 2003) and increased risk of age-related diseases
including cardiovascular disease (Ridker et al., 2000), Alzheimer’s disease
(Licastro et al., 2003), disability (Ferrucci et al., 1999) and frailty (Leng
et al., 2011). The mechanisms responsible for impaired immunity and
inflammation in older adults are unclear, but cells of the innate immune
system including monocytes and macrophages are the first line of
defence against infections and are critical mediators and regulators of the
inflammatory response. Despite the fact that these cells play an important
role in the pathogenesis of many inflammatory diseases associated with
aging such as atherosclerosis (Gerrity & Naito, 1980), the impact of aging
on monocyte phenotype and function remains to be fully defined.
Human monocyte subsets are defined on the basis of CD14 and CD16
expression. The major population of monocytes are CD14++ CD16)
(classical monocytes) whilst CD16+ monocytes are segregated into
intermediate (CD14++ CD16+) and nonclassical (CD14+ CD16++) subsets
[(Ziegler-Heitbrock et al., 2010) and Fig. 1]. Transcriptional profiling
suggests that monocytes expressing CD16 (nonclassical and intermediate
subsets) exhibit a phenotype similar to specific dendritic cell subsets (DCs)
and macrophages and may represent an alternative state of differentia-
tion (Ancuta et al., 2009). Consistent with this, nonclassical monocytes
reportedly patrol the endothelium and sense and respond to viral
antigens, showing similarities to monocyte-derived DCs (Cros et al.,
2010). CD16+ monocytes produce more pro-inflammatory cytokines
upon stimulation, whilst CD14++ monocytes (classical and intermediate)
are more efficient phagocytes and classical monocytes are the major
producers of reactive oxygen species (Cros et al., 2010). The three
monocyte subsets exhibit different cytokine production profiles following
Toll-like receptor (TLR) ligation (Cros et al., 2010; Nyugen et al., 2010),
reinforcing their discreet functions; however, the functional roles of these
subsets and how these properties change with age remain to be fully
characterized.
Increasing age is associated with altered monocyte phenotype includ-
ing an expansion of the CD16+ monocyte population (Sadeghi et al.,
1999; Nyugen et al., 2010), which also occurs during bacterial (Nockher
& Scherberich, 1998) and untreated HIV infection (Hearps et al., 2012).
Surface expression of certain proteins such as HLA-DR, CX3CR1 and
CD62L on monocytes is also reduced in older adults, which may affect
monocyte survival, adherence and migration to sites of inflammation (De
Martinis et al., 2004; Seidler et al., 2010). Whether there are age-related
changes in human monocyte function, such as phagocytosis and pro-
inflammatory cytokine production, is unclear, due in part to conflicting
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data arising from the use of different experimental models and recruit-
ment criteria of ‘aged’ individuals (Panda et al., 2009). An increased basal
level of pro-inflammatory cytokines in monocyte-derived macrophages
from aged individuals has been reported (Sadeghi et al., 1999), but is
disputed elsewhere (Seidler et al., 2010). Production of pro-inflammatory
cytokines by monocytes in response to TLR1 ⁄ 2 ligands ex vivo is impaired
in older adults (van Duin et al., 2007; Nyugen et al., 2010) although
whether age affects response to other TLR agonists such as the bacterial
endotoxin lipopolysaccharide (LPS, a TLR4-agonist) remains controversial
[reviewed in (van Duin & Shaw, 2007)]. Thus, older adults appear to exhi-
bit a dysregulated inflammatory response and an increase in markers of
inflammation, although the mechanism of these changes remains
unclear.
Sex-related differences in monocyte and innate immune function
have received little attention to date; however, a lower incidence
and severity of sepsis in women as compared with men (Wichmann
et al., 2000) suggests that innate immunity may vary with sex. Some
studies (Bouman et al., 2004), but not all (Hodkinson et al., 2006),
report decreased numbers of monocytes in women, whilst women
exhibit a reduced proportion of CD16+ monocytes (Heimbeck et al.,
2010) with a similar phagocytic capacity (Hodkinson et al., 2006) as
men. A study of plasma pro-inflammatory cytokine levels in aged
men and women found no significant sex-related differences (Forsey
et al., 2003); however, elevated TNF levels are linked with all-cause
mortality in men, but not women, whilst IL-6 levels are a predictor
in both sexes (Bruunsgaard et al., 2003). Although limited, these
data indicate that significant differences in innate immune function
exist between men and women and justify the consideration of sex
in gerontological immune studies.
In this study, we sought to determine the impact of age on the
phenotype, function and activation of monocyte subsets and further
explore whether these effects differ between men and women. We
found alterations in monocyte phenotype, increased inflammatory
function and elevated levels of plasma innate immune activation markers
in aged individuals that could have implications for the development of
inflammatory diseases such as cardiovascular disease. Whilst most of
these changes were consistent in men and women, some sex-related
differences in monocyte and innate immune activation markers were
identified, indicating a differential impact of age on certain aspects of
monocyte function in men and women.
(A) (B)
(C) (D) (E)
(H)(G)(F)
Fig. 1 Monocyte phenotyping. (A) Total peripheral blood monocytes were gated via forward and side scatter and monocyte subsets identified based on expression of CD14
and CD16 as indicated. Expression of CD38 (B), HLA-DR (C), CD115 (D), CD11b (E), CD120b (F), CD120a (G) and TLR4 (H) was determined on monocyte subsets using data
from all study participants. Overall expression level (indicated by geometric mean fluorescence intensity (MFI) of stain minus isotype control; left y-axis) and proportion of cells
positive (%, right y-axis) for each marker are indicated. Median values and interquartile ranges are shown. P values were determined by Mann–Whitney analysis;
***P < 0.001, **P < 0.01, *P < 0.05.
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Results
Phenotype analysis of monocyte subsets
We measured surface expression of phenotypic markers of monocyte
function and activation on classical, intermediate and nonclassical
monocyte subsets (defined as in Fig. 1a) in all study participants. The
median percentage of intermediate and nonclassical monocytes was
5.1% and 5.0%, respectively. As previously reported (Ziegler-Heitbrock,
2007), CD62L was expressed exclusively on classical monocytes [median
mean fluorescence intensity (MFI) 55.9 (IQR: 41.2–69.9); median per cent
positive 98.1% (IQR:93.4–99.4%)], which also exhibited the highest
expression of CD38 (P < 0.0001 for both MFI and per cent positive as
compared with intermediate or nonclassical subsets, Fig. 1b). HLA-DR,
CD115, CD11b and CD120b were expressed ubiquitously on monocyte
subsets (Fig. 1c–f), whilst a similar proportion of all subsets were positive
for CD120a (Fig. 1g). With respect to overall expression levels (as indi-
cated by MFI), the intermediate monocyte subset exhibited the highest
expression of HLA-DR, CD11b and CD115 (P < 0.0001 for all) and equal
highest expression of CD120a and CD120b (with the nonclassical subset,
Fig. 1a–g). Classical monocytes showed the lowest expression of HLA-
DR, CD115, CD11b and CD120a and b. Expression of TLR4 was similar
on all three subsets, although fewer nonclassical monocytes were positive
for TLR4 compared with the intermediate and classical subsets (Fig. 1h).
These data confirm that the three monocyte subsets are phenotypically
distinct and indicate that CD14++ CD16+ intermediate monocytes have
the highest expression of a number of key functional and activation
markers.
Age- and sex-related changes in monocyte phenotype
We used linear regression analysis to identify associations between age
and the expression of monocyte phenotypic markers (i.e. HLA-DR, CD38,
CD62L, CD11b, CD115, CD120a ⁄ b and TLR4) as well as the proportion
of monocyte subsets. The parameters that were found to be significantly
associated with age are listed in Table 1. The relative proportion of the
three monocyte subsets was significantly altered by age with the percent-
age of nonclassical and intermediate monocytes increasing (P = 0.004
and 0.002, respectively) and the percentage of classical monocytes
decreasing (P = 0.029) with age (Table 1). Overall expression (as indi-
cated by MFI) of CD38 (on all three monocyte subsets), CD62L and
CD115 (both on classical monocytes) and TLR4 (on nonclassical and inter-
mediate monocytes) was significantly decreased with age, whilst expres-
sion of CD11b (classical and nonclassical monocytes) was significantly
increased with age (Table 1). Confirming previous reports (Wikby et al.,
2002), phenotypic markers indicative of T-cell senescence were also
found to be significantly altered with age; the percentage of CD3+ CD8+
lymphocytes positive for CD28 was decreased (P = 0.037) whilst the
Table 1 Monocyte ⁄ T-cell phenotypic and soluble innate immune activation markers significantly associated with age and the influence of sex on this association
n Subset*
Association with age (adjusted for sex)† Association with sex (adjusted for age)
P value Coefficient 95% CI P value Coefficient§ 95% CI
Monocyte phenotypic markers
CD38 (MFI)– 58 NC 0.030 )0.0125 )0.0238 )0.00126 0.416
CD38 (MFI)** 70 Int 0.033 )0.00513 )0.00983 )0.000417 0.001 0.346 0.142 0.550
CD38 (MFI)** 71 Class 0.036 )0.00275 )0.00530 )0.000190 0.318
CD62L (MFI) 67 Class 0.001 )0.322 )0.508 )0.136 0.016 )9.90 )17.93 )1.88
CD11b (MFI) 65 NC 0.015 0.186 0.0370 0.335 0.054
CD11b (MFI) 74 Class 0.025 0.160 0.0205 0.300 0.958
CD115 (MFI) 75 Class 0.019 )0.0519 )0.0951 )0.00871 0.047 )1.912 )3.80 )0.0244
TLR4 (MFI)†† 31 NC 0.033 )0.0258 )0.00230 )0.0494 ND
TLR4 (MFI)†† 31 Int 0.026 )0.0345 )0.00457 )0.0644 ND
Proportion (%) 76 NC 0.004 0.000588 0.000193 0.000983 0.002 0.0279 0.0106 0.0452
Proportion (%)** 76 Int 0.002 0.00910 0.00336 0.0148 0.765
Proportion (%) 76 Class 0.029 )0.000825 )0.00156 )8.83e)5 0.164
T-cell senescence markers
CD57 (%) 64 CD3+ CD8+ 0.008 0.00319 0.000856 0.00551 0.126
CD28 (%)– 64 CD3+ CD8+ 0.037 )0.00147 )0.00285 )9.37e)5 0.849
CD57+ CD28) (%)– 64 CD3+ CD8+ 0.014 0.00276 0.000580 0.00493 0.427
Soluble innate immune activation markers
sCD14 129 0.984 )0.0318 )3.11 3.05 <0.001 220 106 333
sCD163 111 0.003 3.91 1.39 6.43 <0.001 )173 )250 )96.6
Neopterin** 138 <0.001 0.00464 0.00216 0.00713 0.434
CXCL10** 87 <0.001 0.0123 0.00806 0.0167 0.012 )0.222 )0.395 )0.0492
*Cell subset on which the parameter was analysed. NC, nonclassical monocytes; Int, intermediate monocytes; Class, classical monocytes.
†Determined by linear regression analysis (unless otherwise indicated) adjusting for sex.
Determined by linear regression analysis (unless otherwise indicated) adjusting for age.
§Indicates the difference in the regression analysis owing to sex. A value >0 indicates a higher level of the parameter in men, a value <0 indicates a lower level of the
parameter in men.
Data were transformed as required by either square root (–) or log (**).
††Analysis performed using data from men only.
Analysis was performed using median regression.
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percentage of CD57+ (P = 0.008) and CD28)CD57+ (P = 0.014) CD8+ T
cells increased significantly with age. These data confirm that in addition
to well-documented changes in T-cell phenotype, aging is also associated
with significant changes in monocyte phenotype.
Regression analysis was also used to identify potential sex-related
differences in the relationship between age and monocyte phenotype. Of
the innate parameters found to be significantly associated with aging,
differences between men and women were observed in the expression
levels of certain parameters, with men showing a higher expression of
CD38 (MFI on classical monocytes, P = 0.001) but lower expression of
CD62L and CD115 (MFI on classical monocytes for both, P = 0.016 and
0.047 respectively) as compared with women of a similar age (Table 1).
There were no sex-related differences in the slope of the regression
curves (data not shown), suggesting that monocyte phenotype changes
at the same rate with age in both men and women. Men and women had
similar proportions of classical [median and interquartile range 87.5%
(81.8–90.5) and 89.0% (85.1–93.2), respectively] and intermediate
[5.3% (4.1–8.7) and 7.0% (4.7–9.0), respectively] but men had signifi-
cantly more nonclassical monocytes than women [6.1% (4.6–10.2) and
3.5% (2.0–6.1), respectively, P value=0.002 by regression analysis,
Table 1].
Age-related changes in plasma markers of
innate immune activation
To further investigate the impact of age on monocyte and innate immune
activation, we measured levels of soluble markers of innate immune acti-
vation (neopterin, CXCL10, sCD163 and sCD14) in plasma. Using linear
regression analysis, plasma levels of sCD163 (P = 0.003), neopterin and
CXCL10 (P < 0.001 for both) were found to be significantly increased
with age (Table 1 and Fig. 2a–c). As observed with monocyte phenotype,
there were no significant sex-related differences in the slope of the
association between plasma markers and age (Fig. 2), but men showed
significantly higher overall levels of sCD14 (P < 0.001) but lower levels of
sCD163 (P < 0.001) and CXCL10 (P = 0.012) as compared with women
of an equivalent age (Table 1 and Fig. 2a, c and d). These data show that
aging is associated with an increase in plasma markers of innate immune
activation irrespective of sex, but that differences exist in the levels of
CXCL10 and sCD14 between men and women.
Correlation of plasma activation markers with phenotypic cellular
markers of immune aging revealed significant associations between
CXCL10 and neopterin levels and both monocyte and T-cell aging
biomarkers. Significant associations were found between CXCL10 and
neopterin and the proportion of the three monocyte subsets and the
proportion of CD57+ and CD28) T cells (Table 2). Significant correlations
were also found between CXCL10 levels and CD11b expression (classical
and nonclassical monocytes) and between neopterin levels and expres-
sion of CD38 (intermediate monocytes, Table 2). These data suggest
soluble activation markers such as CXCL10 and neopterin may be useful
indicators of age-related phenotypic changes in both monocytes and
T cells.
The impact of age on monocyte function
Monocytes from aged individuals have been reported to exhibit an
impaired pro-inflammatory response to TLR1 ⁄ 2 agonists (van Duin et al.,
2007; Nyugen et al., 2010), but the effect of age on monocyte TLR4
response remains unclear. To investigate the effect of age on the pro-
inflammatory response of monocyte subsets to TLR4 stimulation, we
measured intracellular levels of TNF in monocyte subsets at baseline and
following LPS stimulation. Similar basal levels of TNF were present in all
three monocyte subsets; however, monocytes from aged individuals
showed significantly higher levels of TNF in unstimulated classical
(P = 0.0005), intermediate (P < 0.0001) and nonclassical (P = 0.016)
(A) (B)
(C) (D)
Fig. 2 Plasma markers of innate immune activation. Plasma levels of (A) sCD163, (B) neopterin, (C) CXCL10 and (D) sCD14 were determined via ELISA. Values and individual
linear regression curves are shown for female (closed circles, solid line) and male (open circles, broken line) participants.
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monocyte subsets (Fig. 3a). Substantial amounts of TNF were produced
by all monocytes subsets following LPS stimulation, with intermediate
monocytes displaying the highest level of TNF production and classical
monocytes the lowest. Intermediate and nonclassical monocytes from
aged individuals produced significantly higher levels of TNF compared
with young individuals (P = 0.034 and 0.006, respectively, Fig. 3b),
suggesting age is associated with a heightened inflammatory response of
monocytes to TLR4 stimulation.
To further explore the function of monocytes in aged individuals, we
assessed the ability of monocytes to phagocytose a bacterial target
(fluorescently labelled Escherichia coli) in a whole blood assay. Monocytes
with low CD14 expression are not efficient phagocytes (Cros et al., 2010)
and were thus not analysed in these experiments. CD14+ monocytes
(classical and intermediate) from older individuals exhibited significantly
impaired phagocytosis of a bacterial target as compared with young indi-
viduals (Fig. 3c, P = 0.04).
Table 2 Significant correlations between plasma and cellular aging biomarkers*
Cellular marker
CXCL10 Neopterin
q P value q P value
% Classical monocytes )0.338 0.002 )0.239 0.024
% Intermediate monocytes )0.405 0.001 0.214 0.045
% Nonclassical monocytes )0.230 0.033 0.229 0.031
CD11b expression – classical monocytes 0.348 0.007 NS
CD11b expression – nonclassical monocytes 0.405 0.003 NS
CD38 expression – intermediate monocytes NS 0.293 0.020
% CD57+ CD8+ T cells 0.224 0.042 0.248 0.029
CD28-CD8+ T cells )0.245 0.026 0.019 )0.267
*Determined by Spearman’s rank correlation.
NS, not statistically significant.
(A) (B)
(C) (D)
Fig. 3 Monocyte LPS response, phagocytosis and telomere length. Intracellular TNF in classical, intermediate and nonclassical monocyte subsets (circles, squares and
triangles, respectively) was determined in whole blood from young (closed symbols, median age 31 years, range 21–45) and older (open symbols, median age 68 years, range
66–72) individuals. Geometric mean fluorescence intensity (MFI of stain minus isotype control) of TNF is shown for samples at baseline (A), and delta (D) MFI (MFI of treated
sample minus untreated sample incubated in parallel) shown following stimulation with 10 ng mL)1 LPS for 4 h (B). (C) The percentage of CD14+ monocytes that
phagocytosed a pHRODO-labelled Escherichia coli target are shown for young (closed circles, median age 28 years, range 20–34) and older men (open circles, median age
72 years, range 67–84). (D) Telomere length of classical (CD14++ CD16), circles) and CD16+ (CD16+ CD14variable, squares) monocyte subsets and CD3+ lymphocytes
(triangles) was determined via FISH-Flow and immunophenotyping. Values represent relative telomere length (RTL) expressed as a percentage of the internal control cell line
1301 for young (closed symbols; median age 28, range 20–34 years) and older individuals (open symbol; median age 73, range 62–84 years). (a–c) Median values and
interquartile ranges are shown. P values were determined by Mann–Whitney analysis; ***P < 0.001, **P < 0.01, *P < 0.05.
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Age- and sex-associated changes in telomere length in
monocyte subsets
Aging is associated with telomere shortening in a number of leuco-
cyte populations; however, the telomere length of monocyte subsets
from young and aged individuals has not been directly compared.
Simultaneous measurement of relative telomere length in multiple
cell populations was performed using a FISH-Flow protocol. Nonclas-
sical and intermediate monocyte subsets were pooled for this analysis
(and termed CD16+ monocytes) owing to low cell yields following
FISH-Flow analysis. No significant sex-related differences in classical
or CD16+ monocytes or CD3+ T cells were found (data not shown);
thus, data from men and women were pooled for further analysis.
We found both classical and CD16+ monocytes from aged individuals
contained significantly shorter telomeres than those from young
individuals (Fig. 3d, P = 0.0005 and 0.001 respectively). Consistent
with previous reports (Rufer et al., 1999), telomere length in CD3+
lymphocytes was also significantly shorter in aged as compared with
young participants (P < 0.0001). Telomere length in classical, but not
CD16+ monocytes, was significantly shorter than CD3+ lymphocytes
(P = 0.04 and 0.002 for young and aged individuals, respectively).
There was no statistically significant difference in telomere length
between classical and CD16+ monocytes in either young or aged
individuals.
Discussion
Significant morbidity in older adults arises from impaired immunity to
pathogens and age-related diseases driven by chronic inflammation.
Monocytes are important cells for both immune defence and inflamma-
tion, and we therefore investigated the impact of age on their phenotype
and function and determined whether these changes differed between
sexes.
Phenotype and function of monocyte subsets
Phenotypic analysis of monocyte subsets revealed that the
CD14++ CD16+ intermediate subset has the highest expression of HLA-
DR, CD11b and CD115 and equal highest expression of CD120a,
CD120b and TLR4, suggesting that phenotypically this subset is not
intermediate between the classical and nonclassical subsets. Higher level
of expression of HLA-DR on the intermediate as compared with other
subsets suggests they may be more efficient at antigen presentation,
whilst increased CD11b indicates a more activated phenotype. The high
expression of both TLR4 and CD14 (required for LPS signal transduction)
on intermediate monocytes corresponds with their considerably higher
production of the pro-inflammatory cytokine TNF in response to the
TLR4-agonist LPS shown here and by others (Cros et al., 2010). Nonclas-
sical monocytes show the greatest level of TNF production following
TLR1 ⁄ 2 (Nyugen et al., 2010) and TLR7 ⁄ 8 ligation (Cros et al., 2010),
indicating that monocyte subsets may have specialized responses to dif-
ferent TLR agonists. These findings suggest that the intermediate subset
represents a specific and highly active monocyte population with height-
ened responsiveness to certain stimuli rather than an intermediate stage
of monocyte differentiation.
Age- and sex-related changes in monocyte phenotype
We identified a number of age-related changes in the phenotype of
all three monocyte subsets, including increased expression of CD11b
on nonclassical and classical subsets. CD11b is involved in mediating
transendothelial migration of monocytes into atherosclerotic vessels
(Sotiriou et al., 2006), and increased CD11b expression has been
associated with increased atherosclerotic plaque formation in mice
(van Royen et al., 2003). Reduced monocyte expression of CD62L in
aged individuals shown here and previously (De Martinis et al.,
2004) is consistent with a generalized downregulation of CD62L
expression on lymphocytes in older adults (De Martinis et al., 2000).
CD62L is responsible for monocyte rolling and adhesion to endothe-
lial cells; downregulation of CD62L is hypothesized to impair rolling
and potentially increase firm attachment of cells to vessels, which is
a precursor to endothelial migration (De Martinis et al., 2004).
Altered expression of CD11b and CD62L on monocytes from older
individuals may therefore affect monocyte migration and promote
atherosclerotic plaque formation. Our finding that CD11b expression
is an independent predictor of arterial wall thickening (an indicator
of atherosclerosis, unpublished data) supports this hypothesis. The
phenotypic changes in CD11b and CD62L expression we observed
on monocytes from the aged are similar to those observed following
treatment of monocytes with LPS or TNF in vitro (Griffin et al.,
1990), suggesting the inflammatory milieu may contribute to pheno-
typic changes in monocytes in older individuals.
Age was also associated with a significant reduction in CD115 and
TLR4 expression on classical monocytes. CD115 internalization can be
induced by LPS (Chen et al., 1993) and IFNc (Delneste et al., 2003). We
have previously shown LPS levels are elevated in aged individuals (Hearps
et al., 2012), and the association between age and increased CXCL10
levels shown here suggests elevated plasma IFNc levels in older adults.
This is consistent with findings of heightened IFNc production by
CD8+ CD28) T cells in older individuals (Eylar et al., 2001) and expansion
of the CD8+ CD28) T-cell population in the aged. The effect of reduced
CD115 expression on monocyte function is not known, but it may skew
differentiation away from M-CSF-induced anti-inflammatory macrop-
hages with a repair phenotype (M2), towards production of inflammatory
M1 macrophages.
We show that increased proportion of CD16+ monocytes in older
adults seen here and elsewhere (Sadeghi et al., 1999; Seidler et al.,
2010) is attributed to significant expansion of both the intermediate and
nonclassical subsets, although we also observed a significantly decreased
proportion of classical monocytes not seen in other cohorts (Nyugen
et al., 2010). The absolute number of CD16+ monocytes is reportedly
increased in aged individuals, whilst the number of classical monocytes is
not significantly altered (Nyugen et al., 2010; Seidler et al., 2010). Inter-
mediate and nonclassical monocytes are significant producers of pro-
inflammatory cytokines and expansion of these populations may contrib-
ute to chronic inflammation in the aged. Our finding of a significantly
lower proportion of nonclassical monocytes in women as compared with
men is consistent with a previous report of decreased CD16+ monocytes
in young ⁄middle-aged women (Heimbeck et al., 2010). These data sug-
gest that there are sex-related differences in the distribution of monocyte
subsets which may translate into an altered functional profile.
Age- and sex-related changes in soluble markers of
innate immune activation
To the best of our knowledge, we are the first to show that sCD163 levels
increase with age, even though sCD163 levels are a predictor of
numerous age-associated diseases including rheumatoid arthritis (Greisen
et al., 2011) and coronary atherosclerosis (Aristoteli et al., 2006).
sCD163 is shed from the surface of monocytes and serves as a marker of
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monocyte activation. Increased levels of the monocyte ⁄macrophage
product, neopterin, shown here and elsewhere (Spencer et al., 2010),
provide further evidence of persistent monocyte activation in older adults
irrespective of sex. Neopterin is also a sensitive indicator of reactive
oxygen species levels (Murr et al., 2002), thus elevated neopterin is
consistent with the known role of oxidative stress in immune aging. Our
finding of an age-related increase in the monocyte ⁄macrophage activa-
tion marker CXCL10 confirms a previous report (Miles et al., 2008), but
the finding of higher levels of CXCL10 in women as compared with men
is novel and warrants further investigation into the functional and clinical
implications of this. CXCL10 and sCD163 production is stimulated by
IFNc, and T cells from women produce significantly more IFNc following
T-cell receptor stimulation (Goetzl et al., 2010), which is consistent with
the findings shown here. CXCL10 and neopterin levels correlated
significantly with a number of age-related changes in both monocyte and
T cell phenotype, suggesting these proteins may be useful biomarkers of
cellular aging of both adaptive and innate immune cells in future geronto-
logical studies.
The impact of age on monocyte function and
telomere length
Our data indicating impaired phagocytosis but heightened pro-inflamma-
tory response to LPS suggest monocyte function is dysregulated in the
aged. Published data regarding monocyte function in aged individuals are
conflicting, likely due to different experimental systems including the use
of purified or cultured monocytes, which is known to alter monocyte phe-
notype (Lundahl et al., 1995) and TLR response (Gabriel et al., 2002; Qian
et al., 2011). To avoid these confounders, we used ex vivo whole blood
models, which have the additional benefit of maintaining the presence of
soluble blood factors (e.g. LPS-binding proteins, complement) to gain a
more accurate picture of in vivo monocyte function. Our finding of
impaired phagocytosis of E. coli by monocytes from older adults may at
least partially explain their increased susceptibility to bacterial infection.
Consistent with our results, others report increased pro-inflammatory
cytokine levels in LPS-stimulated whole blood from older adults (Gabriel
et al., 2002), whilst data from studies using PBMC or plate-adhered
monocytes are inconsistent (Pietschmann et al., 2003; van Duin et al.,
2007; Qian et al., 2011). Thus, extrinsic soluble factors may play an
important role in modulating monocyte LPS response in vivo. We also
found monocytes from older individuals contained significantly increased
basal levels of TNF, suggesting persistently higher pro-inflammatory
activity of these cells in vivo. Whilst these increases were slight, chroni-
cally elevated production of pro-inflammatory cytokines such as TNF over
a period of years is likely to have a significant impact on immune
activation and function. In contrast to our findings of heightened TLR4
response, pro-inflammatory response to TLR1 ⁄ 2 ligation by monocytes is
impaired in the aged (van Duin et al., 2007; Nyugen et al., 2010),
suggesting aging has a differential effect on individual TLR responses in
monocytes.
Reduced TLR4 expression on CD16+ monocyte subsets in older adults
shown here is consistent with previous reports of reduced TLR4
expression on total monocytes (van Duin et al., 2007; Qian et al., 2011).
Taken together with our previous finding of increased LPS levels in the
aged and the heightened pro-inflammatory response to LPS shown here,
reduced expression and ⁄ or internalization of TLR4 may be a mechanism
to reduce the inflammatory response of monocytes to endotoxaemia.
Interestingly, levels of sCD14 (considered a marker of TLR4-mediated acti-
vation of monocytes) were not significantly altered with age in this study,
although elucidating the complex relationship between TLR4 expression,
CD14 shedding and endotoxaemia requires more thorough investigation
in larger, directed studies.
Cellular division of monocytes in the periphery is uncommon; thus, our
finding of telomere shortening in peripheral monocytes may reflect short-
ening in haematopoietic bone marrow precursor cells. Indeed, monocyte
and peripheral CD34+ progenitor cell telomere lengths correlate (Spyrido-
poulos et al., 2009), and shortened telomeres in granulocytes from older
individuals (Rufer et al., 1999) suggest telomere shortening of a common
myeloid precursor. It is not known whether telomere attrition affects
monocyte function, although telomere shortening in leucocytes is associ-
ated with a range of diseases including chronic heart disease (Spyridopo-
ulos et al., 2009).
Summary
This study has shown that aging is associated with significant changes in
monocyte phenotype and dysregulated monocyte function, which may
contribute to impaired immunity to infections in older adults. Further-
more, significant differences exist between men and women in the levels
of certain monocyte phenotypic and soluble activation markers and the
functional implications of these differences warrants further exploration.
Future investigations of the impact of altered expression of molecules
such as CD11b and CD62L on monocyte function may help elucidate the
mechanism of age-related diseases such as atherosclerosis. Older individ-
uals exhibit a state of chronic innate immune activation, and this, coupled
with a hyper-inflammatory response to TLR4-ligation and increased
endotoxaemia, may contribute to the pathogenesis of inflammatory
diseases in the aging population. Future longitudinal studies will
determine the value of monocyte and innate immune aging markers in
predicting age-related disease and may justify their inclusion in disease
risk screening algorithms.
Experimental procedures
Subject recruitment and blood processing
Healthy male [n = 91, mean age 52.4 (range 20–84) years; mean body
mass index 25 (range 16–29); non-Caucasian race, 8.1%; current smok-
ers, 3.3%] and female [n = 55, mean age 48.3 (range 20–82) years;
mean body mass index 25 (range 18–42); non-Caucasian race, 14.5%;
current smokers, 7.3%] participants were recruited from the community
with informed consent, and blood was collected into EDTA and heparin
anticoagulant tubes. Whole blood was processed and analysed within
2 h of blood draw. Peripheral blood mononuclear cells (PBMCs) were
isolated via Ficoll density gradient centrifugation. Plasma and PBMCs
were stored at )80 C and )140 C, respectively, for later analysis.
Information regarding medical history, use of medications and demo-
graphic details was collected from each participant by interview. Exclu-
sion criteria included regular use of anti-inflammatory medication,
recent (within 3 weeks) self-reported mild illness, vaccination or injury
and major illness (e.g. cancer, cardiovascular event, surgery) within the
preceding 6 months. This study received ethical approval from The
Alfred Research and Ethics Committee, Rush University Medical Centre
Institutional Review Board and Monash University Human Research
Ethics Committee.
Analysis of monocyte and T cell phenotype
Owing to previous findings by ourselves and others that PBMC prepara-
tion and storage alters the expression of some monocyte phenotypic
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markers (Lundahl et al., 1995), we analysed monocyte phenotype via
whole blood staining. Blood collected into EDTA anticoagulant was mixed
with a 20 · volume of 1 · FACS lysing solution (BD Biosciences, Franklin
Lakes, NJ, USA) to lyse erythrocytes (a process that was verified to not
significantly alter expression of the surface markers measured in this
study), incubated on ice for 10 min and then washed twice with FACS
wash [1% heat-inactivated cosmic calf serum, 2 mM EDTA in calcium-
and magnesium-free phosphate-buffered saline (Invitrogen, Carlsbad,
CA, USA)]. Cells were stained on ice for 30 min using pretitrated volumes
of the following antibodies: CD14-APC, CD16-PE.Cy7, CD38-PE,
HLA-DR-FITC, CD11b-PE, CD62L-FITC, CD28-APC, CD8-PE, CD57-FITC,
CD4-PCP-Cy5 (BD Biosciences, San Diego, CA, USA), TLR4-FITC (R&D
Systems, Minneapolis, MN, USA) and CD115-PE (eBiosciences, San
Diego, CA, USA), or appropriate isotype control antibodies. Cells were
washed in FACS wash, fixed in 1% formaldehyde and analysed on a
dual-laser BD FACSCalibur flow cytometer.
Assessment of monocyte phagocytosis
The ability of monocytes to phagocytose a bacterial target was assessed
using heat-killed E. coli labelled with the pH-dependent dye pHRODO
(Invitrogen) as per the manufacturer’s instructions. 2 · 108 labelled
E. coli were added to 100 lL of whole blood collected into heparin
anticoagulant and incubated either at 37 C or on ice for 10 min. Blood
cells were washed with FACS wash and monocytes labelled with anti-
CD14-APC and analysed as described above.
Intracellular cytokine staining
Basal and LPS-stimulated levels of TNF were determined in monocyte
subsets via intracellular staining. One hundred microlitre of whole blood
(collected into heparin anticoagulant) was mixed 1:1 with Iscove’s modi-
fied Dulbecco’s medium (Invitrogen) supplemented with L-glutamine,
penicillin, streptomycin and a final concentration of 3 lg mL)1 Brefeldin
A (eBioscience) and 1 lg mL)1 GolgiStop (BD Biosciences). Cells were
stimulated with a final concentration of 10 ng mL)1 LPS (Sigma-Aldrich,
St Louis, MO, USA) for 4 h in a humidified 37 C incubator. Following
stimulation (or at baseline for determination of basal TNF levels), cells
were washed with FACS wash, surface CD14 and CD16 stained as
described above and red cells lysed using FACS lysis buffer (BD
Biosciences). Cells were then permeabilized with Perm ⁄Wash Buffer I
(BD Biosciences) and intracellular cytokines labelled with anti-TNF-a-PE
(BD Biosciences) for 30 min on ice in the dark. Stained cells were
washed, fixed in a final concentration of 1% formaldehyde and stored
at 4 C until analysis on a BD FACSCalibur.
Analysis of telomere length
Telomere length in monocyte subsets and CD3+ lymphocytes was deter-
mined via immunophenotyping and FISH-Flow using modification of a
previously published protocol (Schmid & Jamieson, 2004). PBMCs were
labelled with anti-CD14-Qdot 800, anti-CD3-AlexaFluor 405 (both from
Invitrogen) and anti-CD16-AlexaFluor 647 (Biolegend, San Diego, CA,
USA) and cross-linked with 4 mM bis(sulfosuccinimidyl)suberate. Telo-
mere length in labelled cells was subsequently determined using the FITC
FISH-Flow telomere labelling kit (Dako, Glostrup, Denmark) as per the
manufacturer’s instructions, except the kitsupplied DNA stain was substi-
tuted with a 7-AAD stain (0.1 lg mL)1). Samples were analysed on a
LSRII flow cytometer and relative telomere length determined as a
percentage of the internal control cell line 1301.
Measurement of soluble markers of
innate immune activation
Plasma protein levels were determined using frozen EDTA plasma
(subjected to only one freeze–thaw) clarified via centrifugation at
10 000 g for 10 min prior to analysis. Commercial ELISA kits were used
to determine levels of sCD163 (IQ products, Cat. # IQP-383), neopterin
(Screening EIA, Brahms, Cat. # 99R.096), sCD14 and CXCL10 ⁄ IP-10 (Cat.
# DC140 and DIP100, respectively, all from Quantikine, R&D Systems) as
per the manufacturer’s instructions.
Statistical analysis
Significant differences between grouped data were identified via Mann–
Whitney U test for nonparametric data using GraphPad Prism 5 software.
Associations between immune parameters and age were identified via
linear regression (or median regression where appropriate) using Stata
software and adjusting for sex and ⁄ or age as indicated in the results
tables. Data were transformed as required.
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cardiovascular disease which is independent of antiretroviral therapy and traditional
risk factors. Monocytes play a central role in the development of atherosclerosis, and
HIV-related chronic inflammation and monocyte activation may contribute to
increased atherosclerosis, but the mechanisms are unknown.
Methods: Using an in-vitro model of atherosclerotic plaque formation, we measured
the transendothelial migration of purified monocytes from age-matched HIVþ and
uninfected donors and examined their differentiation into foam cells. Cholesterol efflux
and the expression of cholesterol metabolism genes were also assessed.
Results: Monocytes from HIVþ individuals showed increased foam cell formation
compared with controls (18.9 vs. 0%, respectively, P¼0.004) and serum from vir-
ologically suppressed HIVþ individuals potentiated foam cell formation by monocytes
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formation was inhibited by blocking antibodies to TNF receptors, suggesting a direct
effect on monocyte differentiation to foam cells. Monocytes from virologically sup-
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ABCA1 (P¼0.02).
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Cardiovascular disease (CVD) is an increasing cause of
morbidity and mortality in HIVþ individuals receiving
combination antiretroviral therapy (cART) [1,2]. HIV
infection is associated with an increased risk of
cardiovascular conditions, including atherosclerosis
[3,4] and coronary heart disease [5,6] and an approxi-
mately two-fold increased risk of myocardial infarction
[7,8]. Importantly, increased CVD risk in HIVþ
individuals is independent of traditional risk factors
[5–10] and risk prediction algorithms based on these
factors alone used in the general community setting
underestimate atherosclerosis in HIVþ individuals [11].
Although cART and specific antiretroviral agents may
potentiate CVD [12–14], the increased CVD risk
observed in HIVþ individuals who are treatment naive
[13], undergoing treatment interruption [15], and in elite
controllers [16] suggests the involvement of cART-
independent factors. Taken together, these observations
suggest that unique mechanisms exist in HIVþ individ-
uals which act in addition to traditional factors to
increase CVD risk, and these effects persist despite viral
suppression.
In HIVþ individuals, CVD is associated with markers of
inflammation [17–19] and is increasingly reported in
association with markers of monocyte/macrophage
activation. We have shown that monocyte and innate
immune activation persist in HIVþ individuals despite
viral suppression [20,21], and markers of monocyte/
macrophage activation, including soluble (s)CD163
[22,23], sCD14 [24] and cellular monocyte activation
markers [25–27], are associated with atherosclerosis and
CVD in HIV infection. Despite the significant links
between chronic inflammation/monocyte activation and
increased CVD risk in HIV infection, the mechanism
remains unclear.
Proinflammatory cytokines such as tumour necrosis
factor (TNF) potentiate atherosclerosis; they activate
endothelial cells and monocytes, resulting in increased
expression of adhesion molecules, release of chemoat-
tractants by endothelial cells, lipid transcytosis and
oxidation of low-density lipoprotein (LDL) [28].
Activated monocytes are recruited to inflamed blood
vessels and migrate into the vascular neointima, wherein
they endocytose lipids and either exit via reverse
transendothelial migration or develop into foam cells
by phagocytosing highly inflammatory oxidized low-
density lipoprotein (oxLDL; via scavenger receptors SR-
A and CD36) [29]. Foam cells have reduced migratory
capacity [30] and accumulate in the neointima wherein
they release proinflammatory molecules contributing to
further recruitment of monocytes and progression of
atherosclerosis [31]. The ability of macrophages to exit
the neointima and remove cholesterol via reverse
transendothelial migration is critical to retarding the Copyright © 2015 Wolters Kluwer Hdevelopment of atherosclerotic plaques and promoting
plaque regression [32].
We hypothesized that monocyte activation in the setting
of chronic HIV infection [20] promotes atherosclerosis.
We have previously developed a novel in-vitro model of
the initiation of atherosclerotic plaque formation that
couples transendothelial migration of primary human
monocytes across an activated endothelium with foam
cell formation [33–35]. Here, we adapted this model to
investigate the atherogeneic potential of monocytes
isolated from HIVþ individuals and determine whether
inflammatory factors elevated in HIV infection influence
early atherosclerotic events mediated by monocytes.Methods
Recruitment and blood processing
Blood was obtained from HIVþ donors recruited from
the Department of Infectious Diseases, The Alfred
Hospital, Melbourne, Australia, and healthy control
donors of a similar age following written, informed
consent. Peripheral blood mononuclear cells (PBMCs)
were isolated within 2 h of sample collection and were
either used immediately (for migration assays) or stored in
liquid nitrogen for later mRNA and cholesterol efflux
analysis. Monocytes were further purified from PBMC
via negative selection using magnetic beads (Miltenyi
Biotec, Cologne, Germany) as per the manufacturer’s
protocol, which yields monocytes with a purity of 80–
85% as determined by flow cytometry (not shown). This
study received ethical approval from The Alfred Research
and Ethics Committee and from the Royal Women’s
Hospital Ethics Committee, Melbourne, Australia.
Cell migration assay and analysis
Hydrated collagen gels were prepared in a 96-well format
as described previously [33,36]. Gels were incubated at
378C for 4–6 days until use. Primary human umbilical
vein endothelial cells (HUVEC) were prepared as
described [36] and used without further passage.
2 104 HUVEC were added to each collagen gel and
incubated in Medium 199 (Life Technologies, Carlsbad,
California, USA) containing 20% human serum for 3 days
to allow confluent monolayers to form. Media were
prepared using a single batch of pooled human serum
(pHS) prepared from six HIV-seronegative blood donors
(Australian Red Cross Blood Service, Sydney, Australia)
or autologous serum (from the same donor as the
monocytes) as indicated; all sera were heat inactivated at
56 8C for 30 min before use. Silver staining was
performed on selected wells, in addition to routine
phase-contrast microscopy, to verify HUVEC monolayer
integrity (Supplementary Fig. 1A) [33]. HUVEC were
activated with 10 ng/ml TNF for 4 h [35] or left
unactivated, then freshly isolated PBMCs (2 105/well)
or purified monocytes (5 104/well) added for 1 h atealth, Inc. All rights reserved.
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cultures incubated for a further 48 h as described [33]. For
TNF blocking, 10 or 20mg/ml anti-tumour necrosis
factor receptor (TNFR) I and anti-TNFRII (R&D
Systems, Minneapolis, Minnesota, USA), or respective
isotype controls, were added immediately following
monocyte migration. Forty-eight hours after monocyte
migration, reverse-migrated cells were removed and
collagen gels stained with Oil Red O as described [35].
Gels were excised from wells, mounted on glass slides and
foam cells counted by bright field microscopy (40).
Foam cells were defined as cells containing Oil Red O
stained vesicles within the cytoplasm and determined as a
proportion of total migrated cells within the counted area
of the gel (Supplementary Fig. 1B). To investigate the
phenotype of migrated cells within the collagen matrix,
cells were extracted from the collagen by washing the gels
without fixation and incubating in 1 mg/ml collagenase
D for 20 min at 378C, after which they were macerated
manually and incubated further for 20 min at 37 8C.
Resulting cell suspensions were filtered through 100mm
mesh prior to staining for flow cytometric analysis. Cells
extracted from collagen gels were stained with 0.2mg/ml
BODIPY 493/503 (Life Technologies, Carlsbad, Cali-
fornia, USA) in 150 mmol/l NaCl for 20 min at room
temperature and anti-TNF-PE, CD36-FITC, CD14-
APC and CD11b-PE (all from BD Biosciences, San Jose,
California, USA) as described [20]. Cells stained with
anti-CD14 APC and BODIPY were sorted using a BD
influx cell sorter. The specificity of phenotyping
antibodies was verified via the use of isotype control
antibodies on selected samples (Supplementary Figure 2).
Live cell imaging
Purified monocytes were stained with PKH26 (Sigma-
Aldrich, St Louis, Missouri, USA) according to
manufacturer’s instructions and added to HUVEC
monolayers grown on collagen gels in 96-well optical
plates (Greiner Bio-One, Frickenhausen, Germany).
Cells were immediately incubated at 378C in a
humidified temperature-controlled chamber coupled to
a DeltaVision deconvolution microscope (Applied
Precision-GE Healthcare, Issaquah, Washington, USA)
and images were captured in z-series on a charge-coupled
device camera (AxioCamMRm Rev. 3, Carl Zeiss
Microscopy, Jena, Germany) through a 20, 0.45 NA
lens. Detection and tracking of cell migration was
performed using the tracking module of the Imaris
software (Bitplane, Zurich, Switzerland).
Analysis of plasma lipids and soluble factors
Plasma TNF and CXCL10 levels were measured using
commercial ELISA kits (human TNF-a ELISA, Cardinal
Bio-research, New Farm, Australia, and Human
CXCL10/IP-10 Quantikine ELISA KIT, R&D Systems,
Minneapolis, Minnesota, USA). Cholesterol and oxi-
dized LDL levels in plasma were measured using the HDL
and LDL/VLDL Cholesterol Assay Kit and the Human Copyright © 2015 Wolters KluweOxidized LDL ELISA Kit (CML-LDL) respectively (both
from Cell Biolabs, San Diego, California, USA).
Cholesterol efflux assays
PBMCs (2.5–5 105) were incubated for 1 h at 37 8C in
RPMI containing 10% pHS (RH-10), 1.5mmol/l
BODIPY-cholesterol (Avanti Polar Lipids, Alabaster,
Alabama, USA), 6mmol/l cholesterol and 300mmol/l
methyl-b-cyclodextrin (both from Sigma-Aldrich). Cells
were washed twice with PBS (PBS without Mg2þ or
Ca2þ), resuspended in RH-10 and cholesterol was allowed
to efflux from the cells for 30 min at 37 8C in either the
absence or presence of 1 mmol/l of methyl-b-cyclodex-
trin. Cells were washed, fixed with 1% formaldehyde,
immunostained as above and analyzed by flow cytometry.
Gene expression analysis of cholesterol efflux
and metabolism intermediates
The expression of proteins involved in cholesterol
metabolism and transport was assessed via quantitative
real-time PCR (qPCR). Monocytes were isolated from
frozen PBMC, rested for 4 h in RPMI containing 20%
pHS at 378C and total RNA was extracted. Potential
DNA contamination was removed by DNase I treatment
(378C for 20 min, 758C for 10 min, Roche, Basel,
Switzerland). cDNA synthesis was performed using a
combination (1 : 2) of oligo(dT) and random hexamer
primers, respectively (Transcriptor First Strand cDNA
synthesis kit, Roche) and qPCR analysis was performed
using FastStart Universal SYBR Green Master Mix
(Roche) for GAPDH, adenosine triphosphate (ATP)-
binding cassette transporter A1 (ABCA1) and Acyl-
coenzyme A: cholesterol acyltransferase (ACAT), and
Brilliant SYBR II (Agilent Technologies, Santa Clara,
California, USA) for ABCG1 and HMG-CoA reductase
on a MX3005P qRT-PCR machine (Agilent Technol-
ogies). The primers used were as follows: GAPDH (Fwd
50-CCATGGCACCGTCAAGGC-30, Rev 50-CCAG-
CATCGCCCCACTTG-30), ABCA1 (Fwd 50-GCACT-
GAGGAAGATGCTGAAA-30, Rev 50-AGTTCCTGG
AAGGTCTTGTTCAC-30), ABCG1 (Fwd 50-CAGGA
AGATTAGACACTGTGG-30, Rev 50-GAAAGGG-
GAATGGAGAGA-30), ACAT (Fwd 50-CAAGGCGCT
CTCTCTTAGATGAAC-3, Rev 50-GATAAAGAGAA
TGAGGAGGGCAATAA-30) and HMG-CoA reductase
(Fwd 50-GGGACCAACCTACTACCTCAG-30, Rev
50-CGACCTGTTGTGAATCATGTGACTT-30) at a
final concentration of 280 nmol of each primer. PCR
conditions were 958C for 10 min then 40 cycles of 958C
for 15 s, 608C for 1 min. Absolute quantification of gene
expression was determined via comparison with a
standard curve generated from serial dilution of a plasmid
engineered to contain the amplicon of interest. Expres-
sion of all genes was standardized to GAPDH.
Data and statistical analysis
Nonparametric, two-tailed Mann–Whitney U test was
used for unpaired data and Wilcoxon rank-sum test forr Health, Inc. All rights reserved.
1448 AIDS 2015, Vol 29 No 12paired data. Parametric unpaired t-test was used for data
passing the D’Agostino–Pearson omnibus normality test.
Statistical analysis was performed using GraphPad Prism
software (GraphPad Software Inc., La Jolla, California,
USA) where values of P< 0.05 were considered
statistically significant.Results
HIV infection increases foam cell formation by
monocytes following transendothelial migration
We have previously shown that HIV infection of
monocyte-derived macrophages in vitro impairs their
ability to reverse migrate across a HUVEC-collagen gel
model of early atherosclerotic events [36], suggesting
these cells may have a greater propensity to differentiate
into foam cells, and thus be retained in the collagen
matrix. To investigate whether HIV infection in vivo is
associated with increased propensity for monocytes to
develop into foam cells, we utilized a refined version of
this model to analyze the atherogenic properties of
monocytes isolated by negative selection from fresh
whole blood. Ageing is well documented to increase the
risk of atherosclerosis, thus we investigated the effect of
HIV infection in younger HIVþ individuals and
uninfected controls of a similar age. Monocytes were
isolated from seven healthy controls [all men, median age
(range) 29.0 (25–56) years] and eight HIVþ men
[median age 36.5 (26–47) years]. Of the HIVþ
individuals, four were receiving cART and had low
(80 copies/ml, n¼ 1) or undetectable (<40 copies/ml, Copyright © 2015 Wolters Kluwer H
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Fig. 1. Monocytes fromHIVR individuals show increased foam cel
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migration for seven HIV controls and eight HIVþ male donors
(HUVEC) in the presence of either pooled human control serum (pH
(AS) from each individual donor. Bars represent median and
(c) Percentage of foam cells present within collagen was measure
donors added to TNF-activated HUVEC, and incubated with either
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receiving cART and had a median viral load of
23 400 copies/ml (range: 300–254 800 copies/ml).
When added to unstimulated HUVEC in media
containing 20% pHS, a significantly increased proportion
of monocytes from HIVþ individuals differentiated into
foam cells as compared with monocytes from controls
(median foam cells 18.9 vs. 0%, respectively, P¼ 0.004,
Fig. 1A; all samples tested using the same batch of pHS). To
determine whether factors present in HIVþ serum may
further influence foam cell formation, we analyzed foam
cell formation using culture media containing autologous
serum rather than pHS and found that although foam cell
formation by control monocytes was not significantly
altered in the presence of autologous serum, serum from
HIVþ individuals significantly increased foam cell
formation by autologous monocytes (P¼ 0.03, Fig. 1A).
Consistent with our previous findings, activation of
HUVEC with TNF prior to monocyte migration
significantly increased foam cell formation by monocytes
from control donors (P¼ 0.016 for both pHS and
autologous serum, Fig. 1A vs. B) and also HIVþ
monocytes in the presence of pHS (P¼ 0.008). As seen
with unactivated HUVEC, autologous serum from HIVþ
but not controls, significantly increased foam cell
formation when monocytes were added to TNF-activated
HUVEC (P¼ 0.02 vs. 0.30, respectively, Fig. 1B). The
increased rate of foam cell formation by control monocytes
following endothelial cell activation meant that differences
between control and HIVþ monocytes were only
observed in the presence of autologous serum (P¼ 0.03,ealth, Inc. All rights reserved.
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Foam cell formation by HIVR monocytes Maisa et al. 1449Fig. 1B). Similar levels of foam cell were formed by
monocytes from young HIVþ individuals receiving cART
with low/undetectable viral loads as compared with young
untreated HIVþ individuals with viraemia (Supple-
mentary Fig. 3A and B). We also analyzed foam cell
formation in an expanded cohort of 17 HIVþ men aged
26–68 years consisting of 13 individuals receiving cART
(12 virologically suppressed with plasmaviral loads less than
40 copies/ml and one individual with 80 copies/ml) and
the four viraemic individuals not receiving cART defined
above. This analysis showed a nonsignificant trend towards
increased foam cell formation with age; however, there
were no differences between virologically suppressed
and nonsuppressed HIVþ individuals (Supplementary
Fig. 3C). Data from this expanded cohort of largely
virologically suppressed individuals also confirmed the
proatherogenic effect of autologous HIVþ serum
(Supplementary Fig. 3D).
We then determined whether the proatherogenic effect
of HIVþ serum was only evident in combination with
autologous HIVþ monocytes or whether it was also
capable of enhancing foam cell formation by monocytes
from HIV-seronegative individuals. To investigate this,
we analyzed foam cell formation in the model described
above using monocytes from six HIV-uninfected controls
in the presence of either pHS, or serum from five cART-
treated, virologically suppressed HIVþ individuals. Foam
cell formation by control monocytes was significantly
increased by all five HIVþ sera used (Fig. 1C),
confirming the presence of soluble factor(s) in HIVþ
sera that promote foam cell formation. Significantly, the
sera used in this experiment were all from patients with
undetectable viral load, indicating the responsible factors
remain elevated despite viral suppression. The above data
indicate that HIV infection promotes the differentiation
of monocytes into foam cells via a mechanism involving
both soluble factors present in the serum and an intrinsic
alteration to monocyte function.
Live cell imaging of monocyte migration in the
transendothelial migration assay
To investigate the effect of HIV infection on monocyte
movement postmigration, we labelled monocytes with
the fluorescent membrane dye PKH26, and recorded
individual cell tracks within the collagen layer using live
cell imaging over 48 h (Fig. 2 and Fig2mov1 and
Fig2mov2). Tracks obtained from monocytes from HIVþ
individuals showed a greater number of slowly migrating
cells (indicated by yellow foci in Fig. 2B vs. control donor
in 2A), consistent with more monocytes developing into
nonmotile foam cells. This behaviour was observed for
monocytes from virologically suppressed HIVþ individ-
uals receiving cART using either control serum or
autologous serum (data not shown). We calculated the
distribution of displacement length using tracks com-
bined from at least three independent experiments and
found that monocytes from HIVþ individuals migrated Copyright © 2015 Wolters Kluweshorter distances than those from controls (evidenced by a
shift to the left in the distance frequency histograms for
HIVþ samples, Fig. 2C) and this effect was heightened in
the presence of autologous HIVþ serum (Fig. 2C).
Although the initial migration speed of monocytes from
HIVþ individuals was not different from control mono-
cytes in the presence of pHS, the presence of autologous
serum was associated with a significant increase in initial
migration speed (Fig. 2D), suggesting factors in HIVþ sera
accelerate monocyte migration at early time points after
transendothelial migration. In contrast, tracks from HIVþ
donors during the later stages of observation (i.e., 38–48 h)
showed a lower migration speed as compared with control
monocytes (Fig. 2E). Interestingly, the average migration
speed of monocytes from HIVþ individuals was higher in
the presence of autologous serum vs. pHS, although the
speed was still significantly lower than that of control
monocytes (Fig. 2E). Analysis of monocyte speed over the
entire observation window (0–48h) confirmed the overall
average migration speed of monocytes from HIVþ
individuals was lower than that of controls (data not
shown). These data indicate that monocytes from HIVþ
individuals have impaired movement post-transendothelial
migration, consistent with their differentiation into foam
cells, and that factors present in the serum of HIVþ
individuals enhance this effect.
Plasma tumour necrosis factor and CXCL10
levels are increased in HIVR individuals
HIV infection is associated with dyslipidaemia because of
the combined effects of HIV and certain antiretroviral
drugs which may influence the atherogenic properties of
monocytes and sera from HIVþ individuals. To
determine whether altered cholesterol levels in auto-
logous serum were responsible for the increase in foam
cell formation by monocytes from HIVþ individuals in
this study, we measured plasma levels of high-density
lipoprotein, LDL and oxLDL by ELISA. No significant
differences were observed in plasma levels of any of these
forms of cholesterol between HIVþ and control
individuals (Supplementary Fig. 4), suggesting that the
heightened foam cell formation by HIVþ monocytes
observed here is unlikely to be due solely to altered levels
of these cholesterol species in the blood.
Inflammatory factors activate monocytes and can also
drive foam cell formation independent of dyslipidaemia
[37]; therefore, we measured plasma levels of the
proinflammatory cytokine TNF and the monocyte
activation biomarker CXCL10 in our cohort. Both
CXCL10 and TNF levels were significantly elevated in
HIVþas compared with controls (Fig. 3A and B, P¼ 0.01
and 0.03, respectively). Taken together, these data suggest
that plasma markers of monocyte activation and
inflammation, but not plasma cholesterol levels, are
significantly increased in these HIVþ individuals who
also show increased foam cell formation.r Health, Inc. All rights reserved.
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Fig. 2. Tracking of monocyte migration via live cell imaging. Images were obtained from a representative experiment measuring
migration over 48h of PKH26-labelled monocytes from a control donor (a) and HIVþ donor (b) in the presence of pHS. Cells were
incubated at 37 8C in a humidified temperature controlled chamber coupled to a DeltaVision microscope, images were captured
using a charge-coupled device camera through a 20 0.45 NA lens and cell movement was tracked over 48h. The colour
gradients represent timewith red as the earliest time (closest to 0 h) and yellow as latest time (closest to 48h; see also Fig2mov1 and
Fig2mov2). (c) Tracks from live cell imaging experiments that could be assigned unambiguously to individual cells were identified
and their displacement lengths computed using Imaris software. Frequency histogram of migration track lengths for monocytes
added to unactivated HUVEC from HIV controls in the presence of pHS (black bars, 64 tracks combined from four independent
experiments) or monocytes from HIVþ donors in the presence of pHS (green bars, 51 tracks/three experiments) or autologous
serum (red bars, 35 tracks/three experiments). Histograms are nudged by 10 data points. Average monocyte migration speed
recorded in the first hour (d) or last 10 h (E; hours 38–48) of migration for monocytes from HIV controls in the presence of pHS
and HIVþ donors in the presence of pHS or autologous serum was computed using Imaris software. Box and whisker plots show
median, IQR and 1.5 IQR (Tukey method; dots represent points outside these ranges). Significance was tested using an unpaired
two-tailedMann–WhitneyU test, P<0.0001. HUVEC, human umbilical vein endothelial cells; IQR, interquartile range; pHS,
pooled human serum.Anti-tumour necrosis factor receptor blocks
foam cell formation independent of human
umbilical vein endothelial cell activation
We have shown here and previously [35] that TNF
activates endothelial cells to increase foam cell formation,
and plasma TNF levels have been found to be elevated in
HIV patients irrespective of cART [38]. We therefore
considered whether TNF promotes foam cell differen-
tiation independently of its effects on HUVEC. Mono-
cytes from control donors were allowed to migrate
through TNF-activated HUVEC, then blocking anti-
bodies to TNFR I and II were added to media containing
either control pHS or serum from virologically suppressed
HIVþ donors and cells incubated for 48 h. Monocytes
from each control donor were incubated with serum from
three different HIVþ donors, with serum from a total of
six HIVþ donors utilized for these experiments. Anti- Copyright © 2015 Wolters Kluwer HTNFR antibodies reduced foam cell formation in a dose-
dependent manner compared with cells treated with
isotype control antibodies (Fig. 3C), and this inhibition
was observed when either control serum (pHS) or HIVþ
serum was used. These data suggest that endogenous
TNF in serum, and/or TNF produced by activated
monocytes during foam cell differentiation, enhances
foam cell formation independently of its effects on
endothelial activation, and that increased levels of TNF in
individuals with HIV likely contributes to the proathero-
genic effect of HIVþ serum.
Foam cells downregulate markers associated
with immunity and endothelial attachment
To characterize the foam cells generated in our model
following monocyte transendothelial migration, we
labelled migrated cells extracted from the collagen withealth, Inc. All rights reserved.
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of foam cells and macrophages via flow cytometry. To
confirm the ability of BODIPY staining to identify foam
cells, we analyzed labelled cells using imaging flow
cytometry and found that cells with high BODIPY
staining exhibited a morphology consistent with foam cells
(Supplementary Fig. 5). By gating BODIPYhigh cells, the
percentage of foam cells was determined based on
fluorescence intensity (rather than visually which may be
subjective). This gave similar values to those determined by
Oil Red O staining and light microscopy analysis assayed in
parallel (Supplementary Fig. 5). Taken together, these data
confirm that both BODIPYand Oil Red O staining were
able to identify similar populations of foam cells and
macrophages within our model.
Having validated the use of fluorescent BODIPY staining
for identification of foam cells, we labelled cells extracted
from the collagen matrix with both anti-CD14 and
BODIPYand analyzed them by standard flow cytometry.
This revealed two distinct populations of CD14þ cells;
large, BODIPYhighCD14low cells with high granularity,
consistent with foam cells, and a population of smaller
BODIPYlowCD14high cells with relatively low granular-
ity, consistent with monocytes/immature macrophages
(Fig. 4A). The characterization of these two novel
populations was confirmed by microscopic analysis of
cells sorted by fluorescence-activated cell sorting (FACS)
and was consistent in experiments using monocytes from
14 independent donors (Fig. 4B and C).
We further analyzed the phenotype of macrophages and
foam cells by measuring expression of the b2 integrin
subunit CD11b and the oxLDL receptor CD36. Foam Copyright © 2015 Wolters Kluwecells had lower expression of both receptors compared
with macrophages, consistent with a role in lipid storage
as opposed to migration and active lipid accumulation
(Fig. 4D and E). Moreover, foam cells had significantly
higher intracellular levels of TNF compared with
macrophages (Fig. 4F), indicating a proinflammatory
phenotype. These observations show that foam cell
formation is associated with increased cell size, reduced
surface expression of CD14, CD11b and CD36 but an
increase in the production of the proinflammatory
cytokine TNF.
Monocytes from HIVR individuals showed
impaired cholesterol efflux and reduced
expression of cholesterol transporters
The above data indicate that monocytes from HIVþ
individuals have an increased potential to form foam cells,
independent of the atherogenic effects of serum,
suggesting that HIV is associated with intrinsic changes
to monocytes that may alter lipid transport. We therefore
assessed the ability of monocytes from virologically
suppressed cART-treated individuals to efflux cholesterol
using an ex-vivo assay. PBMC from HIVþ individuals
and controls of a similar age [n¼ 8 each, all men, median
age (range) 43.5 (33–51) and 36.5 (28–52) respectively]
were loaded with BODIPY-labelled cholesterol and the
subsequent cholesterol efflux from monocytes deter-
mined via flow cytometry. This analysis revealed that
monocytes from HIVþ individuals were significantly
impaired in their ability to efflux cholesterol from the cell,
and this impairment was evident both in the absence and
presence of the exogenous cholesterol scavenger methyl-
b-cyclodextrin (Fig. 5A and B, respectively).r Health, Inc. All rights reserved.
1452 AIDS 2015, Vol 29 No 12
0
Macrophages Foam cells Macrophages Foam cells
Macrophages Foam cells
200
400
600
800 1200
800
400
0
0
200
400
600
800
Macrophages
Control HIV+
Foam cells
0
0.0
2.5
5.0
7.5
10
15
100CD
36
 (M
FI)
CD
14
 (M
FI)
Bo
di
py
 (M
FI)
CD
11
b 
(M
FI)
TNF
FSC
SS
C
CD
14
 A
PC
BODIPY FITC
TN
F 
(pg
/m
l)
200
300
*
*
**
**
0
10K
20K
30K
0 10K 20K 30K 100
100
101
102
103
104
101 102 103 104
(a)
(b) (c)
(d)
(f)
(e)
Fig. 4. Flow cytometry analysis and sorting of transmigrated monocytes extracted from collagen gels. (a) Upper panels:
monocytes from a representative HIV donor were extracted from collagen gels 48 h after transmigration, stained with BODIPY
493/503 and anti-CD14-APC, then analyzed by flow cytometry. Left panel: Forward scatter (FSC) vs. side scatter (SSC) plot; Right
panel: CD14-APC vs. BODIPY-FITC scatter plot. The two indicated populations were isolated by cell sorting. Bottom panel: FACS-
purified cells from the gates shownwere counterstained with Hoechst 33258 (Life Technologies), centrifuged onto glass slides and
mounted in Fluoromount-G (Southern Biotech, Birmingham, Alabama, USA). Images were captured on a charge-coupled device
camera through a 1001.3 numerical aperture oil immersion lens on a Zeiss Axio Observer.Z1 inverted microscope (Carl Zeiss
Microscopy, Jena, Germany). (B–F) Cells extracted from collagen gels after 48hwere analyzed by flow cytometry for the following
markers: CD14 (b), BODIPY (c), CD36 (d), CD11b (e) and intracellular TNF (f). Box and whisker plots show median, IQR and
1.5 IQR (Tukey plot). P<0.05; P<0.01 as determined by paired nonparametric two-tailed Wilcoxon rank-sum test. IQR,
interquartile range; TNF, tumour necrosis factor.To investigate the mechanistic basis for this impairment,
we analyzed the expression of key genes involved in
cholesterol synthesis and transport. RNA was extracted
from monocytes purified from virologically suppressed
HIVþ individuals on cART and age-matched controls
and gene expression analyzed via qPCR. This analysis
revealed significantly reduced expression of the key
cholesterol efflux transporter ABCA1 in monocytes
from HIVþ individuals (Fig. 5C, P¼ 0.02), whereas
expression of ABCG1 showed a similar although not
statistically significant downregulation (Fig. 5D).
Expression of HMG-CoA reductase, the rate-determining
enzyme for cholesterol biosynthesis, was also signifi-
cantly reduced in monocytes from individuals with
HIV (Fig. 5E, P¼ 0.02), whereas monocyte expression
of the cholesterol esterase ACAT was not altered by
HIV infection (Fig. 5F). These data indicate that
HIV infection is associated with a decreased expression Copyright © 2015 Wolters Kluwer Hof key cholesterol efflux genes in monocytes and an
impaired ability to efflux cholesterol from the cell, which
likely contributes to the increased potential of monocytes
from HIVþ individuals to form foam cells.Discussion
Using a model of atherosclerosis that couples primary
human monocyte transendothelial migration and foam
cell differentiation, we show that monocytes from HIVþ
individuals have a higher rate of foam cell formation,
which is because of both intrinsic changes to monocyte
function and a proatherogenic effect of soluble factors
present in HIVþ serum. These findings may provide
some of the first mechanistic evidence regarding the
pathogenesis of increased atherosclerosis and CVD in the
setting of HIV infection.ealth, Inc. All rights reserved.
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Fig. 5. Monocytes from virologically suppressed HIVR donors show altered expression of cholesterol metabolism genes and
impaired cholesterol efflux. PBMC from controls and virologically suppressed HIVþ individuals (n¼8 for each) were loaded with
BODIPY-cholesterol and subsequent cholesterol efflux from monocytes was measured via flow cytometry. The percentage
cholesterol efflux after 30min (as a proportion of total loaded) is shown for experiments conducted in the absence (a) or presence
(b) of the cholesterol accepter methyl-b- cyclodextrin. Gene expression of the cholesterol metabolism genes ABCA1 (c), ABCG1
(d), HMG-CoA reductase (e) and ACAT (f) was determined via qPCR analysis of mRNA isolated from purified monocytes from
controls and virologically suppressed HIVþ donors (n¼11 in each group) and standardized to GAPDH expression. Box and
whisker plots showmedian, IQR and 1.5 IQR (Tukey plot). Significance was tested using an unpaired two-tailedMann–Whitney
U test, P<0.05. ACAT, acyl-coenzyme A: cholesterol acyltransferase; IQR, interquartile range; PBMC, peripheral blood
mononuclear cell; qPCR, quantitative real-time PCR.In this study, we adapted our in-vitro model which
couples monocyte transendothelial migration and foam
cell formation to determine the functional properties of
human monocytes purified from an HIVþ patient
cohort. The strengths of this model include the following:
monocytes migrate through an activated primary human
endothelial monolayer in response to chemokines
secreted in situ and into a fibrous collagen matrix that
mimics the subendothelial neointima; it measures foam
cell formation by migrated monocytes, rather than in vitro
differentiated macrophages; and exogenous modified
lipoprotein is not added, therefore, foam cells form in
response to endogenous lipids in the human-serum Copyright © 2015 Wolters Kluwecontaining media and/or generated in response to
endothelial activation. This model is therefore a
physiologically relevant system for studying the early
stages of foam cell formation in vitro by migrating human
monocytes.
Although HIV infection and certain antiretroviral drugs
including protease inhibitors can cause dyslipidaemia
[39], plasma levels of LDL, high-density lipoprotein and
oxLDL in the HIVþ individuals who contributed to this
study were not different from controls, suggesting that
heightened foam cell formation observed here cannot be
explained by lipidaemic HIVþ serum alone. Endothelialr Health, Inc. All rights reserved.
1454 AIDS 2015, Vol 29 No 12activation and/or monocyte transendothelial migration
may affect levels of oxLDL within the gels, however,
which could influence foam cell formation. Significantly,
serum from HIVþ individuals had elevated levels of TNF
and foam cell formation was blocked by anti-TNFR
antibodies added after monocyte migration, supporting a
proatherogenic role for TNF in these individuals via
mediating monocyte activation and increased foam cell
formation. Our data were qualitatively supported by live
cell imaging showing monocytes from HIVþ individuals
moved more slowly within the collagen matrix of the
model, particularly at later times, consistent with
differentiation into foam cells. These novel data regarding
the proatherogenic properties of monocytes from HIVþ
individuals may provide a mechanistic explanation for
increased atherosclerosis in this population.
In addition to the proatherogenic effects of HIVþ serum,
our data suggest HIV infection induces changes to
monocytes that predispose them to foam cell formation.
Indeed, we found an altered expression of critical
cholesterol synthesis and transport proteins in monocytes
from HIVþ individuals. The reduced gene expression of
ABCA1 may translate to an impaired ability to remove
cholesterol from the cell, consistent with our observation
of impaired cholesterol efflux in monocytes from
individuals with HIV. Feeney et al. [40] also examined
the expression of cholesterol metabolism genes in
monocytes and found reduced levels of ABCA1 mRNA
in viraemic but not virologically suppressed HIVþ
participants, whereas expression of the lipid uptake
receptors CD36 and LDL-receptor was reduced in both
HIVþ groups. The different result regarding ABCA1
expression may be because of differences in the
methodology of monocyte isolation (positive selection
in the Feeney et al. study as compared with negative
selection used in our study), differences in the cohorts
used (50% women and 64% non-White vs. 100% White
men in our study) or the smaller sample size in our study.
Thus, these findings need to be confirmed in a larger
cohort adequately powered to examine the effect of
demographic factors including sex and race. The reduced
expression of the cholesterol synthesis enzyme HMG-
CoA reductase in monocytes shown here is consistent with
the previously reported study and may represent a cellular
response to increased intracellular cholesterol levels.
The foam cell data presented here were generated from a
combination of virologically suppressed and nonsup-
pressed individuals. Although analysis of foam cell
formation in an expanded HIVþ cohort aged 26–68
years did not reveal any significant differences associated
with detectable levels of viraemia, this requires confir-
mation in a larger sample set. The fact that serum from
virologically suppressed individuals enhanced foam cell
formation suggests the persistence of proatherogenic
factors in serum in individuals receiving effective cART.
Furthermore, our findings of impaired cholesterol efflux Copyright © 2015 Wolters Kluwer Hfrom monocytes were also made in virologically
suppressed individuals, consistent with our findings that
increased monocyte and innate immune activation
associated with HIV infection are maintained following
viral suppression by cART [20,21]. It remains possible
that antiretroviral agents may contribute to this pheno-
type in cART-treated individuals; however, this requires
investigation. Given only a very small proportion of
monocytes are found to be infected with HIV in vivo
(<0.1%), the proatherogenic monocyte phenotype
observed here is likely secondary to HIV-associated
immune activation and inflammation and not a result of
direct infection, although it remains possible that
nonproductive/latent HIV infection may also alter
monocyte phenotype. Our data suggest monocytes from
virologically suppressed individuals receiving cART
exhibit a proatherogenic activity and that this may be a
pathogenic factor underlying increased atherosclerotic
risk in HIVþ individuals.
Endothelial activation plays an integral role in atheroscle-
rosis and monocyte transendothelial migration via the
expression of adhesion molecules [41], and soluble
endothelial activation markers are elevated in HIVþ
individuals and independently associated with carotid
intima-media thickness, a surrogate measure of athero-
sclerosis [42]. Zietz et al. [43] examined the aortic
endothelium of patients largely with advanced HIV
disease and found structural abnormalities which were
accompanied by increased expression of adhesion
molecules and mononuclear cell infiltration. Thus, the
proatherogenic effects of HIVþ monocytes observed
here may well be potentiated by heightened endothelial
cell activation in vivo. Proinflammatory cytokines are well
documented to be associated with increased cardiovas-
cular risk factors and outcomes in both HIVþ and
seronegative individuals [44]; however, viral factors in the
blood may also contribute to increased atherosclerosis in
HIV infection. HIV infection and HIV-derived single
stranded RNAs increase foam cell formation by
monocyte-derived macrophages in vitro [45,46]. The
HIVaccessory protein Nef promotes foam cell formation
in these cells by inhibiting cholesterol efflux [45], and
high concentrations of Nef persist in plasma of HIVþ
individuals receiving cART [47]. Taken together, it is
therefore likely that changes to both monocyte activation
and gene expression together with inflammatory cyto-
kines and virus-specific factors in serum contribute to the
proatherogenic potential of monocytes observed here.
Heightened foam cell formation by monocytes/macro-
phages in vitro is consistent with increased prevalence of
atherosclerotic plaques in HIVþ as compared with
uninfected individuals [4,22,48], and it would be of
interest to determine whether this is associated with
altered plaque morphology in HIVþ individuals in vivo.
We devised a technique to differentiate between
monocyte-derived macrophages and monocyte-derivedealth, Inc. All rights reserved.
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BODIPY staining and determined that foam cells have an
inflammatory phenotype, as defined by higher TNF and
downregulated CD11b expression similar to that
described by others [49]. Higher intracellular TNF
levels compared with migrated macrophages suggests
foam cells may have a positive feedback role in activating
the endothelium and promoting oxidation of LDL
during the development of atherosclerotic plaques, as
well as acting on nearby foam cells to enhance cellular
activation. We also found foam cells downregulated
expression of CD14, CD11b and CD36, the latter two
being critical for monocyte attachment and lipid uptake,
respectively. Downregulation of CD36 expression was
unexpected as CD36 contributes to foam cell formation
[35]. Although reduced CD36 expression in response to
uptake of modified LDL particles has been reported by
others [50], the majority of studies suggest oxLDL
particles increase CD36 expression [51,52] and CD36 is
highly expressed in foam cells obtained from mature
human plaques [53]. The kinetics of CD36 expression
during the process of foam cell formation is poorly
understood, and the decreased CD36 expression we
observed may be the result of receptor internalization
due to endocytosis of lipid, or may be a transient response
to lipid uptake immediately after migration. Indeed, our
model analyses foam cells formed within 48 h of
migration, whereas foam cells extracted from human
plaques likely developed over longer periods. This,
combined with findings from parallel studies indicating
that foam cells extracted from our model are smaller and
contain less cholesterol ester than mature foam cells
extracted from atherosclerotic plaques (unpublished
findings), suggests they likely represent immature foam
cells or foam cell precursors. Studying the behaviour of
these cells is therefore highly relevant for strategies aimed
at preventing or reversing the early stages of foam
cell formation.
Our study reports novel data indicating that monocytes
from HIVþ individuals, a population characterized by
chronic inflammation and immune activation, have a
greater propensity to differentiate into foam cells and that
elevated levels of TNF in plasma of these individuals
further enhances this effect. This may explain the
increased risk of atherosclerosis in these individuals after
adjusting for viral and traditional risk factors and warrants
further clinical investigation of the relationship between
monocyte activation, atherogenic behaviour and the
development of atherosclerosis in HIVþ individuals
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Abstract
Background: Aging is associated with immune dysfunction and the related development of conditions with an
inflammatory pathogenesis. Some of these immune changes are also observed in HIV infection, but the interaction between
immune changes with aging and HIV infection are unknown. Whilst sex differences in innate immunity are recognized, little
research into innate immune aging has been performed on women.
Methods: This cross-sectional study of HIV positive and negative women used whole blood flow cytometric analysis to
characterize monocyte and CD8+ T cell subsets. Plasma markers of innate immune activation were measured using standard
ELISA-based assays.
Results: HIV positive women exhibited elevated plasma levels of the innate immune activation markers CXCL10 (p,0.001),
soluble CD163 (sCD163, p = 0.001), sCD14 (p = 0.022), neopterin (p = 0.029) and an increased proportion of CD16+
monocytes (p = 0.009) compared to uninfected controls. Levels of the innate immune aging biomarkers sCD163 and the
proportion of CD16+ monocytes were equivalent to those observed in HIV negative women aged 14.5 and 10.6 years older,
respectively. CXCL10 increased with age at an accelerated rate in HIV positive women (p = 0.002) suggesting a synergistic
effect between HIV and aging on innate immune activation. Multivariable modeling indicated that age-related increases in
innate immune biomarkers CXCL10 and sCD163 are independent of senescent changes in CD8+ T lymphocytes.
Conclusions: Quantifying the impact of HIV on immune aging reveals that HIV infection in women confers the equivalent of
a 10–14 year increase in the levels of innate immune aging markers. These changes may contribute to the increased risk of
inflammatory age-related diseases in HIV positive women.
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Introduction
HIV positive individuals are at a greater risk than their
seronegative counterparts of a range of conditions usually
associated with aging such as cardiovascular disease [1], osteopo-
rosis [2], frailty [3] and neurocognitive decline [4]. These
conditions are associated in the elderly with elevated levels of
inflammatory markers including IL-6 and TNF [5,6]. Thus the
finding that young HIV positive and elderly individuals show
similar elevations of these markers [7,8] suggests that systemic
chronic inflammation may be a common feature of both HIV
infection and aging.
Studies of HIV-related immune senescence have mainly focused
on the adaptive immune system and identified markers of adaptive
immune aging including expansion of CD282CD57+ CD8+ T
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cells and shortened telomeres in CD8+ T cells [9,10] occur
prematurely in younger HIV positive individuals [11,12]. How-
ever, expansion of a subset of monocytes that express CD16 and
that are reported to have an activated and inflammatory
phenotype [13] has been demonstrated in both aged [14,15,16]
and HIV positive individuals [17,18]. This suggests that immune
dysfunction in both aging and HIV extends also to innate
immunity.
We and others have shown that soluble plasma markers of
innate immune activation including soluble CD163 (sCD163)
[17,19], soluble CD14 (sCD14) [20], CXCL10 (also known as
interferon inducible protein 10 or IP-10) [8,17,21] and neopterin
[17,22] are elevated in HIV infection. However, these findings
were observed in cohorts consisting either predominantly or
exclusively of men, with only one study focusing on females [8]. In
HIV positive individuals, plasma CXCL10 correlates with the
proportion of CD16+ monocytes [21], which suggests a critical link
between monocytes and HIV related innate immune activation
and dysfunction.
Sex-associated differences in monocyte phenotype and plasma
markers indicate that innate immune changes should be consid-
ered separately in males and females. Females have a lower
proportion of non-classical (CD14+CD16++) monocytes than males
[14,23] and monocytes from the two sexes have different
expression patterns of the surface markers CD38, CD62L and
CD115 on monocyte subsets [14]. We have recently shown that,
when adjusted for age, healthy females have elevated plasma levels
of CXCL10 and sCD163 and decreased sCD14 compared with
males [14]. Adaptive immune activation in HIV infection also
differs significantly between the sexes. In vitro, T cells from healthy
men and women produced different levels of interferon-c (IFNc) in
response to stimulation with anti-CD3 and anti-CD28 antibodies
[24]. Adaptive immune activation in HIV infection differs
significantly between the sexes. Females have significantly higher
percentages of activated CD8+ T cells (CD38+/HLA-DR+) than
their male counterparts when matched for viral load [25],
highlighting the need to consider sex as a variable in immuno-
logical HIV studies. These findings indicate sex is a significant
variable in immunological responses, however sex differences in
monocyte function have not been investigated in the context of
HIV infection to date.
In this study, we sought to investigate the impact of both age
and HIV infection on biomarkers of innate immune activation
that are relevant to age-associated diseases in women and
determine whether changes in these markers are independent of
those of the adaptive immune system.
Methods
Participant recruitment
This study was approved by The Alfred Hospital Ethics
Committee, the Monash University Human Research Ethics
Committee, Rush University Medical Center (RUMC) Institu-
tional Review Board and the University of Illinois at Chicago
(UIC) Institutional Review Board.
HIV positive women aged between 20 and 63 years (n = 23)
were recruited through the UIC Medical Centre and RUMC
infectious diseases clinics (Chicago, IL, United States). A control
group of healthy, HIV negative women aged between 20 and
82 years (n = 53) was recruited from the community (Melbourne,
Australia n = 30 and Chicago, IL, United States n = 23). Women
who were pregnant, using anti-inflammatory drugs (including
steroids and non-steroidal anti-inflammatory drugs) on a daily
basis, had active malignancy, current infection or history of
trauma or vaccination in the three weeks prior to study date were
excluded from participation.
Written, informed consent was obtained from participants.
Participation involved collection of a single blood sample and
completion of a questionnaire requesting demographic, health and
lifestyle information, including a validated menopausal staging
algorithm [26].
Monocyte and lymphocyte phenotyping
Whole blood phenotyping was performed on EDTA-anticoag-
ulated blood within 2 hours of blood collection by a single
individual who worked in both the Australian and the US
laboratories. Standard operating procedures for every assay were
used in the two laboratories to ensure comparability of analyses.
Erythrocytes were lysed using 20x volume of BD FACS Lysing
Solution and subsequently washed twice (450x g for 5 minutes at
4uC) with FACS wash (calcium and magnesium free phosphate
buffered saline (PBS-) pH 7.4, 2 mM EDTA, supplemented with
1% heat inactivated fetal or newborn calf serum (FCS/CCS) or
0.5% bovine serum albumin (BSA)).
Cells were incubated in the dark on ice for 30 minutes with pre-
titrated volumes of monoclonal antibodies specific for CD14 (clone
M5E2, APC, BD Pharmingen), CD16 (3G8, PE-Cy7, BD
Pharmingen), CD3 (SK7, PerCP or PerCP-Cy5.5, BD), CD8
(SK1, PE or APC, BD), CD28 (CD28.2, APC or PE, BD
Pharmingen) and CD57 (NK-1, FITC, BD). Following staining,
cells were washed once with FACS wash (450x g for 5 minutes at
4uC), fixed with 1% formaldehyde and stored in the dark at 4uC
before analysis by flow cytometry.
Data were acquired on a FACSCalibur (BD Biosciences) in both
laboratories. Post-acquisition compensation was performed using
singly-stained cell samples; data were analyzed by the same person
for all samples using Gatelogic (Inivai Technologies) software.
Monocytes and lymphocytes were initially defined using an
appropriate forward scatter (FSC) and side scatter (SSC) gate.
CD14 and CD16 were used to gate monocytes into
CD14++CD162 (classical) and CD14varCD16+ (CD16+, non-
classical and intermediate) populations. CD3 and CD8 were used
to define CD8+ T cells and expression of CD57 and CD28 was
assessed relative to isotype controls. Values derived from plots with
fewer than 200 events were excluded from statistical analyses.
Analyses were performed using the proportion of CD16+
monocytes, as well as using data that further divides this subset
into non-classical (CD14+CD16++) and intermediate
(CD14++CD16+). However, as similar patterns were seen for both
non-classical and intermediate subsets, only results for CD16+
monocytes are presented here.
Measurement of soluble plasma markers
Plasma was separated from EDTA-anticoagulated blood and
stored at 280uC or 2140uC. Plasma samples were thawed once
and clarified by centrifugation (10,000x g for 10 minutes) prior to
measurement of soluble plasma markers. Commercial ELISA kits
used as per manufacturer’s instruction were utilized for the
measurement of sCD163 (IQ products, Cat. #IQP-383), neop-
terin (Screening EIA, Brahms, Cat. #99R.096), sCD14 (Quanti-
kine, R&D Systems, Cat. #DC140) and CXCL10 (Quantikine,
R&D Systems, Cat. #DIP100). Plasma samples were diluted 1:10
and heat inactivated (80uC for 10 minutes) prior to measurement
of lipopolysaccharide (LPS) levels using the chromogenic Limulus
Amebocyte Lysate kit (Lonza, Cat #50–647U). Measurement of
each marker was conducted on all samples at the same time, by the
same person on batched frozen samples.
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Statistical analyses
Comparisons between groups were made using the Students t
test or the Mann-Whitney U test as appropriate. Linear regression
models adjusted on HIV status for each parameter were fitted with
age as an outcome. Age was used as an outcome to allow for
identification of parameters independently associated with age
using multivariable modeling. In order to differentiate from the
multivariable analyses which includes several parameters in the
same model, these models are referred to as ‘‘bivariable analyses’’
hereafter. To assess whether the parameter levels compared to age
differed by HIV status, an interaction model whereby each group
had its own slope for the parameter value over age (stratified by
HIV status) was compared to a model of common slope (non-
stratified model) using the likelihood ratio test. The parameters
significant in the bivariable analyses were entered in a multivar-
iable linear regression model and through a process of stepwise
elimination only significant, independent correlates of age were
retained in the final model. Analyses were performed using Stata
Version 11. p values ,0.05 were considered significant.
Results
Participants
Characteristics of the 23 HIV positive women and the 53 HIV
negative women are shown in Table 1. Women with HIV
infection had a higher body-mass index. There was no significant
difference in history of recreational drug use (p = 0.724) or
menopausal status (p = 0.21) between the two groups.
HIV infection affects age-related changes to innate
immune activation markers
The effect of HIV infection on levels of innate immune
activation markers was determined using linear regression analysis.
Plasma levels of sCD163 (p = 0.001), sCD14 (p = 0.022), neopterin
(p = 0.029) and CXCL10 (p,0.001) were significantly elevated in
HIV positive compared with HIV negative women (Table 2). The
proportion of CD16+ monocytes was also higher in HIV positive
women (p = 0.009). No difference was observed in plasma LPS
levels.
Linear regression analyses were also performed to assess the
relationship between each innate immune parameter and age. The
stratified model was preferred for CXCL10 (p = 0.002, see Table 2
and Figure 1) while for all the other parameters, the non-stratified
model was shown to have a better fit. The slope of age-related
changes in CXCL10 is altered in HIV positive compared to HIV
negative women (Table 2). Soluble CD163 and the proportion of
CD16+ monocytes were shown to increase significantly with age
(p = 0.002 and p = 0.015 respectively, Table 2 and Figure 1). Age-
related increases in the proportion of CD57+ (p = 0.005) and
CD282 (p = 0.025) CD8+ T cells were demonstrated (data not
shown) and were reflected in changes in the CD282CD57+ CD8+
T cell subset (p = 0.034, Table 2), a well-characterised biomarker
of adaptive immune senescence.
The coefficient of the HIV term (shown in Table 2 under ‘‘HIV
status’’) gives a quantitative measure of the average age difference
between the two groups for those parameters fitted with a non-
stratified model. Although the slope (i.e. rate) of increase with age
is the same, the proportion of CD16+ monocytes in HIV positive
women of any given age is similar to those of seronegative women
10.6 years older (p = 0.009, Table 2). In the same way, HIV
positive women have plasma levels of sCD163 similar to those of
seronegative women 14.5 years older (p = 0.001). HIV positive
women have similar levels of CD282CD57+CD8+ T cells to
seronegative women aged 12.6 years older (Table 2).
Increases in plasma CXCL10 and sCD163 are independent
of changes in CD8+ T cells
We next determined whether the observed HIV-related innate
immune changes were independent of adaptive immune changes
and thus whether their inclusion into immunogerontological study
designs would provide additional information beyond that
indicated by T cell markers alone. Multivariable linear regression
modeling was performed on variables identified as significant in
bivariable analyses as associated with age when adjusted for HIV
status. The model with best fit analyzing only innate parameters
contained both sCD163 and CXCL10 (n = 75, Akaike information
criterion = 602.53, R2adj = 0.30; data not shown) demonstrating
that plasma sCD163 and CXCL10 concentrations independently
increase with age.
Table 1. Comparison of demographic variables between HIV positive and HIV negative groups.
HIV negative HIV positive p value
N 53 23 -
Median age (range) years 47 (20–82) 40 (20–63) 0.069
Median BMI (range) 23.8 (18.0–42.0) 30.6 (19.4–43.9) ,0.001
Viral load (copies/mL)
– Detectable viral load, .50 copies/mL (n (%)) - 8 (34.8) -
– Median viral load (range) a - 2256 (208–1.286106) -
CD4 count (cells/mL)
– Median CD4+ T cell count (range) - 433 (4–1433) -
– Median nadir CD4+ T cell count (range) - 123 (1–688) -
Hepatitis C virus (HCV) positive (n(%)) b - 6 (27.3) -
On cART (n (%)) - 20 (87.0) -
amedian and range shown of those patients with detectable viral load.
bHCV status unknown for 1 patient.
Abbreviations: SD, standard deviation; BMI, body mass index; cART, combination antiretroviral therapy.
Continuous variables were compared using the Students t test or the Mann-Whitney U test as appropriate. p values,0.05 were considered significant.
doi:10.1371/journal.pone.0055279.t001
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The optimum model constructed using all parameters (both
innate and adaptive) is shown in Table 3. The inclusion of
CXCL10 and sCD163 alongside total CD282 and CD28+CD572
CD8+ T cells indicates that the observed age-related increases in
CXCL10 and sCD163 are independent of changes in CD8+ T cell
subsets.
Discussion
Here we show that several markers of innate immune activation
and aging occur prematurely in HIV positive women. Of these,
the increased proportion of CD16+ monocytes and plasma
sCD163 appear approximately 10–14 years earlier in HIV
positive compared to HIV negative women. These novel findings
demonstrate an increase in the rate of age-related changes (as
shown here with CXCL10) in women during HIV infection.
We have recently shown that levels of innate immune activation
markers including sCD163 and CXCL10 in young, HIV positive
males are similar to those in elderly seronegative men [17]. Whilst
many studies demonstrate similarities between HIV and age-
related immune changes, few studies address the interaction
between these two factors. To do this, we analysed data with age as
a continuous variable and compared the trajectory in innate
immune changes between HIV positive and negative women. Our
finding of an age-related increase in sCD163 levels (a marker of
monocyte activation) and inflammatory CD16+ monocytes in both
HIV positive and HIV negative women is consistent with previous
findings in men/mixed cohorts [14,15,16,17]. We and others have
previously shown HIV-related increases in both sCD163 levels and
CD16+ monocytes [17,18,19]. In the present study we quantified
this difference and found HIV positive women have levels of
sCD163 and CD16+ monocytes equivalent to those in seroneg-
ative women aged on average 14.47 or 10.55 years older,
respectively. Such premature changes in the inflammatory milieu
may contribute to the early development of age-related diseases in
HIV positive individuals.
In contrast, age-related increases in CXCL10 concentrations
were found to occur at an accelerated rate in HIV positive women,
suggesting age and HIV may act synergistically to increase
CXCL10 levels. CXCL10 is an inflammatory chemokine which
has been associated with risk of coronary heart disease [27] and
myocardial infarct size [28] in the general population. Addition-
ally, a direct role for CXCL10 in the development of atheroscle-
rotic plaques in mice has been demonstrated [29]. Thus, the
finding that HIV acts synergistically with age to increase CXCL10
levels may have implications for the development of cardiovascular
disease in HIV positive individuals.
Multivariable modeling indicated that age-related changes to
sCD163 and CXCL10 were independent, and furthermore that
these innate immune changes were independent of previously
demonstrated changes in the proportion of CD28+CD572 CD8+
T cells indicative of adaptive immune senescence. This novel
finding demonstrates that in aging and HIV infection, adaptive
and innate changes are independent of one another. This finding
suggests that parallel but independent mechanism may be driving
innate and adaptive immune changes during HIV infection and
Table 2. Linear regression analyses to examine the relationship of each parameter with age and the impact of HIV infection on this
relationship.
Parameter HIV status
Parameter n Coefficient 95% CI
p value
(parameter) a Coefficient 95% CI
p value
(HIV status) b
Monocyte subsets
- % of monocytes that are
CD16+
76 0.59 0.12, 1.06 0.015 210.55 218.38, 22.73 0.009
Plasma markers
- sCD163 c 75 0.01 0.01, 0.02 0.002 214.47 222.71, 26.23 0.001
- sCD14 65 0.00 20.00, 0.01 0.373 211.13 220.58, 21.68 0.022
- LPS 71 24.66 218.63, 9.31 0.508 26.60 214.66, 1.46 0.107
- CXCL10 d 76 0.17 0.09, 0.25 ,0.001 2.20 211.23, 15.64 0.745
- Difference in slopes e 20.15 20.24, 20.06 0.002 - - -
- HIV positive 23 0.02 20.00, 0.05 0.056 - - -
- HIV negative 53 0.17 0.08, 0.26 ,0.001 - - -
- Neopterin 73 1.05 21.27, 3.38 0.369 29.60 218.21, 20.99 0.029
Lymphocyte subset
- CD282CD57+ 75 0.26 0.02, 0.50 0.034 212.62 221.57, 23.66 0.006
Bivariable regression analyses shown are performed on combined HIV negative and HIV positive participants with age as an outcome, adjusting for HIV status. An
interaction model whereby each group had its own slope for the parameter value over age (stratified by HIV status) was compared to a model of common slope (non-
stratified model) using the likelihood ratio test and the model of best fit is shown.
ap value that the slope of the line is non-zero.
bp value that the intercept of the line is different for HIV positive and HIV negative.
cOne outlier was excluded from this analysis.
dThe model with the best fit for CXCL10 was stratified by HIV status and as such the slopes for HIV negative and HIV positive groups are different and are shown
separately.
eThis term describes the difference in slope between the HIV positive and HIV negative models. The p value indicates that the slopes are significantly different.
Note. p values ,0.05 were considered statistically significant.
Abbreviations: CI, confidence interval; LPS, lipopolysaccharide.
doi:10.1371/journal.pone.0055279.t002
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justifies the inclusion of innate immune parameters, including
CXCL10 and sCD163, alongside adaptive immune parameters in
studies of immune senescence.
In addition to increases in sCD163 and CXCL10 levels, we also
found elevated plasma levels of neopterin (a GTP metabolite
produced by macrophages following IFN-c stimulation [30]), in
HIV positive women, similar to our previous observation in males
[17]. Unlike our findings in males, we found significantly elevated
levels of sCD14 in HIV positive women which has been linked to
HIV-related mortality [31]. Increased sCD14 levels have been
previously shown in some [20,32] but not all [19] studies in HIV
positive adults and in a pediatric HIV cohort [33]. sCD14 is
required for LPS stimulation of TLR4 and is shed from the surface
of monocytes following activation [34]. In HIV positive individ-
uals, sCD14 has been associated with elevated LPS levels related
to microbial translocation across the gut mucosa [20]. However,
LPS levels within the HIV positive group were not elevated in this
study. Plasma levels of LPS and sCD14 have been shown to be
discrepant in other studies, suggesting the relationship between
LPS and sCD14 may be complex and context-dependent [35,36]
or that LPS may be a less robust biomarker. Taken together, these
results suggest that whilst HIV may have a similar effect in males
and females with respect to augmenting plasma levels of CXCL10,
neopterin and sCD163, HIV positive females may not exhibit
significant changes in factors such as LPS. This, combined with
previously reported significant differences between males and
females in CD4 T cell counts at AIDS onset [37], indicate sex-
related differences exist in certain aspects of HIV-related immune
Figure 1. Bivariable linear regression of plasma CXCL10 and the proportion of CD16+ monocytes. A comparison of the slopes between
HIV negative (open circles, dashed line; n = 53) and HIV positive (closed circles, solid line; n = 23) groups and the relationship with age for (a) % CD16+
monocytes determined by whole-blood flow cytometry, (b) plasma CXCL10 and (c) sCD163 levels determined by ELISA.
doi:10.1371/journal.pone.0055279.g001
Table 3. Multivariable linear regression model.
Parameter Coefficient 95% CI p value
CXCL10 a 0.18 0.10, 0.25 ,0.001
– Difference in
slopes b
20.18 20.26, 20.10 ,0.001
– HIV positive 0.00 20.02, 0.03 0.771
– HIV negative 0.18 0.08, 0.25 ,0.001
sCD163 0.01 0.00, 0.02 0.033
CD28+CD572
CD8+ T cells
21.12 21.74, 20.49 0.001
Total CD282
CD8+ T cells
21.01 21.65, 20.36 0.003
HIV status 0.04 212.36, 12.45 0.995
Constant 122.33 64.60, 180.28 ,0.001
Combinations of parameters identified as significant in bivariable modeling
were included in multivariable linear regression models, with stepwise
elimination of variables that were not statistically significant in the model.
n = 74, Akaike information criterion (AIC) = 585.15, R2adj=0.40.
aThe model with the best fit for CXCL10 was stratified by HIV status and as such
the slopes for HIV positive and HIV negative groups are different and are shown
separately.
bThis term describes the difference in slope between the HIV positive and HIV
negative models. The p value indicates that the slopes are significantly different.
Note. p values ,0.05 were considered statistically significant.
Abbreviations: CI, confidence interval; LPS, lipopolysaccharide.
doi:10.1371/journal.pone.0055279.t003
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dysfunction. It remains to be determined whether these sex-related
differences translate to differences in morbidity risk.
Drivers of immune aging remain to be fully defined. We have
previously shown that although cART is associated with an
improvement in innate immune dysfunction, age-related changes
to innate immune markers persist despite virological suppression
[17], suggesting the involvement of other factors in addition to
HIV viremia. Microbial translocation and resultant endotoxemia,
which persist despite viral suppression, have been postulated to
contribute to persistent immune activation and senescence,
however numerous other factors including reactivation of latent
viruses may also be involved (see [38,39] for review).
There are several limitations to this study. Given the relatively
small number of participants, there was insufficient power to
perform separate analyses for virologically suppressed and viremic
individuals or to control for unmatched demographic variables
between the two groups. Levels of the innate immune parameters
measured here are known to be elevated in viremic as compared to
virologically suppressed HIV positive males and the relationship
between viral load, CD4 T cell count and innate immune
activation markers in HIV positive women requires investigation
in larger cohorts studies. Significant differences existed between
the HIV positive and HIV negative groups with regards to BMI
and co-infection with hepatitis C virus (HCV; seen in 27.3% of
HIV positive participants). CXCL10 levels [8] and the level of
CD8+ T cell activation [40] in HIV/HCV co-infected patients
have been shown to be higher than in patients individually infected
with either virus. Although menopausal status was not significantly
different between our HIV positive and HIV negative cohorts, we
cannot exclude the possibility that hormonal and menopausal
variations may influence the parameters measured here. Signifi-
cantly larger cohort studies would be required to investigate these
more complex associations.
We have shown an increase in the rate of age-related change in
CXCL10 with HIV infection. As the increases in CXCL10 and
sCD163 in HIV positive women were independent of well-
characterized HIV-associated CD8+ T cell senescence, this study
highlights the importance of including innate immune markers in
future investigations. The premature development of innate
immune changes in the setting of HIV infection may underlie
the acceleration and/or heightened risk of diseases associated with
aging in this patient population.
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An NK Cell Population Lacking FcRg Is Expanded in
Chronically Infected HIV Patients
Jingling Zhou,* Fathiah S. Amran,† Marit Kramski,‡ Tom A. Angelovich,*,x
Julian Elliott,{ Anna C. Hearps,*,{ Patricia Price,†,1 and Anthony Jaworowski*,{,‖
We previously demonstrated that NK cells from HIV-infected individuals have elevated expression of activation markers, spon-
taneously degranulate ex vivo, and decrease expression of a signal-transducing protein for NK-activating receptors, FcRg.
Importantly, these changes were maintained in virologically suppressed (VS) individuals receiving combination antiretroviral
therapy (cART). In this study, we show that loss of FcRg is caused by the expansion of a novel subset of FcRg2CD56dim NK cells
with an altered activation receptor repertoire and biological properties. In a cross-sectional study, FcRg2 NK cells as a proportion
of total CD56dim NK cells increased in cART-naive viremic HIV-infected individuals (median [interquartile range] = 25.9 [12.6–
56.1] compared with 3.80 [1.15–11.5] for HIV2 controls, p < 0.0001) and in VS HIV-infected individuals (22.7 [13.1–56.2]
compared with 3.80 [1.15–11.5], p = 0.0004), with no difference between cART-naive and VS patients (p = 0.93). FcRg2 NK cells
expressed no NKp30 or NKp46. They showed greater Ab-dependent cellular cytotoxicity activity against rituximab-opsonized Raji
cells and in a whole-blood assay measuring NK responses to overlapping HIV peptides, despite having reduced CD16 expression
compared with conventional NK cells. Their prevalence correlated with CMV Ab titers in HIV2 subjects but not in HIV+
individuals, and with the inflammatory marker CXCL10 in both groups. The expansion of a subset of NK cells that lacks
NKp30 and NKp46 to ∼90% of CD56dim NK cells in some VS HIV+ individuals may influence NK-mediated immunosurveillance
in patients receiving cART. The Journal of Immunology, 2015, 194: 000–000.
C
ombination antiretroviral therapy (cART) reduces HIV
viremia in peripheral blood to levels undetectable by
standard clinical assays (,20 copies HIV RNA/ml) and
reduces the incidence of AIDS and associated mortality. However
cART does not eliminate HIV infection, and treated individuals
experience elevated rates of non-AIDS comorbidities including
non-AIDS cancers such as Hodgkin’s lymphoma and solid tumors
(1), demonstrating that cART does not fully restore functional
immunity. Understanding why immune defects persist in HIV+
individuals receiving cART will facilitate adjunctive therapies to
improve long-term health outcomes in HIV-infected individuals.
We and others have shown activation of the innate immune
system in patients who achieve virologic suppression on cART,
exemplified by elevation of phenotypic and plasma markers of
activation related to innate immune cells, notably monocytes/
macrophages (2–8). “Elite controllers” (HIV+ individuals who
control HIV viremia without ART) also display innate immune
activation (9), suggesting it may be independent of HIV viremia
and cART. Instead, the causes may include residual HIV repli-
cation in tissues (10, 11), reactivation of latent viruses such as
CMV (12, 13), and/or the presence of circulating bacterial prod-
ucts due to loss of gut integrity (4).
NK cells are innate lymphoid cells (14) that kill transformed and
virus-infected cells via perforin/granzyme and Fas/FasL-dependent
mechanisms. Human NK cells are divided into subsets defined by
expression of CD56 (NCAM-1), an adhesion molecule that partic-
ipates in homotypic interactions, and CD16 (FcgRIIIa), an acti-
vating receptor for IgG-promoting Ab-dependent cellular cytotoxicity
(ADCC). CD56brightCD162 NK cells are less mature and constitute
a minor subset in circulation but more prominent in secondary
lymphoid tissues (15). They have relatively poor cytotoxic activity
but are robust producers of inflammatory cytokines and chemokines
in response to cytokine stimulation. CD56dimCD16+ NK cells are
more mature, secrete inflammatory cytokines such as IFN-g in
response to cytotoxic targets, and are more abundant in circula-
tion. They exhibit cytotoxic and CD16-dependent ADCC activity.
In chronic viral infections, such as HIV, a senescent population of
CD562 NK cells accumulates in circulation (16, 17). These cells
proliferate poorly, have limited cytotoxic ability and proin-
flammatory cytokine secretion, but retain the ability to secrete
chemokines such as CCL4 (18, 19).
NK activation receptors signal via small adaptor proteins
containing ITAM motifs, namely TCRz, FcRg, and DAP12 (20).
ITAM motifs on these proteins are phosphorylated following
engagement of the activation receptors and act as docking sites
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for spleen tyrosine kinase and ZAP70, which in turn activate
downstream signaling pathways such as those required for
cytokine production and degranulation (21). The ITAM-
containing signaling proteins also act as chaperones and are
essential for surface expression of their cognate activating
receptors.
The role of NK cells as antiviral effectors has prompted studies
into how their numbers, subset distribution, phenotype, and activity
are altered in HIV disease. NK cell numbers increase during acute
HIV infection largely due to expansion of the CD56dim subset (22),
whereas the numbers of CD56bright NK cells appear to be rela-
tively unaffected (16). Viremic HIV disease is characterized by
expansion of CD562 NK cells, which disappear in virologically
suppressed (VS) individuals receiving cART (23). HIV infection is
also characterized by the loss of NKG2A+ NK cells and increases
in NKG2C+ NK cells (24). Both NKG2A and NKG2C form
heterodimers with CD94 and recognize HLA-E; however, the
NKG2A heterodimer is an inhibitory receptor whereas the latter
promotes activation. Although changes in the proportion of
NKG2A and NKG2C+ NK cells are independent of viral load (24),
they may be driven by CMV and were reversed following viro-
logic suppression on cART (25). NK natural cytotoxic activity
against the heterologous target cell K562 is decreased in viremic
HIV infection but was restored in one study following virologic
suppression within 24 wk of initiating cART (26).
Whereas HIV viremia is usually well managed by cART, patients
retain innate immune activation and inflammation that may in-
fluence NK activity and function. We have shown that their NK
cells express elevated phenotypic markers of cell activation,
spontaneously degranulate ex vivo, and have altered signal
transduction, which persist following virological suppression (27,
28). In particular, HIV infection was associated with a significant
decrease in expression of FcRg manifest at both the protein and
mRNA levels. In the present study, we show that loss of FcRg in
HIV-infected individuals is due to expansion of an FcRg2
CD56dim NK subset that persists in VS individuals and represents
up to 90% of the total CD56dim population. We compare the
phenotype of FcRg2 and conventional NK cells and investigate
the role of CMV and inflammation in their expansion in HIV+
individuals.
Materials and Methods
Study group
HIV-seropositive individuals were recruited and blood was taken with
informed consent by research staff in the Department of Infectious Diseases,
Alfred Hospital (Melbourne, VIC, Australia). Ethical approval was obtained
from the Alfred Hospital Research and Ethics Committee. Study subjects
included 10 persons not currently receiving cART (mean [SD] viral load =
72,351 [47,565], range = 17,500–153,200 copies/ml), 33 persons receiving
cART at the time of sampling (1 with a viral load of 150 copies/ml and the
remainder with a viral load of #50 copies/ml). As controls, 23 HIV-
seronegative control subjects were recruited from the community and
blood was taken by an experienced phlebotomist.
Antibodies
CD3 PerCP-Cy5.5 (clone UCHT1), CD16 PE-Cy7 (clone 3G8), CD336 PE
(clone p44-8.1), CD107a allophycocyanin-H7 (clone H4A3), TNF PE
(clone Mab11), and IFN-g Alexa Fluor 488 (clone B27) were from BD
Biosciences; CD3 Alexa Fluor 700 (clone UCHT1), CD3 BV510 (clone
OKT3), CD56 Alexa Fluor 700 (clone HCD 56), CD314 PE (clone 1D11),
CD57 Pacific Blue (clone HCD57), CD335 PerCP-Cy5.5 (clone 9E2), and
CD337 Alexa Fluor 647 (clone P30-15) were from BioLegend; CD56
allophycocyanin (clone N901/HLDA6), CD159a allophycocyanin (clone
Z199), and TCRz PE (clone 2H2D9) were from Beckman Coulter;
CD159c PerCP (clone 134591) was from R&D Systems; and FITC-
conjugated rabbit polyclonal Ab to FcRg (Milli-Mark, anti-FcεR1 Ab, g
subunit–FITC, catalog no. FCABS400F) was from Millipore.
NK and monocyte phenotyping
Cells and plasma were prepared from whole blood collected into EDTA
anticoagulant tubes and PBMC were prepared by Ficoll density gradient
centrifugation. Cells (1 3 106) were stained with appropriate cell surface
markers (CD3, CD56, and CD16) for 30 min on ice, permeabilized (Perm/
Wash buffer 1, BD Biosciences), and stained for FcRg or TCRz for 30 min
on ice, then washed (Perm/Wash buffer 1, BD Biosciences) and fixed.
Phenotyping of NK cell subsets was performed by staining with desired
cell surface markers or relevant isotype controls, plus the lineage markers
detailed above, before intracellular staining.
CD107a mobilization and intracellular cytokine production
CD107a mobilization in response to CD16 cross-linking was measured as
described previously (21). Briefly, CD16 was cross-linked by the addition
of 5 ml (5.5 mg) anti-CD16 (clone 3G8, donated by Mark Hogarth, Burnet
Institute, Melbourne, VIC, Australia) to 100 ml whole blood and incuba-
tion on ice for 10 min. Cells were washed once with ice-cold PBS,
incubated with 8 ml goat anti-mouse F(ab9)2 fragment (55487, ICN
Pharmaceuticals/Cappel, Costa Mesa, CA) for a further 5 min, and then
transferred to a 37˚C water bath for the remainder of the incubation. To
measure TNF production, 5 3 105 PBMC were incubated in 1 ml RF10
(RPMI 1640 containing 10% newborn calf serum [HyClone, Cosmic Calf
serum], 100 U/ml pencillin/streptomycin [Life Technologies], and 2 mM
L-glutamine) with an equal number of Raji cells either unopsonized or
opsonized with 10 ng/ml rituximab. One hundred microliters RF10 con-
taining anti–CD107a-allophycocyanin-Cy7, 20 mg/ml brefeldin A, and 10
mM monensin was added and the cells were incubated for 4 h at 37˚C,
stained with anti–CD3-PerCP-Cy5.5, anti–CD16-PE-Cy7, and anti–CD56-
allophycocyanin (30 min on ice) and then permeabilized (Perm/Wash
buffer 1, BD Biosciences). After 10 min on ice, cells were blocked for
a further 10 min using 10 ml rabbit serum plus 10 ml mouse serum and then
stained with anti–TNF-PE and rabbit anti–FcRg-FITC for 30 min, washed,
and fixed. ADCC activity against peptide-pulsed target cells was also
measured in a whole-blood assay (29). Briefly, 150 ml fresh whole blood
was pulsed with 1 mg/ml of an envelope peptide pool (15 aa each with 11
aa overlap: subtype B, strain MN, National Institutes of Health AIDS
Reagent Program) and 25% serum from a single HIV+ donor showing high
ADCC activity, in the presence of anti–CD107a-allophycocyain-Cy7 (BD
Biosciences), 10 mg/ml brefeldin A (Sigma-Aldrich), plus 5 mM monensin
(GolgiStop, BD Biosciences). After 5 h, cells were stained with anti–CD3-
PerCP and anti–CD56-PE-Cy7 and then permeabilized (FACS Perm II, BD
Biosciences) and stained for FcRg.
Measurement of plasma inflammatory markers
Plasma concentrations of soluble CD163 (Macro 163, Trillium Diag-
nostics), CXCL10 (CXCL10/IP-10 Quantikine ELISA, R&D Systems), and
IFN-a (human IFN-a [pan specific] ELISAPRO, Mabtech) were measured
using commercial ELISA kits according to manufacturers’ instructions.
High-sensitivity C-reactive protein (hsCRP) was measured using the
Abbott Architect ci16200 (Abbott Laboratories) by the Alfred Pathology
Service, Alfred Hospital (Melbourne, VIC, Australia).
CMV DNA, Ab, and total Ig ELISAs
Selected plasma samples were screened for CMV DNA using the COBAS
AmpliPrep/COBAS TaqMan CMV test by the Alfred Pathology Service,
Alfred Hospital (Melbourne, VIC, Australia). IgG reactive with CMV was
quantified using CMV lysate, CMV glycoprotein B (CMVgB), and CMV
immediate early Ag-1 (CMVIE-1) Ags. CMV lysate was prepared by
sonication of human foreskin fibroblasts (HFF) infected with CMV strain
AD169. Uninfected HFF were prepared and extracts were analyzed in
parallel. Replicate ELISA plates were coated with CMVgB (produced in
hamster ovary cells, Chiron, 2800-800; 50 ng/ml) and CMVIE-1 (produced
in Escherichia.coli, Miltenyi Biotec, 130-092-137; 2500 ng/ml). Plasma
samples were diluted from 1:200. Binding was detected using goat anti-
human IgG–conjugated horse radish peroxidase, followed by tetrame-
thylbenzidine substrate (Sigma-Aldrich). Reactions were stopped with 1 M
H2SO4 and measured at 450 nm. Four-parameter logistic curves were
generated from titrations of a plasma sample assigned a value of 1000
arbitrary units IgG reactive with each Ag using SoftMax Pro version 5.4
software. The standard was run on each plate and unit values were derived
for all samples. The standard curve of the positive plate was used to
generate units of Ab on plates coated with uninfected HFF. These were
subtracted from those generated using CMV-coated plates. Total IgG was
quantified using plates coated with polyvalent goat anti-human IgG (2.5
mg/ml; Invitrogen) diluted 1:500 in bicarbonate buffer and blocked with
5% BSA in PBS for 60 min. Plasma samples were diluted from 1:100,000
2 NK CELLS IN HIV DISEASE
in 2% BSA/PBS and applied for 120 min. Binding was detected using goat
anti-human IgG–conjugated HRP (Sigma-Aldrich) followed by tetrame-
thylbenzidine substrate as described above.
Statistical analyses
Comparisons between HIV2 and HIV+ groups were made using a non-
parametric Mann–Whitney U test. Differences in properties of FcRg2
and conventional NK cells within HIV+ patients and controls were
assessed using a paired Wilcoxon signed rank test. To measure the
association between inflammatory biomarkers or CMV Abs and the
proportion of FcRg2 NK cells, data were log transformed (where re-
quired) to achieve a normal distribution (D’Agostino–Pearson omnibus
normality test), and Pearson correlation coefficients were determined
from the transformed data. Lines of best fit were computed sepa-
rately using data from HIV2 and HIV+ individuals and their slopes
were compared. All analyses were performed using GraphPad Prism,
version 6.0.
Results
An FcRg2CD56dim NK cell population is present in HIV+
individuals
We have previously reported that FcRg expression in NK cells
from HIV+ individuals is decreased irrespective of CD4 T cell
count or HIV viral load (21, 27, 28). To identify the reason for
this decrease, we examined expression of FcRg and the func-
tionally related signaling molecule TCRz in NK cell subsets.
In healthy control subjects, CD56dim and CD56bright NK cells
expressed both FcRg and TCRz (Fig. 1A, red and gray contour
plots, respectively). The FcRg2CD56dim cells were further char-
acterized as NK cells because they also lacked expression of
monocyte (CD14), T cell (CD3), and B cell (CD19) markers
(Supplemental Fig. 1). The level of FcRg expression coincided
with negative staining using control FITC-conjugated rabbit IgG
(Supplemental Fig. 1) and with the level of staining in CD3+
T lymphocytes, most of which do not express FcRg (not shown).
The expression of FcRg and TCRz was correlated in both NK cell
subsets, but it was lower in the CD56bright NK cells. We also
examined FcRg expression in monocytes and showed that ex-
pression was elevated in both subsets defined by CD16 (non-
classical and intermediate) compared with classical monocytes,
whereas all three subsets had comparable expression of TCRz
(Supplemental Fig. 2). In HIV+ subjects, CD56dim NK cells
showed two populations that differed in either expressing or not
expressing FcRg while having equivalent levels of TCRz ex-
pression (Fig. 1B, red contour plot). In contrast, FcRg expression
was normal in the CD56bright population (Fig. 1B, gray contour
plot). These data show that HIV infection was associated with the
selective loss of FcRg expression in CD56dim NK cells. We next
examined the prevalence of FcRg2CD56dim NK cells (gated as
shown in Fig. 1C and hereafter called FcRg2 NK cells) in a cross-
sectional study comprising 23 HIV2, 10 viremic HIV+, and 33 VS
HIV+ individuals (Table I). The FcRg2 population was greatly
expanded in viremic HIV+ individuals compared with HIV-
uninfected individuals (median [interquartile range, IQR] = 25.9
[12.6–56.1] compared with 3.80 [1.15–11.5], p = 0.0009) and
remained unchanged following virologic suppression (median
[IQR] = 22.7 [13.1–56.2], p , 0.0001 compared with HIV-
uninfected and p = 0.927 compared with HIV+ viremic) (Fig.
1D). We examined FcRg expression in all three monocyte subsets
in a subset of the study participants and found no differences
(Supplemental Fig. 3A). We also determined that TCRz expres-
sion was unchanged by HIV infection in monocytes (Supplemental
Fig. 3B) and in CD56bright and CD56dim NK cells (Supplemental
Fig. 3C). Considered together, these data support the conclusion
that HIV infection selectively affects FcRg expression in NK
cells.
Prevalence of FcRg2 (CD56dim) NK cells is associated with Ab
levels to CMV Ags and plasma markers of inflammation
The proportion of FcRg2 NK cells in VS HIV+ individuals did not
correlate with their duration of ART (Pearson’s r = 20.099 p =
0.589). Neither was there any correlation with current CD4 (r =
20.134, p = 0.415) or nadir CD4 (r = 20.017, p = 0.916) counts.
FcRg-deficient NK cells are present in low abundance in otherwise
healthy blood donors who are seropositive for CMV (30). CMV se-
ropositivity is .90% among HIV patients and may be used as
a marker of their historical burden of CMV. In the present study, we
measured Ab responses by ELISA using a lysate of CMV-infected
fibroblasts (HFF), CMVgB, and the latency-associated CMVIE-1.
HIV+ individuals had elevated levels of Ab to CMV lysate and gB,
but not to IE-1 (Fig. 2A). Because CMV reactivation can increase
with age, and the median age of VS HIV+ individuals in our cohort
was older than viremic HIV+ or uninfected individuals (Table I), we
analyzed CMV Abs in a subset of participants aged #45 y to de-
termine whether the above-mentioned effect was influenced by age.
This analysis confirmed increased levels of Abs to both CMV HFF
lysate (p = 0.003) and gB (p , 0.001) in VS HIV+ individuals as
compared with controls of a similar age (Table II). Although there
was a trend toward higher levels of total IgG in plasma from HIV+
individuals (0.077 and 0.059 for viremic and VS, respectively), these
differences were not significant, suggesting that the increase in Abs to
CMV is not solely attributed to hypergammaglobulinemia. The per-
centage of FcRg2 NK cells correlated strongly with the levels of Ab
to HFF (Pearson’s r = 0.676, p , 0.0001) and gB (r = 0.597, p ,
0.0001) and moderately with IE-1 (r = 0.343, p = 0.0091) (Fig. 2B).
However, when subjects were stratified according to their HIV status,
there was a significant correlation between total CMV lysate Ab and
FcRg2 NK cells in controls (r = 0.759, p = 0.0002) but not in HIV+
subjects (r = 0.024, p = 0.90). We also performed linear regression
analysis on the relationship between FcRg2 NK cells and HFF Ab
levels and adjusted this model for age. This analysis confirmed sig-
nificantly higher levels of CMVAbs in viremic and VS HIV+ indi-
viduals (p = 0.002 and 0.015, respectively), independent of age.
We next measured plasma markers of inflammation (CXCL10,
soluble CD163, hsCRP, soluble TNFR), and IFN-a. In this small
cross-sectional group soluble CD163 and CXCL10 were signifi-
cantly elevated in viremic HIV+ individuals and remained elevated
in VS patients (2), whereas hsCRP, soluble TNFR, and IFN-a
were not significantly different (Fig. 3A–E). Only CXCL10 cor-
related with the prevalence of FcRg2 NK cells (Pearson’s r =
0.550, p , 0.0001; Fig. 3F). Similarly, there was a strong corre-
lation between CXCL10 and FcRg2 NK cells in HIV2 individuals
(r = 0.579, p = 0.015) but the correlation in HIV+ individuals did
not reach significance (r = 0.313, p = 0.060). It is of interest that,
although elevated in HIV+ individuals, there was no relationship
between FcRg2 NK cells and soluble CD163.
FcRg2 NK cells in HIV+ individuals exhibit enhanced ADCC
activity
FcRg expression is associated with CD16-dependent ADCC ac-
tivity (21); therefore, we compared ADCC activity in FcRg2 and
conventional NK cells. PBMC from VS HIV+ individuals were
exposed to rituximab-opsonized or nonopsonized Raji cells and
degranulation was assessed using cell surface CD107a. FcRg2
NK cells showed greater degranulation in response to both non-
opsonized and rituximab-opsonized Raji cells (Fig. 4A). To con-
firm these findings, NK degranulation and IFN-g production in
response to a HIV peptide pool were measured in whole blood
from VS HIV+ individuals (29). The assay was modified to gate on
FcRg2 and conventional NK cells. FcRg2 NK cells degranulated
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and produced more IFN-g in response to overlapping HIV peptide
pools than did conventional NK cells (Fig. 4B). Overall, FcRg2
NK cells present in HIV+ individuals have higher ADCC activity
than do conventional NK cells.
CD38 expression is lower and spontaneous NK cell
degranulation is similar in FcRg2 NK cells compared with
conventional NK cells
We have shown that NK cells from VS HIV+ individuals have
higher expression of the lymphocyte activation marker CD38 and
spontaneously degranulate ex vivo (28). We compared these
parameters in both FcRg2 and conventional NK cells to determine
whether our previous observations could be explained by the high
prevalence of FcRg2 NK cells in HIV patients. Using an ex vivo
whole-blood assay we confirmed NK cells from VS HIV patients
degranulate at a higher rate than do those from HIV2 control
subjects, but the rate of spontaneous degranulation did not differ
between FcRg2 and conventional NK cells (Fig. 4C). FcRg2 NK
cells expressed low levels of HLA-DR, similar to conventional
NK cells, but expressed less CD38 (Fig. 4D). These data suggest
FIGURE 1. NK cells in PBMC
from a representative HIV2 donor
(A) and a VS HIV+ donor (B) were
analyzed for expression of FcRg and
TCRz. Lymphocytes were gated on
forward versus side scatter plots (top
left) and NK cell subsets were gated
on CD56 versus CD3 dot plots (top
right). Coexpression of FcRg and
TCRz were measured in CD56bright
NK cells (gray contour plots) and
in CD56dim NK cells (red contour
plots) (bottom panels). (C) Gating
strategy for determining the propor-
tion of FcRg2CD56dim NK cells
is shown for a VS HIV+ donor
with very few conventional FcRg+
NK cells. (D) FcRg expression was
assessed in CD56dim NK cells [gated
as indicated in (C)] and the pro-
portions of FcRg2CD56dim NK cells
were measured in 23 HIV2 controls,
10 viremic HIV+, and 33 VS HIV+
individuals. Groups were compared
using the Mann–Whitney U test.
***p , 0.001, ****p , 0.0001. ns,
p = 0.93.
Table I. Patient characteristics
HIV Uninfected
HIV Infected
Viremic VS
n 23 10 33
Age (y) 33.5 (30.8–49.8) 33.0 (26.8–38.0) 46.0 (34.5–54.0)
CD4 T cells/ml N.A. 400 (309–457) 493 (378–802)
HIV RNA copies/ml plasma N.A. 52,100 (37,378–109,510) ,50
Nadir CD4 N.A. 309 (281–374) 244 (191–331)
Time on cART (y) N.A. N.A. 6.65 (2.34–16.0)
All study participants were male. VS HIV+ patients were older than viremic HIV+ patients (p = 0.009). Values provided are
median (IQR).
N.A., not applicable.
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that increased NK cell activation in VS HIV+ individuals, mea-
sured phenotypically or via degranulation ex vivo, is not due to an
increased proportion of FcRg2 NK cells in these individuals, as it
is apparent in both this subset and in conventional NK cells.
Expression of NKG2 receptors on FcRg2 and conventional NK
cells
Because chronic HIV infection alters the NKG2A/NKG2C ratio on
NK cells in patients who are CMV seropositive (25), we assessed
NKG2A and NKG2C on FcRg2 and conventional NK cells.
FcRg2 NK cells had lower NKG2A expression in most individ-
uals (Fig. 5A), whereas NKG2C expression was equivalent in both
populations (Fig. 5B).
Phenotypic characterization of FcRg2 NK cells
Both FcRg and TCRz have been shown in transfected cell lines
and using knockout mice to act as molecular chaperones for the
receptors for which they transduce signals (31–35), but their role
as chaperones in primary human NK cells is less clear. We
assessed NK-activating receptors, as well as maturation and se-
nescence markers, on FcRg2 and conventional NK cells from VS
HIV+ patients. FcRg2 NK cells did not express NKp30 or NKp46
(Fig. 5C), consistent with a role for FcRg as a chaperone for these
NK-activating receptors.
FcRg2 NK cells expressed CD16, but with lower mean fluo-
rescence intensity (MFI) (Fig. 5D), whereas CD56 expression was
comparable (Fig. 5E), which does not fit with the normal differ-
entiation of CD56bright to CD56dim cells in which CD16 expres-
sion increases and CD56 expression decreases. CD62L, expressed
on a population of less mature, polyfunctional CD56dim NK cells
(36), was expressed on a minority of NK cells, but CD62L+FcRg2
NK cells had a lower MFI than did CD62L+ conventional NK cells
(Fig. 5F). More FcRg2 NK cells expressed the maturation marker
CD57 (37) but fewer expressed the TNFR family member
CD27 (Fig. 5G and 5H, respectively). It was difficult to assess
the phenotype of FcRg2 NK cells in HIV2 control subjects,
as the populations were small, but no differences were identified
(Supplemental Fig. 4).
Discussion
In this study, we associate HIV infection with expansion of an
FcRg2 NK cell population that lacks expression of the activating
receptors NKp30 and NKp46. FcRg2 NK cells represent up to
90% of the total CD56dim NK cell pool in viremic HIV+ indi-
viduals and patients on cART for.6.5 y. Expansion of the FcRg2
NK cell population did not correlate with CD4 counts, nadir CD4
counts, plasma HIV RNA, or time on cART, as observed when we
measured FcRg expression in the total NK cell population (28).
Hence, our data suggest that FcRg2 NK cell expansion is not due
to HIV infection per se, nor is it a direct consequence of the im-
munological damage caused by HIV before cART. Our finding
FIGURE 2. (A) Levels of Abs to whole-cell lysate of CMV-infected HFF, envelope gB, and IE-1 were measured by ELISA in plasma from HIV2 control
subjects (HIV2), viremic HIV+ individuals, and VS HIV+ individuals. Histograms represent median (IQR), and differences between groups were assessed using
a Mann–Whitney U test. *p , 0.05, **p , 0.01,***p = 0.001, ****p , 0.0001. (B) The relationship between Ab levels to CMVAgs measured in plasma and
the proportion of FcRg2CD56dim NK cells in each subject was determined using Pearson’s correlation (N, HIV2 subjects; s, viremic HIV+; d, VS HIV+).
Table II. CMVAb titers in participants aged #45 y
Controls Viremic HIV+ VS HIV+
n 14 9 14
Age (y), median (range) 31.0 (27–45) 30.0 (24–38) 35.5 (29–46)
CMV HFF Ab titer
Median (IQR) 844 (50–3,455) 5,411 (4,115–41,804) 10,111 (2,006–23,653)
p Value — 0.003 0.003
CMVgB Ab titer
Median (IQR) 46 (28–379) 4,345 (2,464–5,036) 2,835 (1,454–4,824)
p Value — 0.001 ,0.001
CMVIE-1 Ab titer
Median (IQR) 880 (447–1303) 1,820 (973–3,279) 842 (396–3,865)
p Value — 0.019 NS
The p values show comparisons versus controls via a Mann–Whitney U test.
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that FcRg expression is decreased at the level of mRNA and
protein suggests that the FcRg2 gene expression is reduced, rather
than epitopes recognized by the FcRg Ab used for intracellular
flow cytometry being masked.
Similar to an FcRg2 NK cell subset described in CMV-
seropositive blood donors (30), the population we describe in
the present study has enhanced ADCC activity relative to con-
ventional NK cells despite lower expression of CD16, so CD16
expression is not invariably rate determining for ADDC activity.
Because CD16 can signal via both FcRg and TCRz, ADCC sig-
naling may be transduced by TCRz in FcRg-deficient cells and
signaling via FcRg and/or TCRz may be rate determining. CD16
expression on NK cells is reduced in HIV+ individuals via
ADAM17-dependent shedding (38, 39) but it is not clear to what
extent ADAM17 reduces CD16 expression in FcRg2 NK cells and
how much loss of CD16 is due to loss of FcRg chaperone func-
tion. NK cells from ∼40% of individuals express the activating
Fcg receptor, CD32c, which can mediate ADCC via its own cy-
toplasmic ITAM motif (40). It is possible that differential ex-
pression of this receptor between NK subsets might account for
the higher ADCC activity of the FcRg2 population observed in
some HIV patients, but the has not been examined in the present
study. The expansion of a population of NK cells with increased
ADCC activity in HIV+ individuals has relevance to vaccine
strategies aimed at generating ADCC-promoting Ab responses
(41–43).
Other NK cell abnormalities have been associated with CMV
coinfection in HIV+ individuals. In particular, NK cells displayed
skewed expression of NKG2A and NKG2C that normalized after
24 mo cART (25). Given the presence of FcRg2 NK cells in
CMV-seropositive individuals (30), we considered whether this
is the same population. Although FcRg2 NK cells generally
expressed low levels of NKG2A, this is not true for all individuals.
Similarly, NKG2C expression was similar to that on conventional
NK cells within any individual. Thus, although there is overlap
with the NK cell subset expanded in CMV HIV-coinfected indi-
viduals, these are not congruent subsets. FcRg2 NK cells in HIV+
individuals share many characteristics with mature CD56dim NK
cells that lose NKG2A, have lower proliferative capacity, and
acquire CD57 and KIR expression (37). Unlike these cells, FcRg2
NK cells do not lose CD62L expression, a marker that defines
polyfunctional and less mature CD56dim NK cells (36). The
FIGURE 3. (A–E) Levels of the indicated inflammatory and immune activation markers were measured by ELISA in plasma from study subjects. Error
bars represent median 6 IQR. Differences between groups were assessed for significance using the Mann–Whitney U test. *p , 0.05, **p , 0.01,***p =
0.001. (F) The relationship between plasma CXCL10 levels and the proportion of FcRg2CD56dim NK cells in each subject was determined using Pearson’s
correlation (N, HIV2 subjects; s, viremic HIV+; d, VS HIV+).
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presence of these cells in VS HIV+ individuals, their high ADCC
activity, and their high CD56 expression are not consistent with
their being precursors to dysfunctional CD562 NK cells that ac-
cumulate in viremic HIV individuals (17). Whether they represent
a terminally differentiated CD56dim NK cell population that nor-
mally does not accumulate in the periphery of healthy individuals
remains to be determined.
Although FcRg2 NK cells have been associated with CMV
seropositivity in HIV2 individuals (30), all of the HIV+ individ-
uals used in this study were seropositive for CMV, so this alone
cannot explain the variation in prevalence of FcRg2 NK cells in
the setting of HIV infection. Analysis of the plasma from five VS
HIV+ individuals who had no or very low FcRg2 NK cells and
five individuals with a very high proportion of FcRg2 NK cells
showed no detectable CMV viral load using standard clinical
assays (data not shown). We next examined the relationship be-
tween FcRg2 NK cells and CMV infection in our HIV patients
and control subjects by correlating their proportion with levels of
CMVAbs. There was a significant association in HIV2 individuals
that was not evident in HIV+ individuals so, whereas CMV
reactivation may drive low levels of FcRg2 NK cell expansion in
the general population, other factors are responsible for expansion
of this subset in HIV-infected individuals. Rather, the correlation
with levels of CXCL10 in both HIV2 and HIV+ individuals
implicates chronic inflammation. In support of this, we have
detected high proportions of FcRg2 NK cells in heart transplant
patients who receive prophylactic valganciclovir to inhibit CMV
reactivation (A.C. Hearps, unpublished), suggesting that the subset
is not expanded as a result of current CMV reactivation.
We have shown that NK cells from viremic and VS HIV+
individuals are phenotypically activated and degranulate sponta-
neously (28). Our observations of increased NK cell CD38 ex-
pression in viremic HIV+ individuals have been confirmed (44)
and associated with HIV disease progression. Significantly, our
observation that NK activation is elevated in VS HIV+ individuals
has been supported by evidence that it also occurs in elite con-
trollers (44). We asked whether increased NK activation and de-
granulation could be explained by expansion of FcRg2 NK cells,
but there was no difference in spontaneous degranulation. Con-
trary to expectation, FcRg2 NK cells expressed lower levels of
CD38 than did conventional NK cells. Although CD38 expression
is used as a lymphocyte activation marker, its lower expression on
FcRg2 NK cells does not necessarily imply that these cells are
less activated than conventional NK cells, as spontaneous de-
granulation was observed in these cells. CD38 is an NADP gly-
cohydrolase whose product ADP ribose regulates Ca2+ signaling
in lymphocytes (45). In NK cells, CD38 associates with and
transduces signals via TCRz and FcRg (46), so the decreased
FIGURE 4. (A) PBMC prepared from eight VS HIV+ individuals (median age [range] = 52.5 [34–70] y), chosen because they exhibited ∼50% FcRg2
CD56dim NK cells, were incubated with Raji (top panel) or rituximab-opsonized Raji (bottom panel) cells at an E:T ratio of 1:1. CD107a expression on both
FcRg2 and conventional (FcRg+) CD56dim NK cells was measured as described in Materials and Methods. (B) Freshly sampled whole blood from seven
VS HIV+ individuals (additional to those described in Table I) was incubated with a pool of overlapping HIV envelope peptides and serum from a single
ADCC responder as described in Materials and Methods and then surface expression of CD107a and intracellular IFN-g levels in both FcRg2 and
conventional NK cells was measured by flow cytometry. Top panels show the contour plots from a representative donor indicating CD107a (left) and IFN-g
expression (right) versus FcRg. Aggregate data for all seven donors are shown in the bottom panels. (C) Whole blood from 10 HIV2 and 10 VS HIV+
donors was incubated for 4 h at 37˚C then CD107a expression was measured in FcRg2 and conventional (FcRg+) CD56dim NK cells as described in
Materials and Methods. In the left panel, a comparison of CD107a expression on total CD56dim NK cells between HIV2 and HIV+ donors is shown. In the
right panel, CD107a expression on FcRg2 and conventional (FcRg+) CD56dim NK cells from VS HIV+ donors is shown. (D) CD38 and HLA-DR ex-
pression in FcRg2 and conventional NK cells was measured in whole blood collected from eight VS HIV+ donors. HLA-DR versus CD38 contour plots
from FcRg2 (red) and conventional (gray) CD56dim NK cells from a representative donor are shown in the left panel, and CD38 expression in the two
populations from all donors is shown in the right panel. Differences between HIV2 and HIV+ donors (C) were assessed by a Mann–Whitney U test.
Comparisons between FcRg2 and conventional NK cells were made using a Wilcoxon signed rank test. *p , 0.05, **p , 0.01, ***p , 0.001.
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expression of CD38 in FcRg2 NK cells may reflect decreased
chaperone function. Continued activation of NK cells in VS and
elite controller HIV+ individuals adds to the monocyte activation
data we have published (2, 3) demonstrating that the innate im-
mune system is activated in these individuals.
Loss of NKp30 and NKp46 expression has been reported in HIV
infection (47–49) but the mechanism underlying their loss is not
known. Our data suggest that expansion of FcRg2 NK cells in
HIV+ individuals contributes to this loss and that it persists despite
successful cART. Although NKp30 associates with TCRz (50) and
signals via TCRz-dependent mechanisms (51), our data are con-
sistent with a role for FcRg as a molecular chaperone for NKp30.
Similarly, NKp46 associates with TCRz (52) but does not require
it for surface expression (53), which is consistent with a role for
FcRg as the molecular chaperone for this receptor. NKp30 can
mediate recognition and promote killing of fungal pathogens that
cause AIDS-defining illnesses such as Cryptococcus and Candida
spp. (54). Thus, expansion of FcRg2 NK cells in viremic HIV
patients with low CD4 T cell counts may increase the suscepti-
bility of such individuals to fungal opportunistic infections, al-
though the persistence of these cells does not appear to maintain
susceptibility to fungal infections on cART.
In summary, a unique subset of FcRg2 NK cells associated with
CMV Ab levels in the general population is expanded in HIV-
infected individuals and can represent up to 90% of CD56dim
NK cells. In chronically infected HIV+ individuals their expansion
correlates with plasma markers of innate immune activation. The
long-term health consequences of expansion of FcRg2 NK cells
lacking NKp30 and NKp46 need to be determined. Given the
importance of these receptors for immunosurveillance of tumors,
FIGURE 5. FcRg2 and conventional (FcRg+) CD56dim NK cells were analyzed from eight VS HIV+ donors (chosen because they exhibited ∼50%
FcRg2CD56dim NK cells) and compared phenotypically using the following markers: (A) NKG2A, (B) NKG2C, (C) NKp30 and NKp46, (D) CD16, (E)
CD56, (F) CD62L, (G) CD57, and (H) CD27. For each marker, contour plots of that marker versus FcRg are shown for a representative donor (left panels),
as are aggregate data comparing expression for all individuals (right panels). Where markers were present on all NK cells, expression between subsets was
compared using MFI. Differences were assessed using a Wilcoxon signed rank test. *p , 0.05, **p , 0.01.
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the population may contribute to increased incidence of cancer in
HIV+ patients receiving cART (55).
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Combined antiretroviral therapy (cART) extends the lifespan and the quality of life for HIV-infected persons but does not
completely eliminate chronic immune activation and inflammation. The low level of chronic immune activation persisting during
cART-treated HIV infection is associated with the development of diseases which usually occur in the elderly. Although T-cell
activation has been extensively examined in the context of cART-treated HIV infection, monocyte activation is only beginning
to be recognized as an important source of inflammation in this context. Here we examine markers and sources of monocyte
activation during cART-treated HIV infection and discuss the role of monocytes during cardiovascular disease, HIV-associated
neurocognitive disorder, and innate immune aging.
1. Introduction
The introduction of combination antiretroviral therapy
(cART) has dramatically increased survival of HIV-infected
persons [1, 2]. Once only widely available in high-income
countries, access to cART has steadily increased over the
last decade in low- and middle-income countries where the
majority of HIV-infected persons live. In 2011, for the first
time cART became available to the majority (54%) of HIV-
infected persons eligible for treatment in low- and middle-
income countries, with the percentage of cover expected to
continue to increase in the coming years [3].
Due to improved access and adherence to cART, it is
predicted that most HIV-infected persons worldwide will
live longer, healthier lives. However, recent observations have
identified that effectively treated HIV-infected persons do
not live as long as age-matched HIV-uninfected persons
[4]. The cause of death for most HIV-infected persons
has changed from AIDS-related opportunistic infections to
chronic diseases with an inflammatory pathogenesis usually
associated with the elderly [5]. The premature onset and
increased risk of these inflammatory age-related diseases are
associated with low levels of chronic immune activation that
persist during cART treatment, a process that is believed to
contribute to serious non-AIDS events (SNAEs). While most
research examining chronic immune activation has focused
on activation of T cells, the role of activated monocytes in
promoting chronic inflammation during cART-treated HIV
infection has been less thoroughly investigated.
Recent studies indicate that inflammatory mediators
produced by monocytes, but not T-cell activation, predict
SNAEs in virologically suppressed HIV-infected persons
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treated with cART [6, 7], demonstrating the important role
of monocyte activation during cART-treated HIV infection.
In these studies, the level of IL-6, a cytokine produced
at high levels by monocytes that can also be produced at
lower levels by other cell types in certain circumstances
[8], was associated with increased odds of SNAE and death
but not the percentage of activated CD4 and CD8 T cells
(those expressing CD38 or CD38 and HLA-DR). These
recent studies suggest that monocytes are a major source
of inflammation in virologically suppressed persons treated
with cART.
2. HIV Associated Comorbidities
in the cART Era
Many of the diseases observed in cART-treated HIV-infected
persons show similarities with chronic inflammatory disor-
ders and diseases that predominantly occur in the elderly,
such as cardiovascular disease (CVD), neurocognitive dis-
orders, non-AIDS cancers, osteoporosis, and frailty. While
the mechanisms defining these similarities have not been
elucidated, it is believed that chronic inflammation, which
remains a constant between these diseases, contributes to
SNAEs caused by these diseases. Monocytes are chronically
activated during HIV infection, and a large body of evidence
now suggests that activated monocytes in the context of HIV
infection are major mediators for the development of CVD,
neurocognitive disorder, and aging of the innate immune
system.
2.1. Cardiovascular Disease. CVD has emerged as one of the
leading causes of death among HIV-infected persons in the
cART era [5, 9]. HIV-infected persons are at an increased risk
for developing CVD compared to HIV-uninfected controls,
withHIV-infected cART-treated persons having a greater risk
of developing CVD than treatment-naı¨ve HIV-infected per-
sons [10, 11]. The monocyte markers CD11b and CX3CR1 are
associated with subclinical atherosclerosis in HIV-infected
persons treated with cART [12], indicating an important role
for monocytes in promoting CVD for these persons.
CVD-related deaths in the general population aswell as in
HIV-infected persons are attributed to underlying atheroscle-
rosis, a disease in which monocytes play a central role. One
of the earliest events in the development of atherosclerosis is
mediated by activation of endothelial cells lining the wall of
blood vessels [13], a process that is promoted byHIV infection
[14]. Endothelial cell dysfunction leads to the recruitment and
accumulation of circulating monocytes in the subendothelial
lining. Once in the vessel wall, monocytes differentiate into
macrophages that produce a number of proinflammatory
mediators, some of which recruit additional monocytes to
the lesion [15–19]. Macrophages in the vessel wall take
up high levels of the cholesterol-rich particle low-density
lipoprotein (LDL), causing cholesterol to accumulate under
conditions of elevated LDL [20].The accumulation of choles-
terol in macrophages reduces their ability to emigrate out
of atherosclerotic plaques [21] and can induce macrophage
necrosis, resulting in a cholesterol-rich necrotic core that is
prone to rupture and causes a deleterious clinical event [22,
23]. Elevated plasma LDL strongly predicts coronary artery
disease and is the primary target for cholesterol-lowering
therapies [24]. Treatment of HIV infection with cART
may cause elevations in LDL-cholesterol [25–27] and can
be associated with increased risk of cardiovascular disease
compared to treatment-na¨ıve and HIV-uninfected persons
[10]. Certain protease inhibitors and nonnucleoside reverse
transcription inhibitors are associated with elevated LDL-
cholesterol, with some protease inhibitors associated with
greater LDL-cholesterol elevations and risk of cardiovascular
disease [10, 28, 29].
High-density lipoprotein (HDL) can remove cholesterol
frommacrophages using cell surface cholesterol transporters.
However, during conditions of elevated LDL, as observed
during cART-treated HIV infection [25–27], the rate of
LDL-derived cholesterol accumulation in macrophages can
be greater than cholesterol removal by HDL, resulting in
net cholesterol accumulation in the vessel wall. Further
favoring macrophage cholesterol accumulation, removal of
macrophage cholesterol by HDL may be hampered during
HIV infection, as cholesterol removal from HIV-infected
human macrophages by HDL is impaired due to decreased
levels and functionality of the cholesterol transporter ABCA1
[30]. AlthoughHIV-infectedmacrophages within atheroscle-
rotic plaque have been identified in HIV-infected individuals
treated with cART [30], it is unclear if ABCA1-mediated
cholesterol efflux from macrophages is also impaired in vivo.
SIV-infected macaques fed an atherogenic diet have dysfunc-
tional HDL that is likely mediated by nef downregulation of
macrophage and liver ABCA1 [31], suggesting that inhibition
ofABCA1-mediated cholesterol efflux frommacrophages also
occurs in vivo.
Most deaths attributable to atherosclerosis are due to
thrombus formation. During cART-treated HIV infection,
monocytes are chronically activated and can produce factors
that stimulate thrombosis. When monocytes are activated in
vitro with lipopolysaccharide (LPS), they produce micropar-
ticles that stimulate formation of the clotting factor fibrin
[32]. Tissue factor is a clotting factor expressed on leukocytes
that can also initiate thrombus formation. HIV-infected
persons show an association between monocyte expression
of tissue factor and the coagulopathy marker D-dimer [33,
34], providing evidence that monocytes may facilitate a pro-
thrombotic environment. When peripheral blood monocyte
subsets of HIV-uninfected and cART-treated HIV-infected
patients with viral loads <400 copies/mL are compared, an
increased percentage of nonclassical and intermediatemono-
cytes expressing tissue factor are observed in HIV-infected
patients [35]. In HIV-uninfected individuals with coronary
heart disease, both nonclassical and intermediate monocyte
subsets show increased platelet aggregation compared with
healthy controls [36], demonstrating the prothrombotic role
of these monocyte subsets.
Macrophages take up high levels of glucose in atheroscle-
rotic plaques to facilitate the production of proinflammatory
mediators [37]. In vivo plaque-resident macrophages take up
the glucose imaging agent 18fluorodeoxyglucose, a process
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used to identify atherosclerotic plaques with an inflamma-
tory phenotype [37]. In HIV-infected patients treated with
cART, 18fluorodeoxyglucose accumulates at higher levels
in the ascending aorta and carotid arteries compared to
HIV-uninfected controls [38, 39], with aortic uptake of
18fluorodeoxyglucose associated with the macrophage spe-
cific marker soluble CD163 [39]. These studies suggest
that glucose uptake by macrophages may contribute to the
increased cardiovascular disease risk associated with HIV-
infected patients treated with cART. We recently identified
intermediate (CD14++CD16+) monocytes expressing glu-
cose transporter 1 (Glut1) as being significantly elevated in
blood from HIV-infected individuals compared with HIV-
uninfected individuals, regardless of cART treatment status
[40]. These Glut1+ intermediate monocytes are activated
[40], take up high levels of glucose [40], and retain Glut1
expression when differentiated intomacrophages (Palmer CS
and Crowe SM, unpublished observation). As Glut1 mRNA
levels in atherosclerotic plaques predict accumulation of
18fluorodeoxyglucose [41], our results suggest that Glut1+
intermediate monocytes may be important mediators of
cardiovascular disease.
2.2. HIV-AssociatedNeurocognitive Disorder. HIV-associated
neurocognitive disorder (HAND) is a term that encompasses
varying degrees of neurological impairment, from asymp-
tomatic neurocognitive impairment to mild neurocognitive
impairment and the most severe, HIV-associated dementia
(HAD). Although cART has substantially reduced severe
neurological impairment [42], milder forms of HAND con-
tinue to occur in up to fiftypercent ofHIV-infected persons in
the cART era [42–46].This neurological impairment persists
despite virologically suppressive cART treatment and can
lead to non-AIDS neuropsychiatric events even with CD4
counts >500 cells/mm3 [47].
The main HIV-infected cell type in the brain is macro-
phages [48, 49]. As the blood brain barrier is a highly selective
barrier for solutes to traverse [50], it was initially proposed
[51] and is now widely believed that HIV-infected monocytes
traversing the blood brain barrier are a major source of HIV
found in the brain [52].Macrophages are in close proximity to
the vasculature, and fluorescently labeledmonocytes injected
into acutely SIV-infected rhesus macaques accumulate in the
brain and coincide with SIV detection in the brain [53].
Monocytes can remain productively infected with HIV
during cART treatment [54–56] and are likely to represent
a source of HIV found within the brain of HIV-infected per-
sons treated with cART. HIV-infected monocytes that enter
the brain are thought to give rise to perivascularmacrophages
which are commonly infected with HIV. Microglia are less
commonly infected than perivascular macrophages and arise
from different cell precursors [49, 57–59]. The level of HIV
DNA in monocytes, but not plasma viral load or CD4 count,
is associated with HAND for HIV-infected persons before
and after cART treatment [60], with the association persisting
at 3.5 years after cART initiation [61]. It is likely that some
of these HIV-infected monocytes harboring HIVDNA could
cross the blood brain barrier, contributing to the persistent
presence of HIV-infected cells in the brain. As HIV-infected
persons treated with cART show preferential HIV infection
in CD16+ proinflammatory monocytes compared to CD16−
monocytes [62], CD16+monocytes could be a source of HIV-
infectedmonocytes in the brain. In these experiments, T cells
fromPBMCwere removed bymagnetic beads prior tomono-
cyte isolation, making it unlikely that T-cell contamination
could explain the presence of HIV in monocytes. Although
several studies suggest that HIV-infected monocytes can
introduce HIV into the brain, this has not been conclusively
demonstrated.
After HIV-infected persons are treated with cART,
immune activation is decreased considerably but remains ele-
vated comparedwithHIV-uninfected persons [63]. Activated
macrophages produce themonocyte-derived immune activa-
tion marker neopterin, a molecule thought to participate in
maintaining reactive oxygen and nitrogen products produced
bymacrophages [64, 65]. cART-treatedHIV-infected persons
with complete viral suppression for ≥3.5 years have elevated
levels of cerebral spinal fluid neopterin compared with HIV-
uninfected controls [66], indicating persistent low levels of
macrophage activation in the central nervous system. Infec-
tion of monocytes with HIV or stimulation by gp120 causes
monocytes to produce neurotoxic factors that interact with
neuronal N-methyl-D-aspartate receptors [67, 68]. Neuronal
stimulation of N-methyl-D-aspartate receptors can result in
neuron death by apoptosis or necrosis [69]. In addition,
HIV production by macrophages in the brain also results in
neuronal toxicity, as several HIV components can interact
with neurons and cause toxicity [70–72].
2.3. Innate Immune Aging. Chronic immune activation
causes monocytes to become dysfunctional and share char-
acteristics of monocytes from the elderly. In a recent study by
Martin and colleagues, proinflammatory cytokines produced
by monocytes and markers of immune aging were shown
to be elevated in age-matched HIV-infected women (87% of
whom were receiving cART treatment) compared to HIV-
uninfected women [73]. The levels of these cytokines and
markers of immune aging were comparable to the levels seen
in HIV-uninfected women 10.6–14.5 years older, demonstrat-
ing that HIV-infected persons display an aged phenotype
[73].
In young HIV-infected women there are an increased
proportion of CD16+ proinflammatory monocytes, similar
to that observed in HIV-uninfected women 10.6 years older
[73]. Young HIV-infected males, both treated and untreated,
have increased plasma levels of the inflammatory biomarkers
neopterin, sCD163, and CXCL10 when compared to age-
matched HIV-uninfected males [74]. The levels of these
inflammatorymolecules in young treated anduntreatedHIV-
infectedmales are comparable to the levels seen in olderHIV-
uninfected men, indicating that accelerated innate immune
aging induced by HIV infection is not restored by cART
[74]. Similar to what is seen in the elderly, monocytes in
blood from young HIV-infected men have impaired phago-
cytosis and shortened telomeres implicating accelerated
innate immune aging that might underlie the dysfunction of
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monocytes in the setting of HIV infection [74].The “aging” of
monocytes during HIV infection, even during virologically
suppressive cART treatment, is likely to contribute to the
development of premature age-related diseases.
3. Monocyte Parameters of
Systemic Inflammation
The detection of biological markers that identify cART-
treated HIV-infected individuals with increased risk of
comorbid disorders is useful for the management of these
disorders. Recent work has identified biological markers
associated with monocytes and/or macrophages that predict
non-AIDS mortality.
3.1. Interleukin-6. Interleukin-6 (IL-6) is a proinflammatory
cytokine produced by monocytes and macrophages dur-
ing trauma, infection, and stress that instigate acute-phase
protein production and inflammation [8]. Both untreated
and cART-treated HIV-infected persons have elevated levels
of IL-6 [63, 75], with elevated IL-6 levels associated with
increased risk of all-cause mortality and death due to CVD
in HIV-infected persons [34]. Monocytes from HIV-infected
persons at risk for CVD produce higher levels of IL-6
compared with HIV-uninfected persons at risk for CVD
[76], providing a potential explanation for the inflammatory
pathogenesis and related increased CVD risk associated with
HIV infection. The association of IL-6 with increased risk of
CVD for HIV-infected persons is independent of other risk
factors and higher levels of IL-6 are associated with a hazard
ratio higher than for levels of other inflammatory markers
such as hsCRP and D-dimer [77]. In addition to CVD,
persons with HAND have elevated IL-6 levels in cerebral
spinal fluid that remains elevated 12 weeks after initiation of
cART [78]. The elevated levels of IL-6 observed during HIV
infection are also observed in the elderly [79], suggesting that
low levels of chronic inflammation and chronic production
of IL-6 could lead to immunosenescence observed during
normal aging as well as in chronic HIV infection. As lym-
phocytes are activated by IL-6 [80], it is possible that chronic
stimulationwith IL-6 could lead to immunosenescence. Con-
sistent with this idea, elderly persons with elevated IL-6 levels
have decreased responsiveness to vaccination compared to
elderly persons with lower levels of IL-6 [81]. However, it is
currently unresolved whether IL-6 is a cause or consequence
of immunosenescence.
3.2. Soluble CD14. CD14 is a coreceptor expressed predom-
inantly on monocytes and macrophages that together with
TLR4 recognize LPS and other pathogen-associated molec-
ular pattern molecules. After activation, monocytes produce
soluble CD14 (sCD14) by enzymatic shedding of CD14 from
the plasma membrane [82]. Plasma levels of sCD14 are
significantly elevated in HIV-infected persons, regardless
of cART treatment status, compared with healthy controls
[83, 84]. The plasma level of sCD14 in HIV-infected per-
sons is an independent predictor of mortality and corre-
lates with levels of the inflammatory molecules IL-6, CRP,
serum amyloid A, and D-dimer [85]. Plasma sCD14 levels
in HIV-infected persons also correlate with carotid artery
intima-media thickness (a measurement of atherosclerosis)
independent of HIV infection and type of antiretroviral
therapy [86]. In addition to cardiovascular disease, increased
plasma levels of sCD14 have been shown to be associated
with neurological impairment in HIV-infected individuals
as assessed by formal neurological testing and evaluations
[75]. Although sCD14 is produced by activated monocytes,
hepatocytes also secrete sCD14 as an acute-phase protein
[87].Therefore, measurement of plasma sCD14may not be an
exclusive representation of the levels of monocyte activation,
a factor that should be considered when utilizing this plasma
marker.
3.3. Soluble CD163. CD163 is a hemoglobin scavenger recep-
tor expressed exclusively on monocytes and macrophages.
Activation of monocytes and macrophages with LPS and
other stimuli causes CD163 to be shed from the cell surface
in a soluble form, referred to as soluble CD163 (sCD163) [88].
As sCD163 is shed only frommononuclear phagocytes, it is a
specific activation marker for these cells. Although sCD163
is associated with monocyte activation and inflammatory
diseases, it has anti-inflammatory effects and is believed
to be involved in resolving inflammation [88]. Compared
withHIV-seronegative controls, plasma sCD163 is elevated in
chronically HIV-infected persons before ART and is reduced
3 months after ART, but at levels that are elevated compared
to controls [89]. Plasma sCD163 is also increased during
acute HIV infection compared to HIV-seronegative controls
though at lower levels than chronic infection [89]. In acutely
infected patients treatedwith cART for threemonths, sCD163
levels are similar to those in HIV-seronegative controls [89],
suggesting that early cART initiation can limit mononuclear
phagocyte activation.
Elevated levels of sCD163 are observed in several comor-
bidities associated with cART-treated HIV infection. Plasma
sCD163 is associated with an increased prevalence of
atherosclerotic plaques in cART-treated HIV-infected per-
sons with undetectable HIV RNA, a relationship that is not
observed in HIV-negative controls matched for cardiovascu-
lar risk factors [90]. The authors suggest that activation of
mononuclear phagocytes during HIV infection could cause
a unique atherosclerotic plaque phenotype not observed in
HIV-uninfected persons. In support of this, young (23–32
years old) HIV-infected persons show a unique atheroscle-
rotic plaque phenotype that resembles a phenotype observed
in patients that rejected cardiac transplant [91]. cART-treated
HIV-infected patients with HAND have elevated levels of
plasma sCD163 compared with HIV-infected controls with-
out HAND [92], indicating an important role of activated
mononuclear phagocytes during HAND. Finally, elevated
levels of sCD163 occur at an earlier age in HIV-infected
women than in uninfected women [73], suggesting that
chronic mononuclear phagocyte activation is a mediator of
immunosenescence.
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4. Sources of Monocyte Activation
The source of chronic inflammation observed during cART-
treated HIV infection has been an area of intense research
in recent years, as it is believed to be the underlying cause
for the increased risk of SNAEs that are progressively seen
in clinics caring for HIV-infected persons treated with cART.
Three major mechanisms have been proposed to explain the
persistently high levels of inflammation inHIV-infected indi-
vidual on antiretroviral treatment: (1) increased microbial
translocation through the compromised intestinal mucosa,
(2) residual HIV viremia, and (3) coinfection with human
cytomegalovirus (HCMV) and other pathogens. Each of
these mechanisms is associated with monocyte activation
that is likely to contribute directly to SNAEs or indirectly
by induction of innate immune aging (Figure 1). Microbial
translocation, residual HIV viremia, and coinfection with
pathogensmay be codependent processes. For example, coin-
fecting pathogens and products frommicrobial translocation
could activate HIV-infected cells to produce low levels of
HIV that contribute to residual viremia present in HIV-
infected persons treated with cART, and residual viremia
and coinfecting pathogens could contribute to damage of the
intestinal mucosa, enhancing microbial translocation.
4.1. Microbial Translocation. During acute HIV infection
there is a dramatic depletion of gut CD4 T cells, resulting in
increased permeability of the gutmucosal barrier that persists
during chronic untreated HIV infection and also during
cART treatment [93, 94]. This increased gut permeability
allows bacterial components such as the Gram-negative
bacterial cell wall component LPS to become elevated in the
plasma of both untreated and cART-treated HIV-infected
persons compared to HIV-uninfected controls [93]. Elevated
plasma levels of LPS duringHIV infection results in increased
plasma sCD14, signifying that circulating monocytes are
chronically activated by LPS [93]. This increase in sCD14
is positively correlated with LPS levels, suggesting that
monocyte activation by LPS is likely responsible for sCD14
production [93]. Activation of monocytes by LPS also causes
increased levels of sCD163 [88], a mononuclear phagocyte
activation marker that is elevated in untreated and cART-
treated HIV-infected persons compared to HIV-uninfected
controls [89]. These observations indicate that microbial
translocation is likely to be a key inducer of monocyte acti-
vation and chronic low level systemic inflammation observed
in individuals infected with HIV.
Activation of monocytes by LPS may be exacerbated
due to alterations in HDL levels that are associated with
HIV infection. Plasma lipoproteins bind LPS, the majority of
which is bound to HDL [95]. HDL binding of LPS neutralizes
the stimulatory activity of LPS towards monocytes in vitro
[96], and LPS treatment of persons with low HDL levels
is associated with higher levels of inflammatory mediators
compared to personswith higherHDL levels treatedwith LPS
[97]. These data indicate that HDL can limit inflammation
induced by LPS. As cART-treated HIV-infected men and
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Figure 1: Microbial translocation, residual HIV replication, and
coinfections such as HCMV cause persistent monocyte activation
and contribute to chronic inflammation inHIV+ individuals receiv-
ing antiretroviral therapy. This results in innate immune aging
and may influence the development of age-related diseases. Image
created by http://nice-consultants.com/.
certain cART-treated HIV-infected women have decreased
HDL-cholesterol levels [26, 98], the level of neutralized
plasma LPS may be limited in these persons.
In addition to the activation of circulating monocytes,
microbial translocation induces the accumulation of proin-
flammatory, functionally impaired macrophages within the
subepithelium of the gut in untreated HIV-infected individ-
uals [99]. These macrophages show increased expression of
proinflammatory cytokines and chemokines and are unable
to phagocytose microbes or microbial products [99]. The
inflammatory characteristics of thesemacrophagesmay exac-
erbate microbial translocation since the proinflammatory
cytokines they produce can increase gut epithelial perme-
ability and thereby allowmicrobes and microbial products to
cross the mucosal barrier [99].
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4.2. Residual HIV Viremia. The introduction of cART has
resulted in frequent reduction ofHIV viremia to undetectable
levels as assessed by conventional techniques. The SMART
study highlighted that intermittent cART resulted in elevated
inflammation and higher mortality and morbidity among
HIV-infected persons who ceased therapy when compared to
those receiving continuous cART [34, 100]. This underscores
the significance of suppressed viral replication and repression
of inflammation in the management of persons infected with
HIV [100].
Ultrasensitive assays capable of detecting HIV in plasma
at 1 copy/mL have demonstrated that low levels of HIV
viremia continue to occur in individuals with virologic
suppression (i.e., <50 copies/mL) during cART [101–103].
Raltegravir intensification, introduced in patients to suppress
residual viremia, resulted in lower plasma levels of the inflam-
matory procoagulant marker D-dimer in some treated HIV-
infected individuals compared to patients receiving placebo,
illustrating a potential link between low level viral replication
and inflammation [104]. However, residual viremia is unaf-
fected by raltegravir intensification [105]. It therefore remains
unclear if the residual viremia that occurs in virologically
suppressed HIV-infected persons treated with cART is due
to HIV replication or production (i.e., generation of new
viruses without completion of the replication cycle) [106].
Regardless of the mechanism of residual HIV viremia, it is
likely to be a chronic source of monocyte activation because
many components of HIV induce monocytes to produce
proinflammatory molecules [107–109].
4.3. Coinfections. Most HIV-infected persons are latently
infected with HCMV and are able to effectively control
this virus [2, 110, 111]. However, it is now clear that HIV-
infected persons invest a considerable immune response to
limit pathogenesis of HCMV even when HIV replication is
controlled by cART. For example, the percentage of HCMV-
specific CD8 T-cell clones in HIV-infected persons treated
with cART is twice that of HIV-uninfected persons [112],
indicating an important role of the cellular immune response
in controlling HCMV replication. Although HCMV has a
broad cell tropism, monocytes are believed to be important
at disseminating HCMV to tissue as they migrate with latent
virus and produce virus during differentiation [113, 114].
When infected with HCMV, monocytes become activated
and proinflammatory genes are upregulated [115, 116].
HIV-infected persons treated with cART are also com-
monly infected with herpesviruses other than HCMV that
can also establish latency. Epstein-Barr virus (EBV), human
herpesvirus 8 (HHV-8), and herpes simplex virus type 1 are
more commonly detected in the saliva of cART-treated HIV-
infected persons compared to HIV-uninfected controls [117].
Monocytes can be infected with EBV which causes reduced
phagocytic functionality [118, 119], and stimulation of mono-
cyte TLR2 by EBV promotes induction of cytokine secretion
[119]. HHV-8 can infect monocytes and macrophages and
establish productive infection when stimulated with inflam-
matory cytokines [120–122], and HHV-8 infection induces
upregulation of monocyte TLR3 and production of inflam-
matory cytokines [123]. HSV-1 can also infect monocytes and
macrophages, which produce inflammatory cytokines when
exposed to HSV-1 [124, 125]. Though not directly examined,
herpesvirus coinfection is therefore likely to be a source of
chronic monocyte activation in the context of cART-treated
HIV infection.
5. Conclusion
With the majority of cART-eligible HIV-infected persons
now receiving treatment, SNAEs have increased and are one
of the greatest health concerns for HIV-infected persons. In
HIV-infected persons treated with cART, monocytes are an
important source of proinflammatory mediators associated
with cardiovascular disease, HIV-associated neurocognitive
development, and innate immune aging. It remains to be
determined if monocytes are also mediators of other pre-
mature age-related diseases such as non-AIDS cancer and
liver diseases that cART-treated HIV-infected persons are
at an increased risk for developing. With sources of mono-
cyte activation and identification of monocyte activation
pathways emerging in recent years, therapeutically targeting
sources and pathways of monocyte activation could be a
useful strategy to limit immune activation associated with
the premature development of age-related diseases for HIV-
infected persons treated with cART.
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